Tue May 08 2018 16:47:43 GMT+0000 (UTC)

Feature:CTRPSTRAP-133: Change the algorithm for determining "Multi Institutional?" for Data Table 4 Reports 12

Scenario Outline:#1 CTRPSTRAP-133 Ensure for a single participating site Multi Institutional is set to NO for trial NCI-2009-00819 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00819" 0s

Then I want to verify for the Multi Institutional fields as "ad_nci_id" the corresponding values as "NCI-2009-00819" are correct 0s

Scenario Outline:#1 CTRPSTRAP-133 Ensure for a single participating site Multi Institutional is set to NO for trial NCI-2009-00819 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00819" 0s

Then I want to verify for the Multi Institutional fields as "is_multiinstitutional" the corresponding values as "N" are correct 0s

Scenario Outline:#2 CTRPSTRAP-133 Ensure for a single participating site Multi Institutional is set to NO for trial NCI-2009-01308 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01308" 0s

Then I want to verify for the Multi Institutional fields as "ad_nci_id" the corresponding values as "NCI-2009-01308" are correct 0s

Scenario Outline:#2 CTRPSTRAP-133 Ensure for a single participating site Multi Institutional is set to NO for trial NCI-2009-01308 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01308" 0s

Then I want to verify for the Multi Institutional fields as "is_multiinstitutional" the corresponding values as "N" are correct 0s

Scenario Outline:#3 CTRPSTRAP-133 TWO participating sites are in the same family for the trial NCI-2009-01692 and the Multi Institutional should be NO 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01692" 0s

Then I want to verify for the Multi Institutional fields as "ad_nci_id" the corresponding values as "NCI-2009-01692" are correct 0s

Scenario Outline:#3 CTRPSTRAP-133 TWO participating sites are in the same family for the trial NCI-2009-01692 and the Multi Institutional should be NO 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01692" 0s

Then I want to verify for the Multi Institutional fields as "is_multiinstitutional" the corresponding values as "N" are correct 0s

Scenario Outline:#5 CTRPSTRAP-133 TWO participating sites are not in same family for the trial NCI-2010-00978 and the Multi Institutional should be YES 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2010-00978" 0s

Then I want to verify for the Multi Institutional fields as "ad_nci_id" the corresponding values as "NCI-2010-00978" are correct 0s

Scenario Outline:#5 CTRPSTRAP-133 TWO participating sites are not in same family for the trial NCI-2010-00978 and the Multi Institutional should be YES 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2010-00978" 0s

Then I want to verify for the Multi Institutional fields as "is_multiinstitutional" the corresponding values as "Y" are correct 0s

Scenario Outline:#6 CTRPSTRAP-133 TWO participating sites are not in same family for the trial NCI-2010-02106 and the Multi Institutional should be YES 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2010-02106" 0s

Then I want to verify for the Multi Institutional fields as "ad_nci_id" the corresponding values as "NCI-2010-02106" are correct 0s

Scenario Outline:#6 CTRPSTRAP-133 TWO participating sites are not in same family for the trial NCI-2010-02106 and the Multi Institutional should be YES 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2010-02106" 0s

Then I want to verify for the Multi Institutional fields as "is_multiinstitutional" the corresponding values as "Y" are correct 0s

Scenario Outline:#7 CTRPSTRAP-133 TWO participating sites are not in same family for the trial NCI-2011-00530 and the Multi Institutional should be YES 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2011-00530" 0s

Then I want to verify for the Multi Institutional fields as "ad_nci_id" the corresponding values as "NCI-2011-00530" are correct 0s

Scenario Outline:#7 CTRPSTRAP-133 TWO participating sites are not in same family for the trial NCI-2011-00530 and the Multi Institutional should be YES 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2011-00530" 0s

Then I want to verify for the Multi Institutional fields as "is_multiinstitutional" the corresponding values as "Y" are correct 0s

Feature:CTRPSTRAP-146: DT4 Trial Inclusion/Exclusion based on overall Trial "Terminal Status" 5

Scenario Outline:#8 CTRPSTRAP-146 *NCI-2009-00751* should not show up under *Fred & Pamela Buffett Cancer Center* from *May 01, 2017 to Mar 15, 2018* (Family affiliation ended in *2017-04-20*.) 3

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

And service call status code returned "200" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2009-00751" in the response 0s

Scenario Outline:#9 CTRPSTRAP-146 *NCI-2009-00751* should show up under Jan 20, 2017 to Feb 20, 2017 for Family *Fred & Pamela Buffett Cancer Center* 3

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 3s

And service call status code returned "200" 0s

Then DT4 report SHOULD contains following trials: "NCI-2009-00751" in the response 0s

Scenario Outline:#10 CTRPSTRAP-146 NCI-2009-00336 should not show up for Date range Jan 20, 2017 to Feb 20, 2017 for Family Georgetown Lombardi Comprehensive Cancer Center 3

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 3s

And service call status code returned "200" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2009-00336" in the response 0s

Scenario Outline:#11 CTRPSTRAP-146 NCI-2009-00336 should show up for Date range Jan 01, 2012 to Jul 01, 2013 for Family Georgetown Lombardi Comprehensive Cancer Center 3

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

And service call status code returned "200" 0s

Then DT4 report SHOULD contains following trials: "NCI-2009-00336" in the response 0s

Scenario Outline:#12 CTRPSTRAP-146 NCI-2009-00336 should show up for Date range Jan 20, 2017 to Feb 20, 2017 for Fred & Pamela Buffett Cancer Center 3

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

Then DT4 report SHOULD contains following trials: "NCI-2009-00336" in the response 0s

Feature:CTRPSTRAP-147: DT4 - get new Center PI and Local Trial Identifier onto DT4 report 5 1

Scenario Outline:#16 CTRPSTRAP-147 Ensure new Center PI not presents in the DT4 results for trial NCI-2011-00940 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 4s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2012-00009" 0s

And ensure Accrual Counts are accurate for column: "nci_id" and it's corresponding values: "NCI-2012-00009" for the trial 0s

Scenario Outline:#16 CTRPSTRAP-147 Ensure new Center PI not presents in the DT4 results for trial NCI-2011-00940 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2012-00009" 0s

And ensure Accrual Counts are accurate for column: "inv_f_nm" and it's corresponding values: "" for the trial 0s

Scenario Outline:#16 CTRPSTRAP-147 Ensure new Center PI not presents in the DT4 results for trial NCI-2011-00940 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2012-00009" 0s

And ensure Accrual Counts are accurate for column: "inv_l_nm" and it's corresponding values: "" for the trial 0s

Scenario Outline:#16 CTRPSTRAP-147 Ensure new Center PI not presents in the DT4 results for trial NCI-2011-00940 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2012-00009" 0s

And ensure Accrual Counts are accurate for column: "inv_m_init" and it's corresponding values: "" for the trial 0s

Scenario Outline:#18 CTRPSTRAP-147 Ensure new Local Trial Identifier presents in the DT4 results 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2012-00009" 0s

And ensure Accrual Counts are accurate for column: "nci_id" and it's corresponding values: "NCI-2012-00009" for the trial 0s

Scenario Outline:#18 CTRPSTRAP-147 Ensure new Local Trial Identifier presents in the DT4 results 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2012-00009" 0s

And ensure Accrual Counts are accurate for column: "local_site_identifier" and it's corresponding values: "12875" for the trial 0s + Show Error 

expected: "12875"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:77:in `/^ensure Accrual Counts are accurate for column: "([^"]*)" and it's corresponding values: "([^"]*)" for the trial$/'
features/strap_api/bug_fix_tracker_147.feature:44:in `And ensure Accrual Counts are accurate for column: "local_site_identifier" and it's corresponding values: "12875" for the trial'
features/strap_api/bug_fix_tracker_147.feature:40:in `And ensure Accrual Counts are accurate for column: "(columns)" and it's corresponding values: "(values)" for the trial'

Feature:DT4 csv export verification 1

Column header name verification when report exported to the CSV file

Scenario:#1 Exported CSV file column(s) verification for DT4 report 7

Given the "DT4" service is called by providing following parameters 5s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

And verify the DT4 exported CSV file column header value is present 0s

Feature:A set of API tests to verify nci-strap-api endpoints page is not null 1

Scenario:ensure that NCI STRAP service is running and the response body return all the available endpoints 4

Given "ENDPOINTS" endpoint is called 0s

Then the service status code should return "200" 0s

And the reponse for "ENDPOINTS" is not null 0s

And the matching ENDPOINTS response list of endpoints "list_of_endpoints" is returned 0s

Feature:This feature will list the Data Table 4 report 116 10

Scenario:#1 Verifying the trial type is "INTERVENTIONAL" based on the trial type criteria in the DT4 report 4

Given the "DT4" service is called by providing following criteria: 3s

Then service status code should return "200" 0s

Then I want to verify response has the trial types: "clinical_research_cat" key 0s

And trial type is "INTERVENTIONAL" 0s

Scenario:#2 Verifying the trial type is "NON-INTERVENTIONAL" based on the trial type criteria in the DT4 report 4

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify response has the trial types: "clinical_research_cat" key 0s

And trial type is "NON-INTERVENTIONAL" 0s

Scenario:#3 valid DT4 GET endpoint response code should return 200 2

Given the "DT4" service is called by providing following parameters 4s

Then service status code should return "200" 0s

Scenario:#4 malformed DT4 trial type GET endpoint response code should return 400 BAD REQUEST 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And service should return invalid parameters message 0s

Scenario:#5 verify "trial_type" is a required parameter 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And service should return failed message: "required_trial_type" due to missing required parameter 0s

Scenario:#6 malformed DT4 start date GET endpoint response code should return 400 BAD REQUEST 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And the response should return request failed message for "malformed_start_date" parameters 0s

Scenario:#7 verify "start_date" is a required parameter 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And service should return failed message: "required_start_date" due to missing required parameter 0s

Scenario:#8 malformed DT4 end date GET endpoint response code should return 400 BAD REQUEST 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And the response should return request failed message for "malformed_end_date" parameters 0s

Scenario:#10 verify "end_date" is a required parameter 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And service should return failed message: "required_end_date" due to missing required parameter 0s

Scenario:#11 malformed DT4 center GET endpoint response code should return 400 BAD REQUEST 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And the response should return request failed message for "malformed_center" parameters 0s

Scenario:#12 verify "center" is a required parameter 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And service should return failed message: "required_center" due to missing required parameter 0s

Scenario:#13 service should return 200 status code with non-required parameter: "fiscal_year" 2

Given the "DT4" service is called by providing following parameters along with fiscal_year optional parameter 3s

Then service status code should return "200" 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 1s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "ad_nci_id" the corresponding values as "NCI-2009-00315" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "affiliate_total" the corresponding values as "0" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "affiliate_total_rp" the corresponding values as "0" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "center_total" the corresponding values as "0" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "center_total_rp" the corresponding values as "0" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "clinical_research_cat" the corresponding values as "ANC/COR" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "close_date" the corresponding values as "21-Feb-2014" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "comments" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "consortia_trial_category" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "ctep_dcp_id" the corresponding values as "AALL06N1" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "dt4_program_codes" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "entire_study" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "inv_f_nm" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "inv_l_nm" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "inv_m_init" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "is_industrial" the corresponding values as "False" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "is_multiinstitutional" the corresponding values as "Y" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "islead" the corresponding values as "False" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "lead_org_id" the corresponding values as "AALL06N1" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "lead_org_po_id" the corresponding values as "60948" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "local_site_identifier" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "nci_id" the corresponding values as "NCI-2009-00315" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "nct_id" the corresponding values as "NCT00437060" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "official_title" the corresponding values as "A Study of Neurocognitive Function in Children Treated for ALL" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "open_date" the corresponding values as "29-Jan-2007" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "other_ids" the corresponding values as "CDR0000528920" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "other_protocol_ids" the corresponding values as "AALL06N1, CDR0000528920" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "p30grant" the corresponding values as "CA082103" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "phase" the corresponding values as "NA" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "phase_additional_qualifier_code" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "phase_description" the corresponding values as "NA" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "pi_first_name" the corresponding values as "Naomi" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "pi_last_name" the corresponding values as "Winick" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "pi_middle_initial" the corresponding values as "J" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "primary_purpose" the corresponding values as "Oth" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "prog_code" the corresponding values as "" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "site" the corresponding values as "Lymphoid Leukemia" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "sp_id" the corresponding values as "74445775" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "specific_funding_source" the corresponding values as "Childrens Oncology Group" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "study_source" the corresponding values as "N" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "summary_level_accrual" the corresponding values as "False" are correct 0s

Scenario Outline:#14 List the report for UCSF Helen Diller Family Comprehensive Cancer Center from 01/01/2016 to 01/01/2017 with Non-interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00315" 0s

Then I want to verify for the fields as "your_center_total" the corresponding values as "0" are correct 0s

Scenario Outline:#15 This scenario will check for the Date filter criteria. All the trials returned should have Open_Date less than the End_date 2

Given the "DT4" services is called by providing "Abramson Cancer Center" and "2009-01-1" and "2009-09-01" and "1" and "200" and "1" with the sort option: "nci_id" 2s

And It shall return the trials with "open_date" less than "2009-09-01" 0s

Scenario Outline:#15 This scenario will check for the Date filter criteria. All the trials returned should have Open_Date less than the End_date 2

Given the "DT4" services is called by providing "Case Comprehensive Cancer Center" and "2015-01-1" and "2017-01-1" and "2" and "200" and "1" with the sort option: "nci_id" 3s

And It shall return the trials with "open_date" less than "2017-01-1" 0s

Scenario Outline:#15 This scenario will check for the Date filter criteria. All the trials returned should have Open_Date less than the End_date 2

Given the "DT4" services is called by providing "Fox Chase Cancer Center" and "2010-01-1" and "2011-01-1" and "3" and "100" and "1" with the sort option: "nci_id" 1s

And It shall return the trials with "open_date" less than "2011-01-1" 0s

Scenario Outline:#15 This scenario will check for the Date filter criteria. All the trials returned should have Open_Date less than the End_date 2

Given the "DT4" services is called by providing "Mayo Clinic Cancer Center" and "2014-01-1" and "2014-01-1" and "1" and "5" and "2" with the sort option: "nci_id" 1s

And It shall return the trials with "open_date" less than "2014-01-1" 0s

Scenario Outline:#15 This scenario will check for the Date filter criteria. All the trials returned should have Open_Date less than the End_date 2

Given the "DT4" services is called by providing "Comprehensive Cancer Center - James Cancer Hospital & Solove" and "2014-01-1" and "2017-01-1" and "1" and "200" and "1" with the sort option: "nci_id" 1s

And It shall return the trials with "open_date" less than "2017-01-1" 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 3s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "ad_nci_id" the corresponding values as "NCI-2009-00310" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "affiliate_total" the corresponding values as "1" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "affiliate_total_rp" the corresponding values as "0" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "center_total" the corresponding values as "0" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "center_total_rp" the corresponding values as "0" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "clinical_research_cat" the corresponding values as "ANC/COR" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "close_date" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "comments" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "consortia_trial_category" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "ctep_dcp_id" the corresponding values as "AALL05B1" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "dt4_program_codes" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "entire_study" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "inv_f_nm" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "inv_l_nm" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "inv_m_init" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "is_industrial" the corresponding values as "False" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "is_multiinstitutional" the corresponding values as "Y" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "islead" the corresponding values as "False" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "lead_org_id" the corresponding values as "AALL05B1" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "lead_org_po_id" the corresponding values as "60948" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "nci_id" the corresponding values as "NCI-2009-00310" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "nct_id" the corresponding values as "NCT00897325" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "official_title" the corresponding values as "A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "open_date" the corresponding values as "25-Sep-2006" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "other_ids" the corresponding values as "CDR0000491159\rCOG-AALL05B1" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "other_protocol_ids" the corresponding values as "AALL05B1, CDR0000491159, COG-AALL05B1" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "p30grant" the corresponding values as "CA014236" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "phase" the corresponding values as "NA" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "phase_description" the corresponding values as "NA" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "pi_first_name" the corresponding values as "Stephen" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "pi_last_name" the corresponding values as "Hunger" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "pi_middle_initial" the corresponding values as "P" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "primary_purpose" the corresponding values as "Oth" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "prog_code" the corresponding values as "" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "site" the corresponding values as "multiple" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "sp_id" the corresponding values as "74445057" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "specific_funding_source" the corresponding values as "Childrens Oncology Group" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "study_source" the corresponding values as "N" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "summary_level_accrual" the corresponding values as "False" are correct 0s

Scenario Outline:#16 List the DT4 report for Duke Cancer Institute from 11/01/2016 to 01/10/2017 with Interventional trials 3

Given the "DT4" service is called by providing criteria: 0s

And It shall return the response which should include nci id "NCI-2009-00310" 0s

Then I want to verify for the fields as "your_center_total" the corresponding values as "0" are correct 0s

Scenario:#17 List the DT4 report for Fox Chase Cancer Center from 11/01/2016 to 01/10/2017 with interventional and non-interventional trials for 20 records 2 1 1

Given the "DT4" service is called by providing following criteria: 2s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "fox_chase_list_20" parameters in the "fox_chase_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_... "paging"=){"items_per_page"=)20, "page"=)1, "pages"=)9, "sort"=)[["nci_id", "ASC"]], "total"=)167}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_... "paging"=){"items_per_page"=)20, "page"=)1, "pages"=)9, "sort"=)[["nci_id", "ASC"]], "total"=)167}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-140503", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 140503", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00447", "nct_id"=)"NCT00499330", "official_title"=)"A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer", "open_date"=)"15-Jun-2007", "other_ids"=)"CDR0000555324\rECOG-40503", "other_protocol_ids"=)"CALGB-140503, CDR0000555324, ECOG-40503", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Nasser", "pi_last_name"=)"Altorki", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74412640", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"MC083I", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA006927", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"13-049", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00055", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-019", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00055", "nct_id"=)"NCT01281514", "official_title"=)"Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients with Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse", "open_date"=)"14-Dec-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Lainie", "pi_last_name"=)"Martin", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74125922", "specific_funding_source"=)"Fox Chase Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01314", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"OER-SAR-043", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01314", "nct_id"=)"NCT01462630", "official_title"=)"Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma", "open_date"=)"07-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Margaret", "pi_last_name"=)"von Mehren", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74366157", "specific_funding_source"=)"National Comprehensive Cancer Network", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01972", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"35", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACRIN-6685", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACRIN 6685", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01972", "nct_id"=)"NCT00983697", "official_title"=)"A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients", "open_date"=)"01-Apr-2010", "other_ids"=)"CDR0000654703\rCA80098", "other_protocol_ids"=)"ACRIN-6685, CDR0000654703, CA80098", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Val", "pi_last_name"=)"Lowe", "pi_middle_initial"=)"J", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74457401", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01973", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0724", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0724/GOG-0724", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01973", "nct_id"=)"NCT00980954", "official_title"=)"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy", "open_date"=)"15-Sep-2014", "other_ids"=)"GOG-0724\rCDR0000654709", "other_protocol_ids"=)"RTOG-0724, GOG-0724, CDR0000654709", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuja", "pi_last_name"=)"Jhingran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74432640", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01974", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0926", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0926", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01974", "nct_id"=)"NCT00981656", "official_title"=)"A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging", "open_date"=)"11-Nov-2009", "other_ids"=)"PRTOG-0926_A05PAMDREVW01\rCDR0000654727\r13-C-0175", "other_protocol_ids"=)"RTOG-0926, PRTOG-0926_A05PAMDREVW01, CDR0000654727, 13-C-0175", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"William", "pi_last_name"=)"Shipley", "pi_middle_initial"=)"U", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"74432754", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01987", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0848", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0848", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01987", "nct_id"=)"NCT01013649", "official_title"=)"A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma", "open_date"=)"17-Nov-2009", "other_ids"=)"CDR0000659092\rRTOG 0848", "other_protocol_ids"=)"RTOG-0848, CDR0000659092, RTOG, 0848", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ross", "pi_last_name"=)"Abrams", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"74433795", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E7208", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7208", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02018", "nct_id"=)"NCT01079780", "official_title"=)"A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-Ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy", "open_date"=)"08-Oct-2010", "other_ids"=)"CDR0000666736\rECOG-E7208", "other_protocol_ids"=)"E7208, CDR0000666736, ECOG-E7208", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Howard", "pi_last_name"=)"Hochster", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74436423", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0263", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0263", "lead_org_po_id"=)"88642", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02037", "nct_id"=)"NCT01101451", "official_title"=)"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy", "open_date"=)"12-Apr-2010", "other_ids"=)"CDR0000670125", "other_protocol_ids"=)"GOG-0263, CDR0000670125", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sang", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74437876", "specific_funding_source"=)"Gynecologic Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02623", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1007", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1007", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02623", "nct_id"=)"NCT01272037", "official_title"=)"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer", "open_date"=)"15-Jan-2011", "other_ids"=)"SWOG-S1007\rPS1007_A11PAMDREVW01\rCDR0000692475", "other_protocol_ids"=)"S1007, SWOG-S1007, PS1007_A11PAMDREVW01, CDR0000692475", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kevin", "pi_last_name"=)"Kalinsky", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74723280", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02673", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1001", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02673", "nct_id"=)"NCT01359592", "official_title"=)"A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)", "open_date"=)"18-Jul-2011", "other_ids"=)"SWOG-S1001\rCDR0000700624", "other_protocol_ids"=)"S1001, SWOG-S1001, CDR0000700624", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"Persky", "pi_middle_initial"=)"O", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74754334", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02674", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0924", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0924", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02674", "nct_id"=)"NCT01368588", "official_title"=)"Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial", "open_date"=)"07-Jul-2011", "other_ids"=)"PRTOG-0924_A03PAMDREVW01\rCDR0000701128", "other_protocol_ids"=)"RTOG-0924, PRTOG-0924_A03PAMDREVW01, CDR0000701128", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mack", "pi_last_name"=)"Roach", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74754892", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02939", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NU 11I03", "lead_org_po_id"=)"95754", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02939", "nct_id"=)"NCT01465659", "official_title"=)"A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)", "open_date"=)"15-Nov-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Halla", "pi_last_name"=)"Nimeiri", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"75182923", "specific_funding_source"=)"Northwestern University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-140503", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 140503", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00447", "nct_id"=)"NCT00499330", "official_title"=)"A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer", "open_date"=)"15-Jun-2007", "other_ids"=)"CDR0000555324\rECOG-40503", "other_protocol_ids"=)"CALGB-140503, CDR0000555324, ECOG-40503", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Nasser", "pi_last_name"=)"Altorki", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74412640", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA006927", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00055", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-019", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00055", "nct_id"=)"NCT01281514", "official_title"=)"Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients with Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse", "open_date"=)"14-Dec-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Lainie", "pi_last_name"=)"Martin", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74125922", "specific_funding_source"=)"Fox Chase Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01314", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"OER-SAR-043", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01314", "nct_id"=)"NCT01462630", "official_title"=)"Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma", "open_date"=)"07-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Margaret", "pi_last_name"=)"von Mehren", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74366157", "specific_funding_source"=)"National Comprehensive Cancer Network", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01972", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"35", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACRIN-6685", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACRIN 6685", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01972", "nct_id"=)"NCT00983697", "official_title"=)"A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients", "open_date"=)"01-Apr-2010", "other_ids"=)"CDR0000654703\rCA80098", "other_protocol_ids"=)"ACRIN-6685, CDR0000654703, CA80098", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Val", "pi_last_name"=)"Lowe", "pi_middle_initial"=)"J", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74457401", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01973", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0724", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0724/GOG-0724", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01973", "nct_id"=)"NCT00980954", "official_title"=)"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy", "open_date"=)"15-Sep-2014", "other_ids"=)"GOG-0724\rCDR0000654709", "other_protocol_ids"=)"RTOG-0724, GOG-0724, CDR0000654709", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuja", "pi_last_name"=)"Jhingran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74432640", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01974", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0926", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0926", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01974", "nct_id"=)"NCT00981656", "official_title"=)"A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging", "open_date"=)"11-Nov-2009", "other_ids"=)"PRTOG-0926_A05PAMDREVW01\rCDR0000654727\r13-C-0175", "other_protocol_ids"=)"RTOG-0926, PRTOG-0926_A05PAMDREVW01, CDR0000654727, 13-C-0175", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"William", "pi_last_name"=)"Shipley", "pi_middle_initial"=)"U", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"74432754", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01987", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0848", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0848", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01987", "nct_id"=)"NCT01013649", "official_title"=)"A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma", "open_date"=)"17-Nov-2009", "other_ids"=)"CDR0000659092\rRTOG 0848", "other_protocol_ids"=)"RTOG-0848, CDR0000659092, RTOG, 0848", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ross", "pi_last_name"=)"Abrams", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"74433795", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E7208", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7208", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02018", "nct_id"=)"NCT01079780", "official_title"=)"A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-Ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy", "open_date"=)"08-Oct-2010", "other_ids"=)"CDR0000666736\rECOG-E7208", "other_protocol_ids"=)"E7208, CDR0000666736, ECOG-E7208", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Howard", "pi_last_name"=)"Hochster", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74436423", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0263", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0263", "lead_org_po_id"=)"88642", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02037", "nct_id"=)"NCT01101451", "official_title"=)"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy", "open_date"=)"12-Apr-2010", "other_ids"=)"CDR0000670125", "other_protocol_ids"=)"GOG-0263, CDR0000670125", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sang", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74437876", "specific_funding_source"=)"Gynecologic Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02623", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1007", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1007", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02623", "nct_id"=)"NCT01272037", "official_title"=)"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer", "open_date"=)"15-Jan-2011", "other_ids"=)"SWOG-S1007\rPS1007_A11PAMDREVW01\rCDR0000692475", "other_protocol_ids"=)"S1007, SWOG-S1007, PS1007_A11PAMDREVW01, CDR0000692475", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kevin", "pi_last_name"=)"Kalinsky", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74723280", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02673", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1001", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02673", "nct_id"=)"NCT01359592", "official_title"=)"A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)", "open_date"=)"18-Jul-2011", "other_ids"=)"SWOG-S1001\rCDR0000700624", "other_protocol_ids"=)"S1001, SWOG-S1001, CDR0000700624", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"Persky", "pi_middle_initial"=)"O", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74754334", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02674", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0924", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0924", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02674", "nct_id"=)"NCT01368588", "official_title"=)"Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial", "open_date"=)"07-Jul-2011", "other_ids"=)"PRTOG-0924_A03PAMDREVW01\rCDR0000701128", "other_protocol_ids"=)"RTOG-0924, PRTOG-0924_A03PAMDREVW01, CDR0000701128", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mack", "pi_last_name"=)"Roach", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74754892", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02939", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NU 11I03", "lead_org_po_id"=)"95754", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02939", "nct_id"=)"NCT01465659", "official_title"=)"A Phase I/II Study of the Combination of Temozolomide and Pazopanib in Advanced Pancreatic Neuroendocrine Tumors (PNET)", "open_date"=)"15-Nov-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Halla", "pi_last_name"=)"Nimeiri", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"75182923", "specific_funding_source"=)"Northwestern University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)20, "page"=)1, "pages"=)9, "sort"=)[["nci_id", "ASC"]], "total"=)167},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:415:in `Then I want to verify DT4 response contains the correct data for "fox_chase_list_20" parameters in the "fox_chase_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "20" records

Scenario:#18 List Fox Chase Cancer Centers DT4 report for 10 records 2 1 1

Given the "DT4" service is called by providing following criteria: 2s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "fox_chase_list_10" parameters in the "fox_chase_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_..."paging"=){"items_per_page"=)10, "page"=)1, "pages"=)17, "sort"=)[["nci_id", "ASC"]], "total"=)167}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_..."paging"=){"items_per_page"=)10, "page"=)1, "pages"=)17, "sort"=)[["nci_id", "ASC"]], "total"=)167}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-140503", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 140503", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00447", "nct_id"=)"NCT00499330", "official_title"=)"A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer", "open_date"=)"15-Jun-2007", "other_ids"=)"CDR0000555324\rECOG-40503", "other_protocol_ids"=)"CALGB-140503, CDR0000555324, ECOG-40503", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Nasser", "pi_last_name"=)"Altorki", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74412640", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"MC083I", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA006927", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"13-049", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00055", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-019", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00055", "nct_id"=)"NCT01281514", "official_title"=)"Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients with Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse", "open_date"=)"14-Dec-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Lainie", "pi_last_name"=)"Martin", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74125922", "specific_funding_source"=)"Fox Chase Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01314", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"OER-SAR-043", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01314", "nct_id"=)"NCT01462630", "official_title"=)"Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma", "open_date"=)"07-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Margaret", "pi_last_name"=)"von Mehren", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74366157", "specific_funding_source"=)"National Comprehensive Cancer Network", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-140503", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 140503", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00447", "nct_id"=)"NCT00499330", "official_title"=)"A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer", "open_date"=)"15-Jun-2007", "other_ids"=)"CDR0000555324\rECOG-40503", "other_protocol_ids"=)"CALGB-140503, CDR0000555324, ECOG-40503", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Nasser", "pi_last_name"=)"Altorki", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74412640", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA006927", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00055", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-019", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00055", "nct_id"=)"NCT01281514", "official_title"=)"Phase I Study of Carboplatin, Pegylated Liposomal Doxorubicin (PLD) and Everolimus in Patients with Platinum-Sensitive Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer in First Relapse", "open_date"=)"14-Dec-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Lainie", "pi_last_name"=)"Martin", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74125922", "specific_funding_source"=)"Fox Chase Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA006927", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01314", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"OER-SAR-043", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01314", "nct_id"=)"NCT01462630", "official_title"=)"Phase II Study Evaluating the Role of Pazopanib in Angiosarcoma", "open_date"=)"07-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006927", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Margaret", "pi_last_name"=)"von Mehren", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74366157", "specific_funding_source"=)"National Comprehensive Cancer Network", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)10, "page"=)1, "pages"=)17, "sort"=)[["nci_id", "ASC"]], "total"=)167},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:424:in `Then I want to verify DT4 response contains the correct data for "fox_chase_list_10" parameters in the "fox_chase_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "10" records

Scenario:#19 List Fox Chase Cancer Centers DT4 report for only one record 4

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "fox_chase_list_1" parameters in the "fox_chase_dt4" json file 0s

And I want to verify items_per_page: "ad_nci_id" and response contain "1" records 0s

Scenario:#20 List the DT4 report for Abramson Cancer Center from 11/01/2016 to 01/10/2017 with ALL trial type 4

Given the "DT4" service is called by providing following criteria: 2s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "abramson_cancer_list_10" parameters in the "abramson_cancer_dt4" json file 0s

And I want to verify items_per_page: "ad_nci_id" and response contain "10" records 0s

Scenario:#21 List the DT4 report for Dana-Farber/Harvard Cancer Center from 11/01/2016 to 01/10/2017 ALL trial type 2 1 1

Given the "DT4" service is called by providing following criteria: 4s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "dana_farber_list_50" parameters in the "dana_farber_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_..."paging"=){"items_per_page"=)50, "page"=)1, "pages"=)16, "sort"=)[["nci_id", "ASC"]], "total"=)773}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_..."paging"=){"items_per_page"=)50, "page"=)1, "pages"=)16, "sort"=)[["nci_id", "ASC"]], "total"=)773}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"ABTR01B1", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00331", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"680", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCRN07", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCRN07", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00331", "nct_id"=)"NCT01117168", "official_title"=)"Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)", "open_date"=)"24-Dec-2007", "other_ids"=)"CDR0000069496", "other_protocol_ids"=)"ACCRN07, CDR0000069496", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Julie", "pi_last_name"=)"Ross", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"249603", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00334", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS02B3", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS02B3", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00334", "nct_id"=)"NCT00919750", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens", "open_date"=)"16-Feb-2004", "other_ids"=)"CDR0000352347\rCOG-ACNS02B3", "other_protocol_ids"=)"ACNS02B3, CDR0000352347, COG-ACNS02B3", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Pomeroy", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74442841", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00336", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0332", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0332", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00336", "nct_id"=)"NCT00392327", "official_title"=)"Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients", "open_date"=)"26-Mar-2007", "other_ids"=)"CDR0000511991\rCOG-ACNS0332", "other_protocol_ids"=)"ACNS0332, CDR0000511991, COG-ACNS0332", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Olson", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74409372", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"25", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00383", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"1", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE07C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE07C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00383", "nct_id"=)"NCT00772200", "official_title"=)"Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer", "open_date"=)"15-Sep-2008", "other_ids"=)"CDR0000594326\rCOG-ALTE07C1", "other_protocol_ids"=)"ALTE07C1, CDR0000594326, COG-ALTE07C1", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leanne", "pi_last_name"=)"Embry", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74447321", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"240", "center_total_rp"=)"3", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"124", "center_total_rp"=)"10", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"74", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00635", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"MA.17ICSC", "dt4_program_codes"=)"", "entire_study"=)"957", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"MA.17ICSC", "lead_org_po_id"=)"120689", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00635", "nct_id"=)"NCT00897065", "official_title"=)"Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort", "open_date"=)"29-Jun-2006", "other_ids"=)"CDR0000466578\rMGH-MA.17ICSC", "other_protocol_ids"=)"MA.17ICSC, CDR0000466578, MGH-MA.17ICSC", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Paul", "pi_last_name"=)"Goss", "pi_middle_initial"=)"E", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74459770", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00751", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0000B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0000B", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00751", "nct_id"=)"NCT00784225", "official_title"=)"Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE), Ancillary Study to SELECT", "open_date"=)"29-Jul-2010", "other_ids"=)"SWOG-S0000B\rCDR0000617778", "other_protocol_ids"=)"S0000B, SWOG-S0000B, CDR0000617778", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Frank", "pi_last_name"=)"Meyskens", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"74448410", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00926", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GE 122-008", "lead_org_po_id"=)"88518", "local_site_identifier"=)"08-111", "nci_id"=)"NCI-2009-00926", "nct_id"=)"NCT00730444", "official_title"=)"Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma", "open_date"=)"12-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jean", "pi_last_name"=)"De Serres, MD", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"282928", "specific_funding_source"=)"GE Healthcare", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00963", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"CYC682-07", "lead_org_po_id"=)"914322", "local_site_identifier"=)"08-271, CYC682-07", "nci_id"=)"NCI-2009-00963", "nct_id"=)"NCT00999401", "official_title"=)"A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors", "open_date"=)"17-Apr-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Shapiro", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"337614", "specific_funding_source"=)"Cyclacel", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7977", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"7977", "lead_org_po_id"=)"62311", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01057", "nct_id"=)"NCT00576654", "official_title"=)"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors", "open_date"=)"05-Dec-2007", "other_ids"=)"HIC1410014852\rCDR0000579642\r2007-014\rHIC 1410014852", "other_protocol_ids"=)"7977, HIC1410014852, CDR0000579642, 2007-014, HIC, 1410014852", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Patricia", "pi_last_name"=)"LoRusso", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"350511", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"MC083I", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01138", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"HOD08", "lead_org_po_id"=)"221716", "local_site_identifier"=)"09273", "nci_id"=)"NCI-2009-01138", "nct_id"=)"NCT00846742", "official_title"=)"Reduced Duration Stanford V Chemotherapy with or without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma", "open_date"=)"17-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Monika", "pi_last_name"=)"Metzger", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"351994", "specific_funding_source"=)"St. Jude Children's Research Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01775", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A8081001", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"06-068", "nci_id"=)"NCI-2009-01775", "nct_id"=)"NCT00585195", "official_title"=)"Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"5940653", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"08-007", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00088", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"32", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"55", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"04-063", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00088", "nct_id"=)"NCT00165503", "official_title"=)"A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed by Adjuvant ALIMTA/Cisplatin", "open_date"=)"07-Jan-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Sugarbaker", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Respiratory/Intrathoracic Organs", "sp_id"=)"11536720", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00094", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"06-275", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00094", "nct_id"=)"NCT00487305", "official_title"=)"A Phase I Trial of Vaccination with Lethally Irradiated Lymphoma Cells Admixed with Granulocyte-Macrophage Colony Stimulating Factor Secreting K562 Cells for the Treatment of Follicular Lymphoma", "open_date"=)"07-Jan-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Eric", "pi_last_name"=)"Jacobsen", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"11548621", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00111", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"44", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"23-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-263", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00111", "nct_id"=)"NCT01049230", "official_title"=)"Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors; Evaluation of Acute and Late Side Effects", "open_date"=)"22-Dec-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Shannon", "pi_last_name"=)"MacDonald", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"15325327", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00294", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"34", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-342", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00294", "nct_id"=)"NCT01058408", "official_title"=)"A Phase I Trial Using RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer", "open_date"=)"22-Feb-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jochen", "pi_last_name"=)"Lorch", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"21006599", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01303", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ171", "entire_study"=)"26", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-421", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01303", "nct_id"=)"NCT01066663", "official_title"=)"A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma and T-Large Granular Lymphocytic Leukemia", "open_date"=)"31-Mar-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Brown", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"56812896", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01326", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"47", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"63", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-061", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01326", "nct_id"=)"NCT01067287", "official_title"=)"Pidilizumab in Conjunction with the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation", "open_date"=)"19-Mar-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Avigan", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"58828721", "specific_funding_source"=)"National Cancer Institute Clinical Research Branch, Medivation Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01612", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"64", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ197", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-412", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01612", "nct_id"=)"NCT01096602", "official_title"=)"Dendritic Cell/AML Fusion Vaccination following chemotherapy induced remission", "open_date"=)"24-May-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jacalyn", "pi_last_name"=)"Rosenblatt", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"69513124", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01918", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"58", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-134", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01918", "nct_id"=)"NCT01228435", "official_title"=)"A Phase II Study of IPI-504, a Novel Hsp90 Inhibitor, in NSCLC Patients with ALK Translocations", "open_date"=)"19-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Lecia", "pi_last_name"=)"Sequist", "pi_middle_initial"=)"V", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"73952324", "specific_funding_source"=)"Infinity Pharmaceuticals Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01929", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"23", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"09452", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01929", "nct_id"=)"NCT01158651", "official_title"=)"A Phase II Study of RAD001 (Everolimus) For Children with Neurofibromatosis Type 1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas", "open_date"=)"19-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Kieran", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"73952564", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01930", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"52", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-042", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"09-042", "nci_id"=)"NCI-2010-01930", "nct_id"=)"NCT01071941", "official_title"=)"rRp450 - Phase I Trial in Liver Metastases and Primary Liver Tumors", "open_date"=)"19-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Kenneth", "pi_last_name"=)"Tanabe", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"73952585", "specific_funding_source"=)"National Cancer Institute Clinical Research Branch", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02211", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"263", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ171", "entire_study"=)"1450", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"10-106", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02211", "nct_id"=)"NCT01208662", "official_title"=)"A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age", "open_date"=)"27-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Paul", "pi_last_name"=)"Richardson", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74027624", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00034", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"55", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-166", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00034", "nct_id"=)"NCT01184326", "official_title"=)"An Expanded Phase I Study of Pazopanib and Everolimus in Patients with Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer", "open_date"=)"07-Dec-210", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Mark", "pi_last_name"=)"Pomerantz", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74124967", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00201", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"94", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ221", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-206", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00201", "nct_id"=)"NCT01288235", "official_title"=)"A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine, and Ototoxicity Outcomes", "open_date"=)"25-Jan-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Torunn", "pi_last_name"=)"Yock", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74167338", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00493", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-096", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00493", "nct_id"=)"NCT01294670", "official_title"=)"A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients ( 21 Years at Diagnosis With Refractory Solid Tumors", "open_date"=)"23-Mar-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Tanya", "pi_last_name"=)"Trippett", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74227055", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00774", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"55", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"64", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"10-133", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00774", "nct_id"=)"NCT01346124", "official_title"=)"Phase II Study of High Dose Beam Scanning Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine and Sacrum", "open_date"=)"18-Feb-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Thomas", "pi_last_name"=)"Delaney", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74271246", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center, Massachusetts General Hospital Cancer Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00894", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ231", "entire_study"=)"22", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-269", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00894", "nct_id"=)"NCT01600040", "official_title"=)"Pilot Study of Adjuvant Proton Beam Teletherapy for Post-hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes", "open_date"=)"05-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Karen", "pi_last_name"=)"De Amorim Bernstein", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74291723", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00896", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"39", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"39", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-241", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00896", "nct_id"=)"NCT01228448", "official_title"=)"Pilot Study of In-Room PET in Proton Radiation Therapy", "open_date"=)"15-Oct-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Helen", "pi_last_name"=)"Shih", "pi_middle_initial"=)"A", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74291866", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00899", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"25", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ171", "entire_study"=)"18", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-346", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00899", "nct_id"=)"NCT01286675", "official_title"=)"A Pilot Study to Evaluate the Effect of Eltrombopag plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation", "open_date"=)"11-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nancy", "pi_last_name"=)"Berliner", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74292204", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00912", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ434", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PMT4979g", "lead_org_po_id"=)"87945", "local_site_identifier"=)"11-010", "nci_id"=)"NCI-2011-00912", "nct_id"=)"NCT01296555", "official_title"=)"An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74293536", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00915", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"53", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"63", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-439", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"10-439", "nci_id"=)"NCI-2011-00915", "nct_id"=)"NCT01358058", "official_title"=)"Phase II Study of Proton Radiation Therapy for Low Grade and Favorable Grade 3 Gliomas", "open_date"=)"11-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Helen", "pi_last_name"=)"Shih", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74293907", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00940", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"8109-002", "lead_org_po_id"=)"69198", "local_site_identifier"=)"11-027", "nci_id"=)"NCI-2011-00940", "nct_id"=)"NCT01170650", "official_title"=)"A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer", "open_date"=)"01-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74297487", "specific_funding_source"=)"Endocyte Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00963", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"51", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"153", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"09-333", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00963", "nct_id"=)"NCT01288963", "official_title"=)"The High-Dose Aldesleukin (IL-2) \"SELECT\" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatment in Patients with Advanced Melanoma", "open_date"=)"09-Feb-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"David", "pi_last_name"=)"McDermott", "pi_middle_initial"=)"F", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"74301006", "specific_funding_source"=)"Prometheus, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ434", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398X2101", "lead_org_po_id"=)"170150", "local_site_identifier"=)"10-446", "nci_id"=)"NCI-2011-01165", "nct_id"=)"NCT01004224", "official_title"=)"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74337768", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01283", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"16-C-0009", "lead_org_po_id"=)"16108126", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01283", "nct_id"=)"NCT01295944", "official_title"=)"Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial", "open_date"=)"19-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Gilbert", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74358897", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01974", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0926", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0926", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01974", "nct_id"=)"NCT00981656", "official_title"=)"A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging", "open_date"=)"11-Nov-2009", "other_ids"=)"PRTOG-0926_A05PAMDREVW01\rCDR0000654727\r13-C-0175", "other_protocol_ids"=)"RTOG-0926, PRTOG-0926_A05PAMDREVW01, CDR0000654727, 13-C-0175", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"William", "pi_last_name"=)"Shipley", "pi_middle_initial"=)"U", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"74432754", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01975", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHEP0731", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHEP0731", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01975", "nct_id"=)"NCT00980460", "official_title"=)"Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment", "open_date"=)"14-Sep-2009", "other_ids"=)"COG-AHEP0731\rNCT02265692\rCDR0000654889", "other_protocol_ids"=)"AHEP0731, COG-AHEP0731, NCT02265692, CDR0000654889", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Howard", "pi_last_name"=)"Katzenstein", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"74432842", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02034", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-50801", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-50801", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02034", "nct_id"=)"NCT01118026", "official_title"=)"Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)", "open_date"=)"15-May-2010", "other_ids"=)"CDR0000669076", "other_protocol_ids"=)"CALGB-50801, CDR0000669076", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ann", "pi_last_name"=)"LaCasce", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"74456784", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00331", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"680", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCRN07", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCRN07", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00331", "nct_id"=)"NCT01117168", "official_title"=)"Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)", "open_date"=)"24-Dec-2007", "other_ids"=)"CDR0000069496", "other_protocol_ids"=)"ACCRN07, CDR0000069496", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Julie", "pi_last_name"=)"Ross", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"249603", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00334", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS02B3", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS02B3", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00334", "nct_id"=)"NCT00919750", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens", "open_date"=)"16-Feb-2004", "other_ids"=)"CDR0000352347\rCOG-ACNS02B3", "other_protocol_ids"=)"ACNS02B3, CDR0000352347, COG-ACNS02B3", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Pomeroy", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74442841", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00336", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0332", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0332", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00336", "nct_id"=)"NCT00392327", "official_title"=)"Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients", "open_date"=)"26-Mar-2007", "other_ids"=)"CDR0000511991\rCOG-ACNS0332", "other_protocol_ids"=)"ACNS0332, CDR0000511991, COG-ACNS0332", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Olson", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74409372", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"25", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00383", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"1", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE07C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE07C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00383", "nct_id"=)"NCT00772200", "official_title"=)"Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer", "open_date"=)"15-Sep-2008", "other_ids"=)"CDR0000594326\rCOG-ALTE07C1", "other_protocol_ids"=)"ALTE07C1, CDR0000594326, COG-ALTE07C1", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leanne", "pi_last_name"=)"Embry", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74447321", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"240", "center_total_rp"=)"3", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"124", "center_total_rp"=)"10", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"74", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00635", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"MA.17ICSC", "dt4_program_codes"=)"", "entire_study"=)"957", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"MA.17ICSC", "lead_org_po_id"=)"120689", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00635", "nct_id"=)"NCT00897065", "official_title"=)"Quantitative Protein and Gene Expression Biomarkers of Tamoxifen and Letrozole Recurrence in the NCIC CTG MA.17 Cohort", "open_date"=)"29-Jun-2006", "other_ids"=)"CDR0000466578\rMGH-MA.17ICSC", "other_protocol_ids"=)"MA.17ICSC, CDR0000466578, MGH-MA.17ICSC", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Paul", "pi_last_name"=)"Goss", "pi_middle_initial"=)"E", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74459770", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00751", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0000B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0000B", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00751", "nct_id"=)"NCT00784225", "official_title"=)"Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE), Ancillary Study to SELECT", "open_date"=)"29-Jul-2010", "other_ids"=)"SWOG-S0000B\rCDR0000617778", "other_protocol_ids"=)"S0000B, SWOG-S0000B, CDR0000617778", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Frank", "pi_last_name"=)"Meyskens", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"74448410", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00926", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GE 122-008", "lead_org_po_id"=)"88518", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00926", "nct_id"=)"NCT00730444", "official_title"=)"Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma", "open_date"=)"12-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jean", "pi_last_name"=)"De Serres, MD", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"282928", "specific_funding_source"=)"GE Healthcare", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00963", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"CYC682-07", "lead_org_po_id"=)"914322", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00963", "nct_id"=)"NCT00999401", "official_title"=)"A Phase I Study of Oral Sapacitabine and Oral Seliciclib in Patients With Advanced Solid Tumors", "open_date"=)"17-Apr-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Shapiro", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"337614", "specific_funding_source"=)"Cyclacel", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7977", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"7977", "lead_org_po_id"=)"62311", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01057", "nct_id"=)"NCT00576654", "official_title"=)"A Phase I Dose-Escalation Study of Oral ABT-888 (NSC #737664) plus Intravenous Irinotecan (CPT-11, NSC#616348) Administered in Patients with Advanced Solid Tumors", "open_date"=)"05-Dec-2007", "other_ids"=)"HIC1410014852\rCDR0000579642\r2007-014\rHIC 1410014852", "other_protocol_ids"=)"7977, HIC1410014852, CDR0000579642, 2007-014, HIC, 1410014852", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Patricia", "pi_last_name"=)"LoRusso", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"350511", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01138", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"HOD08", "lead_org_po_id"=)"221716", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01138", "nct_id"=)"NCT00846742", "official_title"=)"Reduced Duration Stanford V Chemotherapy with or without Low-Dose Tailored-Field Radiation Therapy for Favorable Risk Pediatric Hodgkin Lymphoma", "open_date"=)"17-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Monika", "pi_last_name"=)"Metzger", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"351994", "specific_funding_source"=)"St. Jude Children's Research Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01775", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A8081001", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01775", "nct_id"=)"NCT00585195", "official_title"=)"Phase 1 Safety, Pharmacokinetic And Pharmacodynamic Study Of Pf-02341066, A C-met/Hgfr Selective Tyrosine Kinase Inhibitor, Administered Orally To Patients With Advanced Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"5940653", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00088", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"32", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"55", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"04-063", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00088", "nct_id"=)"NCT00165503", "official_title"=)"A Phase II Feasibility Study of Pleurectomy/Decortication With Intraoperative Intrathoracic/Intraperitoneal Heated Cisplatin With Sodium Thiosulfate Followed by Adjuvant ALIMTA/Cisplatin", "open_date"=)"07-Jan-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Sugarbaker", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Respiratory/Intrathoracic Organs", "sp_id"=)"11536720", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00094", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"06-275", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00094", "nct_id"=)"NCT00487305", "official_title"=)"A Phase I Trial of Vaccination with Lethally Irradiated Lymphoma Cells Admixed with Granulocyte-Macrophage Colony Stimulating Factor Secreting K562 Cells for the Treatment of Follicular Lymphoma", "open_date"=)"07-Jan-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Eric", "pi_last_name"=)"Jacobsen", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"11548621", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00111", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"44", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"23-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-263", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00111", "nct_id"=)"NCT01049230", "official_title"=)"Phase II Study of Proton Radiation Therapy for CNS Germ Cell Tumors; Evaluation of Acute and Late Side Effects", "open_date"=)"22-Dec-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Shannon", "pi_last_name"=)"MacDonald", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"15325327", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00294", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"34", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-342", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00294", "nct_id"=)"NCT01058408", "official_title"=)"A Phase I Trial Using RAD001 With Weekly Cisplatin and Radiation Therapy in Patients With Locally Advanced Head and Neck Cancer", "open_date"=)"22-Feb-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jochen", "pi_last_name"=)"Lorch", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"21006599", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01303", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ171", "entire_study"=)"26", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-421", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01303", "nct_id"=)"NCT01066663", "official_title"=)"A Phase I/II Study of Pyrimethamine, a STAT3 Inhibitor, for the Treatment of Relapsed Chronic Lymphocytic Leukemia / Small Lymphocytic Lymphoma and T-Large Granular Lymphocytic Leukemia", "open_date"=)"31-Mar-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Brown", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"56812896", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01326", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"47", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"63", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-061", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01326", "nct_id"=)"NCT01067287", "official_title"=)"Pidilizumab in Conjunction with the Dendritic Cell/Myeloma Vaccines Following Stem Cell Transplantation", "open_date"=)"19-Mar-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Avigan", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"58828721", "specific_funding_source"=)"National Cancer Institute Clinical Research Branch, Medivation Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01612", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"64", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ197", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-412", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01612", "nct_id"=)"NCT01096602", "official_title"=)"Dendritic Cell/AML Fusion Vaccination following chemotherapy induced remission", "open_date"=)"24-May-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jacalyn", "pi_last_name"=)"Rosenblatt", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"69513124", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01918", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"58", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-134", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01918", "nct_id"=)"NCT01228435", "official_title"=)"A Phase II Study of IPI-504, a Novel Hsp90 Inhibitor, in NSCLC Patients with ALK Translocations", "open_date"=)"19-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Lecia", "pi_last_name"=)"Sequist", "pi_middle_initial"=)"V", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"73952324", "specific_funding_source"=)"Infinity Pharmaceuticals Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01929", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"23", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"09452", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01929", "nct_id"=)"NCT01158651", "official_title"=)"A Phase II Study of RAD001 (Everolimus) For Children with Neurofibromatosis Type 1 and Chemotherapy-Refractory Radiographic Progressive Low-Grade Gliomas", "open_date"=)"19-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Kieran", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"73952564", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01930", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"52", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"09-042", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01930", "nct_id"=)"NCT01071941", "official_title"=)"rRp450 - Phase I Trial in Liver Metastases and Primary Liver Tumors", "open_date"=)"19-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Kenneth", "pi_last_name"=)"Tanabe", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"73952585", "specific_funding_source"=)"National Cancer Institute Clinical Research Branch", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02211", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"263", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ171", "entire_study"=)"1450", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"10-106", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02211", "nct_id"=)"NCT01208662", "official_title"=)"A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age", "open_date"=)"27-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Paul", "pi_last_name"=)"Richardson", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74027624", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00034", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"55", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-166", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00034", "nct_id"=)"NCT01184326", "official_title"=)"An Expanded Phase I Study of Pazopanib and Everolimus in Patients with Advanced Solid Tumors and Previously Treated Advanced Urothelial Cancer", "open_date"=)"07-Dec-210", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Mark", "pi_last_name"=)"Pomerantz", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74124967", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00201", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"94", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ221", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-206", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00201", "nct_id"=)"NCT01288235", "official_title"=)"A Phase II Study of Proton Radiotherapy for Pediatric Brain Tumors Requiring Partial Brain Irradiation: An Assessment of Long Term Neurocognitive, Neuroendocrine, and Ototoxicity Outcomes", "open_date"=)"25-Jan-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Torunn", "pi_last_name"=)"Yock", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74167338", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00493", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-096", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00493", "nct_id"=)"NCT01294670", "official_title"=)"A Phase I/II Clinical Study of Vorinostat in Combination With Etoposide in Pediatric Patients ( 21 Years at Diagnosis With Refractory Solid Tumors", "open_date"=)"23-Mar-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Tanya", "pi_last_name"=)"Trippett", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74227055", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00774", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"55", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"64", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"10-133", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00774", "nct_id"=)"NCT01346124", "official_title"=)"Phase II Study of High Dose Beam Scanning Proton Radiation Treatment +/- Surgical Resection of Sarcomas of the Spine and Sacrum", "open_date"=)"18-Feb-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Thomas", "pi_last_name"=)"Delaney", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74271246", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center, Massachusetts General Hospital Cancer Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00894", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ231", "entire_study"=)"22", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-269", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00894", "nct_id"=)"NCT01600040", "official_title"=)"Pilot Study of Adjuvant Proton Beam Teletherapy for Post-hysterectomy Cancers of the Uterus and Cervix with Metastases to Regional Lymph Nodes", "open_date"=)"05-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Karen", "pi_last_name"=)"De Amorim Bernstein", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74291723", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00896", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"39", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"39", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-241", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00896", "nct_id"=)"NCT01228448", "official_title"=)"Pilot Study of In-Room PET in Proton Radiation Therapy", "open_date"=)"15-Oct-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Helen", "pi_last_name"=)"Shih", "pi_middle_initial"=)"A", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74291866", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00899", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"25", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ171", "entire_study"=)"18", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-346", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00899", "nct_id"=)"NCT01286675", "official_title"=)"A Pilot Study to Evaluate the Effect of Eltrombopag plus G-CSF on Human CD34+ Cell Mobilization and Ex Vivo Colony Proliferative Capacity in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation", "open_date"=)"11-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nancy", "pi_last_name"=)"Berliner", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74292204", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00912", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ434", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PMT4979g", "lead_org_po_id"=)"87945", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00912", "nct_id"=)"NCT01296555", "official_title"=)"An Open-Label, Phase I/II, Dose-Escalation Study Evaluating the Safety and Tolerability of GDC-0032 in Patients With Locally Advanced or Metastatic Solid Tumors or Non-Hodgkin's Lymphoma and in Combination With Endocrine Therapy in Patients With Locally Advanced or Metastatic Hormone Receptor-Positive Breast Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74293536", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00915", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"53", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"63", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"10-439", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00915", "nct_id"=)"NCT01358058", "official_title"=)"Phase II Study of Proton Radiation Therapy for Low Grade and Favorable Grade 3 Gliomas", "open_date"=)"11-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Helen", "pi_last_name"=)"Shih", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74293907", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00940", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"8109-002", "lead_org_po_id"=)"69198", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00940", "nct_id"=)"NCT01170650", "official_title"=)"A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer", "open_date"=)"01-May-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74297487", "specific_funding_source"=)"Endocyte Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00963", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"51", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"153", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"09-333", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00963", "nct_id"=)"NCT01288963", "official_title"=)"The High-Dose Aldesleukin (IL-2) \"SELECT\" Trial: A Prospective Tissue Collection Protocol to Investigate Predictive Models of Response to High-Dose IL-2 Treatment in Patients with Advanced Melanoma", "open_date"=)"09-Feb-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"David", "pi_last_name"=)"McDermott", "pi_middle_initial"=)"F", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"74301006", "specific_funding_source"=)"Prometheus, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ434", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398X2101", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01165", "nct_id"=)"NCT01004224", "official_title"=)"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74337768", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01283", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"16-C-0009", "lead_org_po_id"=)"16108126", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01283", "nct_id"=)"NCT01295944", "official_title"=)"Phase II Trial of Carboplatin and Bevacizumab for the Treatment of Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma in Adults: A Multi-Center Trial", "open_date"=)"19-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Gilbert", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74358897", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01974", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0926", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0926", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01974", "nct_id"=)"NCT00981656", "official_title"=)"A Phase II Protocol for Patients with Stage T1 Bladder Cancer to Evaluate Selective Bladder Preserving Treatment by Radiation Therapy Concurrent with Radiosensitizing Chemotherapy following a Thorough Transurethral Surgical Re-staging", "open_date"=)"11-Nov-2009", "other_ids"=)"PRTOG-0926_A05PAMDREVW01\rCDR0000654727\r13-C-0175", "other_protocol_ids"=)"RTOG-0926, PRTOG-0926_A05PAMDREVW01, CDR0000654727, 13-C-0175", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"William", "pi_last_name"=)"Shipley", "pi_middle_initial"=)"U", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"74432754", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01975", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHEP0731", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHEP0731", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01975", "nct_id"=)"NCT00980460", "official_title"=)"Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment", "open_date"=)"14-Sep-2009", "other_ids"=)"COG-AHEP0731\rNCT02265692\rCDR0000654889", "other_protocol_ids"=)"AHEP0731, COG-AHEP0731, NCT02265692, CDR0000654889", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Howard", "pi_last_name"=)"Katzenstein", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"74432842", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA006516", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02034", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-50801", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-50801", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02034", "nct_id"=)"NCT01118026", "official_title"=)"Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)", "open_date"=)"15-May-2010", "other_ids"=)"CDR0000669076", "other_protocol_ids"=)"CALGB-50801, CDR0000669076", "p30grant"=)"CA006516", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ann", "pi_last_name"=)"LaCasce", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"74456784", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)50, "page"=)1, "pages"=)16, "sort"=)[["nci_id", "ASC"]], "total"=)773},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:451:in `Then I want to verify DT4 response contains the correct data for "dana_farber_list_50" parameters in the "dana_farber_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "50" records

Scenario:#22 List the DT4 report for Harold C. Simmons Comprehensive Cancer Center from 11/01/2016 to 01/10/2017 with Interventional trials 2 1 1

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "harlod_simmons_list_30" parameters in the "harlod_simmons_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00335", "affiliate_total"=)"0", "affiliate_..."paging"=){"items_per_page"=)30, "page"=)1, "pages"=)11, "sort"=)[["nct_id", "ASC"]], "total"=)322}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00335", "affiliate_total"=)"0", "affiliate_..."paging"=){"items_per_page"=)30, "page"=)1, "pages"=)11, "sort"=)[["nct_id", "ASC"]], "total"=)322}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00335", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00335", "nct_id"=)"NCT00085735", "official_title"=)"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial", "open_date"=)"12-Apr-2004", "other_ids"=)"CDR0000365506\rCOG-ACNS0331", "other_protocol_ids"=)"ACNS0331, CDR0000365506, COG-ACNS0331", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeff", "pi_last_name"=)"Michalski", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74397976", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00421", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ARET0321", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ARET0321", "lead_org_po_id"=)"60948", "local_site_identifier"=)"ARET0321", "nci_id"=)"NCI-2009-00421", "nct_id"=)"NCT00554788", "official_title"=)"A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000573987\rCOG-ARET0321", "other_protocol_ids"=)"ARET0321, CDR0000573987, COG-ARET0321", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ira", "pi_last_name"=)"Dunkel", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"74415420", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00478", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"V0706", "lead_org_po_id"=)"34801235", "local_site_identifier"=)"SCCC-10Y14", "nci_id"=)"NCI-2014-00478", "nct_id"=)"NCT00601003", "official_title"=)"A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.", "open_date"=)"24-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"136371490", "specific_funding_source"=)"Giselle Sholler", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01193", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"32", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"19-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SJYC07", "lead_org_po_id"=)"221716", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01193", "nct_id"=)"NCT00602667", "official_title"=)"Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma", "open_date"=)"27-Nov-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amar", "pi_last_name"=)"Gajjar", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74340435", "specific_funding_source"=)"St. Jude Children's Research Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00420", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"FDA IND 100712", "lead_org_po_id"=)"35276075", "local_site_identifier"=)"032013-027", "nci_id"=)"NCI-2014-00420", "nct_id"=)"NCT00611208", "official_title"=)"A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma", "open_date"=)"01-Jan-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"135855638", "specific_funding_source"=)"Angimmune LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02070", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0834", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0834", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02070", "nct_id"=)"NCT00626990", "official_title"=)"Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial", "open_date"=)"22-Jul-2009", "other_ids"=)"CAN-NCIC-CEC1\rCDR0000582632\rMRC-BR14\rCOGNO-EORTC-26053\rEUDRACT-2006-001533-17\rEORTC-26053\rEORTC-22054\rMERCK-EORTC-26053", "other_protocol_ids"=)"RTOG-0834, CAN-NCIC-CEC1, CDR0000582632, MRC-BR14, COGNO-EORTC-26053, EUDRACT-2006-001533-17, EORTC-26053, EORTC-22054, MERCK-EORTC-26053", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Michael", "pi_last_name"=)"Vogelbaum", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74440923", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00532", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2607", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2607", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"E2607", "nci_id"=)"NCI-2009-00532", "nct_id"=)"NCT00700882", "official_title"=)"A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas", "open_date"=)"16-Nov-2011", "other_ids"=)"CDR0000598300", "other_protocol_ids"=)"E2607, CDR0000598300", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Donald", "pi_last_name"=)"Lawrence", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74421576", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00764", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"H-23409", "lead_org_po_id"=)"227546", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00764", "nct_id"=)"NCT00831480", "official_title"=)"NEOADJUVANT EVEROLIMUS ( RAD001) FOR ADVANCED RCC BEFORE CYTOREDUCTIVE NEPHRECTOMY, WITH CORRELATIVE TUMOR STUDIES", "open_date"=)"03-Jun-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Gilad", "pi_last_name"=)"Amiel", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"91786209", "specific_funding_source"=)"Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01674", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"47", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"42", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"STU 072010-134", "lead_org_po_id"=)"226789", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01674", "nct_id"=)"NCT00855803", "official_title"=)"Phase II Study of Stereotactic Body Radiation Therapy and Vertebroplasty for Localized Spinal Metastasis", "open_date"=)"23-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Robert", "pi_last_name"=)"Timmerman", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"205089279", "specific_funding_source"=)"UT Southwestern/Simmons Cancer Center-Dallas", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01915", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N0577", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N0577", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01915", "nct_id"=)"NCT00887146", "official_title"=)"CODEL: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma", "open_date"=)"22-Sep-2009", "other_ids"=)"NCCTG-N0577\rEudraCT-2008-007295-14\rEORTC-26081-22086\rCDR0000640442", "other_protocol_ids"=)"N0577, NCCTG-N0577, EudraCT-2008-007295-14, EORTC-26081-22086, CDR0000640442", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kurt", "pi_last_name"=)"Jaeckle", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74426926", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01687", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0631", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0631", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01687", "nct_id"=)"NCT00922974", "official_title"=)"Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis", "open_date"=)"07-Aug-2009", "other_ids"=)"CDR0000646803", "other_protocol_ids"=)"RTOG-0631, CDR0000646803", "p30grant"=)"CA142543", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Samuel", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74428054", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01948", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"31", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0815", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0815", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"RTOG 0815", "nci_id"=)"NCI-2011-01948", "nct_id"=)"NCT00936390", "official_title"=)"A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer", "open_date"=)"14-Sep-2009", "other_ids"=)"CDR0000648194", "other_protocol_ids"=)"RTOG-0815, CDR0000648194", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alvaro", "pi_last_name"=)"Martinez", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74430433", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01953", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN0534", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN0534", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01953", "nct_id"=)"NCT00945009", "official_title"=)"Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor", "open_date"=)"13-Jul-2009", "other_ids"=)"CDR0000649716", "other_protocol_ids"=)"AREN0534, CDR0000649716", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Peter", "pi_last_name"=)"Ehrlich", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74430903", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01971", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3F05", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3F05", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01971", "nct_id"=)"NCT00978458", "official_title"=)"Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas", "open_date"=)"11-Sep-2009", "other_ids"=)"ECOG-E3F05\rCDR0000654697", "other_protocol_ids"=)"E3F05, ECOG-E3F05, CDR0000654697", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Schiff", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74432502", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01973", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0724", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0724/GOG-0724", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01973", "nct_id"=)"NCT00980954", "official_title"=)"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy", "open_date"=)"15-Sep-2014", "other_ids"=)"GOG-0724\rCDR0000654709", "other_protocol_ids"=)"RTOG-0724, GOG-0724, CDR0000654709", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuja", "pi_last_name"=)"Jhingran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74432640", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02779", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"T2008-002", "lead_org_po_id"=)"25451649", "local_site_identifier"=)"SCCC-09914", "nci_id"=)"NCI-2011-02779", "nct_id"=)"NCT00981799", "official_title"=)"A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74900811", "specific_funding_source"=)"Therapeutic Advances in Childhood Leukemia Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01972", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACRIN-6685", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACRIN 6685", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01972", "nct_id"=)"NCT00983697", "official_title"=)"A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients", "open_date"=)"01-Apr-2010", "other_ids"=)"CDR0000654703\rCA80098", "other_protocol_ids"=)"ACRIN-6685, CDR0000654703, CA80098", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Val", "pi_last_name"=)"Lowe", "pi_middle_initial"=)"J", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74457401", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Neogenix 0901", "lead_org_po_id"=)"49385246", "local_site_identifier"=)"SCCC-04212", "nci_id"=)"NCI-2012-01393", "nct_id"=)"NCT01040000", "official_title"=)"A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"97619580", "specific_funding_source"=)"Precision Biologics, Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00014", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"097517", "lead_org_po_id"=)"39584846", "local_site_identifier"=)"SCCC-04110", "nci_id"=)"NCI-2015-00014", "nct_id"=)"NCT01042379", "official_title"=)"I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)", "open_date"=)"06-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"175560683", "specific_funding_source"=)"QuantumLeap Healthcare Collaborative", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02000", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0264", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0264", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02000", "nct_id"=)"NCT01042522", "official_title"=)"A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary", "open_date"=)"08-Feb-2010", "other_ids"=)"CDR0000662814", "other_protocol_ids"=)"GOG-0264, CDR0000662814", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jubilee", "pi_last_name"=)"Brown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"74434968", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E7208", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7208", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02018", "nct_id"=)"NCT01079780", "official_title"=)"A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-Ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy", "open_date"=)"08-Oct-2010", "other_ids"=)"CDR0000666736\rECOG-E7208", "other_protocol_ids"=)"E7208, CDR0000666736, ECOG-E7208", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Howard", "pi_last_name"=)"Hochster", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74436423", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00915", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9177", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9177", "lead_org_po_id"=)"16108126", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00915", "nct_id"=)"NCT01092182", "official_title"=)"Phase II Study of  Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma, and Plasmablastic Lymphoma", "open_date"=)"13-Apr-2012", "other_ids"=)"100052\rCDR0000669336\r10-C-0052", "other_protocol_ids"=)"9177, 100052, CDR0000669336, 10-C-0052", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Roschewski", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"116301985", "specific_funding_source"=)"NCI - Center for Cancer Research", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0263", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0263", "lead_org_po_id"=)"88642", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02037", "nct_id"=)"NCT01101451", "official_title"=)"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy", "open_date"=)"12-Apr-2010", "other_ids"=)"CDR0000670125", "other_protocol_ids"=)"GOG-0263, CDR0000670125", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sang", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74437876", "specific_funding_source"=)"Gynecologic Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00793", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E5508", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E5508", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00793", "nct_id"=)"NCT01107626", "official_title"=)"Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-squamous NSCLC", "open_date"=)"12-Aug-2010", "other_ids"=)"ECOG-E5508\rPE5508_A10PAMDREVW01\rCDR0000666482", "other_protocol_ids"=)"E5508, ECOG-E5508, PE5508_A10PAMDREVW01, CDR0000666482", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Suresh", "pi_last_name"=)"Ramalingam", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74436393", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02050", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"20-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80702", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80702", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02050", "nct_id"=)"NCT01150045", "official_title"=)"A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer", "open_date"=)"22-Jun-2010", "other_ids"=)"CALGB/SWOG C80702\rCDR0000675693\rCALGB-SWOG C80702\rCALGB 80702", "other_protocol_ids"=)"CALGB-80702, CALGB/SWOG, C80702, CDR0000675693, CALGB-SWOG, C80702, CALGB, 80702", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Meyerhardt", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Colon", "sp_id"=)"74438921", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00335", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00335", "nct_id"=)"NCT00085735", "official_title"=)"A Study Evaluating Limited Target Volume Boost Irradiation and Reduced Dose Craniospinal Radiotherapy (18.00 Gy) and Chemotherapy in Children with Newly Diagnosed Standard Risk Medulloblastoma: A Phase III Double Randomized Trial", "open_date"=)"12-Apr-2004", "other_ids"=)"CDR0000365506\rCOG-ACNS0331", "other_protocol_ids"=)"ACNS0331, CDR0000365506, COG-ACNS0331", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeff", "pi_last_name"=)"Michalski", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74397976", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00421", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ARET0321", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ARET0321", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00421", "nct_id"=)"NCT00554788", "official_title"=)"A Trial of Intensive Multi-Modality Therapy for Extra-Ocular Retinoblastoma", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000573987\rCOG-ARET0321", "other_protocol_ids"=)"ARET0321, CDR0000573987, COG-ARET0321", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ira", "pi_last_name"=)"Dunkel", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"74415420", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00478", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"V0706", "lead_org_po_id"=)"34801235", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00478", "nct_id"=)"NCT00601003", "official_title"=)"A Phase II Trial of Nifurtimox for Refractory or Relapsed Neuroblastoma or Medulloblastoma.", "open_date"=)"24-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"136371490", "specific_funding_source"=)"Giselle Sholler", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01193", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"32", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"19-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SJYC07", "lead_org_po_id"=)"221716", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01193", "nct_id"=)"NCT00602667", "official_title"=)"Risk-Adapted Therapy for Young Children with Embryonal Brain Tumors, High-Grade Glioma, Choroid Plexus Carcinoma or Ependymoma", "open_date"=)"27-Nov-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amar", "pi_last_name"=)"Gajjar", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74340435", "specific_funding_source"=)"St. Jude Children's Research Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00420", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"FDA IND 100712", "lead_org_po_id"=)"35276075", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00420", "nct_id"=)"NCT00611208", "official_title"=)"A Phase II Study of A-dmDT390-bisFv(UCHT1) Fusion Protein in Patients With Cutaneous T Cell Lymphoma", "open_date"=)"01-Jan-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"135855638", "specific_funding_source"=)"Angimmune LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02070", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0834", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0834", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02070", "nct_id"=)"NCT00626990", "official_title"=)"Phase III Trial on Concurrent and Adjuvant Temozolomide Chemotherapy in Non-1p/19q Deleted Anaplastic Glioma: The CATNON Intergroup Trial", "open_date"=)"22-Jul-2009", "other_ids"=)"CAN-NCIC-CEC1\rCDR0000582632\rMRC-BR14\rCOGNO-EORTC-26053\rEUDRACT-2006-001533-17\rEORTC-26053\rEORTC-22054\rMERCK-EORTC-26053", "other_protocol_ids"=)"RTOG-0834, CAN-NCIC-CEC1, CDR0000582632, MRC-BR14, COGNO-EORTC-26053, EUDRACT-2006-001533-17, EORTC-26053, EORTC-22054, MERCK-EORTC-26053", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Michael", "pi_last_name"=)"Vogelbaum", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74440923", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00532", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2607", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2607", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00532", "nct_id"=)"NCT00700882", "official_title"=)"A Phase II Trial of Dasatinib in KIT-Positive Patients with Unresectable Locally Advanced or Stage IV Mucosal, Acral and Vulvovaginal Melanomas", "open_date"=)"16-Nov-2011", "other_ids"=)"CDR0000598300", "other_protocol_ids"=)"E2607, CDR0000598300", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Donald", "pi_last_name"=)"Lawrence", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74421576", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00764", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"H-23409", "lead_org_po_id"=)"227546", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00764", "nct_id"=)"NCT00831480", "official_title"=)"NEOADJUVANT EVEROLIMUS ( RAD001) FOR ADVANCED RCC BEFORE CYTOREDUCTIVE NEPHRECTOMY, WITH CORRELATIVE TUMOR STUDIES", "open_date"=)"03-Jun-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Gilad", "pi_last_name"=)"Amiel", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"91786209", "specific_funding_source"=)"Baylor College of Medicine/Dan L Duncan Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01674", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"47", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"42", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"STU 072010-134", "lead_org_po_id"=)"226789", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01674", "nct_id"=)"NCT00855803", "official_title"=)"Phase II Study of Stereotactic Body Radiation Therapy and Vertebroplasty for Localized Spinal Metastasis", "open_date"=)"23-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Robert", "pi_last_name"=)"Timmerman", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"205089279", "specific_funding_source"=)"UT Southwestern/Simmons Cancer Center-Dallas", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01915", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N0577", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N0577", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01915", "nct_id"=)"NCT00887146", "official_title"=)"CODEL: Phase III Intergroup Study of Radiotherapy with Concomitant and Adjuvant Temozolomide versus Radiotherapy with Adjuvant PCV Chemotherapy in Patients with 1p/19q Co-deleted Anaplastic Glioma or Low Grade Glioma", "open_date"=)"22-Sep-2009", "other_ids"=)"NCCTG-N0577\rEudraCT-2008-007295-14\rEORTC-26081-22086\rCDR0000640442", "other_protocol_ids"=)"N0577, NCCTG-N0577, EudraCT-2008-007295-14, EORTC-26081-22086, CDR0000640442", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kurt", "pi_last_name"=)"Jaeckle", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74426926", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01687", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0631", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0631", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01687", "nct_id"=)"NCT00922974", "official_title"=)"Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis", "open_date"=)"07-Aug-2009", "other_ids"=)"CDR0000646803", "other_protocol_ids"=)"RTOG-0631, CDR0000646803", "p30grant"=)"CA142543", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Samuel", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74428054", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01948", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"31", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0815", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0815", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01948", "nct_id"=)"NCT00936390", "official_title"=)"A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer", "open_date"=)"14-Sep-2009", "other_ids"=)"CDR0000648194", "other_protocol_ids"=)"RTOG-0815, CDR0000648194", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alvaro", "pi_last_name"=)"Martinez", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74430433", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01953", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN0534", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN0534", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01953", "nct_id"=)"NCT00945009", "official_title"=)"Treatment for Patients with Bilateral, Multicentric, or Bilaterally-Predisposed Unilateral Wilms Tumor", "open_date"=)"13-Jul-2009", "other_ids"=)"CDR0000649716", "other_protocol_ids"=)"AREN0534, CDR0000649716", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Peter", "pi_last_name"=)"Ehrlich", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74430903", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01971", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3F05", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3F05", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01971", "nct_id"=)"NCT00978458", "official_title"=)"Phase III Study of Radiation Therapy with or without Temozolomide for Symptomatic or Progressive Low-Grade Gliomas", "open_date"=)"11-Sep-2009", "other_ids"=)"ECOG-E3F05\rCDR0000654697", "other_protocol_ids"=)"E3F05, ECOG-E3F05, CDR0000654697", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Schiff", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74432502", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01973", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0724", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0724/GOG-0724", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01973", "nct_id"=)"NCT00980954", "official_title"=)"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy", "open_date"=)"15-Sep-2014", "other_ids"=)"GOG-0724\rCDR0000654709", "other_protocol_ids"=)"RTOG-0724, GOG-0724, CDR0000654709", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuja", "pi_last_name"=)"Jhingran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74432640", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02779", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"T2008-002", "lead_org_po_id"=)"25451649", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02779", "nct_id"=)"NCT00981799", "official_title"=)"A Phase I Trial of NECTAR (Nelarabine, Etoposide and Cyclophosphamide in T-ALL Relapse): A Joint Study of TACL and POETIC", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74900811", "specific_funding_source"=)"Therapeutic Advances in Childhood Leukemia Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01972", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACRIN-6685", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACRIN 6685", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01972", "nct_id"=)"NCT00983697", "official_title"=)"A Multicenter Trial of FDG-PET/CT Staging of Head and Neck Cancer and Its Impact on the N0 Neck Surgical Treatment in Head and Neck Cancer Patients", "open_date"=)"01-Apr-2010", "other_ids"=)"CDR0000654703\rCA80098", "other_protocol_ids"=)"ACRIN-6685, CDR0000654703, CA80098", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Val", "pi_last_name"=)"Lowe", "pi_middle_initial"=)"J", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74457401", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Neogenix 0901", "lead_org_po_id"=)"49385246", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01393", "nct_id"=)"NCT01040000", "official_title"=)"A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"97619580", "specific_funding_source"=)"Precision Biologics, Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00014", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"097517", "lead_org_po_id"=)"39584846", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00014", "nct_id"=)"NCT01042379", "official_title"=)"I-SPY 2 Trial (Investigation of Serial Studies to Predict Your Therapeutic Response With Imaging And moLecular Analysis 2)", "open_date"=)"06-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"175560683", "specific_funding_source"=)"QuantumLeap Healthcare Collaborative", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02000", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0264", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0264", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02000", "nct_id"=)"NCT01042522", "official_title"=)"A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary", "open_date"=)"08-Feb-2010", "other_ids"=)"CDR0000662814", "other_protocol_ids"=)"GOG-0264, CDR0000662814", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jubilee", "pi_last_name"=)"Brown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"74434968", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E7208", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7208", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02018", "nct_id"=)"NCT01079780", "official_title"=)"A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-Ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy", "open_date"=)"08-Oct-2010", "other_ids"=)"CDR0000666736\rECOG-E7208", "other_protocol_ids"=)"E7208, CDR0000666736, ECOG-E7208", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Howard", "pi_last_name"=)"Hochster", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74436423", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00915", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9177", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9177", "lead_org_po_id"=)"16108126", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00915", "nct_id"=)"NCT01092182", "official_title"=)"Phase II Study of  Dose-Adjusted EPOCH +/- Rituximab in Adults with Untreated Burkitt Lymphoma, C-Myc Positive Diffuse Large B-Cell Lymphoma, and Plasmablastic Lymphoma", "open_date"=)"13-Apr-2012", "other_ids"=)"100052\rCDR0000669336\r10-C-0052", "other_protocol_ids"=)"9177, 100052, CDR0000669336, 10-C-0052", "p30grant"=)"CA142543", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Roschewski", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"116301985", "specific_funding_source"=)"NCI - Center for Cancer Research", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0263", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0263", "lead_org_po_id"=)"88642", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02037", "nct_id"=)"NCT01101451", "official_title"=)"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy", "open_date"=)"12-Apr-2010", "other_ids"=)"CDR0000670125", "other_protocol_ids"=)"GOG-0263, CDR0000670125", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sang", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74437876", "specific_funding_source"=)"Gynecologic Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00793", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E5508", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E5508", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00793", "nct_id"=)"NCT01107626", "official_title"=)"Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-squamous NSCLC", "open_date"=)"12-Aug-2010", "other_ids"=)"ECOG-E5508\rPE5508_A10PAMDREVW01\rCDR0000666482", "other_protocol_ids"=)"E5508, ECOG-E5508, PE5508_A10PAMDREVW01, CDR0000666482", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Suresh", "pi_last_name"=)"Ramalingam", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74436393", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02050", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"20-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80702", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80702", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02050", "nct_id"=)"NCT01150045", "official_title"=)"A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer", "open_date"=)"22-Jun-2010", "other_ids"=)"CALGB/SWOG C80702\rCDR0000675693\rCALGB-SWOG C80702\rCALGB 80702", "other_protocol_ids"=)"CALGB-80702, CALGB/SWOG, C80702, CDR0000675693, CALGB-SWOG, C80702, CALGB, 80702", "p30grant"=)"CA142543", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Meyerhardt", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Colon", "sp_id"=)"74438921", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)30, "page"=)1, "pages"=)11, "sort"=)[["nct_id", "ASC"]], "total"=)322},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:460:in `Then I want to verify DT4 response contains the correct data for "harlod_simmons_list_30" parameters in the "harlod_simmons_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "30" records

Scenario:#23 List the Interventional trial type DT4 report for Albert Einstein Cancer Center 2 1 1

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "albert_einstein_list_20" parameters in the "albert_einstein_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2014-01579", "affiliate_total"=)"0", "affiliate_...paging"=){"items_per_page"=)20, "page"=)1, "pages"=)2, "sort"=)[["open_date", "ASC"]], "total"=)33}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2014-01579", "affiliate_total"=)"0", "affiliate_...paging"=){"items_per_page"=)20, "page"=)1, "pages"=)2, "sort"=)[["open_date", "ASC"]], "total"=)33}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2014-01579", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"279", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Oct-2014", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"250", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"CCI# 00-7", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01579", "nct_id"=)"NCT00179348", "official_title"=)"Evaluation of a Yoga-Based Cancer Rehabilitation Program", "open_date"=)"28-Feb-2001", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Alyson", "pi_last_name"=)"Moadel", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"150638870", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00226", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Apr-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ414", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"01-09-227", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00226", "nct_id"=)"NCT00231868", "official_title"=)"A Pilot Phase II Trial of Radiation Therapy \"Sandwiched\" between Paclitaxel and Carboplatin in Patients with Uterine Papillary Serous Carcinoma", "open_date"=)"14-Dec-2001", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Einstein", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"88659021", "specific_funding_source"=)"National Cancer Institute Clinical Research Branch", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01773", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"18", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"03-02-040", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01773", "nct_id"=)"NCT00231842", "official_title"=)"A Pilot Phase II Trial of Adjuvant Radiation Therapy \"Sandwiched\" between Ifosfamide in Patients with Mixed Mesodermal Tumors", "open_date"=)"14-Mar-2003", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Einstein", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"122901519", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00108", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"17-May-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"6981", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"0501007709", "lead_org_po_id"=)"171351", "local_site_identifier"=)"0501007709", "nci_id"=)"NCI-2009-00108", "nct_id"=)"NCT00121251", "official_title"=)"A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma", "open_date"=)"19-Apr-2005", "other_ids"=)"CDR0000434851", "other_protocol_ids"=)"6981, CDR0000434851", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Scott", "pi_last_name"=)"Tagawa", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"246255", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03352", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-Dec-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"05-001", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03352", "nct_id"=)"NCT00400946", "official_title"=)"Treatment of Acute Lymphoblastic Leukemia in Children", "open_date"=)"22-Apr-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Lewis", "pi_last_name"=)"Silverman", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"76516022", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00140", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Dec-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7229", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"0504007857", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00140", "nct_id"=)"NCT00182767", "official_title"=)"A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients with Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated with a Platinum and a Taxane", "open_date"=)"01-Jan-2006", "other_ids"=)"CDR0000441122", "other_protocol_ids"=)"7229, CDR0000441122", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Ellen", "pi_last_name"=)"Chuang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"246764", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00053", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Oct-2009", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"6317", "dt4_program_codes"=)"", "entire_study"=)"52", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"NYU 03-67", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00053", "nct_id"=)"NCT00313612", "official_title"=)"A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan as Chemotherapy for Patients with Previously Treated Ovarian Cancer", "open_date"=)"24-Jan-2006", "other_ids"=)"CDR0000467190", "other_protocol_ids"=)"6317, CDR0000467190", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Amy", "pi_last_name"=)"Tiersten", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"245380", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01128", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Jun-2012", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"82", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"05-10-277", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01128", "nct_id"=)"NCT00950365", "official_title"=)"A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients with Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)", "open_date"=)"10-Apr-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Roman", "pi_last_name"=)"Perez-Soler", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"118070173", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00475", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jul-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"Onconova 04-03", "lead_org_po_id"=)"192840", "local_site_identifier"=)"20-05-659", "nci_id"=)"NCI-2012-00475", "nct_id"=)"NCT01538563", "official_title"=)"Phase I Dose Escalation Study of ON 01910.Na by 24 Hour Continuous Infusion Per Week in Patients With Advanced Cancer", "open_date"=)"01-Jun-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"89994204", "specific_funding_source"=)"Onconova Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01519", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"164", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"06-08-367", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01519", "nct_id"=)"NCT00726934", "official_title"=)"Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients", "open_date"=)"11-Aug-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Gill", "pi_middle_initial"=)"B", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"149736279", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00503", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1104", "dt4_program_codes"=)"", "entire_study"=)"41", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"E1104", "lead_org_po_id"=)"68593", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00503", "nct_id"=)"NCT00258349", "official_title"=)"A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer", "open_date"=)"23-Aug-2006", "other_ids"=)"CDR0000449963", "other_protocol_ids"=)"E1104, CDR0000449963", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Ramona", "pi_last_name"=)"Swaby", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"252109", "specific_funding_source"=)"Eastern Cooperative Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01439", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Dec-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OSI-774-302", "lead_org_po_id"=)"192932", "local_site_identifier"=)"06-12-496", "nci_id"=)"NCI-2009-01439", "nct_id"=)"NCT00373425", "official_title"=)"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors", "open_date"=)"07-Sep-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"unknown", "pi_last_name"=)"unknown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"493451", "specific_funding_source"=)"OSI Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00471", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7389-A001-104", "lead_org_po_id"=)"68715", "local_site_identifier"=)"06-12-488", "nci_id"=)"NCI-2012-00471", "nct_id"=)"NCT00268905", "official_title"=)"A Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors", "open_date"=)"01-Oct-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"89989931", "specific_funding_source"=)"Eisai Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01050", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Nov-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"6898", "dt4_program_codes"=)"", "entire_study"=)"135", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"6898", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01050", "nct_id"=)"NCT00392353", "official_title"=)"A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Azacitidine in Patients with the Myelodysplastic Syndrome (MDS)", "open_date"=)"22-Nov-2006", "other_ids"=)"NCI-6898\rNYCC-6898\r11-1773\rCDR0000511887", "other_protocol_ids"=)"6898, NCI-6898, NYCC-6898, 11-1773, CDR0000511887", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Lewis", "pi_last_name"=)"Silverman", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74375270", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00181", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7521", "dt4_program_codes"=)"", "entire_study"=)"6", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"0608008688", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00181", "nct_id"=)"NCT00437034", "official_title"=)"A Phase 2 Study of VEGF Trap (NSC 724770) for the Treatment of Relapsed or Refractory Multiple Myeloma", "open_date"=)"05-Jan-2007", "other_ids"=)"CDR0000530040\rNYWCCC-0608008688", "other_protocol_ids"=)"7521, CDR0000530040, NYWCCC-0608008688", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ruben", "pi_last_name"=)"Niesvizky-Iszaevich", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74375623", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00239", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"18", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Oct-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7868", "dt4_program_codes"=)"", "entire_study"=)"86", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"06-12-487", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00239", "nct_id"=)"NCT00470301", "official_title"=)"A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer", "open_date"=)"10-Apr-2007", "other_ids"=)"CDR0000543434", "other_protocol_ids"=)"7868, CDR0000543434", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Dawn", "pi_last_name"=)"Hershman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"248264", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00472", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Feb-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"REO 014", "lead_org_po_id"=)"192599", "local_site_identifier"=)"07-10-377", "nci_id"=)"NCI-2012-00472", "nct_id"=)"NCT00503295", "official_title"=)"A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung", "open_date"=)"01-Jun-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"89990319", "specific_funding_source"=)"Oncolytics Biotech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00481", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-Feb-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EFC6546", "lead_org_po_id"=)"214637", "local_site_identifier"=)"07-09-316", "nci_id"=)"NCI-2010-00481", "nct_id"=)"NCT00519285", "official_title"=)"A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer", "open_date"=)"21-Aug-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"21020762", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00478", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Feb-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EFC10261", "lead_org_po_id"=)"214637", "local_site_identifier"=)"07-10-373", "nci_id"=)"NCI-2012-00478", "nct_id"=)"NCT00532155", "official_title"=)"A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer", "open_date"=)"09-Sep-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"89994964", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01022", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Dec-2009", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA163-100", "lead_org_po_id"=)"36140", "local_site_identifier"=)"07-05-143", "nci_id"=)"NCI-2011-01022", "nct_id"=)"NCT00455533", "official_title"=)"A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer", "open_date"=)"01-Oct-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74309729", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2014-01579", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"279", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Oct-2014", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"250", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"CCI# 00-7", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01579", "nct_id"=)"NCT00179348", "official_title"=)"Evaluation of a Yoga-Based Cancer Rehabilitation Program", "open_date"=)"28-Feb-2001", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Alyson", "pi_last_name"=)"Moadel", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"150638870", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00226", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Apr-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ414", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"01-09-227", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00226", "nct_id"=)"NCT00231868", "official_title"=)"A Pilot Phase II Trial of Radiation Therapy \"Sandwiched\" between Paclitaxel and Carboplatin in Patients with Uterine Papillary Serous Carcinoma", "open_date"=)"14-Dec-2001", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Einstein", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"88659021", "specific_funding_source"=)"National Cancer Institute Clinical Research Branch", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01773", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"18", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"03-02-040", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01773", "nct_id"=)"NCT00231842", "official_title"=)"A Pilot Phase II Trial of Adjuvant Radiation Therapy \"Sandwiched\" between Ifosfamide in Patients with Mixed Mesodermal Tumors", "open_date"=)"14-Mar-2003", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Einstein", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"122901519", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00108", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"17-May-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"6981", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"0501007709", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00108", "nct_id"=)"NCT00121251", "official_title"=)"A Phase I/II Trial of BAY 43-9006 Plus Gemcitabine and Capecitabine in the Treatment of Patients With Advanced Renal Cell Carcinoma", "open_date"=)"19-Apr-2005", "other_ids"=)"CDR0000434851", "other_protocol_ids"=)"6981, CDR0000434851", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Scott", "pi_last_name"=)"Tagawa", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"246255", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03352", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-Dec-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"05-001", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03352", "nct_id"=)"NCT00400946", "official_title"=)"Treatment of Acute Lymphoblastic Leukemia in Children", "open_date"=)"22-Apr-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Lewis", "pi_last_name"=)"Silverman", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"76516022", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00140", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Dec-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7229", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"0504007857", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00140", "nct_id"=)"NCT00182767", "official_title"=)"A Phase I/II Study of BMS-247550 and Pegylated Liposomal Doxorubicin (Doxil®) in Patients with Advanced Epithelial Ovarian Cancer or Primary Peritoneal Cancer Who Have Been Previously Treated with a Platinum and a Taxane", "open_date"=)"01-Jan-2006", "other_ids"=)"CDR0000441122", "other_protocol_ids"=)"7229, CDR0000441122", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Ellen", "pi_last_name"=)"Chuang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"246764", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00053", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Oct-2009", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"6317", "dt4_program_codes"=)"", "entire_study"=)"52", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"NYU 03-67", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00053", "nct_id"=)"NCT00313612", "official_title"=)"A Phase II Study of Oxaliplatin Combined with Continuous Infusion Topotecan as Chemotherapy for Patients with Previously Treated Ovarian Cancer", "open_date"=)"24-Jan-2006", "other_ids"=)"CDR0000467190", "other_protocol_ids"=)"6317, CDR0000467190", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Amy", "pi_last_name"=)"Tiersten", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"245380", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01128", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Jun-2012", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"82", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"05-10-277", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01128", "nct_id"=)"NCT00950365", "official_title"=)"A Randomized Phase II Study of Schedule-Modulated Concomitant Pemetrexed (Alimta) and Erlotinib (Tarceva) vs Single Agent Pemetrexed (Alimta®) in Patients with Progressive or Recurrent Non-small Cell Lung Cancer (NSCLC)", "open_date"=)"10-Apr-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Roman", "pi_last_name"=)"Perez-Soler", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"118070173", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00475", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jul-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"Onconova 04-03", "lead_org_po_id"=)"192840", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00475", "nct_id"=)"NCT01538563", "official_title"=)"Phase I Dose Escalation Study of ON 01910.Na by 24 Hour Continuous Infusion Per Week in Patients With Advanced Cancer", "open_date"=)"01-Jun-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"89994204", "specific_funding_source"=)"Onconova Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01519", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"164", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"06-08-367", "lead_org_po_id"=)"171322", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01519", "nct_id"=)"NCT00726934", "official_title"=)"Effectiveness of the Neutropenic Diet in Pediatric Oncology Patients", "open_date"=)"11-Aug-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Gill", "pi_middle_initial"=)"B", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"149736279", "specific_funding_source"=)"Montefiore Medical Center-Weiler Hospital", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00503", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1104", "dt4_program_codes"=)"", "entire_study"=)"41", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"E1104", "lead_org_po_id"=)"68593", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00503", "nct_id"=)"NCT00258349", "official_title"=)"A Phase I/II Study of Suberoylanilide Hydroxamic Acid (SAHA) in Combination with Trastuzumab (Herceptin) in Patients with Advanced Metastatic and/or Local Chest Wall Recurrent Her-2 Amplified Breast Cancer", "open_date"=)"23-Aug-2006", "other_ids"=)"CDR0000449963", "other_protocol_ids"=)"E1104, CDR0000449963", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Ramona", "pi_last_name"=)"Swaby", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"252109", "specific_funding_source"=)"Eastern Cooperative Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01439", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Dec-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OSI-774-302", "lead_org_po_id"=)"192932", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01439", "nct_id"=)"NCT00373425", "official_title"=)"A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 3 Study of Single-agent Tarceva® (Erlotinib) Following Complete Tumor Resection With or Without Adjuvant Chemotherapy in Patients With Stage IB-IIIA Non-small Cell Lung Carcinoma Who Have EGFR-positive Tumors", "open_date"=)"07-Sep-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"unknown", "pi_last_name"=)"unknown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"493451", "specific_funding_source"=)"OSI Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00471", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7389-A001-104", "lead_org_po_id"=)"68715", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00471", "nct_id"=)"NCT00268905", "official_title"=)"A Phase Ib Open-Label, Two-Arm, Dose-Finding Study of E7389 in Combination With Carboplatin in Patients With Solid Tumors", "open_date"=)"01-Oct-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"89989931", "specific_funding_source"=)"Eisai Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01050", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Nov-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"6898", "dt4_program_codes"=)"", "entire_study"=)"135", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"6898", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01050", "nct_id"=)"NCT00392353", "official_title"=)"A Phase 1/2 Study of Vorinostat [Suberoylanilide Hydroxamic Acid (SAHA)] in Combination with Azacitidine in Patients with the Myelodysplastic Syndrome (MDS)", "open_date"=)"22-Nov-2006", "other_ids"=)"NCI-6898\rNYCC-6898\r11-1773\rCDR0000511887", "other_protocol_ids"=)"6898, NCI-6898, NYCC-6898, 11-1773, CDR0000511887", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Lewis", "pi_last_name"=)"Silverman", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74375270", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00181", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7521", "dt4_program_codes"=)"", "entire_study"=)"6", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"0608008688", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00181", "nct_id"=)"NCT00437034", "official_title"=)"A Phase 2 Study of VEGF Trap (NSC 724770) for the Treatment of Relapsed or Refractory Multiple Myeloma", "open_date"=)"05-Jan-2007", "other_ids"=)"CDR0000530040\rNYWCCC-0608008688", "other_protocol_ids"=)"7521, CDR0000530040, NYWCCC-0608008688", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ruben", "pi_last_name"=)"Niesvizky-Iszaevich", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74375623", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00239", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"18", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Oct-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"7868", "dt4_program_codes"=)"", "entire_study"=)"86", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"06-12-487", "lead_org_po_id"=)"171351", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00239", "nct_id"=)"NCT00470301", "official_title"=)"A Phase I-II Study of R115777 (Tipifarnib, Zarnestra®) Plus Sequential Weekly Paclitaxel Followed by Dose-Dense Doxorubicin and Cyclophosphamide in Patients with Stage IIB-IIIC Breast Cancer", "open_date"=)"10-Apr-2007", "other_ids"=)"CDR0000543434", "other_protocol_ids"=)"7868, CDR0000543434", "p30grant"=)"CA013330", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Dawn", "pi_last_name"=)"Hershman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"248264", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00472", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Feb-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"REO 014", "lead_org_po_id"=)"192599", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00472", "nct_id"=)"NCT00503295", "official_title"=)"A Phase 2 Study of Intravenous REOLYSIN® (Wild-Type Reovirus) in the Treatment of Patients With Bone and Soft Tissue Sarcomas Metastatic to the Lung", "open_date"=)"01-Jun-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"89990319", "specific_funding_source"=)"Oncolytics Biotech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00481", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-Feb-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EFC6546", "lead_org_po_id"=)"214637", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00481", "nct_id"=)"NCT00519285", "official_title"=)"A Multicenter, Randomized, Double Blind Study Comparing the Efficacy and Safety of Aflibercept Versus Placebo Administered Every 3 Weeks in Patients Treated With Docetaxel/ Prednisone for Metastatic Androgen-independent Prostate Cancer", "open_date"=)"21-Aug-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"21020762", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00478", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Feb-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EFC10261", "lead_org_po_id"=)"214637", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00478", "nct_id"=)"NCT00532155", "official_title"=)"A Multinational, Randomized, Double-Blind Study Comparing Aflibercept Versus Placebo in Patients Treated With Second-Line Docetaxel After Failure of One Platinum Based Therapy for Locally Advanced or Metastatic Non-Small-Cell Lung Cancer", "open_date"=)"09-Sep-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"89994964", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01022", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Dec-2009", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA163-100", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01022", "nct_id"=)"NCT00455533", "official_title"=)"A Randomized Phase II Biomarker Neoadjuvant Study of Sequential AC Followed by Ixabepilone Compared to Sequential AC Followed by Paclitaxel in Women With Early Stage Breast Cancer", "open_date"=)"01-Oct-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74309729", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)20, "page"=)1, "pages"=)2, "sort"=)[["open_date", "ASC"]], "total"=)33},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:469:in `Then I want to verify DT4 response contains the correct data for "albert_einstein_list_20" parameters in the "albert_einstein_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "20" records

Scenario:#24 List the Alvin J. Siteman Cancer Center Interventional trial type DT4 report 2 1 1

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "alvin_siteman_int_list_20" parameters in the "alvin_siteman_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2011-00754", "affiliate_total"=)"0", "affiliate_...ging"=){"items_per_page"=)20, "page"=)1, "pages"=)7, "sort"=)[["close_date", "ASC"]], "total"=)127}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2011-00754", "affiliate_total"=)"0", "affiliate_...ging"=){"items_per_page"=)20, "page"=)1, "pages"=)7, "sort"=)[["close_date", "ASC"]], "total"=)127}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2011-00754", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"52", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"19-Jan-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"52", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201011796", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00754", "nct_id"=)"NCT00512252", "official_title"=)"A Phase I/II Study of AMD3100 with Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML", "open_date"=)"12-Jul-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Uy", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74268025", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00689", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Feb-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TM601-007", "lead_org_po_id"=)"221129", "local_site_identifier"=)"08-0401", "nci_id"=)"NCI-2010-00689", "nct_id"=)"NCT00591058", "official_title"=)"A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma", "open_date"=)"01-Feb-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"24856467", "specific_funding_source"=)"TransMolecular Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00801", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Mar-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201101709", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00801", "nct_id"=)"NCT00555256", "official_title"=)"A Phase I Study of SUNITINIB and Rapamycin in Advanced Non Small Cell Lung Cancer (NSCLC)", "open_date"=)"05-Nov-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74276243", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00467", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"5108-001", "lead_org_po_id"=)"147288", "local_site_identifier"=)"201012996", "nci_id"=)"NCI-2010-00467", "nct_id"=)"NCT00543387", "official_title"=)"A Phase I Investigation of MK-5108 and MK-5108 With Docetaxel in Patients With Advanced Solid Tumors", "open_date"=)"10-Mar-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"21020330", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01688", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Mar-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GV001.004", "lead_org_po_id"=)"89156", "local_site_identifier"=)"03-1015", "nci_id"=)"NCI-2009-01688", "nct_id"=)"NCT00051467", "official_title"=)"A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer", "open_date"=)"08-Dec-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"1407701", "specific_funding_source"=)"GenVec Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02368", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2010", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN0603", "lead_org_po_id"=)"249581", "local_site_identifier"=)"201107292", "nci_id"=)"NCI-2014-02368", "nct_id"=)"NCT00849147", "official_title"=)"A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)", "open_date"=)"01-Oct-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170987414", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AVF4095g", "lead_org_po_id"=)"87945", "local_site_identifier"=)"08-1300", "nci_id"=)"NCI-2010-01255", "nct_id"=)"NCT00434642", "official_title"=)"A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma", "open_date"=)"01-Mar-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"55314358", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00849", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-May-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"76", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201107340", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00849", "nct_id"=)"NCT00263211", "official_title"=)"The Impact of Platelet Function Inhibition on Circulating Cancer Cells in Metastatic Breast Cancer Patients", "open_date"=)"10-Jan-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Katherine", "pi_last_name"=)"Weilbaecher", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74283177", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01241", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"HBS701", "lead_org_po_id"=)"219099", "local_site_identifier"=)"08-1165", "nci_id"=)"NCI-2009-01241", "nct_id"=)"NCT00656786", "official_title"=)"A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash", "open_date"=)"01-Apr-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"unknown", "pi_last_name"=)"unknown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"396992", "specific_funding_source"=)"Spectrum Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00155", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"02-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2004UC035", "lead_org_po_id"=)"139049", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00155", "nct_id"=)"NCT00392782", "official_title"=)"A Multicenter, Prospective Trial to Evaluate the Role of NK Cell Kir Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation from HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies", "open_date"=)"06-Jul-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"Weisdorf", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74150310", "specific_funding_source"=)"University of Minnesota/Masonic Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00837", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"18", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"07-0265", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00837", "nct_id"=)"NCT00732082", "official_title"=)"Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients with Advanced Pancreas Cancer", "open_date"=)"13-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"William", "pi_last_name"=)"Hawkins", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"74280932", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00815", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jul-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"20080257", "lead_org_po_id"=)"50366803", "local_site_identifier"=)"201103074", "nci_id"=)"NCI-2011-00815", "nct_id"=)"NCT00807612", "official_title"=)"A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer", "open_date"=)"01-Apr-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74277297", "specific_funding_source"=)"NantCell, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00931", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Jul-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"HEMMPD0003", "lead_org_po_id"=)"40496", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00931", "nct_id"=)"NCT00233454", "official_title"=)"A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)", "open_date"=)"18-Mar-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jason", "pi_last_name"=)"Gotlib", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"74297049", "specific_funding_source"=)"Stanford Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00782", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"46", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Aug-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201101866", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00782", "nct_id"=)"NCT00660699", "official_title"=)"A Feasibility Phase II Study of Gemcitabine with Docetaxel Followed by Concurrent 3-D Conformal Radiation plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers", "open_date"=)"14-Sep-2002", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Benjamin", "pi_last_name"=)"Tan", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74272506", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01749", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Sep-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"07-199", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01749", "nct_id"=)"NCT00542451", "official_title"=)"Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2- Positive Breast Cancer", "open_date"=)"09-Oct-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Eric", "pi_last_name"=)"Winer", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"5258312", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00782", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-Nov-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201109027 09-0085", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00782", "nct_id"=)"", "official_title"=)"Quantitative Advanced MRI Imaging to Predict Brian Tumor Response to Stereotactic Radiosurgery", "open_date"=)"01-Apr-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tammie", "pi_last_name"=)"Benzinger", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"187688999", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00766", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"27", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Nov-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201104019", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00766", "nct_id"=)"NCT00359866", "official_title"=)"Pelvic IMRT with Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients", "open_date"=)"09-Feb-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Perry", "pi_last_name"=)"Grigsby", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74269525", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02405", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Nov-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BCX1777-210", "lead_org_po_id"=)"35385", "local_site_identifier"=)"201102318", "nci_id"=)"NCI-2010-02405", "nct_id"=)"NCT00640523", "official_title"=)"Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"01-Mar-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"74108041", "specific_funding_source"=)"BioCryst Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00028", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Dec-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CC-4047-MM-002", "lead_org_po_id"=)"57944", "local_site_identifier"=)"201102387", "nci_id"=)"NCI-2010-00028", "nct_id"=)"NCT00833833", "official_title"=)"A Phase I/II Multicenter, Randomized, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of CC-4047 Alone Or In Combination With Low-Dose Dexamethasone In Patients Wth Relapsed And Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide And Bortezomib", "open_date"=)"01-Jun-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"10094442", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02138", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jan-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3129K5-2005", "lead_org_po_id"=)"248758", "local_site_identifier"=)"201105148", "nci_id"=)"NCI-2010-02138", "nct_id"=)"NCT00867087", "official_title"=)"An Open-Label, Single-Arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible For Autologous Stem Cell Transplantation", "open_date"=)"01-Jun-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74008775", "specific_funding_source"=)"Wyeth Laboratories Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2011-00754", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"52", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"19-Jan-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"52", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201011796", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00754", "nct_id"=)"NCT00512252", "official_title"=)"A Phase I/II Study of AMD3100 with Mitoxantrone, Etoposide and Cytarabine (AMD3100+MEC) in Relapsed or Refractory AML", "open_date"=)"12-Jul-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Uy", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74268025", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00689", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Feb-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TM601-007", "lead_org_po_id"=)"221129", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00689", "nct_id"=)"NCT00591058", "official_title"=)"A Phase I Dose Escalation Study Evaluating the Safety and Biologically Active Dose of TM-601 Based on Perfusion MRI Imaging Criteria in Patients With Progressive and/or Recurrent Malignant Glioma", "open_date"=)"01-Feb-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"24856467", "specific_funding_source"=)"TransMolecular Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00801", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Mar-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201101709", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00801", "nct_id"=)"NCT00555256", "official_title"=)"A Phase I Study of SUNITINIB and Rapamycin in Advanced Non Small Cell Lung Cancer (NSCLC)", "open_date"=)"05-Nov-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74276243", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00467", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"5108-001", "lead_org_po_id"=)"147288", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00467", "nct_id"=)"NCT00543387", "official_title"=)"A Phase I Investigation of MK-5108 and MK-5108 With Docetaxel in Patients With Advanced Solid Tumors", "open_date"=)"10-Mar-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"21020330", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01688", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Mar-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GV001.004", "lead_org_po_id"=)"89156", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01688", "nct_id"=)"NCT00051467", "official_title"=)"A Randomized, Phase II/III, Study of TNFerade™ Biologic With 5-FU and Radiation Therapy for First-line Treatment of Unresectable Locally Advanced Pancreatic Cancer", "open_date"=)"08-Dec-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"1407701", "specific_funding_source"=)"GenVec Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02368", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2010", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN0603", "lead_org_po_id"=)"249581", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02368", "nct_id"=)"NCT00849147", "official_title"=)"A Multi-Center, Phase II Trial of Nonmyeloablative Conditioning (NST) and Transplantation of Partially HLA-Mismatched Bone Marrow From Related Donors for Patients With Hematologic Malignancies (BMT CTN #0603)", "open_date"=)"01-Oct-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170987414", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AVF4095g", "lead_org_po_id"=)"87945", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01255", "nct_id"=)"NCT00434642", "official_title"=)"A Phase III, Multicenter, Randomized, Blinded, Placebo-controlled Trial of Carboplatin and Gemcitabine Plus Bevacizumab in Patients With Platinum-sensitive Recurrent Ovary, Primary Peritoneal, or Fallopian Tube Carcinoma", "open_date"=)"01-Mar-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"55314358", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00849", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-May-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"76", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201107340", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00849", "nct_id"=)"NCT00263211", "official_title"=)"The Impact of Platelet Function Inhibition on Circulating Cancer Cells in Metastatic Breast Cancer Patients", "open_date"=)"10-Jan-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Katherine", "pi_last_name"=)"Weilbaecher", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74283177", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01241", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"HBS701", "lead_org_po_id"=)"219099", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01241", "nct_id"=)"NCT00656786", "official_title"=)"A Phase 1, Multi-center, Randomized, Double-Blind, Placebo Controlled Study of the Safety, Tolerability, and Systemic Absorption of Menadione Topical Lotion as an Emergent and Pre-emergent Treatment for Epidermal-Growth-Factor-Receptor (EGFR) Inhibitor-Associated Rash", "open_date"=)"01-Apr-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"unknown", "pi_last_name"=)"unknown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"396992", "specific_funding_source"=)"Spectrum Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00155", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"02-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2004UC035", "lead_org_po_id"=)"139049", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00155", "nct_id"=)"NCT00392782", "official_title"=)"A Multicenter, Prospective Trial to Evaluate the Role of NK Cell Kir Epitope Mismatch on Mortality and Disease Relapse in T-Cell Depleted Hematopoietic Stem Cell Transplantation from HLA-C Mismatched, Unrelated Donors for Myeloid Malignancies", "open_date"=)"06-Jul-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"Weisdorf", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74150310", "specific_funding_source"=)"University of Minnesota/Masonic Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00837", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"18", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Jun-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"07-0265", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00837", "nct_id"=)"NCT00732082", "official_title"=)"Phase I Study of Soluble LAG-3 (IMP321) and Gemcitabine in Patients with Advanced Pancreas Cancer", "open_date"=)"13-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"William", "pi_last_name"=)"Hawkins", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"74280932", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00815", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jul-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"20080257", "lead_org_po_id"=)"50366803", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00815", "nct_id"=)"NCT00807612", "official_title"=)"A Phase 1b/2 Study of AMG 479 in Combination With Paclitaxel and Carboplatin for the First-Line Treatment of Advanced Squamous Non-Small Cell Lung Cancer", "open_date"=)"01-Apr-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74277297", "specific_funding_source"=)"NantCell, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00931", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Jul-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"HEMMPD0003", "lead_org_po_id"=)"40496", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00931", "nct_id"=)"NCT00233454", "official_title"=)"A Single Arm, Phase II, Open-Label Study to Determine the Efficacy of Twice Daily Oral Dosing of PKC412 Administered to Patients With Aggressive Systemic Mastocytosis (ASM) and Mast Cell Leukemia (MCL)", "open_date"=)"18-Mar-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jason", "pi_last_name"=)"Gotlib", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"74297049", "specific_funding_source"=)"Stanford Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00782", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"46", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Aug-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201101866", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00782", "nct_id"=)"NCT00660699", "official_title"=)"A Feasibility Phase II Study of Gemcitabine with Docetaxel Followed by Concurrent 3-D Conformal Radiation plus Continuous Infusion 5-Fluorouracil in the Treatment of Resected Cholangiocarcinoma, Gallbladder, Pancreatic and Ampullary Cancers", "open_date"=)"14-Sep-2002", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Benjamin", "pi_last_name"=)"Tan", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74272506", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01749", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Sep-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"07-199", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01749", "nct_id"=)"NCT00542451", "official_title"=)"Adjuvant Paclitaxel and Trastuzumab for Node-Negative HER2- Positive Breast Cancer", "open_date"=)"09-Oct-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Eric", "pi_last_name"=)"Winer", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"5258312", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00782", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-Nov-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201109027 09-0085", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00782", "nct_id"=)"", "official_title"=)"Quantitative Advanced MRI Imaging to Predict Brian Tumor Response to Stereotactic Radiosurgery", "open_date"=)"01-Apr-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tammie", "pi_last_name"=)"Benzinger", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"187688999", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00766", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"27", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Nov-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201104019", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00766", "nct_id"=)"NCT00359866", "official_title"=)"Pelvic IMRT with Tomotherapy: A Phase I Feasibility Study in Post-Hysterectomy Cervical Cancer Patients", "open_date"=)"09-Feb-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Perry", "pi_last_name"=)"Grigsby", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74269525", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02405", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Nov-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BCX1777-210", "lead_org_po_id"=)"35385", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02405", "nct_id"=)"NCT00640523", "official_title"=)"Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"01-Mar-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"74108041", "specific_funding_source"=)"BioCryst Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00028", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Dec-2010", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CC-4047-MM-002", "lead_org_po_id"=)"57944", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00028", "nct_id"=)"NCT00833833", "official_title"=)"A Phase I/II Multicenter, Randomized, Open Label, Dose-Escalation Study To Determine The Maximum Tolerated Dose, Safety, And Efficacy Of CC-4047 Alone Or In Combination With Low-Dose Dexamethasone In Patients Wth Relapsed And Refractory Multiple Myeloma Who Have Received Prior Treatment That Includes Lenalidomide And Bortezomib", "open_date"=)"01-Jun-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"10094442", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02138", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jan-2011", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3129K5-2005", "lead_org_po_id"=)"248758", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02138", "nct_id"=)"NCT00867087", "official_title"=)"An Open-Label, Single-Arm, Phase 2 Study Of Inotuzumab Ozogamicin Plus Rituximab In Subjects With Relapsed/Refractory CD22-Positive Diffuse Large B-Cell Lymphoma, Eligible For Autologous Stem Cell Transplantation", "open_date"=)"01-Jun-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74008775", "specific_funding_source"=)"Wyeth Laboratories Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)20, "page"=)1, "pages"=)7, "sort"=)[["close_date", "ASC"]], "total"=)127},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:478:in `Then I want to verify DT4 response contains the correct data for "alvin_siteman_int_list_20" parameters in the "alvin_siteman_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "20" records

Scenario:#25 List the Non-Interventional trial type DT4 report for Alvin J. Siteman Cancer Center 2 1 1

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "alvin_siteman_non_int_list_10" parameters in the "alvin_siteman_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00734", "affiliate_total"=)"0", "affiliate_...aging"=){"items_per_page"=)10, "page"=)1, "pages"=)2, "sort"=)[["close_date", "ASC"]], "total"=)14}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00734", "affiliate_total"=)"0", "affiliate_...aging"=){"items_per_page"=)10, "page"=)1, "pages"=)2, "sort"=)[["close_date", "ASC"]], "total"=)14}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00734", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"12-Mar-2012", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0612", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0612", "lead_org_po_id"=)"214245", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00734", "nct_id"=)"NCT00899912", "official_title"=)"Investigating Markers of Radiation Outcome in Patients with Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study", "open_date"=)"20-Jun-2006", "other_ids"=)"CDR0000490025", "other_protocol_ids"=)"RTOG-0612, CDR0000490025", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Arnab", "pi_last_name"=)"Chakravarti", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74444952", "specific_funding_source"=)"Radiation Therapy Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00534", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"2", "clinical_research_cat"=)"ANC/COR", "close_date"=)"21-Mar-2012", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"196", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"201103059", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00534", "nct_id"=)"", "official_title"=)"Molecular Signature Predicts Recurrence of Stage II Colon Cancer", "open_date"=)"17-Feb-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Matthew", "pi_last_name"=)"Mutch", "pi_middle_initial"=)"G", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Colon", "sp_id"=)"182865575", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00115", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"05-Jun-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AMC-064", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMC-064", "lead_org_po_id"=)"27984", "local_site_identifier"=)"AMC-064", "nci_id"=)"NCI-2013-00115", "nct_id"=)"NCT00981097", "official_title"=)"Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma from Patients with Aggressive B-Cell Lymphomas", "open_date"=)"13-Aug-2009", "other_ids"=)"U01CA121947", "other_protocol_ids"=)"AMC-064, U01CA121947", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nina", "pi_last_name"=)"Wagner-Johnston", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"105833920", "specific_funding_source"=)"AIDS Malignancy Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02257", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Oct-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEPI07N1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEPI07N1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02257", "nct_id"=)"NCT01119560", "official_title"=)"Genetic Susceptibility Factors in the Etiology of Neuroblastoma also known as Neuroblastoma Epidemiology in North America (NENA)", "open_date"=)"03-Feb-2009", "other_ids"=)"CDR0000594334\rCOG-AEPI07N1", "other_protocol_ids"=)"AEPI07N1, CDR0000594334, COG-AEPI07N1", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Olshan", "pi_middle_initial"=)"F", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74452761", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00439", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"16-Dec-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"10", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201102283", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00439", "nct_id"=)"", "official_title"=)"Ovarian Tissue Cryopreservation", "open_date"=)"29-Apr-2004", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Valerie", "pi_last_name"=)"Ratts", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"181821790", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01083", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"28-Feb-2014", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0235", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0235", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01083", "nct_id"=)"NCT00899093", "official_title"=)"A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy", "open_date"=)"24-Sep-2007", "other_ids"=)"CDR0000540250", "other_protocol_ids"=)"GOG-0235, CDR0000540250", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Katherine", "pi_last_name"=)"Bell-McGuinn", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74446174", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00494", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-8461", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 8461", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00494", "nct_id"=)"NCT00048958", "official_title"=)"Cytogenetic Studies in Acute Leukemia and Multiple Myeloma", "open_date"=)"22-Jun-1984", "other_ids"=)"CDR0000256897", "other_protocol_ids"=)"CALGB-8461, CDR0000256897", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Clara", "pi_last_name"=)"Bloomfield", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74394012", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"242", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-9665", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 9665", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00497", "nct_id"=)"NCT00899223", "official_title"=)"The CALGB Leukemia Tissue Bank", "open_date"=)"15-May-1996", "other_ids"=)"CDR0000271412", "other_protocol_ids"=)"CALGB-9665, CDR0000271412", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Caligiuri", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74441400", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00458", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-20203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 20203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00458", "nct_id"=)"NCT01005368", "official_title"=)"Molecular Markers of Chronic Lymphocytic Leukemia", "open_date"=)"15-Oct-2004", "other_ids"=)"CDR0000398201", "other_protocol_ids"=)"CALGB-20203, CDR0000398201", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Byrd", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"74443164", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00383", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE07C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE07C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00383", "nct_id"=)"NCT00772200", "official_title"=)"Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer", "open_date"=)"15-Sep-2008", "other_ids"=)"CDR0000594326\rCOG-ALTE07C1", "other_protocol_ids"=)"ALTE07C1, CDR0000594326, COG-ALTE07C1", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leanne", "pi_last_name"=)"Embry", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74447321", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00734", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"12-Mar-2012", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0612", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0612", "lead_org_po_id"=)"214245", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00734", "nct_id"=)"NCT00899912", "official_title"=)"Investigating Markers of Radiation Outcome in Patients with Intermediate-Risk Prostate Cancer Using DNA Microarray Analysis: An RTOG Pilot Study", "open_date"=)"20-Jun-2006", "other_ids"=)"CDR0000490025", "other_protocol_ids"=)"RTOG-0612, CDR0000490025", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Arnab", "pi_last_name"=)"Chakravarti", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74444952", "specific_funding_source"=)"Radiation Therapy Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00534", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"2", "clinical_research_cat"=)"ANC/COR", "close_date"=)"21-Mar-2012", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"196", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"201103059", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00534", "nct_id"=)"", "official_title"=)"Molecular Signature Predicts Recurrence of Stage II Colon Cancer", "open_date"=)"17-Feb-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Matthew", "pi_last_name"=)"Mutch", "pi_middle_initial"=)"G", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Colon", "sp_id"=)"182865575", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00115", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"05-Jun-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AMC-064", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMC-064", "lead_org_po_id"=)"27984", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00115", "nct_id"=)"NCT00981097", "official_title"=)"Evaluation of Serum Free Light Chains and Clonal Ig DNA in Plasma from Patients with Aggressive B-Cell Lymphomas", "open_date"=)"13-Aug-2009", "other_ids"=)"U01CA121947", "other_protocol_ids"=)"AMC-064, U01CA121947", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nina", "pi_last_name"=)"Wagner-Johnston", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"105833920", "specific_funding_source"=)"AIDS Malignancy Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02257", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Oct-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEPI07N1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEPI07N1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02257", "nct_id"=)"NCT01119560", "official_title"=)"Genetic Susceptibility Factors in the Etiology of Neuroblastoma also known as Neuroblastoma Epidemiology in North America (NENA)", "open_date"=)"03-Feb-2009", "other_ids"=)"CDR0000594334\rCOG-AEPI07N1", "other_protocol_ids"=)"AEPI07N1, CDR0000594334, COG-AEPI07N1", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Olshan", "pi_middle_initial"=)"F", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74452761", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00439", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"16-Dec-2013", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"10", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"201102283", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00439", "nct_id"=)"", "official_title"=)"Ovarian Tissue Cryopreservation", "open_date"=)"29-Apr-2004", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Valerie", "pi_last_name"=)"Ratts", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"181821790", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01083", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"28-Feb-2014", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0235", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0235", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01083", "nct_id"=)"NCT00899093", "official_title"=)"A Prospective, Longitudinal Study of YKL-40 in Patients with FIGO Stage III or IV Invasive Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer Undergoing Primary Chemotherapy", "open_date"=)"24-Sep-2007", "other_ids"=)"CDR0000540250", "other_protocol_ids"=)"GOG-0235, CDR0000540250", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Katherine", "pi_last_name"=)"Bell-McGuinn", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74446174", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00494", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-8461", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 8461", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00494", "nct_id"=)"NCT00048958", "official_title"=)"Cytogenetic Studies in Acute Leukemia and Multiple Myeloma", "open_date"=)"22-Jun-1984", "other_ids"=)"CDR0000256897", "other_protocol_ids"=)"CALGB-8461, CDR0000256897", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Clara", "pi_last_name"=)"Bloomfield", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74394012", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"242", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-9665", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 9665", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00497", "nct_id"=)"NCT00899223", "official_title"=)"The CALGB Leukemia Tissue Bank", "open_date"=)"15-May-1996", "other_ids"=)"CDR0000271412", "other_protocol_ids"=)"CALGB-9665, CDR0000271412", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Caligiuri", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74441400", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00458", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-20203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 20203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00458", "nct_id"=)"NCT01005368", "official_title"=)"Molecular Markers of Chronic Lymphocytic Leukemia", "open_date"=)"15-Oct-2004", "other_ids"=)"CDR0000398201", "other_protocol_ids"=)"CALGB-20203, CDR0000398201", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Byrd", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"74443164", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00383", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE07C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE07C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00383", "nct_id"=)"NCT00772200", "official_title"=)"Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer", "open_date"=)"15-Sep-2008", "other_ids"=)"CDR0000594326\rCOG-ALTE07C1", "other_protocol_ids"=)"ALTE07C1, CDR0000594326, COG-ALTE07C1", "p30grant"=)"CA091842", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leanne", "pi_last_name"=)"Embry", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74447321", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)10, "page"=)1, "pages"=)2, "sort"=)[["close_date", "ASC"]], "total"=)14},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:487:in `Then I want to verify DT4 response contains the correct data for "alvin_siteman_non_int_list_10" parameters in the "alvin_siteman_dt4" json file'

And I want to verify items_per_page: "ad_nci_id" and response contain "10" records

Scenario:#26 Search for "Mayo Clinic Cancer Center" DT4 report and trial types as "INTERVENTIONAL" 5

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "mayo_clinic_int_list_1" parameters in the "mayo_clinic_dt4" json file 0s

And I want to verify items_per_page: "ad_nci_id" and response contain "1" records 0s

And trial type is "INTERVENTIONAL" 0s

Scenario:#27 Search for "Mayo Clinic Cancer Center" DT4 report and trial types as "NON-INTERVENTIONAL" 5

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "mayo_clinic_non_int_list_1" parameters in the "mayo_clinic_dt4" json file 0s

And I want to verify items_per_page: "ad_nci_id" and response contain "1" records 0s

And trial type is "NON-INTERVENTIONAL" 0s

Scenario:#29 DT4 report can be sort by "nct_id" as ascending order 2 2 1

Given the "DT4" service is called by providing following parameters to verify sort 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "sort_default" parameters in the "sort_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_..."page"=)1, "pages"=)9, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)180}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_..."page"=)1, "pages"=)9, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)180}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL05B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL05B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00310", "nct_id"=)"NCT00897325", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens", "open_date"=)"25-Sep-2006", "other_ids"=)"CDR0000491159\rCOG-AALL05B1", "other_protocol_ids"=)"AALL05B1, CDR0000491159, COG-AALL05B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Hunger", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74445057", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"MC083I", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00718", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AMC-083", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMC-083", "lead_org_po_id"=)"27984", "local_site_identifier"=)"AMC-083", "nci_id"=)"NCI-2012-00718", "nct_id"=)"NCT01567722", "official_title"=)"Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies", "open_date"=)"31-Jul-2012", "other_ids"=)"CDR0000729843", "other_protocol_ids"=)"AMC-083, CDR0000729843", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Lee", "pi_last_name"=)"Ratner", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"91632223", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00069", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE11C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE11C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00069", "nct_id"=)"NCT01793233", "official_title"=)"Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma", "open_date"=)"17-Jun-2013", "other_ids"=)"", "other_protocol_ids"=)"ALTE11C1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Levine", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"105416826", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01871", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-121", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01871", "nct_id"=)"NCT01470105", "official_title"=)"Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases", "open_date"=)"08-Nov-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Healey", "pi_middle_initial"=)"H", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"279089430", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01687", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0631", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0631", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01687", "nct_id"=)"NCT00922974", "official_title"=)"Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis", "open_date"=)"07-Aug-2009", "other_ids"=)"CDR0000646803", "other_protocol_ids"=)"RTOG-0631, CDR0000646803", "p30grant"=)"CA013330", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Samuel", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74428054", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398X2101", "lead_org_po_id"=)"170150", "local_site_identifier"=)"14-06-328-01", "nci_id"=)"NCI-2011-01165", "nct_id"=)"NCT01004224", "official_title"=)"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74337768", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3A06", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3A06", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02057", "nct_id"=)"NCT01169337", "official_title"=)"Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma", "open_date"=)"05-Oct-2010", "other_ids"=)"CDR0000682012\rECOG-E3A06", "other_protocol_ids"=)"E3A06, CDR0000682012, ECOG-E3A06", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sagar", "pi_last_name"=)"Lonial", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74439478", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02500", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"8808", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"8808", "lead_org_po_id"=)"197080", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02500", "nct_id"=)"NCT01366144", "official_title"=)"An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors", "open_date"=)"20-Jun-2011", "other_ids"=)"UPCI-10-115\rCDR0000700997\rUPCI 10-115", "other_protocol_ids"=)"8808, UPCI-10-115, CDR0000700997, UPCI, 10-115", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Hussein", "pi_last_name"=)"Tawbi", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74695238", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02599", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL0932", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL0932", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02599", "nct_id"=)"NCT01190930", "official_title"=)"Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)", "open_date"=)"09-Aug-2010", "other_ids"=)"CDR0000683227", "other_protocol_ids"=)"AALL0932, CDR0000683227", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anne", "pi_last_name"=)"Angiolillo", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74707439", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL05B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL05B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00310", "nct_id"=)"NCT00897325", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens", "open_date"=)"25-Sep-2006", "other_ids"=)"CDR0000491159\rCOG-AALL05B1", "other_protocol_ids"=)"AALL05B1, CDR0000491159, COG-AALL05B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Hunger", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74445057", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00718", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AMC-083", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMC-083", "lead_org_po_id"=)"27984", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00718", "nct_id"=)"NCT01567722", "official_title"=)"Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies", "open_date"=)"31-Jul-2012", "other_ids"=)"CDR0000729843", "other_protocol_ids"=)"AMC-083, CDR0000729843", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Lee", "pi_last_name"=)"Ratner", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"91632223", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00069", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE11C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE11C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00069", "nct_id"=)"NCT01793233", "official_title"=)"Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma", "open_date"=)"17-Jun-2013", "other_ids"=)"", "other_protocol_ids"=)"ALTE11C1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Levine", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"105416826", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01871", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-121", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01871", "nct_id"=)"NCT01470105", "official_title"=)"Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases", "open_date"=)"08-Nov-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Healey", "pi_middle_initial"=)"H", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"279089430", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01687", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0631", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0631", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01687", "nct_id"=)"NCT00922974", "official_title"=)"Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis", "open_date"=)"07-Aug-2009", "other_ids"=)"CDR0000646803", "other_protocol_ids"=)"RTOG-0631, CDR0000646803", "p30grant"=)"CA013330", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Samuel", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74428054", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398X2101", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01165", "nct_id"=)"NCT01004224", "official_title"=)"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74337768", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3A06", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3A06", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02057", "nct_id"=)"NCT01169337", "official_title"=)"Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma", "open_date"=)"05-Oct-2010", "other_ids"=)"CDR0000682012\rECOG-E3A06", "other_protocol_ids"=)"E3A06, CDR0000682012, ECOG-E3A06", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sagar", "pi_last_name"=)"Lonial", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74439478", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02500", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"8808", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"8808", "lead_org_po_id"=)"197080", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02500", "nct_id"=)"NCT01366144", "official_title"=)"An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors", "open_date"=)"20-Jun-2011", "other_ids"=)"UPCI-10-115\rCDR0000700997\rUPCI 10-115", "other_protocol_ids"=)"8808, UPCI-10-115, CDR0000700997, UPCI, 10-115", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Hussein", "pi_last_name"=)"Tawbi", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74695238", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02599", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL0932", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL0932", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02599", "nct_id"=)"NCT01190930", "official_title"=)"Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)", "open_date"=)"09-Aug-2010", "other_ids"=)"CDR0000683227", "other_protocol_ids"=)"AALL0932, CDR0000683227", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anne", "pi_last_name"=)"Angiolillo", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74707439", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)20, "page"=)1, "pages"=)9, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)180},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:540:in `Then I want to verify DT4 response contains the correct data for "sort_default" parameters in the "sort_dt4" json file'

And the "DT4" service is called by providing following parameters to verify sort

Then I want to verify DT4 response contains the ASC data for "sort_by_nct_id_asc" parameters in the "sort_dt4" json file

Scenario:#30 DT4 report can be sort by "nct_id" as descending order 2 2 1

Given the "DT4" service is called by providing following parameters to verify sort 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "sort_default" parameters in the "sort_dt4" json file 0s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_..."page"=)1, "pages"=)9, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)180}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_..."page"=)1, "pages"=)9, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)180}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL05B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL05B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00310", "nct_id"=)"NCT00897325", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens", "open_date"=)"25-Sep-2006", "other_ids"=)"CDR0000491159\rCOG-AALL05B1", "other_protocol_ids"=)"AALL05B1, CDR0000491159, COG-AALL05B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Hunger", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74445057", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"MC083I", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00718", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AMC-083", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMC-083", "lead_org_po_id"=)"27984", "local_site_identifier"=)"AMC-083", "nci_id"=)"NCI-2012-00718", "nct_id"=)"NCT01567722", "official_title"=)"Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies", "open_date"=)"31-Jul-2012", "other_ids"=)"CDR0000729843", "other_protocol_ids"=)"AMC-083, CDR0000729843", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Lee", "pi_last_name"=)"Ratner", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"91632223", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00069", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE11C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE11C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00069", "nct_id"=)"NCT01793233", "official_title"=)"Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma", "open_date"=)"17-Jun-2013", "other_ids"=)"", "other_protocol_ids"=)"ALTE11C1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Levine", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"105416826", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01871", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-121", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01871", "nct_id"=)"NCT01470105", "official_title"=)"Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases", "open_date"=)"08-Nov-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Healey", "pi_middle_initial"=)"H", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"279089430", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01687", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0631", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0631", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01687", "nct_id"=)"NCT00922974", "official_title"=)"Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis", "open_date"=)"07-Aug-2009", "other_ids"=)"CDR0000646803", "other_protocol_ids"=)"RTOG-0631, CDR0000646803", "p30grant"=)"CA013330", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Samuel", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74428054", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398X2101", "lead_org_po_id"=)"170150", "local_site_identifier"=)"14-06-328-01", "nci_id"=)"NCI-2011-01165", "nct_id"=)"NCT01004224", "official_title"=)"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74337768", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3A06", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3A06", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02057", "nct_id"=)"NCT01169337", "official_title"=)"Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma", "open_date"=)"05-Oct-2010", "other_ids"=)"CDR0000682012\rECOG-E3A06", "other_protocol_ids"=)"E3A06, CDR0000682012, ECOG-E3A06", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sagar", "pi_last_name"=)"Lonial", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74439478", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02500", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"8808", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"8808", "lead_org_po_id"=)"197080", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02500", "nct_id"=)"NCT01366144", "official_title"=)"An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors", "open_date"=)"20-Jun-2011", "other_ids"=)"UPCI-10-115\rCDR0000700997\rUPCI 10-115", "other_protocol_ids"=)"8808, UPCI-10-115, CDR0000700997, UPCI, 10-115", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Hussein", "pi_last_name"=)"Tawbi", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74695238", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02599", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL0932", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL0932", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02599", "nct_id"=)"NCT01190930", "official_title"=)"Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)", "open_date"=)"09-Aug-2010", "other_ids"=)"CDR0000683227", "other_protocol_ids"=)"AALL0932, CDR0000683227", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anne", "pi_last_name"=)"Angiolillo", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74707439", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL05B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL05B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00310", "nct_id"=)"NCT00897325", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens", "open_date"=)"25-Sep-2006", "other_ids"=)"CDR0000491159\rCOG-AALL05B1", "other_protocol_ids"=)"AALL05B1, CDR0000491159, COG-AALL05B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Hunger", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74445057", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"22", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00718", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AMC-083", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMC-083", "lead_org_po_id"=)"27984", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00718", "nct_id"=)"NCT01567722", "official_title"=)"Tissue Acquisition for Analysis of Prognostic Factors, Immunology, and Genetic Progression of HIV-1 Associated Malignancies", "open_date"=)"31-Jul-2012", "other_ids"=)"CDR0000729843", "other_protocol_ids"=)"AMC-083, CDR0000729843", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Lee", "pi_last_name"=)"Ratner", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"91632223", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00069", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE11C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE11C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00069", "nct_id"=)"NCT01793233", "official_title"=)"Longitudinal Assessment of Ovarian Reserve in Adolescents with Lymphoma", "open_date"=)"17-Jun-2013", "other_ids"=)"", "other_protocol_ids"=)"ALTE11C1", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Levine", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"105416826", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01871", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-121", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01871", "nct_id"=)"NCT01470105", "official_title"=)"Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases", "open_date"=)"08-Nov-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Healey", "pi_middle_initial"=)"H", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"279089430", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01687", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0631", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0631", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01687", "nct_id"=)"NCT00922974", "official_title"=)"Phase II/III Study of Image-Guided Radiosurgery/SBRT for Localized Spine Metastasis", "open_date"=)"07-Aug-2009", "other_ids"=)"CDR0000646803", "other_protocol_ids"=)"RTOG-0631, CDR0000646803", "p30grant"=)"CA013330", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Samuel", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74428054", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ427", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398X2101", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01165", "nct_id"=)"NCT01004224", "official_title"=)"A Phase I, Open-label, Multi-center, Dose Escalation Study of Oral BGJ398, a Pan FGF-R Kinase Inhibitor, in Adult Patients With Advanced Solid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74337768", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3A06", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3A06", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02057", "nct_id"=)"NCT01169337", "official_title"=)"Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma", "open_date"=)"05-Oct-2010", "other_ids"=)"CDR0000682012\rECOG-E3A06", "other_protocol_ids"=)"E3A06, CDR0000682012, ECOG-E3A06", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sagar", "pi_last_name"=)"Lonial", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74439478", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02500", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"8808", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"8808", "lead_org_po_id"=)"197080", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02500", "nct_id"=)"NCT01366144", "official_title"=)"An Early Phase 1 Study of ABT-888 in Combination with Carboplatin and Paclitaxel in Patients with Hepatic or Renal Dysfunction and Solid Tumors", "open_date"=)"20-Jun-2011", "other_ids"=)"UPCI-10-115\rCDR0000700997\rUPCI 10-115", "other_protocol_ids"=)"8808, UPCI-10-115, CDR0000700997, UPCI, 10-115", "p30grant"=)"CA013330", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Hussein", "pi_last_name"=)"Tawbi", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74695238", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02599", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL0932", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL0932", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02599", "nct_id"=)"NCT01190930", "official_title"=)"Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)", "open_date"=)"09-Aug-2010", "other_ids"=)"CDR0000683227", "other_protocol_ids"=)"AALL0932, CDR0000683227", "p30grant"=)"CA013330", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anne", "pi_last_name"=)"Angiolillo", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74707439", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)20, "page"=)1, "pages"=)9, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)180},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:588:in `Then I want to verify DT4 response contains the correct data for "sort_default" parameters in the "sort_dt4" json file'

And the "DT4" service is called by providing following parameters to verify sort

Then I want to verify DT4 response contains the DESC data for "sort_by_nct_id_desc" parameters in the "sort_dt4" json file

Scenario:#31 DT4 report can be sort by "P30 Grant Number(p30grant)" as ascending order 5

Given the "DT4" service is called by providing following parameters to verify sort 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "sort_default_1" parameters in the "sort_dt4" json file 0s

And the "DT4" service is called by providing following parameters to verify sort 1s

Then I want to verify DT4 response contains the ASC data for "p30_grant_number_asc" parameters in the "sort_dt4" json file 0s

Scenario:#32 DT4 report can be sort by "P30 Grant Number(p30grant)" as descending order 5

Given the "DT4" service is called by providing following parameters to verify sort 1s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "sort_default_1" parameters in the "sort_dt4" json file 0s

And the "DT4" service is called by providing following parameters to verify sort 1s

Then I want to verify DT4 response contains the DESC data for "p30_grant_number_desc" parameters in the "sort_dt4" json file 0s

Scenario:#33 item per page "-1" should return All list of trial in the DT4 report for "Duke Cancer Institute" 2 1

Given the "DT4" service is called by providing following parameters 2s

Then service status code should return "200" 0s

Then I want to verify DT4 response contains the correct data for "item_per_page_all" parameters in the "duke_cancer_dt4" json file 2s + Show Error 

expected: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"1", "affiliate_..."page"=)1, "pages"=)1, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)674}}
     got: {"can_export_pdf"=)true, "data"=)[{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"1", "affiliate_..."page"=)1, "pages"=)1, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)674}}

(compared using eql?)

Diff:
@@ -1,4 +1,4 @@
 "can_export_pdf" =) true,
-"data" =) [{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL05B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL05B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00310", "nct_id"=)"NCT00897325", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens", "open_date"=)"25-Sep-2006", "other_ids"=)"CDR0000491159\rCOG-AALL05B1", "other_protocol_ids"=)"AALL05B1, CDR0000491159, COG-AALL05B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Hunger", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74445057", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00334", "affiliate_total"=)"3", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS02B3", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS02B3", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00334", "nct_id"=)"NCT00919750", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens", "open_date"=)"16-Feb-2004", "other_ids"=)"CDR0000352347\rCOG-ACNS02B3", "other_protocol_ids"=)"ACNS02B3, CDR0000352347, COG-ACNS02B3", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Pomeroy", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74442841", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00378", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"10-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHOD04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHOD04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00378", "nct_id"=)"NCT00900250", "official_title"=)"Hodgkin Disease (HD) Banking Study", "open_date"=)"23-Oct-2006", "other_ids"=)"COG-AHOD04B1\rCDR0000495369", "other_protocol_ids"=)"AHOD04B1, COG-AHOD04B1, CDR0000495369", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Meghan", "pi_last_name"=)"Higman", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"74445260", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"44", "affiliate_total_rp"=)"4", "center_total"=)"54", "center_total_rp"=)"10", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"23", "affiliate_total_rp"=)"7", "center_total"=)"26", "center_total_rp"=)"7", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00494", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-8461", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 8461", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00494", "nct_id"=)"NCT00048958", "official_title"=)"Cytogenetic Studies in Acute Leukemia and Multiple Myeloma", "open_date"=)"22-Jun-1984", "other_ids"=)"CDR0000256897", "other_protocol_ids"=)"CALGB-8461, CDR0000256897", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Clara", "pi_last_name"=)"Bloomfield", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74394012", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"19", "affiliate_total_rp"=)"0", "center_total"=)"42", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"23", "affiliate_total_rp"=)"0", "center_total"=)"43", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00751", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0000B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0000B", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00751", "nct_id"=)"NCT00784225", "official_title"=)"Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE), Ancillary Study to SELECT", "open_date"=)"29-Jul-2010", "other_ids"=)"SWOG-S0000B\rCDR0000617778", "other_protocol_ids"=)"S0000B, SWOG-S0000B, CDR0000617778", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Frank", "pi_last_name"=)"Meyskens", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"74448410", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"MC083I", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01208", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2010LSUC043", "lead_org_po_id"=)"139049", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01208", "nct_id"=)"NCT01288222", "official_title"=)"KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor", "open_date"=)"20-Jun-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Daniel", "pi_last_name"=)"Weisdorf", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74346339", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02976", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-151107", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 151107", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02976", "nct_id"=)"NCT01414595", "official_title"=)"Molecular Characterization of Lung Cancer: A Collaboration with the Cancer Genome Atlas Project (TGCA)", "open_date"=)"15-Oct-2011", "other_ids"=)"CDR0000706375", "other_protocol_ids"=)"CALGB-151107, CDR0000706375", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"75343061", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03822", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE03N1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE03N1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03822", "nct_id"=)"NCT00082745", "official_title"=)"Key Adverse Events after Childhood Cancer", "open_date"=)"22-Mar-2004", "other_ids"=)"CDR0000360708\rCOG-ALTE03N1\rNCT00228787", "other_protocol_ids"=)"ALTE03N1, CDR0000360708, COG-ALTE03N1, NCT00228787", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Smita", "pi_last_name"=)"Bhatia", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"80132371", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01996", "affiliate_total"=)"3", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A211201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A211201", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01996", "nct_id"=)"NCT01666171", "official_title"=)"Change in Mammographic Density with Metformin Use: A Companion Study to NCIC Study MA.32", "open_date"=)"22-Aug-2012", "other_ids"=)"CDR0000738328\rCALGB-A211201\rMA.32D", "other_protocol_ids"=)"A211201, CDR0000738328, CALGB-A211201, MA.32D", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Marie", "pi_last_name"=)"Wood", "pi_middle_initial"=)"E", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"100000519", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02421", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"220", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"400", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00006143", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02421", "nct_id"=)"", "official_title"=)"Malignant Melanoma Optimizing the Efficacy of Therapies thru a Better Understanding of Alkylating Drug Resistance Mechanisms, Gene Expression, Immune Responses, Pharacokinetics, and Pathologic Responses to Treatment", "open_date"=)"04-Jun-2002", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Paul", "pi_last_name"=)"Mosca", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"128724263", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00021", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"128", "center_total_rp"=)"34", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"200", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00030747", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00021", "nct_id"=)"", "official_title"=)"Evaluation of a Novel Pancreatic Cancer Biomarker", "open_date"=)"04-Oct-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rebekah", "pi_last_name"=)"White", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"130520678", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00050", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1598", "center_total_rp"=)"148", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"150", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00012010", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00050", "nct_id"=)"", "official_title"=)"Early Detection of Breast Cancer Using Circulating Markers", "open_date"=)"03-Nov-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Marks", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130563044", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01585", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9671", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9671", "lead_org_po_id"=)"16108126", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01585", "nct_id"=)"NCT02243592", "official_title"=)"Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients Who Are Exceptional Responders", "open_date"=)"24-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"9671", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Barbara", "pi_last_name"=)"Conley", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"150767079", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00863", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9846", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9846", "lead_org_po_id"=)"37942400", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00863", "nct_id"=)"NCT02474160", "official_title"=)"Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)", "open_date"=)"15-May-2015", "other_ids"=)"P9846_R02PAPPHOLD01\rP9846", "other_protocol_ids"=)"9846, P9846_R02PAPPHOLD01, P9846", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Doroshow", "pi_middle_initial"=)"H", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"190447033", "specific_funding_source"=)"National Cancer Institute LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02072", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"2", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047147", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02072", "nct_id"=)"NCT02026960", "official_title"=)"RNA Extraction and Amplification from Biopsy Specimens in Subjects with Metastatic Renal Cell Carcinoma", "open_date"=)"28-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212691436", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02075", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"155", "center_total_rp"=)"81", "clinical_research_cat"=)"ANC/COR", "close_date"=)"17-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"400", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050074", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02075", "nct_id"=)"", "official_title"=)"Thyroid Cancer and Polybrominated Diphenyl Ether (PBDE) Exposure ", "open_date"=)"14-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Julie", "pi_last_name"=)"Sosa", "pi_middle_initial"=)"A", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"212694580", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02077", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050745", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02077", "nct_id"=)"NCT02132182", "official_title"=)"A Canine/ Human Translational Model of Phenotypic and Functional Differences between Monocytes in Patients with and without Osteosarcoma", "open_date"=)"24-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"William", "pi_last_name"=)"Eward", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"212696664", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02081", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"60", "center_total_rp"=)"7", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"95", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00052149", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02081", "nct_id"=)"NCT02080650", "official_title"=)"Characterization of Circulating Tumor Cells captured by c-MET", "open_date"=)"18-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212699939", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02114", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"97", "center_total_rp"=)"93", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"400", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00044981", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02114", "nct_id"=)"", "official_title"=)"Acquisition of Tissue and Blood (Optional) from Patients with a History of Breast Cancer ", "open_date"=)"01-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Herbert", "pi_last_name"=)"Lyerly", "pi_middle_initial"=)"K", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"213887178", "specific_funding_source"=)"Department of Defense", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02116", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"148", "center_total_rp"=)"144", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"550", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053535", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02116", "nct_id"=)"NCT02229565", "official_title"=)"Molecular Mechanisms Underlying Prostate Cancer Disparities", "open_date"=)"16-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Steven", "pi_last_name"=)"Patierno", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"213895546", "specific_funding_source"=)"Bayer Corporation, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02118", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"15", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053925", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02118", "nct_id"=)"NCT02204943", "official_title"=)"Pharmacodynamic Study of Radium-223 in Men with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC) ", "open_date"=)"28-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"213899899", "specific_funding_source"=)"Bayer Corporation, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02122", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"150", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054422", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02122", "nct_id"=)"", "official_title"=)"Identification of Novel Angiogenesis Biomarkers Correlating with Tumor Response after Hepatic Arterial Embolization for Hepatocellular Carcinoma", "open_date"=)"29-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Charles", "pi_last_name"=)"Kim", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"213903965", "specific_funding_source"=)"Radiological Society of North America, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02148", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"48", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"120", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00056936", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02148", "nct_id"=)"NCT02269982", "official_title"=)"Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)", "open_date"=)"14-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"214168377", "specific_funding_source"=)"Prostate Cancer Foundation, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02162", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"20", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"160", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00059349", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02162", "nct_id"=)"NCT02694965", "official_title"=)"Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma ", "open_date"=)"13-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Brent", "pi_last_name"=)"Hanks", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"214207553", "specific_funding_source"=)"Merck and Company Inc, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02180", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00062142", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02180", "nct_id"=)"NCT02580045", "official_title"=)"CSF Pharmacokinetics and Cell-Free DNA in Patients with Advanced Cancer", "open_date"=)"02-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Kimberly", "pi_last_name"=)"Blackwell", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214386213", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00448", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"11", "center_total_rp"=)"11", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00064629", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00448", "nct_id"=)"NCT02638818", "official_title"=)"A Pilot Study Evaluating Health-related Quality of Life Endpoints in Patients Undergoing Minimally Invasive versus Open Pancreaticoduodenectomy", "open_date"=)"14-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Dan", "pi_last_name"=)"Blazer", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"234522556", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00589", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"122", "center_total_rp"=)"122", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"2000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065084", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00589", "nct_id"=)"", "official_title"=)"Duke GI BEST: Duke Gastrointestinal Biomarkers and Epidemiology Study", "open_date"=)"05-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Qingyi", "pi_last_name"=)"Wei", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"238442455", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00829", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00069742", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00829", "nct_id"=)"NCT02848872", "official_title"=)"Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-Small Cell Lung Cancer", "open_date"=)"19-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Clarke", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"246773971", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00976", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"5", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072146", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00976", "nct_id"=)"", "official_title"=)"Immune Expression in Pediatric Wilms Tumor", "open_date"=)"20-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Routh", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"251721307", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01174", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"120", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072748", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01174", "nct_id"=)"", "official_title"=)"Monitoring of Immune Profiles of Adult Patients Diagnosed with Glioma", "open_date"=)"20-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"258684301", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00063", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00074697", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00063", "nct_id"=)"", "official_title"=)"Pilot Study to Assess Feasibility of Pleural Fluid for Tumor DNA", "open_date"=)"06-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kamran", "pi_last_name"=)"Mahmood", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"284755689", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00336", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0332", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0332", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00336", "nct_id"=)"NCT00392327", "official_title"=)"Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients", "open_date"=)"26-Mar-2007", "other_ids"=)"CDR0000511991\rCOG-ACNS0332", "other_protocol_ids"=)"ACNS0332, CDR0000511991, COG-ACNS0332", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Olson", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74409372", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-140503", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 140503", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00447", "nct_id"=)"NCT00499330", "official_title"=)"A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer", "open_date"=)"15-Jun-2007", "other_ids"=)"CDR0000555324\rECOG-40503", "other_protocol_ids"=)"CALGB-140503, CDR0000555324, ECOG-40503", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Nasser", "pi_last_name"=)"Altorki", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74412640", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"6", "affiliate_total_rp"=)"1", "center_total"=)"6", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00496", "affiliate_total"=)"10", "affiliate_total_rp"=)"5", "center_total"=)"11", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-90203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-90203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00496", "nct_id"=)"NCT00430183", "official_title"=)"A Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer", "open_date"=)"15-Dec-2006", "other_ids"=)"CDR0000526353", "other_protocol_ids"=)"CALGB-90203, CDR0000526353", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Eastham", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74410017", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00507", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1305", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1305", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00507", "nct_id"=)"NCT00588770", "official_title"=)"A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer", "open_date"=)"08-Aug-2008", "other_ids"=)"CDR0000582533", "other_protocol_ids"=)"E1305, CDR0000582533", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Athanassios (Ethan)", "pi_last_name"=)"Argiris", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74416180", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"23", "affiliate_total_rp"=)"2", "center_total"=)"19", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00733", "affiliate_total"=)"22", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0534", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0534", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00733", "nct_id"=)"NCT00567580", "official_title"=)"A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy", "open_date"=)"13-Feb-2008", "other_ids"=)"CDR0000577574", "other_protocol_ids"=)"RTOG-0534, CDR0000577574", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alan", "pi_last_name"=)"Pollack", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74418627", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00926", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GE 122-008", "lead_org_po_id"=)"88518", "local_site_identifier"=)"Pro00012332", "nci_id"=)"NCI-2009-00926", "nct_id"=)"NCT00730444", "official_title"=)"Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma", "open_date"=)"12-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jean", "pi_last_name"=)"De Serres, MD", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"282928", "specific_funding_source"=)"GE Healthcare", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01064", "affiliate_total"=)"9", "affiliate_total_rp"=)"1", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL0032", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL0032", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01064", "nct_id"=)"NCT00026312", "official_title"=)"Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Rescue", "open_date"=)"18-Oct-2001", "other_ids"=)"PANBL0032_A33PAMDREVW01\rCOG-ANBL0032\rCDR0000069018", "other_protocol_ids"=)"ANBL0032, PANBL0032_A33PAMDREVW01, COG-ANBL0032, CDR0000069018", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alice", "pi_last_name"=)"Yu", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74439628", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"Pro00005540", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00454", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"111767", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00029704", "nci_id"=)"NCI-2010-00454", "nct_id"=)"NCT00790816", "official_title"=)"An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"21019472", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01344", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MIP-IB12B", "lead_org_po_id"=)"48834314", "local_site_identifier"=)"Pro00016040", "nci_id"=)"NCI-2010-01344", "nct_id"=)"NCT00874614", "official_title"=)"A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma", "open_date"=)"01-Jun-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Endocrine System", "sp_id"=)"61642327", "specific_funding_source"=)"Molecular Insight Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02211", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"28", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-106", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02211", "nct_id"=)"NCT01208662", "official_title"=)"A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age", "open_date"=)"27-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Paul", "pi_last_name"=)"Richardson", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74027624", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02332", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TED10893", "lead_org_po_id"=)"214637", "local_site_identifier"=)"Pro00057344", "nci_id"=)"NCI-2010-02332", "nct_id"=)"NCT01084252", "official_title"=)"A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74089494", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00116", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10112", "lead_org_po_id"=)"38249", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00116", "nct_id"=)"NCT01273610", "official_title"=)"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Aged 60 or Older with HER2 Positive Locally Advanced or Metastatic Breast Cancer", "open_date"=)"13-Apr-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Arti", "pi_last_name"=)"Hurria", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74143229", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation, City of Hope Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00793", "affiliate_total"=)"23", "affiliate_total_rp"=)"3", "center_total"=)"24", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"08-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E5508", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E5508", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00793", "nct_id"=)"NCT01107626", "official_title"=)"Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-squamous NSCLC", "open_date"=)"12-Aug-2010", "other_ids"=)"ECOG-E5508\rPE5508_A10PAMDREVW01\rCDR0000666482", "other_protocol_ids"=)"E5508, ECOG-E5508, PE5508_A10PAMDREVW01, CDR0000666482", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Suresh", "pi_last_name"=)"Ramalingam", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74436393", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00883", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KB004-01", "lead_org_po_id"=)"14203561", "local_site_identifier"=)"Pro00057985", "nci_id"=)"NCI-2011-00883", "nct_id"=)"NCT01211691", "official_title"=)"Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74291095", "specific_funding_source"=)"KaloBios Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01164", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"VB-111-122", "lead_org_po_id"=)"242384", "local_site_identifier"=)"Pro00028030", "nci_id"=)"NCI-2011-01164", "nct_id"=)"NCT01260506", "official_title"=)"", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74337723", "specific_funding_source"=)"Vascular Biogenics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01190", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2533.00", "lead_org_po_id"=)"39492311", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01190", "nct_id"=)"NCT01413100", "official_title"=)"A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of Systemic Sclerosis", "open_date"=)"15-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"George", "pi_last_name"=)"Georges", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Skin", "sp_id"=)"74339835", "specific_funding_source"=)"Scleroderma Research Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01438", "affiliate_total"=)"31", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"06-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"SCUSF-0806", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SCUSF 0806", "lead_org_po_id"=)"36324157", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01438", "nct_id"=)"NCT01009918", "official_title"=)"Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)adjuvant Chemotherapy with Trastuzumab (Herceptin®)", "open_date"=)"01-Mar-2010", "other_ids"=)"HLMCC-0806\rCDR0000654123", "other_protocol_ids"=)"SCUSF-0806, HLMCC-0806, CDR0000654123", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Maya", "pi_last_name"=)"Guglin", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74377539", "specific_funding_source"=)"SunCoast CCOP Research Base at the University of South Florida", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01745", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"06-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL09P1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL09P1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"ANBL09P1", "nci_id"=)"NCI-2011-01745", "nct_id"=)"NCT01175356", "official_title"=)"A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma", "open_date"=)"04-Oct-2010", "other_ids"=)"CDR0000682629", "other_protocol_ids"=)"ANBL09P1, CDR0000682629", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Brian", "pi_last_name"=)"Weiss", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74411070", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01919", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0260", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0260", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01919", "nct_id"=)"NCT00888615", "official_title"=)"A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "open_date"=)"13-Dec-2010", "other_ids"=)"CDR0000641202", "other_protocol_ids"=)"GOG-0260, CDR0000641202", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Bradley", "pi_last_name"=)"Monk", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74427167", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01948", "affiliate_total"=)"16", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0815", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0815", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"RTOG 0815", "nci_id"=)"NCI-2011-01948", "nct_id"=)"NCT00936390", "official_title"=)"A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer", "open_date"=)"14-Sep-2009", "other_ids"=)"CDR0000648194", "other_protocol_ids"=)"RTOG-0815, CDR0000648194", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alvaro", "pi_last_name"=)"Martinez", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74430433", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01973", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0724", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0724/GOG-0724", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01973", "nct_id"=)"NCT00980954", "official_title"=)"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy", "open_date"=)"15-Sep-2014", "other_ids"=)"GOG-0724\rCDR0000654709", "other_protocol_ids"=)"RTOG-0724, GOG-0724, CDR0000654709", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuja", "pi_last_name"=)"Jhingran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74432640", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01975", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHEP0731", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHEP0731", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01975", "nct_id"=)"NCT00980460", "official_title"=)"Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment", "open_date"=)"14-Sep-2009", "other_ids"=)"COG-AHEP0731\rNCT02265692\rCDR0000654889", "other_protocol_ids"=)"AHEP0731, COG-AHEP0731, NCT02265692, CDR0000654889", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Howard", "pi_last_name"=)"Katzenstein", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"74432842", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01987", "affiliate_total"=)"9", "affiliate_total_rp"=)"3", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0848", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0848", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"RTOG 0848", "nci_id"=)"NCI-2011-01987", "nct_id"=)"NCT01013649", "official_title"=)"A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma", "open_date"=)"17-Nov-2009", "other_ids"=)"CDR0000659092\rRTOG 0848", "other_protocol_ids"=)"RTOG-0848, CDR0000659092, RTOG, 0848", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ross", "pi_last_name"=)"Abrams", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"74433795", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01989", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80802", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80802", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01989", "nct_id"=)"NCT01015833", "official_title"=)"Phase III Randomized Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)", "open_date"=)"15-Feb-2010", "other_ids"=)"CDR0000659348", "other_protocol_ids"=)"CALGB-80802, CDR0000659348", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ghassan", "pi_last_name"=)"Abou-Alfa", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"74433954", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01992", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2906", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2906", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"E2906", "nci_id"=)"NCI-2011-01992", "nct_id"=)"NCT02085408", "official_title"=)"Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age )/= 60 Years)", "open_date"=)"28-Dec-2010", "other_ids"=)"NCT01041703\rECOG-E2906\rCDR0000659585", "other_protocol_ids"=)"E2906, NCT01041703, ECOG-E2906, CDR0000659585", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Foran", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74434175", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02000", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0264", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0264", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02000", "nct_id"=)"NCT01042522", "official_title"=)"A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary", "open_date"=)"08-Feb-2010", "other_ids"=)"CDR0000662814", "other_protocol_ids"=)"GOG-0264, CDR0000662814", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jubilee", "pi_last_name"=)"Brown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"74434968", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02008", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0937", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0937", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02008", "nct_id"=)"NCT01055197", "official_title"=)"Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)", "open_date"=)"18-Mar-2010", "other_ids"=)"CDR0000663959", "other_protocol_ids"=)"RTOG-0937, CDR0000663959", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Gore", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74435576", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02015", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0905", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0905", "lead_org_po_id"=)"220068", "local_site_identifier"=)"S0905", "nci_id"=)"NCI-2011-02015", "nct_id"=)"NCT01064648", "official_title"=)"A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma", "open_date"=)"15-Mar-2010", "other_ids"=)"CDR0000665415", "other_protocol_ids"=)"S0905, CDR0000665415", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Anne", "pi_last_name"=)"Tsao", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Respiratory/Intrathoracic Organs", "sp_id"=)"74436203", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02028", "affiliate_total"=)"9", "affiliate_total_rp"=)"2", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0931", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0931", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02028", "nct_id"=)"NCT01120249", "official_title"=)"EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study", "open_date"=)"01-Apr-2011", "other_ids"=)"SWOG-S0931\rCDR0000668388", "other_protocol_ids"=)"S0931, SWOG-S0931, CDR0000668388", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Christopher", "pi_last_name"=)"Ryan", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74437329", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"2", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02034", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-50801", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-50801", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02034", "nct_id"=)"NCT01118026", "official_title"=)"Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)", "open_date"=)"15-May-2010", "other_ids"=)"CDR0000669076", "other_protocol_ids"=)"CALGB-50801, CDR0000669076", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ann", "pi_last_name"=)"LaCasce", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"74456784", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0263", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0263", "lead_org_po_id"=)"88642", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02037", "nct_id"=)"NCT01101451", "official_title"=)"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy", "open_date"=)"12-Apr-2010", "other_ids"=)"CDR0000670125", "other_protocol_ids"=)"GOG-0263, CDR0000670125", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sang", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74437876", "specific_funding_source"=)"Gynecologic Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02050", "affiliate_total"=)"49", "affiliate_total_rp"=)"13", "center_total"=)"13", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"20-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80702", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80702", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02050", "nct_id"=)"NCT01150045", "official_title"=)"A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer", "open_date"=)"22-Jun-2010", "other_ids"=)"CALGB/SWOG C80702\rCDR0000675693\rCALGB-SWOG C80702\rCALGB 80702", "other_protocol_ids"=)"CALGB-80702, CALGB/SWOG, C80702, CDR0000675693, CALGB-SWOG, C80702, CALGB, 80702", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Meyerhardt", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Colon", "sp_id"=)"74438921", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3A06", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3A06", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02057", "nct_id"=)"NCT01169337", "official_title"=)"Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma", "open_date"=)"05-Oct-2010", "other_ids"=)"CDR0000682012\rECOG-E3A06", "other_protocol_ids"=)"E3A06, CDR0000682012, ECOG-E3A06", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sagar", "pi_last_name"=)"Lonial", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74439478", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02572", "affiliate_total"=)"76", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-47", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-47", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02572", "nct_id"=)"NCT01275677", "official_title"=)"A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer", "open_date"=)"06-Jan-2011", "other_ids"=)"CDR0000692574", "other_protocol_ids"=)"NSABP-B-47, CDR0000692574", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Louis", "pi_last_name"=)"Fehrenbacher", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74677970", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02599", "affiliate_total"=)"24", "affiliate_total_rp"=)"6", "center_total"=)"22", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL0932", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL0932", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02599", "nct_id"=)"NCT01190930", "official_title"=)"Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)", "open_date"=)"09-Aug-2010", "other_ids"=)"CDR0000683227", "other_protocol_ids"=)"AALL0932, CDR0000683227", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anne", "pi_last_name"=)"Angiolillo", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74707439", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02601", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1010", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1010", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02601", "nct_id"=)"NCT01196390", "official_title"=)"A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma", "open_date"=)"30-Dec-2010", "other_ids"=)"CDR0000683717", "other_protocol_ids"=)"RTOG-1010, CDR0000683717", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Howard", "pi_last_name"=)"Safran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Esophagus", "sp_id"=)"74708646", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02605", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0821", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0821", "lead_org_po_id"=)"60948", "local_site_identifier"=)"ACNS0821", "nci_id"=)"NCI-2011-02605", "nct_id"=)"NCT01217437", "official_title"=)"Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial", "open_date"=)"22-Nov-2010", "other_ids"=)"COG-ACNS0821\rCDR0000686608", "other_protocol_ids"=)"ACNS0821, COG-ACNS0821, CDR0000686608", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Adam", "pi_last_name"=)"Levy", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74711654", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02611", "affiliate_total"=)"3", "affiliate_total_rp"=)"1", "center_total"=)"7", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS1031", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS1031", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02611", "nct_id"=)"NCT01231906", "official_title"=)"A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma", "open_date"=)"22-Nov-2010", "other_ids"=)"CDR0000687639\rCOG-AEWS1031", "other_protocol_ids"=)"AEWS1031, CDR0000687639, COG-AEWS1031", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Patrick", "pi_last_name"=)"Leavey", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74715539", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02613", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-70807", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 70807", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02613", "nct_id"=)"NCT01238172", "official_title"=)"The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance", "open_date"=)"01-Dec-2010", "other_ids"=)"CDR0000687958", "other_protocol_ids"=)"CALGB-70807, CDR0000687958", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"John", "pi_last_name"=)"Parsons", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74717134", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02623", "affiliate_total"=)"15", "affiliate_total_rp"=)"1", "center_total"=)"33", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1007", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1007", "lead_org_po_id"=)"220068", "local_site_identifier"=)"S1007", "nci_id"=)"NCI-2011-02623", "nct_id"=)"NCT01272037", "official_title"=)"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer", "open_date"=)"15-Jan-2011", "other_ids"=)"SWOG-S1007\rPS1007_A11PAMDREVW01\rCDR0000692475", "other_protocol_ids"=)"S1007, SWOG-S1007, PS1007_A11PAMDREVW01, CDR0000692475", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kevin", "pi_last_name"=)"Kalinsky", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74723280", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02625", "affiliate_total"=)"4", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-50904", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 50904", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"CALGB-50904", "nci_id"=)"NCI-2011-02625", "nct_id"=)"NCT01286272", "official_title"=)"A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239) and Bendamustine in Patients with Untreated Follicular Lymphoma", "open_date"=)"08-Apr-2011", "other_ids"=)"CDR0000694298", "other_protocol_ids"=)"CALGB-50904, CDR0000694298", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Kristie", "pi_last_name"=)"Blum", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74724720", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02636", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL0934", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL0934", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02636", "nct_id"=)"NCT01371656", "official_title"=)"A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)", "open_date"=)"20-Jun-2011", "other_ids"=)"CDR0000695661", "other_protocol_ids"=)"ACCL0934, CDR0000695661", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sarah", "pi_last_name"=)"Alexander", "pi_middle_initial"=)"W", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74729630", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02640", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL0933", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL0933", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02640", "nct_id"=)"NCT01307579", "official_title"=)"A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)", "open_date"=)"04-Apr-2011", "other_ids"=)"COG-ACCL0933\rCDR0000695748", "other_protocol_ids"=)"ACCL0933, COG-ACCL0933, CDR0000695748", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Theoklis", "pi_last_name"=)"Zaoutis", "pi_middle_initial"=)"E", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74732800", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02642", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80803", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80803", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02642", "nct_id"=)"NCT01333033", "official_title"=)"Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer", "open_date"=)"15-Jul-2011", "other_ids"=)"CDR0000698428", "other_protocol_ids"=)"CALGB-80803, CDR0000698428", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Karyn", "pi_last_name"=)"Goodman", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74734227", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02645", "affiliate_total"=)"3", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2108", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2108", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02645", "nct_id"=)"NCT01242800", "official_title"=)"A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer", "open_date"=)"08-Feb-2011", "other_ids"=)"ECOG-E2108\rCDR0000688097", "other_protocol_ids"=)"E2108, ECOG-E2108, CDR0000688097", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Seema", "pi_last_name"=)"Khan", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74736422", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02649", "affiliate_total"=)"20", "affiliate_total_rp"=)"0", "center_total"=)"11", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1609", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1609", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02649", "nct_id"=)"NCT01274338", "official_title"=)"A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma", "open_date"=)"25-May-2011", "other_ids"=)"ECOG-E1609\rCDR0000692568", "other_protocol_ids"=)"E1609, ECOG-E1609, CDR0000692568", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ahmad", "pi_last_name"=)"Tarhini", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"74738057", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02670", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AAML1031", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAML1031", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02670", "nct_id"=)"NCT01371981", "official_title"=)"A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD", "open_date"=)"20-Jun-2011", "other_ids"=)"CDR0000701850\rCOG-AAML1031", "other_protocol_ids"=)"AAML1031, CDR0000701850, COG-AAML1031", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Richard", "pi_last_name"=)"Aplenc", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74751754", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02673", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1001", "lead_org_po_id"=)"220068", "local_site_identifier"=)"S1001", "nci_id"=)"NCI-2011-02673", "nct_id"=)"NCT01359592", "official_title"=)"A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)", "open_date"=)"18-Jul-2011", "other_ids"=)"SWOG-S1001\rCDR0000700624", "other_protocol_ids"=)"S1001, SWOG-S1001, CDR0000700624", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"Persky", "pi_middle_initial"=)"O", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74754334", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02674", "affiliate_total"=)"28", "affiliate_total_rp"=)"7", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0924", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0924", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02674", "nct_id"=)"NCT01368588", "official_title"=)"Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial", "open_date"=)"07-Jul-2011", "other_ids"=)"PRTOG-0924_A03PAMDREVW01\rCDR0000701128", "other_protocol_ids"=)"RTOG-0924, PRTOG-0924_A03PAMDREVW01, CDR0000701128", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mack", "pi_last_name"=)"Roach", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74754892", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02676", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N107C", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N107C", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"N107C", "nci_id"=)"NCI-2011-02676", "nct_id"=)"NCT01372774", "official_title"=)"A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease", "open_date"=)"08-Jul-2011", "other_ids"=)"CDR0000701474\rNCCTG-N107C", "other_protocol_ids"=)"N107C, CDR0000701474, NCCTG-N107C", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Paul", "pi_last_name"=)"Brown", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74756305", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02702", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-009", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02702", "nct_id"=)"NCT01340300", "official_title"=)"Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors", "open_date"=)"30-Jun-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Meyerhardt", "pi_middle_initial"=)"A", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74781096", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02978", "affiliate_total"=)"16", "affiliate_total_rp"=)"5", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANZGOG-0902-GOG-0274", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANZGOG-0902-GOG-0274", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02978", "nct_id"=)"NCT01414608", "official_title"=)"A Phase III Trial of Adjuvant Chemotherapy following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial", "open_date"=)"09-Jan-2012", "other_ids"=)"ANZGOG-0902\rRTOG-1174\rGOG-0274\rCDR0000706698", "other_protocol_ids"=)"ANZGOG-0902-GOG-0274, ANZGOG-0902, RTOG-1174, GOG-0274, CDR0000706698", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kathleen", "pi_last_name"=)"Moore", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"75343881", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02980", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1411", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1411", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02980", "nct_id"=)"NCT01415752", "official_title"=)"Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+ Bendamustine Followed by Rituximab Consolidation (RB --)R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidation (RBV--) R), Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB --) LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed by Lenalidomide + Rituximab Consolidation (RBV --) LR)", "open_date"=)"22-May-2012", "other_ids"=)"ECOG-E1411\rCDR0000707057", "other_protocol_ids"=)"E1411, ECOG-E1411, CDR0000707057", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Smith", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"75347136", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03059", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"02-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-321", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03059", "nct_id"=)"NCT01182350", "official_title"=)"Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas", "open_date"=)"01-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Kieran", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"75631011", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03132", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB18424-258", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00031423", "nci_id"=)"NCI-2011-03132", "nct_id"=)"NCT01348490", "official_title"=)"An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"75707169", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03452", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"25-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-40903", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 40903", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"CALGB 40903", "nci_id"=)"NCI-2011-03452", "nct_id"=)"NCT01439711", "official_title"=)"Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)", "open_date"=)"15-Feb-2012", "other_ids"=)"CDR0000701992", "other_protocol_ids"=)"CALGB-40903, CDR0000701992", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Eun-Sil (Shelley)", "pi_last_name"=)"Hwang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"76642201", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03797", "affiliate_total"=)"18", "affiliate_total_rp"=)"4", "center_total"=)"18", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL1131", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03797", "nct_id"=)"NCT02883049", "official_title"=)"A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations", "open_date"=)"27-Feb-2012", "other_ids"=)"COG-AALL1131\rNCT01406756\rCDR0000706370", "other_protocol_ids"=)"AALL1131, COG-AALL1131, NCT01406756, CDR0000706370", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Michael", "pi_last_name"=)"Burke", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"77859432", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03837", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"65", "center_total_rp"=)"19", "clinical_research_cat"=)"INT", "close_date"=)"26-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"62", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00025164", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03837", "nct_id"=)"NCT01186978", "official_title"=)"Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-Cell Lymphoma", "open_date"=)"21-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Christopher", "pi_last_name"=)"Kelsey", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"80477956", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03848", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"50", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"31-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"64", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00000581", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03848", "nct_id"=)"NCT00626483", "official_title"=)"REGULATe: REGULATory T-Cell Inhibition with Basiliximab (Simulect®) during Recovery from Therapeutic Temozolomide-Induced Lymphopenia during Antitumor Immunotherapy Targeted against Cytomegalovirus in Patients with Newly-Diagnosed Glioblastoma Multiforme", "open_date"=)"16-Apr-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"80537438", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03861", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"0", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00026864", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03861", "nct_id"=)"", "official_title"=)"Treatment of Metastatic Liver Disease With Humanitarian Use Device:  TheraSphere® (yttrium-90 Glass Microsphere)", "open_date"=)"08-Dec-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Paul", "pi_last_name"=)"Suhocki", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"80539059", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2010-0794", "lead_org_po_id"=)"227400", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00037", "nct_id"=)"NCT01471106", "official_title"=)"Phase II Short-Term Adjuvant Therapy and Biomarker Studies with Targeted Agents in Women with Estrogen Receptor Negative Breast Cancer", "open_date"=)"21-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Banu", "pi_last_name"=)"Arun", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"80732462", "specific_funding_source"=)"Bristol-Myers Squibb, Susan G Komen Breast Cancer Foundation, M D Anderson Cancer Center CCOP Research Base", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00053", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RC1126", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00053", "nct_id"=)"NCT01532089", "official_title"=)"A Randomized Phase II Trial of Erlotinib Alone or in Combination with Bevacizumab in Patients with Non-small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations", "open_date"=)"16-Mar-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Thomas", "pi_last_name"=)"Stinchcombe", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"80783694", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00082", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"29-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-033", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-033", "lead_org_po_id"=)"208502", "local_site_identifier"=)"PBTC-033", "nci_id"=)"NCI-2012-00082", "nct_id"=)"NCT01514201", "official_title"=)"A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)", "open_date"=)"17-Nov-2011", "other_ids"=)"P12978\rNCT01507324\rCDR0000717423\r12-C-0213", "other_protocol_ids"=)"PBTC-033, P12978, NCT01507324, CDR0000717423, 12-C-0213", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Patricia", "pi_last_name"=)"Baxter", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"81059272", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00096", "affiliate_total"=)"10", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1201", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00096", "nct_id"=)"NCT01498289", "official_title"=)"A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer", "open_date"=)"08-Feb-2012", "other_ids"=)"CDR0000720255", "other_protocol_ids"=)"S1201, CDR0000720255", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Syma", "pi_last_name"=)"Iqbal", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"81066674", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00102", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL1131", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00102", "nct_id"=)"NCT01503515", "official_title"=)"A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) following Allogeneic Hematopoietic Cell Transplantation (HCT)", "open_date"=)"21-Mar-2013", "other_ids"=)"CDR0000721415", "other_protocol_ids"=)"ACCL1131, CDR0000721415", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Christopher", "pi_last_name"=)"Dvorak", "pi_middle_initial"=)"C", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"81069466", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00105", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL1033", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL1033", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00105", "nct_id"=)"NCT01503632", "official_title"=)"A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL", "open_date"=)"21-Feb-2012", "other_ids"=)"NCT01476852\rCDR0000721559", "other_protocol_ids"=)"ACCL1033, NCT01476852, CDR0000721559", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Smita", "pi_last_name"=)"Bhatia", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"81070761", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00110", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"02-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-51101", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-51101", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00110", "nct_id"=)"NCT01511562", "official_title"=)"A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma", "open_date"=)"15-Jun-2012", "other_ids"=)"CDR0000721927", "other_protocol_ids"=)"CALGB-51101, CDR0000721927", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Tracy", "pi_last_name"=)"Batchelor", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"81073217", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00234", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N1048", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N1048", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00234", "nct_id"=)"NCT01515787", "official_title"=)"A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision", "open_date"=)"13-Jan-2012", "other_ids"=)"PN1048_A11PAMDREVW01\rNCCTG-N1048\rCDR0000715321", "other_protocol_ids"=)"N1048, PN1048_A11PAMDREVW01, NCCTG-N1048, CDR0000715321", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Deborah", "pi_last_name"=)"Schrag", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Rectum", "sp_id"=)"88713679", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00249", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"20-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0277", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0277", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00249", "nct_id"=)"NCT01533207", "official_title"=)"A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma", "open_date"=)"04-Jun-2012", "other_ids"=)"IRCI 001\rCDR0000724874", "other_protocol_ids"=)"GOG-0277, IRCI, 001, CDR0000724874", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Martee", "pi_last_name"=)"Hensley", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"88721567", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-344", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00255", "nct_id"=)"NCT01494662", "official_title"=)"A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases", "open_date"=)"02-Feb-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Rachel", "pi_last_name"=)"Freedman", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"88983658", "specific_funding_source"=)"Serenex Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00268", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MPD-RC 111", "lead_org_po_id"=)"170797", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00268", "nct_id"=)"NCT01259817", "official_title"=)"Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis", "open_date"=)"13-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Lewis", "pi_last_name"=)"Silverman", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"89039847", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00269", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MPD-RC 112", "lead_org_po_id"=)"170797", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00269", "nct_id"=)"NCT01259856", "official_title"=)"Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia", "open_date"=)"13-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ronald", "pi_last_name"=)"Hoffman", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"89040826", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00350", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-012", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00033496", "nci_id"=)"NCI-2012-00350", "nct_id"=)"NCT01454102", "official_title"=)"A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"89554647", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00352", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M12-895", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00032731", "nci_id"=)"NCI-2012-00352", "nct_id"=)"NCT01506609", "official_title"=)"A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"89555034", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00578", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TTX404", "lead_org_po_id"=)"219099", "local_site_identifier"=)"Pro00034153", "nci_id"=)"NCI-2012-00578", "nct_id"=)"NCT01439347", "official_title"=)"Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects )or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"90998490", "specific_funding_source"=)"Spectrum Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00703", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS1022", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS1022", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00703", "nct_id"=)"NCT01553149", "official_title"=)"A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas", "open_date"=)"19-Mar-2012", "other_ids"=)"COG-ACNS1022\rCDR0000728296", "other_protocol_ids"=)"ACNS1022, COG-ACNS1022, CDR0000728296", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Katherine", "pi_last_name"=)"Warren", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"91624546", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00707", "affiliate_total"=)"5", "affiliate_total_rp"=)"3", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Z11102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Z11102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00707", "nct_id"=)"NCT01556243", "official_title"=)"Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)", "open_date"=)"23-Jul-2012", "other_ids"=)"CDR0000728605\rACOSOG-Z11102", "other_protocol_ids"=)"Z11102, CDR0000728605, ACOSOG-Z11102", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Judy", "pi_last_name"=)"Boughey", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"91626441", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00719", "affiliate_total"=)"11", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00719", "nct_id"=)"NCT01573442", "official_title"=)"Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias", "open_date"=)"07-Sep-2012", "other_ids"=)"CDR0000730083", "other_protocol_ids"=)"A221102, CDR0000730083", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Charles", "pi_last_name"=)"Loprinzi", "pi_middle_initial"=)"L", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"91632684", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00723", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2810", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2810", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00723", "nct_id"=)"NCT01575548", "official_title"=)"Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease following Metastatectomy", "open_date"=)"08-Aug-2012", "other_ids"=)"ECOG-E2810\rCDR0000730383", "other_protocol_ids"=)"E2810, ECOG-E2810, CDR0000730383", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Leonard", "pi_last_name"=)"Appleman", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"91635101", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01153", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PRI-724-201", "lead_org_po_id"=)"45912155", "local_site_identifier"=)"Pro00049667", "nci_id"=)"NCI-2012-01153", "nct_id"=)"NCT01606579", "official_title"=)"An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies", "open_date"=)"01-Jul-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"96334408", "specific_funding_source"=)"Prism Pharma Co., Ltd.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01279", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMyC 10-MM-01", "lead_org_po_id"=)"25978205", "local_site_identifier"=)"Pro00029413", "nci_id"=)"NCI-2012-01279", "nct_id"=)"NCT01464034", "official_title"=)"A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"97037167", "specific_funding_source"=)"Academic Myeloma Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Neogenix 0901", "lead_org_po_id"=)"49385246", "local_site_identifier"=)"Pro00025347", "nci_id"=)"NCI-2012-01393", "nct_id"=)"NCT01040000", "official_title"=)"A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"97619580", "specific_funding_source"=)"Precision Biologics, Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01513", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"201209135", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01513", "nct_id"=)"NCT01670877", "official_title"=)"A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer", "open_date"=)"11-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Cynthia", "pi_last_name"=)"Ma", "pi_middle_initial"=)"X", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"97860423", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01572", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2603.00", "lead_org_po_id"=)"39492311", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01572", "nct_id"=)"NCT01690520", "official_title"=)"Multi-center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies", "open_date"=)"11-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Filippo", "pi_last_name"=)"Milano", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"98013008", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01732", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1205", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1205", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01732", "nct_id"=)"NCT01730950", "official_title"=)"Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma", "open_date"=)"20-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1205", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Christina", "pi_last_name"=)"Tsien", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"99195295", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01960", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1202", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1202", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01960", "nct_id"=)"NCT01598298", "official_title"=)"A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer", "open_date"=)"10-Jun-2013", "other_ids"=)"SWOG-S1202\rCDR0000730691", "other_protocol_ids"=)"S1202, SWOG-S1202, CDR0000730691", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Norah", "pi_last_name"=)"Henry", "pi_middle_initial"=)"L", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"99948386", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01963", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL1131", "lead_org_po_id"=)"60948", "local_site_identifier"=)"ANHL1131", "nci_id"=)"NCI-2012-01963", "nct_id"=)"NCT01595048", "official_title"=)"Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients", "open_date"=)"11-Jun-2012", "other_ids"=)"2010-019224-31\rIGR2009/1593\rCDR0000732604", "other_protocol_ids"=)"ANHL1131, 2010-019224-31, IGR2009/1593, CDR0000732604", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Thomas", "pi_last_name"=)"Gross", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"99950089", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01964", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0279", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0279", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01964", "nct_id"=)"NCT01595061", "official_title"=)"A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)", "open_date"=)"02-Jul-2012", "other_ids"=)"CDR0000732793", "other_protocol_ids"=)"GOG-0279, CDR0000732793", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Neil", "pi_last_name"=)"Horowitz", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Female Genital", "sp_id"=)"99950723", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01967", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS1123", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS1123", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01967", "nct_id"=)"NCT01602666", "official_title"=)"Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)", "open_date"=)"29-May-2012", "other_ids"=)"CDR0000734032", "other_protocol_ids"=)"ACNS1123, CDR0000734032", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ute", "pi_last_name"=)"Bartels", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"99952246", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01977", "affiliate_total"=)"3", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1119", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1119", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"RTOG-1119", "nci_id"=)"NCI-2012-01977", "nct_id"=)"NCT01622868", "official_title"=)"Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG", "open_date"=)"26-Jul-2012", "other_ids"=)"CDR0000735353", "other_protocol_ids"=)"RTOG-1119, CDR0000735353", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"In", "pi_last_name"=)"Kim", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"99987387", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01985", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2511", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2511", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01985", "nct_id"=)"NCT01642251", "official_title"=)"Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer", "open_date"=)"28-Sep-2012", "other_ids"=)"CDR0000736704\rECOG-E2511", "other_protocol_ids"=)"E2511, CDR0000736704, ECOG-E2511", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Taofeek", "pi_last_name"=)"Owonikoko", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"99992668", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01989", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N1174", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N1174", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01989", "nct_id"=)"NCT01648348", "official_title"=)"Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme", "open_date"=)"09-Nov-2012", "other_ids"=)"NCCTG-N1174\rCDR0000737109", "other_protocol_ids"=)"N1174, NCCTG-N1174, CDR0000737109", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Evanthia", "pi_last_name"=)"Galanis", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"99995576", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01995", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1207", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1207", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01995", "nct_id"=)"NCT01674140", "official_title"=)"Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.", "open_date"=)"04-Sep-2013", "other_ids"=)"S1207/NSABP B-53\rSWOG-S1207\rCDR0000738280", "other_protocol_ids"=)"S1207, S1207/NSABP, B-53, SWOG-S1207, CDR0000738280", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mariana", "pi_last_name"=)"Chavez Mac Gregor", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"99999640", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01998", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1211", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1211", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01998", "nct_id"=)"NCT01668719", "official_title"=)"A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)", "open_date"=)"09-Nov-2012", "other_ids"=)"CDR0000738512\rPS1211_A12PAMDREVW01", "other_protocol_ids"=)"S1211, CDR0000738512, PS1211_A12PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Saad", "pi_last_name"=)"Usmani", "pi_middle_initial"=)"Z", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"100002105", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02001", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 1203", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02001", "nct_id"=)"NCT01672892", "official_title"=)"A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)", "open_date"=)"28-Nov-2012", "other_ids"=)"CDR0000738944", "other_protocol_ids"=)"RTOG-1203, CDR0000738944", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ann", "pi_last_name"=)"Klopp", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"100004132", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02020", "affiliate_total"=)"8", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221101", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221101", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02020", "nct_id"=)"NCT01781468", "official_title"=)"A Phase III Randomized, Double-blind Placebo Controlled Study of Armodafinil (Nuvigil) to\r\nReduce Cancer-Related Fatigue in Patients with High Grade Glioma", "open_date"=)"03-Jun-2013", "other_ids"=)"N10C3", "other_protocol_ids"=)"A221101, N10C3", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alyx", "pi_last_name"=)"Umphrey", "pi_middle_initial"=)"B", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"100223340", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAA-III-01", "lead_org_po_id"=)"25119592", "local_site_identifier"=)"Pro00043263", "nci_id"=)"NCI-2012-02037", "nct_id"=)"NCT01578239", "official_title"=)"A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"100428078", "specific_funding_source"=)"Advanced Accelerator Applications SA", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02045", "affiliate_total"=)"4", "affiliate_total_rp"=)"3", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011104", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011104", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02045", "nct_id"=)"NCT01805076", "official_title"=)"Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer", "open_date"=)"21-Feb-2014", "other_ids"=)"ACRIN 6694", "other_protocol_ids"=)"A011104, ACRIN, 6694", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Isabelle", "pi_last_name"=)"Bedrosian", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"100479303", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02067", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0820", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0820", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02067", "nct_id"=)"NCT01349881", "official_title"=)"A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)", "open_date"=)"01-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"S0820", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jason", "pi_last_name"=)"Zell", "pi_middle_initial"=)"A", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"100639166", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02078", "affiliate_total"=)"34", "affiliate_total_rp"=)"34", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"SCUSF-1102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"SCUSF 1102", "lead_org_po_id"=)"36324157", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02078", "nct_id"=)"NCT01789684", "official_title"=)"A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics\r\nServices Among Breast Cancer Patients", "open_date"=)"21-Feb-2013", "other_ids"=)"RSB002", "other_protocol_ids"=)"SCUSF-1102, RSB002", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Sutphen", "pi_middle_initial"=)"", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"100741021", "specific_funding_source"=)"SunCoast CCOP Research Base at the University of South Florida", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02213", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"17-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9197", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9197", "lead_org_po_id"=)"38249", "local_site_identifier"=)"PHI-69", "nci_id"=)"NCI-2012-02213", "nct_id"=)"NCT01729806", "official_title"=)"A Phase I Study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma", "open_date"=)"19-Nov-2012", "other_ids"=)"NCI# 9197\rCDR0000743246\rPHI-69", "other_protocol_ids"=)"9197, NCI#, 9197, CDR0000743246, PHI-69", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Joseph", "pi_last_name"=)"Tuscano", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"101579366", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02217", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-258", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02217", "nct_id"=)"NCT01670500", "official_title"=)"Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (“AC”) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations", "open_date"=)"25-Oct-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Nadine", "pi_last_name"=)"Tung", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"101844827", "specific_funding_source"=)"Myriad Genetics Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02228", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2011-155", "lead_org_po_id"=)"131559", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02228", "nct_id"=)"NCT01728259", "official_title"=)"Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease", "open_date"=)"05-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Zonder", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"101973429", "specific_funding_source"=)"Wayne State University/Karmanos Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02289", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PRLX93936-0002", "lead_org_po_id"=)"211513", "local_site_identifier"=)"Pro00037237", "nci_id"=)"NCI-2012-02289", "nct_id"=)"NCT01695590", "official_title"=)"Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"102088358", "specific_funding_source"=)"Prolexys Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02608", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1A11", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1A11", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02608", "nct_id"=)"NCT01863550", "official_title"=)"Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)", "open_date"=)"02-Dec-2013", "other_ids"=)"ECOG-E1A11", "other_protocol_ids"=)"E1A11, ECOG-E1A11", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Shaji", "pi_last_name"=)"Kumar", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"102651560", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02876", "affiliate_total"=)"4", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1216", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1216", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02876", "nct_id"=)"NCT01809691", "official_title"=)"A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer", "open_date"=)"06-Mar-2013", "other_ids"=)"SWOG-S1216", "other_protocol_ids"=)"S1216, SWOG-S1216", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Neeraj", "pi_last_name"=)"Agarwal", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"103688308", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02880", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EPZ-5676-12-001", "lead_org_po_id"=)"69406", "local_site_identifier"=)"Pro00043252", "nci_id"=)"NCI-2012-02880", "nct_id"=)"NCT01684150", "official_title"=)"A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"103727036", "specific_funding_source"=)"Epizyme, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02990", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"22-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9214", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9214", "lead_org_po_id"=)"125217", "local_site_identifier"=)"J1276", "nci_id"=)"NCI-2012-02990", "nct_id"=)"NCT01757639", "official_title"=)"A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Minimal Residual Disease", "open_date"=)"14-Dec-2012", "other_ids"=)"CDR0000744584\rJ1276\rNA_00076038", "other_protocol_ids"=)"9214, CDR0000744584, J1276, NA_00076038", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"B.", "pi_last_name"=)"Smith", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"104010930", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02996", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"297", "center_total_rp"=)"82", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"320", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00033339", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02996", "nct_id"=)"NCT01908504", "official_title"=)"FDG-PET for the Delivery of Adaptive Radiation Therapy", "open_date"=)"", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"104029591", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03085", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GO27826", "lead_org_po_id"=)"90971", "local_site_identifier"=)"23896878", "nci_id"=)"NCI-2012-03085", "nct_id"=)"NCT01667419", "official_title"=)"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence", "open_date"=)"01-Sep-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"104391310", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03125", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL1221", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03125", "nct_id"=)"NCT01767194", "official_title"=)"A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma", "open_date"=)"12-Feb-2013", "other_ids"=)"CDR0000745188\rCOG-ANBL1221\rPANBL1221_A08PAMDREVW01", "other_protocol_ids"=)"ANBL1221, CDR0000745188, COG-ANBL1221, PANBL1221_A08PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Rajen", "pi_last_name"=)"Mody", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"104622123", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03130", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-187", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03130", "nct_id"=)"NCT01751451", "official_title"=)"A Phase 2, Randomized, 3-Arm Study of Abiraterone Acetate Alone, Abiraterone Acetate plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients with Prostate Cancer with a Rising PSA or a Rising PSA and Nodal Disease following Definitive Radical Prostatectomy", "open_date"=)"20-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Howard", "pi_last_name"=)"Scher", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"104641990", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03142", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M13-367", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00055550", "nci_id"=)"NCI-2012-03142", "nct_id"=)"NCT01794520", "official_title"=)"A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"104715958", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03198", "affiliate_total"=)"16", "affiliate_total_rp"=)"10", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-51", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-51", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03198", "nct_id"=)"NCT01872975", "official_title"=)"A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy", "open_date"=)"22-Aug-2013", "other_ids"=)"NSABP-B-51/RTOG-1304", "other_protocol_ids"=)"NSABP-B-51, NSABP-B-51/RTOG-1304", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Eleftherios (Terry)", "pi_last_name"=)"Mamounas", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"105039873", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00084", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CC-486-AML-001", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"Pro00043164", "nci_id"=)"NCI-2013-00084", "nct_id"=)"NCT01757535", "official_title"=)"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"105601593", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00426", "affiliate_total"=)"5", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1Z11", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1Z11", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00426", "nct_id"=)"NCT01824836", "official_title"=)"A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)", "open_date"=)"21-May-2013", "other_ids"=)"", "other_protocol_ids"=)"E1Z11", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Vered", "pi_last_name"=)"Stearns", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"107120237", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00444", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A071101", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A071101", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00444", "nct_id"=)"NCT01814813", "official_title"=)"A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)", "open_date"=)"22-May-2013", "other_ids"=)"", "other_protocol_ids"=)"A071101", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ian", "pi_last_name"=)"Parney", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"107427299", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00454", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"24-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00033820", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00454", "nct_id"=)"NCT01627288", "official_title"=)"Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL – Gyn Trial)", "open_date"=)"04-Jun-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"107625696", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00455", "affiliate_total"=)"5", "affiliate_total_rp"=)"3", "center_total"=)"15", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"56", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00033060", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00455", "nct_id"=)"NCT01669798", "official_title"=)"Phase II Evaluation of Nintedanib (BIBF 1120) in the Treatment of Bevacizumab-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma", "open_date"=)"09-Oct-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Angeles", "pi_last_name"=)"Secord", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"107629271", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00472", "affiliate_total"=)"22", "affiliate_total_rp"=)"10", "center_total"=)"75", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"20-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"62", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00037688", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00472", "nct_id"=)"NCT01661972", "official_title"=)"X-TRAP: Phase I/II Study of Capecitabine plus Ziv-Aflibercept in Metastatic Colorectal Cancer", "open_date"=)"27-Aug-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"John", "pi_last_name"=)"Strickler", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"107830678", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00475", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"6", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"31-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"X05397", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00475", "nct_id"=)"NCT01729338", "official_title"=)"Phase II Study of Subcutaneous VELCADE and Oral Cyclophosphamide-Based Induction Followed by Sequential Maintenance Therapy with VELCADE and Revlimid (Lenalidomide) for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen", "open_date"=)"09-Nov-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Gwynn", "pi_last_name"=)"Long", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"107833188", "specific_funding_source"=)"Takeda", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00480", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"27", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"56", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00040206", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00480", "nct_id"=)"NCT01754402", "official_title"=)"A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma", "open_date"=)"18-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Gwynn", "pi_last_name"=)"Long", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"107845226", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00490", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"04-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1203", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00490", "nct_id"=)"NCT01802333", "official_title"=)"A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)", "open_date"=)"12-Feb-2013", "other_ids"=)"SWOG-S1203\rPS1203_A06PAMDREVW01", "other_protocol_ids"=)"S1203, SWOG-S1203, PS1203_A06PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Guillermo", "pi_last_name"=)"Garcia-Manero", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"107909826", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00494", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"30", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"16153", "lead_org_po_id"=)"238118", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00494", "nct_id"=)"NCT01610206", "official_title"=)"A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma", "open_date"=)"06-Aug-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Linda", "pi_last_name"=)"Duska", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"107958249", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00500", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1216", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1216", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00500", "nct_id"=)"NCT01810913", "official_title"=)"Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck", "open_date"=)"18-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1216", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Paul", "pi_last_name"=)"Harari", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"108017957", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00503", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"52M51-001", "lead_org_po_id"=)"192780", "local_site_identifier"=)"Pro00050468", "nci_id"=)"NCI-2013-00503", "nct_id"=)"NCT01703572", "official_title"=)"A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"108055339", "specific_funding_source"=)"OncoMed Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00509", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GP28328", "lead_org_po_id"=)"87945", "local_site_identifier"=)"Pro00038486", "nci_id"=)"NCI-2013-00509", "nct_id"=)"NCT01633970", "official_title"=)"A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"108103137", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00520", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"136", "center_total_rp"=)"85", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"136", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00031206", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00520", "nct_id"=)"NCT01450826", "official_title"=)"A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination with Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen", "open_date"=)"31-Oct-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mary", "pi_last_name"=)"Affronti", "pi_middle_initial"=)"L", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"108390307", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00525", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"26", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"19-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00034612", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00525", "nct_id"=)"NCT01526473", "official_title"=)"A Phase I Study to Evaluate the Antitumor Activity and Safety of DUKE-002-VRP(HUHER2-ECD+TM), an Alphaviral Vector Encoding the HER2 Extracellular Domain and Transmembrane Region, in Patients with Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer", "open_date"=)"20-Apr-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Michael", "pi_last_name"=)"Morse", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"108486062", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00526", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-037", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-037", "lead_org_po_id"=)"208502", "local_site_identifier"=)"PBTC-037", "nci_id"=)"NCI-2013-00526", "nct_id"=)"NCT02031965", "official_title"=)"A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients with Refractory or Recurrent High Grade Gliomas (HGG)", "open_date"=)"02-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"PBTC-037", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Mariko", "pi_last_name"=)"DeWire", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"108487103", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00567", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"39", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"42", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00003975", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00567", "nct_id"=)"NCT01627275", "official_title"=)"Naive T-Cell Depleted Donor Lymphocyte Infusion following Allogeneic Stem Cell Transplantation", "open_date"=)"02-Apr-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Horwitz", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"110456299", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00572", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMyC 11-MM-01", "lead_org_po_id"=)"25978205", "local_site_identifier"=)"Pro00038926", "nci_id"=)"NCI-2013-00572", "nct_id"=)"NCT01660750", "official_title"=)"A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"110463278", "specific_funding_source"=)"Academic Myeloma Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00579", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00013947", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00579", "nct_id"=)"NCT01274377", "official_title"=)"A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation", "open_date"=)"22-Feb-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nelson", "pi_last_name"=)"Chao", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"110865425", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00581", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00041857", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00581", "nct_id"=)"NCT01763944", "official_title"=)"A Randomized Controlled Clinical Trial of Carbohydrate Restriction among Men with a Rising PSA after Failed Primary Therapy for Prostate Cancer", "open_date"=)"17-Jan-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Pao-Hwa", "pi_last_name"=)"Lin", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"110865842", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00583", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"59R5-002", "lead_org_po_id"=)"192780", "local_site_identifier"=)"Pro00041741", "nci_id"=)"NCI-2013-00583", "nct_id"=)"NCT01647828", "official_title"=)"A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"110888127", "specific_funding_source"=)"OncoMed Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00630", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"115523", "lead_org_po_id"=)"88367", "local_site_identifier"=)"Pro00041236", "nci_id"=)"NCI-2013-00630", "nct_id"=)"NCT01610414", "official_title"=)"Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"111790172", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00666", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MI-CP216", "lead_org_po_id"=)"130639", "local_site_identifier"=)"Pro00027069", "nci_id"=)"NCI-2013-00666", "nct_id"=)"NCT01284231", "official_title"=)"A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"112660251", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00717", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AGS-003-007", "lead_org_po_id"=)"52548764", "local_site_identifier"=)"Pro00042182", "nci_id"=)"NCI-2013-00717", "nct_id"=)"NCT01582672", "official_title"=)"An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"113083363", "specific_funding_source"=)"Argos Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00721", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"25-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00038093", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00721", "nct_id"=)"NCT01820754", "official_title"=)"Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes with Specificities against Tumor Associated Antigens during and after Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"28-Feb-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Neal", "pi_last_name"=)"Ready", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"113092477", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00737", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1306", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1306", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"RTOG-1306", "nci_id"=)"NCI-2013-00737", "nct_id"=)"NCT01822496", "official_title"=)"A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"04-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1306", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"113220963", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00796", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1304", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1304", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00796", "nct_id"=)"NCT01903811", "official_title"=)"A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease", "open_date"=)"18-Oct-2013", "other_ids"=)"SWOG-S1304\rPS1304_A07PAMDREVW01", "other_protocol_ids"=)"S1304, SWOG-S1304, PS1304_A07PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sikander", "pi_last_name"=)"Ailawadhi", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"114031091", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00810", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MM-111-13-02-04", "lead_org_po_id"=)"9346107", "local_site_identifier"=)"Pro00043152", "nci_id"=)"NCI-2013-00810", "nct_id"=)"NCT01774851", "official_title"=)"Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"114331856", "specific_funding_source"=)"Merrimack Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00814", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3311", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3311", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00814", "nct_id"=)"NCT01898494", "official_title"=)"Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer", "open_date"=)"08-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"E3311", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Robert", "pi_last_name"=)"Ferris", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"114430323", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00820", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"06-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A031203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A031203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00820", "nct_id"=)"NCT01835158", "official_title"=)"Randomized Phase II Study Comparing Cabozantinib  (NSC #761968) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma", "open_date"=)"08-Jul-2013", "other_ids"=)"", "other_protocol_ids"=)"A031203", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Toni", "pi_last_name"=)"Choueiri", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"114537758", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00821", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"06-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091201", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00821", "nct_id"=)"NCT01835145", "official_title"=)"Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma", "open_date"=)"31-Jul-2013", "other_ids"=)"CALGB-A091201", "other_protocol_ids"=)"A091201, CALGB-A091201", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jason", "pi_last_name"=)"Luke", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"114539182", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00875", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011202", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011202", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00875", "nct_id"=)"NCT01901094", "official_title"=)"A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy", "open_date"=)"07-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"A011202", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Judy", "pi_last_name"=)"Boughey", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"115873799", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00894", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"1012007786", "lead_org_po_id"=)"62311", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00894", "nct_id"=)"NCT01367002", "official_title"=)"Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma", "open_date"=)"29-Apr-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Alessandro", "pi_last_name"=)"Santin", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"116035552", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00939", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 1221", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00939", "nct_id"=)"NCT01953952", "official_title"=)"Randomized Phase II Trial of Transoral Endoscopic Head and Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer", "open_date"=)"30-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1221", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Floyd", "pi_last_name"=)"Holsinger", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"116502962", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00943", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1028", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00943", "nct_id"=)"NCT01361113", "official_title"=)"Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Report on Possible Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma", "open_date"=)"15-Feb-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Kimryn", "pi_last_name"=)"Rathmell", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"116519078", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00951", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"07-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1024", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00951", "nct_id"=)"NCT01300962", "official_title"=)"A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients with Metastatic Breast Cancer", "open_date"=)"25-Jul-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Dees", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"116522888", "specific_funding_source"=)"UNC Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00954", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1029", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00954", "nct_id"=)"NCT01298570", "official_title"=)"A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) versus Placebo with FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer", "open_date"=)"02-Mar-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Hanna", "pi_last_name"=)"Sanoff", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"116524303", "specific_funding_source"=)"UNC Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00959", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"17-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1412", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1412", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00959", "nct_id"=)"NCT01856192", "official_title"=)"Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma", "open_date"=)"27-Aug-2013", "other_ids"=)"ECOG-E1412", "other_protocol_ids"=)"E1412, ECOG-E1412", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Grzegorz", "pi_last_name"=)"Nowakowski", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"116534699", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00995", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A211102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A211102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00995", "nct_id"=)"NCT01905046", "official_title"=)"Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women", "open_date"=)"01-Feb-2015", "other_ids"=)"CALGB-A211102", "other_protocol_ids"=)"A211102, CALGB-A211102", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Victoria", "pi_last_name"=)"Seewaldt", "pi_middle_initial"=)"L", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"116815020", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01099", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LX1606.1-301-CS", "lead_org_po_id"=)"9774850", "local_site_identifier"=)"Pro00050854", "nci_id"=)"NCI-2013-01099", "nct_id"=)"NCT01677910", "official_title"=)"A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Stomach", "sp_id"=)"117928518", "specific_funding_source"=)"Lexicon Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01125", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SJMB12", "lead_org_po_id"=)"221716", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01125", "nct_id"=)"NCT01878617", "official_title"=)"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (SJMB12)", "open_date"=)"17-Jun-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Amar", "pi_last_name"=)"Gajjar", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"118027628", "specific_funding_source"=)"St. Jude Children's Research Hospital, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01139", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC1221", "lead_org_po_id"=)"139137", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01139", "nct_id"=)"NCT01880528", "official_title"=)"A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung", "open_date"=)"31-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Steven", "pi_last_name"=)"Schild", "pi_middle_initial"=)"E", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"118140347", "specific_funding_source"=)"Mayo Clinic", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01220", "affiliate_total"=)"3", "affiliate_total_rp"=)"2", "center_total"=)"10", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"28-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A041202", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A041202", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"A041202", "nci_id"=)"NCI-2013-01220", "nct_id"=)"NCT01886872", "official_title"=)"A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ()/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"09-Dec-2013", "other_ids"=)"ALLIANCE A041202", "other_protocol_ids"=)"A041202, ALLIANCE, A041202", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Woyach", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"118981555", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01221", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COVLARL0287", "lead_org_po_id"=)"61194", "local_site_identifier"=)"Pro00041328", "nci_id"=)"NCI-2013-01221", "nct_id"=)"NCT01706822", "official_title"=)"Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Rectum", "sp_id"=)"118982229", "specific_funding_source"=)"Covidien", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01245", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00010324", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01245", "nct_id"=)"NCT00849745", "official_title"=)"Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases", "open_date"=)"15-Sep-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Keith", "pi_last_name"=)"Sullivan", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Unknown Sites", "sp_id"=)"119098725", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01259", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"10", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045700", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01259", "nct_id"=)"NCT01881334", "official_title"=)"A Compassionate Release Protocol: Expanded Access to T-Cell Depleted Haplo-identical Stem Cells for Patients Receiving Allogeneic Transplantation Using a Related Haplo-identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-malignant Disorders Requiring Allogeneic Transplantation", "open_date"=)"30-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Joanne", "pi_last_name"=)"Kurtzberg", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"119122334", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMyC 11MM02", "lead_org_po_id"=)"25978205", "local_site_identifier"=)"Pro00040205", "nci_id"=)"NCI-2013-01324", "nct_id"=)"NCT01789242", "official_title"=)"A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"119917356", "specific_funding_source"=)"Academic Myeloma Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01411", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PB1201", "lead_org_po_id"=)"49385246", "local_site_identifier"=)"Pro00043261", "nci_id"=)"NCI-2013-01411", "nct_id"=)"NCT01834235", "official_title"=)"A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"120949386", "specific_funding_source"=)"Precision Biologics, Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01605", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"10-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CITN-04", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CITN-04", "lead_org_po_id"=)"12715537", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01605", "nct_id"=)"NCT01961115", "official_title"=)"A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced Melanoma", "open_date"=)"13-Sep-2013", "other_ids"=)"", "other_protocol_ids"=)"CITN-04", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Craig", "pi_last_name"=)"Slingluff", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"121133684", "specific_funding_source"=)"Cancer Immunotherapy Trials Network", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01639", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-039", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-039", "lead_org_po_id"=)"208502", "local_site_identifier"=)"PBTC-039", "nci_id"=)"NCI-2013-01639", "nct_id"=)"NCT01964300", "official_title"=)"Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma", "open_date"=)"05-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"PBTC-039", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Stewart", "pi_last_name"=)"Goldman", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"121531092", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01642", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-266", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01642", "nct_id"=)"NCT01920737", "official_title"=)"A Novel “Pediatric-Inspired” Regimen with Reduced Myelosuppressive Drugs for Adults (Aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia", "open_date"=)"07-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jae", "pi_last_name"=)"Park", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"121599898", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01684", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GC P#03.01.020", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"Pro00024454", "nci_id"=)"NCI-2013-01684", "nct_id"=)"NCT01816230", "official_title"=)"Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122076406", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01689", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"114271", "lead_org_po_id"=)"88367", "local_site_identifier"=)"Pro00029689", "nci_id"=)"NCI-2013-01689", "nct_id"=)"NCT01328054", "official_title"=)"A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer", "open_date"=)"01-Dec-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122079865", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01692", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"A8851008", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"Pro00033549", "nci_id"=)"NCI-2013-01692", "nct_id"=)"NCT00761267", "official_title"=)"A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122081600", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01694", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TGR-1202-101 (HEMREF 31)", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"Pro00043378", "nci_id"=)"NCI-2013-01694", "nct_id"=)"NCT01767766", "official_title"=)"A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"122086019", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01696", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"0517-029", "lead_org_po_id"=)"147288", "local_site_identifier"=)"Pro00044511", "nci_id"=)"NCI-2013-01696", "nct_id"=)"NCT01697579", "official_title"=)"A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy Sub-title: Open-Label Cohort to Further Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients Birth to (12 Years Old", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122096319", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01697", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12PLK02", "lead_org_po_id"=)"211483", "local_site_identifier"=)"Pro00044810", "nci_id"=)"NCI-2013-01697", "nct_id"=)"NCT01856023", "official_title"=)"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"122096697", "specific_funding_source"=)"Prometheus", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01737", "affiliate_total"=)"9", "affiliate_total_rp"=)"8", "center_total"=)"10", "center_total_rp"=)"10", "clinical_research_cat"=)"INT", "close_date"=)"31-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A031201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A031201", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01737", "nct_id"=)"NCT01949337", "official_title"=)"Phase III Trial of Enzalutamide (NSC # 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer", "open_date"=)"22-Jan-2014", "other_ids"=)"CALGB-A031201", "other_protocol_ids"=)"A031201, CALGB-A031201", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Michael", "pi_last_name"=)"Morris", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"122379619", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01760", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"WF-98213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"98213", "lead_org_po_id"=)"213850", "local_site_identifier"=)"98213", "nci_id"=)"NCI-2013-01760", "nct_id"=)"NCT01988571", "official_title"=)"Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)", "open_date"=)"05-Feb-2014", "other_ids"=)"WFU-98213\rWF 98213\rCCCWFU 98213\rWFU 98213\r00024197", "other_protocol_ids"=)"WF-98213, WFU-98213, WF, 98213, CCCWFU, 98213, WFU, 98213, 00024197", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"William", "pi_last_name"=)"Hundley", "pi_middle_initial"=)"G", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122741869", "specific_funding_source"=)"Wake Forest NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01776", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1313", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1313", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01776", "nct_id"=)"NCT01959139", "official_title"=)"A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma", "open_date"=)"06-Jan-2014", "other_ids"=)"PS1313_A09PAMDREVW01", "other_protocol_ids"=)"S1313, PS1313_A09PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Ramesh", "pi_last_name"=)"Ramanathan", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"122968436", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01793", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CAMN107AUS37", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00045766", "nci_id"=)"NCI-2013-01793", "nct_id"=)"NCT01744665", "official_title"=)"A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"123134376", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01803", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"29", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"37", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00044071", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01803", "nct_id"=)"NCT01717053", "official_title"=)"A Phase II Trial of Abiraterone Acetate, Radiotherapy, and Short-Term Androgen Deprivation in Men with Unfavorable Risk Localized Prostate Cancer", "open_date"=)"09-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Bridget", "pi_last_name"=)"Koontz", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"123195451", "specific_funding_source"=)"Janssen Pharmaceuticals", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01818", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"16-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"13-048", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01818", "nct_id"=)"NCT01853748", "official_title"=)"A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)", "open_date"=)"17-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sara", "pi_last_name"=)"Tolaney", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"123421842", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01874", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"29", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"130", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00010519", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01874", "nct_id"=)"NCT00932672", "official_title"=)"Randomized Controlled Clinical Trial of Carbohydrate Restriction among Men on Androgen Deprivation Therapy for Prostate Cancer", "open_date"=)"08-Jun-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Brant", "pi_last_name"=)"Inman", "pi_middle_initial"=)"A", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"124092244", "specific_funding_source"=)"Abbott Laboratories", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01899", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"51", "center_total_rp"=)"30", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"110", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00031169", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01899", "nct_id"=)"NCT01491893", "official_title"=)"Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant against Recurrent WHO Grade IV Malignant Glioma", "open_date"=)"11-Jan-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"124218874", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01900", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"22-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"38", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00032421", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01900", "nct_id"=)"NCT01513733", "official_title"=)"The CATCH Prostate Cancer Trial: Cabazitaxel and Tasquinimod in Men with Castration-Resistant Heavily Pre-treated Prostate Cancer", "open_date"=)"01-Dec-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"124247368", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01904", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"URCC-13059", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"URCC#13059", "lead_org_po_id"=)"35608105", "local_site_identifier"=)"URCC#13059", "nci_id"=)"NCI-2013-01904", "nct_id"=)"NCT02054741", "official_title"=)"A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults", "open_date"=)"15-May-2014", "other_ids"=)"NCT02066168\r13059", "other_protocol_ids"=)"URCC-13059, NCT02066168, 13059", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Supriya", "pi_last_name"=)"Mohile", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124262014", "specific_funding_source"=)"University of Rochester NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01922", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SPI-BEL-12-104", "lead_org_po_id"=)"219099", "local_site_identifier"=)"Pro00045788", "nci_id"=)"NCI-2013-01922", "nct_id"=)"NCT01839097", "official_title"=)"Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"124309674", "specific_funding_source"=)"Spectrum Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01934", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CFZ002", "lead_org_po_id"=)"28076", "local_site_identifier"=)"Pro00049094", "nci_id"=)"NCI-2013-01934", "nct_id"=)"NCT01949545", "official_title"=)"An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124435016", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01951", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D0818C00001", "lead_org_po_id"=)"34899", "local_site_identifier"=)"Pro00045020", "nci_id"=)"NCI-2013-01951", "nct_id"=)"NCT01844986", "official_title"=)"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"124605008", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01952", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CR100845", "lead_org_po_id"=)"48659622", "local_site_identifier"=)"Pro00047793", "nci_id"=)"NCI-2013-01952", "nct_id"=)"NCT01703481", "official_title"=)"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124614363", "specific_funding_source"=)"Janssen Research & Development, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01964", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CMX001-301", "lead_org_po_id"=)"46747919", "local_site_identifier"=)"Pro00048557", "nci_id"=)"NCI-2013-01964", "nct_id"=)"NCT01769170", "official_title"=)"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients", "open_date"=)"23-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124648643", "specific_funding_source"=)"Chimerix", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01983", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D1532C00065", "lead_org_po_id"=)"34899", "local_site_identifier"=)"Pro00044927", "nci_id"=)"NCI-2013-01983", "nct_id"=)"NCT01843062", "official_title"=)"A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"124821826", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02008", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"07-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"13-262", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02008", "nct_id"=)"NCT01965353", "official_title"=)"A Phase I Open Label Study of Panobinostat in Combination with Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma", "open_date"=)"18-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jacob", "pi_last_name"=)"Laubach", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"125066661", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02087", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"0103-014", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"Pro00047416", "nci_id"=)"NCI-2013-02087", "nct_id"=)"NCT02018926", "official_title"=)"A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)", "open_date"=)"01-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"125232573", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02164", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"32", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00012947", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02164", "nct_id"=)"NCT00978432", "official_title"=)"A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "open_date"=)"24-Aug-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Anne", "pi_last_name"=)"Beaven", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"125808014", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02167", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL12P1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL12P1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02167", "nct_id"=)"NCT01979536", "official_title"=)"A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)", "open_date"=)"08-Nov-2013", "other_ids"=)"COG-ANHL12P1", "other_protocol_ids"=)"ANHL12P1, COG-ANHL12P1", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Eric", "pi_last_name"=)"Lowe", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"125817960", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02192", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"60", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00021317", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02192", "nct_id"=)"NCT01061788", "official_title"=)"A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer (The RAP Trial)", "open_date"=)"09-Apr-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Herbert", "pi_last_name"=)"Hurwitz", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"125933484", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02201", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"11-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00030834", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02201", "nct_id"=)"NCT01491841", "official_title"=)"Phase I/II Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma", "open_date"=)"21-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Anne", "pi_last_name"=)"Beaven", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"125963365", "specific_funding_source"=)"Cell Therapeutics Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02221", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PR-30-5011-C", "lead_org_po_id"=)"25957265", "local_site_identifier"=)"Pro00046277", "nci_id"=)"NCI-2013-02221", "nct_id"=)"NCT01847274", "official_title"=)"A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"126125207", "specific_funding_source"=)"Tesaro Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02228", "affiliate_total"=)"4", "affiliate_total_rp"=)"4", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-52", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-52", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"NSABP-B-52", "nci_id"=)"NCI-2013-02228", "nct_id"=)"NCT02003209", "official_title"=)"A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation", "open_date"=)"15-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"NSABP-B-52", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mothaffar", "pi_last_name"=)"Rimawi", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"126184536", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02284", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0286B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0286B", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02284", "nct_id"=)"NCT02065687", "official_title"=)"A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer", "open_date"=)"17-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"GOG-0286B", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Victoria", "pi_last_name"=)"Bae-Jump", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"126986253", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02333", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"COVLARO0286", "lead_org_po_id"=)"61194", "local_site_identifier"=)"Pro00041019", "nci_id"=)"NCI-2013-02333", "nct_id"=)"NCT01717014", "official_title"=)"Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series", "open_date"=)"09-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Rectum", "sp_id"=)"127743842", "specific_funding_source"=)"Covidien", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02335", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7080-G000-304", "lead_org_po_id"=)"41888289", "local_site_identifier"=)"Pro00047005", "nci_id"=)"NCI-2013-02335", "nct_id"=)"NCT01761266", "official_title"=)"A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma", "open_date"=)"01-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"127744200", "specific_funding_source"=)"Eisai Limited", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02336", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"117146", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00046669", "nci_id"=)"NCI-2013-02336", "nct_id"=)"NCT01890746", "official_title"=)"A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy", "open_date"=)"01-Sep-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"127744403", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02337", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-032", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00048169", "nci_id"=)"NCI-2013-02337", "nct_id"=)"NCT01928394", "official_title"=)"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"127744599", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02377", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"20120216", "lead_org_po_id"=)"28076", "local_site_identifier"=)"Pro00047830", "nci_id"=)"NCI-2013-02377", "nct_id"=)"NCT02000427", "official_title"=)"A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)", "open_date"=)"20-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"128309956", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02379", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS1221", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02379", "nct_id"=)"NCT02017964", "official_title"=)"A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age", "open_date"=)"23-Dec-2013", "other_ids"=)"COG-ACNS1221", "other_protocol_ids"=)"ACNS1221, COG-ACNS1221", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Lucie", "pi_last_name"=)"Lafay-Cousin", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"128364006", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MDV3100-14", "lead_org_po_id"=)"8007919", "local_site_identifier"=)"Pro00057133", "nci_id"=)"NCI-2013-02393", "nct_id"=)"NCT02003924", "official_title"=)"A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"128499368", "specific_funding_source"=)"Medivation Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02398", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-352-0101", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00049676", "nci_id"=)"NCI-2013-02398", "nct_id"=)"NCT01969838", "official_title"=)"A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"128574413", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02429", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"407", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"530", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00007857", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02429", "nct_id"=)"NCT00734955", "official_title"=)"An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients with Breast Cancer", "open_date"=)"25-May-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"128749625", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02435", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CMEK162AUS11", "lead_org_po_id"=)"23609", "local_site_identifier"=)"Pro00059225", "nci_id"=)"NCI-2013-02435", "nct_id"=)"NCT01885195", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"128859925", "specific_funding_source"=)"Array Biopharma Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02485", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1310", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1310", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02485", "nct_id"=)"NCT02042443", "official_title"=)"Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer", "open_date"=)"15-Feb-2014", "other_ids"=)"SWOG-S1310", "other_protocol_ids"=)"S1310, SWOG-S1310", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Richard", "pi_last_name"=)"Kim", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"129078990", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00012", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBSC", "lead_org_po_id"=)"57642", "local_site_identifier"=)"Pro00008434", "nci_id"=)"NCI-2014-00012", "nct_id"=)"NCT00785525", "official_title"=)"Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors", "open_date"=)"02-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"", "sp_id"=)"130377858", "specific_funding_source"=)"Center for International Blood and Marrow Transplant Research", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00024", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"50", "center_total_rp"=)"22", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00032263", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00024", "nct_id"=)"NCT01725022", "official_title"=)"A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care", "open_date"=)"13-Mar-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nelson", "pi_last_name"=)"Chao", "pi_middle_initial"=)"J", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"130521819", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00025", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"26", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"17-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00032595", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00025", "nct_id"=)"NCT02019199", "official_title"=)"Magnetic Resonance Imaging (MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver, and Pancreatic Motion", "open_date"=)"", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Brian", "pi_last_name"=)"Czito", "pi_middle_initial"=)"G", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"130525824", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00028", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00038021", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00028", "nct_id"=)"", "official_title"=)"Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects with Triple Negative Breast Cancer", "open_date"=)"23-Feb-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Eun-Sil (Shelley)", "pi_last_name"=)"Hwang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"130530540", "specific_funding_source"=)"Susan G Komen Breast Cancer Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00031", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"19-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00044274", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00031", "nct_id"=)"NCT01954030", "official_title"=)"A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Bevacizumab for Adult Patients with Recurrent Malignant Glioma Post-Bevacizumab Failure", "open_date"=)"21-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"130533897", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00032", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00044446", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00032", "nct_id"=)"NCT01927081", "official_title"=)"Self-Management Interventions for Living Well with Breast Cancer", "open_date"=)"03-Sep-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130534160", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00033", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"92", "center_total_rp"=)"51", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"138", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045975", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00033", "nct_id"=)"NCT01905397", "official_title"=)"A Randomized Phase II Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery", "open_date"=)"08-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Dan", "pi_last_name"=)"Blazer", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"130534504", "specific_funding_source"=)"Kinetic Concepts Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00036", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"43", "center_total_rp"=)"15", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047214", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00036", "nct_id"=)"NCT01947166", "official_title"=)"Pancreatic Resection, Malnutrition, and Readmission: Assessment and Prevention", "open_date"=)"30-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kara", "pi_last_name"=)"Penne", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"130536291", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00041", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"55", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"165", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00006458", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00041", "nct_id"=)"", "official_title"=)"Acoustic Radiation Force Impulse (ARFI) Imaging of the Prostate in Vivo", "open_date"=)"27-Jul-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Kathryn", "pi_last_name"=)"Nightingale", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"130545763", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00042", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"83", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"245", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00008173", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00042", "nct_id"=)"NCT00900575", "official_title"=)"Cervical Cancer Detection Using Optical Spectroscopy", "open_date"=)"09-Jun-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"130548162", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00058", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"130", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"14-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"250", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00022895", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00058", "nct_id"=)"NCT02189278", "official_title"=)"Improving Adherence to Recommended Surveillance in Breast Cancer Survivors", "open_date"=)"03-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130609152", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00059", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"120", "center_total_rp"=)"61", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"220", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00028284", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00059", "nct_id"=)"NCT01372631", "official_title"=)"Spectral and High Resolution Measurements for Improved Optical Margin Assessment", "open_date"=)"25-Feb-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130610179", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00061", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"36", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047952", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00061", "nct_id"=)"NCT01984671", "official_title"=)"Home-Based Tablet Computer Pain Coping Skills Following Stem Cell Transplant", "open_date"=)"08-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"130611263", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00075", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"467", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"900", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00008472", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00075", "nct_id"=)"", "official_title"=)"Breast MRI Screening and Prevention for High-Risk Women", "open_date"=)"27-Jun-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Victoria", "pi_last_name"=)"Seewaldt", "pi_middle_initial"=)"L", "primary_purpose"=)"Scr", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130623860", "specific_funding_source"=)"Susan G Komen Breast Cancer Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00079", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-170", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00079", "nct_id"=)"NCT01725633", "official_title"=)"Safety and Tolerability of Nonlinear Aerobic Training in Women with Metastatic Breast Cancer", "open_date"=)"17-Nov-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Lee", "pi_last_name"=)"Jones", "pi_middle_initial"=)"W", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130626319", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00118", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1912", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1912", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00118", "nct_id"=)"NCT02048813", "official_title"=)"A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"20-Feb-2014", "other_ids"=)"ECOG-E1912", "other_protocol_ids"=)"E1912, ECOG-E1912", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Tait", "pi_last_name"=)"Shanafelt", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"131086466", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00149", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBYL719A2201", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00054363", "nci_id"=)"NCI-2014-00149", "nct_id"=)"NCT01923168", "official_title"=)"A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer", "open_date"=)"15-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"132477774", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00156", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CINC280X2204", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00049029", "nci_id"=)"NCI-2014-00156", "nct_id"=)"NCT01870726", "official_title"=)"A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma", "open_date"=)"16-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"132793633", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00162", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBKM120ZUS40", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00052758", "nci_id"=)"NCI-2014-00162", "nct_id"=)"NCT01833169", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors", "open_date"=)"16-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"132818427", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00185", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADU-CL-04", "lead_org_po_id"=)"48498433", "local_site_identifier"=)"Pro00051292", "nci_id"=)"NCI-2014-00185", "nct_id"=)"NCT02004262", "official_title"=)"A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma", "open_date"=)"28-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"133067112", "specific_funding_source"=)"Aduro Biotech, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00209", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0283", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0283", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00209", "nct_id"=)"NCT02059265", "official_title"=)"A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression", "open_date"=)"03-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"GOG-0283", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Hyman", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"133353493", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00222", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AC220-007", "lead_org_po_id"=)"68015", "local_site_identifier"=)"Pro00062876", "nci_id"=)"NCI-2014-00222", "nct_id"=)"NCT02039726", "official_title"=)"A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation", "open_date"=)"29-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"133987772", "specific_funding_source"=)"Daiichi Sankyo Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00229", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INO-VT-464-CL-001", "lead_org_po_id"=)"38235419", "local_site_identifier"=)"Pro00048629", "nci_id"=)"NCI-2014-00229", "nct_id"=)"NCT02012920", "official_title"=)"A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer", "open_date"=)"29-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"134164225", "specific_funding_source"=)"Innocrin Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00256", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15983", "lead_org_po_id"=)"35145", "local_site_identifier"=)"Pro00048692", "nci_id"=)"NCI-2014-00256", "nct_id"=)"NCT01939223", "official_title"=)"A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases", "open_date"=)"31-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"134482660", "specific_funding_source"=)"Bayer Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00257", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-006", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00049036", "nci_id"=)"NCI-2014-00257", "nct_id"=)"NCT01946074", "official_title"=)"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors", "open_date"=)"31-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"134482921", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00258", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"31", "center_total_rp"=)"15", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045042", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00258", "nct_id"=)"NCT01996202", "official_title"=)"A Pilot Study of Ipilimumab and Radiation in Poor Prognosis Melanoma", "open_date"=)"05-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"April", "pi_last_name"=)"Salama", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"134483914", "specific_funding_source"=)"Bristol-Myers Squibb, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00259", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"11", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045976", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00259", "nct_id"=)"NCT01890213", "official_title"=)"A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer", "open_date"=)"13-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Morse", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"134484461", "specific_funding_source"=)"AlphaVax Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00260", "affiliate_total"=)"5", "affiliate_total_rp"=)"5", "center_total"=)"45", "center_total_rp"=)"37", "clinical_research_cat"=)"INT", "close_date"=)"03-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00046383", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00260", "nct_id"=)"NCT01940276", "official_title"=)"A Phase II Open-Label, Parallel Group Study of Abiraterone Acetate plus Prednisone in African American and Caucasian Men with Metastatic Castrate-Resistant Prostate Cancer", "open_date"=)"21-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"George", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"134484910", "specific_funding_source"=)"Janssen Pharmaceuticals", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00264", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"01-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091105", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091105", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00264", "nct_id"=)"NCT02066181", "official_title"=)"A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)", "open_date"=)"21-Mar-2014", "other_ids"=)"1 R01 FD005105-01A1\rPA091105_A04PAMDREVW01", "other_protocol_ids"=)"A091105, 1, R01, FD005105-01A1, PA091105_A04PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mrinal", "pi_last_name"=)"Gounder", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"134524399", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00304", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"20-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"159", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047969", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00304", "nct_id"=)"NCT01989052", "official_title"=)"A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Naïve Adult Patients with Recurrent Malignant Glioma", "open_date"=)"10-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"134747525", "specific_funding_source"=)"Tactical Therapeutics Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00305", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"105SAR101", "lead_org_po_id"=)"23305594", "local_site_identifier"=)"Pro00050117", "nci_id"=)"NCI-2014-00305", "nct_id"=)"NCT01975519", "official_title"=)"A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma", "open_date"=)"04-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"134747813", "specific_funding_source"=)"TRACON Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00307", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1101", "lead_org_po_id"=)"249581", "local_site_identifier"=)"Pro00037305", "nci_id"=)"NCI-2014-00307", "nct_id"=)"NCT01597778", "official_title"=)"A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT CTN #1101)", "open_date"=)"04-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"134752051", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00328", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-143", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00050586", "nci_id"=)"NCI-2014-00328", "nct_id"=)"NCT02017717", "official_title"=)"A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma", "open_date"=)"12-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"134880805", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00365", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-026", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00052054", "nci_id"=)"NCI-2014-00365", "nct_id"=)"NCT02041533", "official_title"=)"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer", "open_date"=)"28-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"135357538", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00373", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CDX011-04", "lead_org_po_id"=)"56901", "local_site_identifier"=)"Pro00051804", "nci_id"=)"NCI-2014-00373", "nct_id"=)"NCT01997333", "official_title"=)"A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)", "open_date"=)"11-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"135380274", "specific_funding_source"=)"Celldex Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00422", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D1532C00079", "lead_org_po_id"=)"34899", "local_site_identifier"=)"Pro00048490", "nci_id"=)"NCI-2014-00422", "nct_id"=)"NCT01933932", "official_title"=)"A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)", "open_date"=)"18-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"135895289", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00446", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221301", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221301", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00446", "nct_id"=)"NCT02116530", "official_title"=)"Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC);  A Randomized, Double-Blind, Placebo-Controlled Trial", "open_date"=)"05-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"A221301", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Rudolph", "pi_last_name"=)"Navari", "pi_middle_initial"=)"M", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"136123867", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00483", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SCRX16-001", "lead_org_po_id"=)"39897311", "local_site_identifier"=)"Pro00046359", "nci_id"=)"NCI-2014-00483", "nct_id"=)"NCT01901653", "official_title"=)"Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer", "open_date"=)"25-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"136442914", "specific_funding_source"=)"Stemcentrx", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00491", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLEE011A2301", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00049619", "nci_id"=)"NCI-2014-00491", "nct_id"=)"NCT01958021", "official_title"=)"A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease", "open_date"=)"25-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"136454680", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00616", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A071102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A071102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00616", "nct_id"=)"NCT02152982", "official_title"=)"A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation", "open_date"=)"15-Dec-2014", "other_ids"=)"CALGB-A071102", "other_protocol_ids"=)"A071102, CALGB-A071102", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Jann", "pi_last_name"=)"Sarkaria", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"137447064", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00619", "affiliate_total"=)"8", "affiliate_total_rp"=)"8", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"URCC-13070", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"URCC# 13070", "lead_org_po_id"=)"35608105", "local_site_identifier"=)"URCC# 13070", "nci_id"=)"NCI-2014-00619", "nct_id"=)"NCT02107443", "official_title"=)"Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers", "open_date"=)"26-Jun-2014", "other_ids"=)"URCC13070", "other_protocol_ids"=)"URCC-13070, URCC13070", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Supriya", "pi_last_name"=)"Mohile", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"137481249", "specific_funding_source"=)"University of Rochester NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00627", "affiliate_total"=)"11", "affiliate_total_rp"=)"9", "center_total"=)"23", "center_total_rp"=)"23", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00627", "nct_id"=)"NCT02154490", "official_title"=)"A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)", "open_date"=)"16-Jun-2014", "other_ids"=)"S1400B\rS1400D\rS1400C\rS1400I\rS1400A\rS1400E", "other_protocol_ids"=)"S1400, S1400B, S1400D, S1400C, S1400I, S1400A, S1400E", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"137570059", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00629", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0281", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0281", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00629", "nct_id"=)"NCT02101788", "official_title"=)"A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer", "open_date"=)"27-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"GOG-0281", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"David", "pi_last_name"=)"Gershenson", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"137589214", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00631", "affiliate_total"=)"4", "affiliate_total_rp"=)"4", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL1331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL1331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00631", "nct_id"=)"NCT02101853", "official_title"=)"Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)", "open_date"=)"08-Dec-2014", "other_ids"=)"COG-AALL1331", "other_protocol_ids"=)"AALL1331, COG-AALL1331", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Patrick", "pi_last_name"=)"Brown", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"137592455", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00635", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-HN001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-HN001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00635", "nct_id"=)"NCT02135042", "official_title"=)"Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)", "open_date"=)"21-Apr-2014", "other_ids"=)"NCT02179164\rRTOG-1305", "other_protocol_ids"=)"NRG-HN001, NCT02179164, RTOG-1305", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Nancy", "pi_last_name"=)"Lee", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"137650585", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00640", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-042", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-042", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00640", "nct_id"=)"NCT02255461", "official_title"=)"Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors", "open_date"=)"05-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"PBTC-042", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Sridharan", "pi_last_name"=)"Gururangan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"137710132", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00644", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-55", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-55", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00644", "nct_id"=)"NCT02032823", "official_title"=)"A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy", "open_date"=)"03-Jul-2014", "other_ids"=)"NSABP B-55/BIG 6-13\rNSABP B-55\rBIG 6-13\rB-55/BIG 6-13\rD081CC00006", "other_protocol_ids"=)"NSABP-B-55, NSABP, B-55/BIG, 6-13, NSABP, B-55, BIG, 6-13, B-55/BIG, 6-13, D081CC00006", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Charles", "pi_last_name"=)"Geyer", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"137744148", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00660", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PCYC-1119-CA", "lead_org_po_id"=)"50366884", "local_site_identifier"=)"Pro00049683", "nci_id"=)"NCI-2014-00660", "nct_id"=)"NCT01962792", "official_title"=)"A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma", "open_date"=)"10-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"139054283", "specific_funding_source"=)"Pharmacyclics LLC.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00663", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"38", "center_total_rp"=)"33", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00043247", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00663", "nct_id"=)"NCT02046122", "official_title"=)"A Phase 1/2 Study of the Safety and Efficacy of Chemotherapy Combined with Adoptive Transfer of HLA-Haploidentical Donor Lymphocyte Infusion in Older Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome", "open_date"=)"11-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Anthony", "pi_last_name"=)"Sung", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"139061297", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00677", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL1232", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL1232", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00677", "nct_id"=)"NCT02176967", "official_title"=)"Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-high-risk Neuroblastoma", "open_date"=)"28-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"ANBL1232", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Holly", "pi_last_name"=)"Meany", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"139231605", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00679", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GRASPALL 2012-09", "lead_org_po_id"=)"38740143", "local_site_identifier"=)"Pro00046940", "nci_id"=)"NCI-2014-00679", "nct_id"=)"NCT01910428", "official_title"=)"A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma", "open_date"=)"09-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"139241091", "specific_funding_source"=)"ERYtech Pharma", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00702", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-BR001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-BR001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00702", "nct_id"=)"NCT02206334", "official_title"=)"A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases", "open_date"=)"04-Aug-2014", "other_ids"=)"NRG BR001", "other_protocol_ids"=)"NRG-BR001, NRG, BR001", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Steven", "pi_last_name"=)"Chmura", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"139634803", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00704", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"DEK-Dkk1-P102", "lead_org_po_id"=)"48834287", "local_site_identifier"=)"Pro00049984", "nci_id"=)"NCI-2014-00704", "nct_id"=)"NCT02013154", "official_title"=)"A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination With Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients With Relapsed or Refractory (R/R) Esophageal Cancer (EC) or Gastro-esophageal Junction (GEJ) Tumors; Part B: An Expansion Cohort in Patients With R/R EC or GEJ Tumors; Part C: An Expansion Cohort in Patients With R/R Esophageal or GEJ Adenocarcinoma; Part D: An Expansion Cohort in Patients With R/R Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients With R/R Gastric Adenocarcinoma With Wnt Signaling Alterations", "open_date"=)"17-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"139649872", "specific_funding_source"=)"Leap Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00712", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL1231", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL1231", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00712", "nct_id"=)"NCT02112916", "official_title"=)"A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)", "open_date"=)"30-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"AALL1231", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Teachey", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"139737692", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00746", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2112", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2112", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00746", "nct_id"=)"NCT02115282", "official_title"=)"A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer", "open_date"=)"29-Mar-2014", "other_ids"=)"ECOG-E2112", "other_protocol_ids"=)"E2112, ECOG-E2112", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Roisin", "pi_last_name"=)"Connolly", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"140237851", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00793", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-142", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00052582", "nci_id"=)"NCI-2014-00793", "nct_id"=)"NCT02060188", "official_title"=)"A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer", "open_date"=)"27-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"140585092", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00814", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1406", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1406", "lead_org_po_id"=)"220068", "local_site_identifier"=)"S1406", "nci_id"=)"NCI-2014-00814", "nct_id"=)"NCT02164916", "official_title"=)"Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer", "open_date"=)"13-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"S1406", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Edmund", "pi_last_name"=)"Kopetz", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"140750017", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00820", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-008", "lead_org_po_id"=)"54187152", "local_site_identifier"=)"Pro00058275", "nci_id"=)"NCI-2014-00820", "nct_id"=)"NCT02088541", "official_title"=)"A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation", "open_date"=)"16-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"140817612", "specific_funding_source"=)"Karyopharm Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00848", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CITN-09", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CITN-09", "lead_org_po_id"=)"12715537", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00848", "nct_id"=)"NCT02267603", "official_title"=)"A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)", "open_date"=)"25-Nov-2014", "other_ids"=)"MK-3475", "other_protocol_ids"=)"CITN-09, MK-3475", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Paul", "pi_last_name"=)"Nghiem", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Skin", "sp_id"=)"141089497", "specific_funding_source"=)"Cancer Immunotherapy Trials Network", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00853", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BO28407", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00049761", "nci_id"=)"NCI-2014-00853", "nct_id"=)"NCT01966471", "official_title"=)"A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer", "open_date"=)"04-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"141157002", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00869", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TL32711-POC-0090-PTL", "lead_org_po_id"=)"220676", "local_site_identifier"=)"Pro00048713", "nci_id"=)"NCI-2014-00869", "nct_id"=)"NCT01940172", "official_title"=)"A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer", "open_date"=)"08-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"141404892", "specific_funding_source"=)"TetraLogic Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00898", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"03-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CITN-07-FLT3L", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CITN-07-FLT3L", "lead_org_po_id"=)"12715537", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00898", "nct_id"=)"NCT02129075", "official_title"=)"A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand", "open_date"=)"09-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"CITN-07-FLT3L", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Nina", "pi_last_name"=)"Bhardwaj", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"141728259", "specific_funding_source"=)"Cancer Immunotherapy Trials Network", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00909", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GC P#02.01.020", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"Pro00034479", "nci_id"=)"NCI-2014-00909", "nct_id"=)"NCT01590628", "official_title"=)"Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hemoglobinopathies", "open_date"=)"11-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"141780481", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00926", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-237", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00052355", "nci_id"=)"NCI-2014-00926", "nct_id"=)"NCT02099058", "official_title"=)"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors", "open_date"=)"14-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"141902803", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00948", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"47", "center_total_rp"=)"27", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"182", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00052239", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00948", "nct_id"=)"NCT02090582", "official_title"=)"Pilot Study on H.O.P.E: Helping Ovarian Cancer Patients Cope during Disease Recurrence ", "open_date"=)"19-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Paula", "pi_last_name"=)"Lee", "pi_middle_initial"=)"S", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"141997240", "specific_funding_source"=)"Foundation for Women's Cancer, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00955", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"13-383", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00955", "nct_id"=)"NCT01982448", "official_title"=)"A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker", "open_date"=)"29-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Erica", "pi_last_name"=)"Mayer", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"142006183", "specific_funding_source"=)"Myriad Genetics Inc, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00956", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MCC-17651", "lead_org_po_id"=)"71815", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00956", "nct_id"=)"NCT02115542", "official_title"=)"Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers", "open_date"=)"10-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Richard", "pi_last_name"=)"Kim", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"142006505", "specific_funding_source"=)"Bayer Corporation, Moffitt Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00985", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TSP0147", "lead_org_po_id"=)"35215944", "local_site_identifier"=)"Expr1000", "nci_id"=)"NCI-2014-00985", "nct_id"=)"NCT02066103", "official_title"=)"Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients", "open_date"=)"17-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"142201599", "specific_funding_source"=)"Mercator MedSystems Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01071", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-LU001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-LU001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01071", "nct_id"=)"NCT02186847", "official_title"=)"Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC", "open_date"=)"25-Aug-2014", "other_ids"=)"PNRG-LU001_A01PAMDREVW01", "other_protocol_ids"=)"NRG-LU001, PNRG-LU001_A01PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Theodoros", "pi_last_name"=)"Tsakiridis", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"143526473", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01104", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"JDI2007-01", "lead_org_po_id"=)"3890853", "local_site_identifier"=)"Pro00012332", "nci_id"=)"NCI-2014-01104", "nct_id"=)"NCT01590680", "official_title"=)"An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma", "open_date"=)"07-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"143984691", "specific_funding_source"=)"DRAXIMAGE", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01146", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"STML-401-0114", "lead_org_po_id"=)"10912561", "local_site_identifier"=)"Pro00050098", "nci_id"=)"NCI-2014-01146", "nct_id"=)"NCT02113982", "official_title"=)"SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "open_date"=)"17-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"144365298", "specific_funding_source"=)"Stemline Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053306", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01159", "nct_id"=)"", "official_title"=)"Cancer Distress Coach Pilot Study  ", "open_date"=)"14-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"144527155", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01160", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"23", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00049983", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01160", "nct_id"=)"NCT02008383", "official_title"=)"Cabozantinib (XL184) with Panitumumab in Subjects with RAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects with MET Amplified Treatment-Refractory Colorectal Cancer", "open_date"=)"29-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"John", "pi_last_name"=)"Strickler", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"144527719", "specific_funding_source"=)"Exelixis Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01161", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"21", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"38", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00049865", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01161", "nct_id"=)"NCT02057939", "official_title"=)"Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer (STREAM) ", "open_date"=)"15-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"144528010", "specific_funding_source"=)"Astellas Pharma US Inc, Medivation Inc, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01167", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-140", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00050901", "nci_id"=)"NCI-2014-01167", "nct_id"=)"NCT02038946", "official_title"=)"A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)", "open_date"=)"13-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"144552329", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01193", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9785-CL-0403", "lead_org_po_id"=)"48002713", "local_site_identifier"=)"Pro00049594", "nci_id"=)"NCI-2014-01193", "nct_id"=)"NCT01977651", "official_title"=)"A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure", "open_date"=)"19-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"144964314", "specific_funding_source"=)"Astellas Pharma Global Development, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01220", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"35", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"66", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00053588", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01220", "nct_id"=)"", "official_title"=)"Usability Testing and Development of a Web-Based Patient Distress Intervention ", "open_date"=)"13-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"145515592", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01223", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHOD1331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHOD1331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01223", "nct_id"=)"NCT02166463", "official_title"=)"A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents", "open_date"=)"16-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"AHOD1331", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sharon", "pi_last_name"=)"Castellino", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"145528769", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01237", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-312-0123", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00054839", "nci_id"=)"NCI-2014-01237", "nct_id"=)"NCT01980888", "official_title"=)"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia", "open_date"=)"28-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"145713075", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01253", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AV001", "lead_org_po_id"=)"38736123", "local_site_identifier"=)"Pro00054859", "nci_id"=)"NCI-2014-01253", "nct_id"=)"NCT02130557", "official_title"=)"A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase (CP) Chronic Myelogenous Leukemia (CML)", "open_date"=)"08-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"145960736", "specific_funding_source"=)"Avillion LLP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01261", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E4112", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E4112", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01261", "nct_id"=)"NCT02352883", "official_title"=)"Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)", "open_date"=)"17-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"E4112", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Constance", "pi_last_name"=)"Lehman", "pi_middle_initial"=)"D", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"146207180", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01268", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-141", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00052949", "nci_id"=)"NCI-2014-01268", "nct_id"=)"NCT02105636", "official_title"=)"An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "open_date"=)"03-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"146224627", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01279", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-HN002", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-HN002", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01279", "nct_id"=)"NCT02254278", "official_title"=)"A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer", "open_date"=)"27-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"NRG-HN002", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sue", "pi_last_name"=)"Yom", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"146409149", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01282", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BP29262", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00058309", "nci_id"=)"NCI-2014-01282", "nct_id"=)"NCT02141295", "official_title"=)"A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 (Vanucizumab) Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer", "open_date"=)"01-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"146439394", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01321", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-352-1214", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00056238", "nci_id"=)"NCI-2014-01321", "nct_id"=)"NCT02101268", "official_title"=)"A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib", "open_date"=)"12-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"146897244", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 18424-362", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00053183", "nci_id"=)"NCI-2014-01324", "nct_id"=)"NCT02117479", "official_title"=)"A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)", "open_date"=)"13-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"146948597", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01340", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ARST1321", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ARST1321", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01340", "nct_id"=)"NCT02180867", "official_title"=)"Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation plus or minus Pazopanib (NSC# 737754)", "open_date"=)"11-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"ARST1321", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Aaron", "pi_last_name"=)"Weiss", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"147120168", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01345", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-287", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01345", "nct_id"=)"NCT02164019", "official_title"=)"A Randomized Trial to Assess Patient Quality of Life and Function after Alternative Surgeries for Pathologic Fractures of the Femur", "open_date"=)"11-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Healey", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"147199543", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01350", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OPZ007", "lead_org_po_id"=)"28076", "local_site_identifier"=)"Pro00054374", "nci_id"=)"NCI-2014-01350", "nct_id"=)"NCT01999335", "official_title"=)"Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects", "open_date"=)"17-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"147213560", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01378", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"18-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400A", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400A", "lead_org_po_id"=)"220068", "local_site_identifier"=)"S1400A", "nci_id"=)"NCI-2014-01378", "nct_id"=)"NCT02766335", "official_title"=)"A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung- Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400A, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147525658", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01379", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"13-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400B", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01379", "nct_id"=)"NCT02785913", "official_title"=)"A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400B, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147527145", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01380", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400C", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400C", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01380", "nct_id"=)"NCT02785939", "official_title"=)"A Phase II Study of Palbociclib for Prevoiusly Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400C, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147527427", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01381", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400D", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400D", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01381", "nct_id"=)"NCT02965378", "official_title"=)"A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400D, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147528449", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01403", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RF-3501", "lead_org_po_id"=)"214245", "local_site_identifier"=)"Pro00044780", "nci_id"=)"NCI-2014-01403", "nct_id"=)"NCT01711658", "official_title"=)"TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation", "open_date"=)"20-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"147628364", "specific_funding_source"=)"Radiation Therapy Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01408", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1317", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01408", "nct_id"=)"NCT02138617", "official_title"=)"GENIC, A Genotype-Directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab", "open_date"=)"06-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Hanna Kelly", "pi_last_name"=)"Sanoff", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"147708807", "specific_funding_source"=)"UNC Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"44", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00046479", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01416", "nct_id"=)"NCT02115243", "official_title"=)"A Phase I Trial of Neoadjuvant Ipilimumab Followed by Melphalan via Isolated Limb Infusion for Patients with Unresectable In-Transit Extremity Melanoma", "open_date"=)"09-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"April", "pi_last_name"=)"Salama", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"147782013", "specific_funding_source"=)"Bristol-Myers Squibb, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01434", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALN-TTR02-004", "lead_org_po_id"=)"27710", "local_site_identifier"=)"Pro00053066", "nci_id"=)"NCI-2014-01434", "nct_id"=)"NCT01960348", "official_title"=)"APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)", "open_date"=)"26-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"148149370", "specific_funding_source"=)"Alnylam Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01442", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M12-914", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00054924", "nci_id"=)"NCI-2014-01442", "nct_id"=)"NCT02163694", "official_title"=)"A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer", "open_date"=)"21-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"148449851", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01443", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB18424-267", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00055658", "nci_id"=)"NCI-2014-01443", "nct_id"=)"NCT02119676", "official_title"=)"A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer", "open_date"=)"30-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"148451762", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01470", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1320", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1320", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01470", "nct_id"=)"NCT02196181", "official_title"=)"A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma", "open_date"=)"22-Jul-2014", "other_ids"=)"NCT02199730\rS1221", "other_protocol_ids"=)"S1320, NCT02199730, S1221", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Alain", "pi_last_name"=)"Algazi", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"148768613", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1316", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1316", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01497", "nct_id"=)"NCT02270450", "official_title"=)"Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction", "open_date"=)"09-Mar-2015", "other_ids"=)"SWOG/S1316", "other_protocol_ids"=)"S1316, SWOG/S1316", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Krouse", "pi_middle_initial"=)"S", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"149112389", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01507", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E4512", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E4512", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01507", "nct_id"=)"NCT02201992", "official_title"=)"A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein", "open_date"=)"18-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"E4512", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Gerber", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"149348456", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01508", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A081105", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A081105", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01508", "nct_id"=)"NCT02193282", "official_title"=)"Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"18-Aug-2014", "other_ids"=)"CALGB A081105", "other_protocol_ids"=)"A081105, CALGB, A081105", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"149348877", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01526", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CP-MGD006-01", "lead_org_po_id"=)"124446", "local_site_identifier"=)"Pro00057708", "nci_id"=)"NCI-2014-01526", "nct_id"=)"NCT02152956", "official_title"=)"A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS", "open_date"=)"11-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"150008789", "specific_funding_source"=)"MacroGenics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01549", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TL32711-RAN-0094-PTL", "lead_org_po_id"=)"220676", "local_site_identifier"=)"Pro00054579", "nci_id"=)"NCI-2014-01549", "nct_id"=)"NCT02147873", "official_title"=)"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "open_date"=)"15-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"150265234", "specific_funding_source"=)"TetraLogic Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01550", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ARRAY-520-215", "lead_org_po_id"=)"23609", "local_site_identifier"=)"Pro00054375", "nci_id"=)"NCI-2014-01550", "nct_id"=)"NCT02092922", "official_title"=)"A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)", "open_date"=)"15-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"150265850", "specific_funding_source"=)"Array Biopharma Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01598", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D6011C00001", "lead_org_po_id"=)"34899", "local_site_identifier"=)"Pro00053148", "nci_id"=)"NCI-2014-01598", "nct_id"=)"NCT02087176", "official_title"=)"A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients", "open_date"=)"22-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"150966665", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01689", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Sep-2015", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"1210013164", "lead_org_po_id"=)"170710", "local_site_identifier"=)"Pro00049675", "nci_id"=)"NCI-2014-01689", "nct_id"=)"NCT01799278", "official_title"=)"A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer", "open_date"=)"30-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"152564286", "specific_funding_source"=)"Weill Medical College of Cornell University", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01763", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-358", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00055547", "nci_id"=)"NCI-2014-01763", "nct_id"=)"NCT02203773", "official_title"=)"A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy", "open_date"=)"23-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"155068080", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01785", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MP-001", "lead_org_po_id"=)"51968392", "local_site_identifier"=)"Pro00053834", "nci_id"=)"NCI-2014-01785", "nct_id"=)"NCT02160106", "official_title"=)"First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects With Advanced Stage Solid Tumors", "open_date"=)"06-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"155599090", "specific_funding_source"=)"MedPacto, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01810", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-BR002", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-BR002", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01810", "nct_id"=)"NCT02364557", "official_title"=)"A Phase IIR/III Trial of  Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer", "open_date"=)"24-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"NRG-BR002", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Steven", "pi_last_name"=)"Chmura", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"157824532", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01811", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ML28897", "lead_org_po_id"=)"87945", "local_site_identifier"=)"Pro00070333", "nci_id"=)"NCI-2014-01811", "nct_id"=)"NCT02091141", "official_title"=)"My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents", "open_date"=)"12-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"158322232", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01820", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EA1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EA1131", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01820", "nct_id"=)"NCT02445391", "official_title"=)"A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy", "open_date"=)"29-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"EA1131", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ingrid", "pi_last_name"=)"Mayer", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"158867277", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01844", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-312-0133", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00055942", "nci_id"=)"NCI-2014-01844", "nct_id"=)"NCT02044822", "official_title"=)"A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion", "open_date"=)"15-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"159576742", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01877", "affiliate_total"=)"26", "affiliate_total_rp"=)"26", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221304", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221304", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01877", "nct_id"=)"NCT02229539", "official_title"=)"A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy with or without Chemotherapy", "open_date"=)"01-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"A221304", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Miller", "pi_middle_initial"=)"C", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"160735744", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01894", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-046", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01894", "nct_id"=)"NCT02218606", "official_title"=)"An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate with or without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer", "open_date"=)"19-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Susan", "pi_last_name"=)"Slovin", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"162573305", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01899", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"J13161", "lead_org_po_id"=)"125217", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01899", "nct_id"=)"NCT02120157", "official_title"=)"A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Multi-Center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched T Cell Replete Bone Marrow with Post-Transplantation Cyclophosphamide for Children and Young Adults with Hematologic Malignancies", "open_date"=)"18-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Heather", "pi_last_name"=)"Symons", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"162943523", "specific_funding_source"=)"Johns Hopkins University/Sidney Kimmel Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01939", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CD-ON-CAT-8015-1036", "lead_org_po_id"=)"130639", "local_site_identifier"=)"Pro00045629", "nci_id"=)"NCI-2014-01939", "nct_id"=)"NCT02227108", "official_title"=)"A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin", "open_date"=)"08-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"165176224", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01940", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"00035055", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01940", "nct_id"=)"", "official_title"=)"Feasibility of a Couple-Based Intervention for Parents of Children with Cancer", "open_date"=)"11-Jun-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"", "sp_id"=)"165178177", "specific_funding_source"=)"National Institutes of Health Clinical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01942", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051024", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01942", "nct_id"=)"NCT02218151", "official_title"=)"Patient-Centered Home-Based Hematopoietic Stem Cell Transplantation", "open_date"=)"03-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Nelson", "pi_last_name"=)"Chao", "pi_middle_initial"=)"J", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"165179580", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01943", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"41", "center_total_rp"=)"41", "clinical_research_cat"=)"INT", "close_date"=)"10-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221303", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221303", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01943", "nct_id"=)"NCT02349412", "official_title"=)"Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-colorectal Gastrointestinal Malignancies", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"A221303", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Temel", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"165180052", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01945", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"04-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051541", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01945", "nct_id"=)"NCT02116894", "official_title"=)"Phase Ib Study of the Combination Regorafenib with PF-03446962 in Patients with Refractory Metastatic Colorectal Cancer (REGAL-1 Trial) ", "open_date"=)"19-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Herbert", "pi_last_name"=)"Hurwitz", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"165181249", "specific_funding_source"=)"Pfizer, Inc., National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01948", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CAMN107A2203", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00054643", "nci_id"=)"NCI-2014-01948", "nct_id"=)"NCT01844765", "official_title"=)"A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib", "open_date"=)"08-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"165216571", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01955", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-007790", "lead_org_po_id"=)"139137", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01955", "nct_id"=)"NCT01500304", "official_title"=)"Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma", "open_date"=)"01-Apr-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"James", "pi_last_name"=)"Jakub", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"165254108", "specific_funding_source"=)"Mayo Clinic", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01993", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-214", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00058078", "nci_id"=)"NCI-2014-01993", "nct_id"=)"NCT02231749", "official_title"=)"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma", "open_date"=)"17-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"165825224", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01999", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398XUS04", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00058827", "nci_id"=)"NCI-2014-01999", "nct_id"=)"NCT02160041", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations", "open_date"=)"17-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"165959400", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02023", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SARC024", "lead_org_po_id"=)"138099", "local_site_identifier"=)"Pro00052320", "nci_id"=)"NCI-2014-02023", "nct_id"=)"NCT02048371", "official_title"=)"A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas", "open_date"=)"23-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"166576226", "specific_funding_source"=)"Sarcoma Alliance for Research Through Collaboration", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02047", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OX4218s", "lead_org_po_id"=)"47617319", "local_site_identifier"=)"Pro00054331", "nci_id"=)"NCI-2014-02047", "nct_id"=)"NCT02132468", "official_title"=)"A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers", "open_date"=)"06-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"166697582", "specific_funding_source"=)"Mateon Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02061", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GU001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GU001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02061", "nct_id"=)"NCT02316548", "official_title"=)"Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer", "open_date"=)"23-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"NRG-GU001", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Libni", "pi_last_name"=)"Eapen", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"166730293", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02066", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"147", "center_total_rp"=)"137", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054792", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02066", "nct_id"=)"NCT02266017", "official_title"=)"An Accessible Mobile Health Behavioral Intervention for Cancer Pain", "open_date"=)"03-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"166982497", "specific_funding_source"=)"American Cancer Society, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02093", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MM-302-02-02-03", "lead_org_po_id"=)"9346107", "local_site_identifier"=)"Pro00065267", "nci_id"=)"NCI-2014-02093", "nct_id"=)"NCT02213744", "official_title"=)"A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer", "open_date"=)"01-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"167248394", "specific_funding_source"=)"Merrimack Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02128", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLDK378AUS23", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00058297", "nci_id"=)"NCI-2014-02128", "nct_id"=)"NCT02186821", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1", "open_date"=)"07-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"167638558", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02143", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PNT2258-03-DLBCL", "lead_org_po_id"=)"52548814", "local_site_identifier"=)"Pro00063749", "nci_id"=)"NCI-2014-02143", "nct_id"=)"NCT02226965", "official_title"=)"A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "open_date"=)"24-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"168112999", "specific_funding_source"=)"Sierra Oncology, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02182", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-043", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-043", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02182", "nct_id"=)"NCT02415153", "official_title"=)"A Phase I Trial of Pomalidomide for Children with Recurrent, Progressive, or Refractory CNS Tumors", "open_date"=)"14-Jul-2015", "other_ids"=)"CC-4047-PBTC-043\rPPBTC-043_R04PAPP01", "other_protocol_ids"=)"PBTC-043, CC-4047-PBTC-043, PPBTC-043_R04PAPP01", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jason", "pi_last_name"=)"Fangusaro", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"168646433", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02266", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AAML1331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAML1331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02266", "nct_id"=)"NCT02339740", "official_title"=)"A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid", "open_date"=)"29-Jun-2015", "other_ids"=)"PAAML1331_A01PAMDREVW0", "other_protocol_ids"=)"AAML1331, PAAML1331_A01PAMDREVW0", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Matthew", "pi_last_name"=)"Kutny", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"169771226", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02300", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CO-1686-022 (TIGER-1)", "lead_org_po_id"=)"30178935", "local_site_identifier"=)"Pro00059010", "nci_id"=)"NCI-2014-02300", "nct_id"=)"NCT02186301", "official_title"=)"TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC", "open_date"=)"18-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"170298784", "specific_funding_source"=)"Clovis Oncology", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02316", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00051736", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02316", "nct_id"=)"NCT02215070", "official_title"=)"A Phase II Trial for the Prevention of Gastrointestinal Toxicity from Total Body Irradiation or High Dose Chemotherapy with Pasireotide", "open_date"=)"22-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Anthony", "pi_last_name"=)"Sung", "pi_middle_initial"=)"D", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170513635", "specific_funding_source"=)"Duke University Medical Center, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02317", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"29", "center_total_rp"=)"29", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"472", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00057512", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02317", "nct_id"=)"NCT02430467", "official_title"=)"Caregiver-Guided Pain Management in Palliative Care", "open_date"=)"27-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170514411", "specific_funding_source"=)"NIH - National Institute of Nursing Research, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02364", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"01-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-296", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02364", "nct_id"=)"NCT02251548", "official_title"=)"A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia", "open_date"=)"03-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Matthew", "pi_last_name"=)"Davids", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"170965178", "specific_funding_source"=)"Pharmacyclics Inc, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02380", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS1221", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02380", "nct_id"=)"NCT02306161", "official_title"=)"Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma", "open_date"=)"08-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"AEWS1221", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Steven", "pi_last_name"=)"DuBois", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"171266659", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02405", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1403", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02405", "nct_id"=)"NCT02438722", "official_title"=)"A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) (BI 1200.124)", "open_date"=)"25-Mar-2015", "other_ids"=)"BI 1200.124", "other_protocol_ids"=)"S1403, BI, 1200.124", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Sarah", "pi_last_name"=)"Goldberg", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"171640719", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02409", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"17-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02409", "nct_id"=)"NCT02311933", "official_title"=)"A Randomized Phase II Trial of Tamoxifen versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer", "open_date"=)"06-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"A011203", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Matthew", "pi_last_name"=)"Goetz", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"171656120", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02418", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PIN-PHO1201", "lead_org_po_id"=)"41861741", "local_site_identifier"=)"Pro00054576", "nci_id"=)"NCI-2014-02418", "nct_id"=)"NCT02082522", "official_title"=)"Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma", "open_date"=)"21-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"171830703", "specific_funding_source"=)"Concordia Laboratories Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02420", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"03-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9673", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9673", "lead_org_po_id"=)"37888781", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02420", "nct_id"=)"NCT02314169", "official_title"=)"A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal", "open_date"=)"01-May-2015", "other_ids"=)"P9673_R03PAPPHOLD01\rNCI9673", "other_protocol_ids"=)"9673, P9673_R03PAPPHOLD01, NCI9673", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Cathy", "pi_last_name"=)"Eng", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Anus", "sp_id"=)"171839627", "specific_funding_source"=)"University of Texas MD Anderson Cancer Center LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02508", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLEE011E2301", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00060557", "nci_id"=)"NCI-2014-02508", "nct_id"=)"NCT02278120", "official_title"=)"A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer", "open_date"=)"12-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"172608877", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02541", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"13", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00053924", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02541", "nct_id"=)"NCT02256111", "official_title"=)"EXTEND: Safety and Efficacy of Exercise Training in Men Receiving Enzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer", "open_date"=)"26-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"173217129", "specific_funding_source"=)"National Institutes of Health Clinical Center, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02585", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WIRB Protocol: 20141932", "lead_org_po_id"=)"38724643", "local_site_identifier"=)"Pro00068598", "nci_id"=)"NCI-2014-02585", "nct_id"=)"NCT02301611", "official_title"=)"A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.", "open_date"=)"19-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"173952351", "specific_funding_source"=)"Cancer Insight, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02596", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA001-030", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00056092", "nci_id"=)"NCI-2014-02596", "nct_id"=)"NCT02247349", "official_title"=)"A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer", "open_date"=)"17-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"174039443", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02676", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1404", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1404", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02676", "nct_id"=)"NCT02506153", "official_title"=)"A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma", "open_date"=)"15-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"S1404", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kenneth", "pi_last_name"=)"Grossmann", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"175010868", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00025", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 24360-203 / ECHO-203", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00073140", "nci_id"=)"NCI-2015-00025", "nct_id"=)"NCT02318277", "official_title"=)"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)", "open_date"=)"29-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"175684036", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00040", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 24360-204 / ECHO-204", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00058492", "nci_id"=)"NCI-2015-00040", "nct_id"=)"NCT02327078", "official_title"=)"A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)", "open_date"=)"08-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"175932339", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00051", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9825", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9825", "lead_org_po_id"=)"37883561", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00051", "nct_id"=)"NCT02345265", "official_title"=)"A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer", "open_date"=)"04-Dec-2015", "other_ids"=)"16-700", "other_protocol_ids"=)"9825, 16-700", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Joyce", "pi_last_name"=)"Liu", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"176071830", "specific_funding_source"=)"Dana-Farber - Harvard Cancer Center LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00054", "affiliate_total"=)"29", "affiliate_total_rp"=)"29", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EAY131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EAY131", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00054", "nct_id"=)"NCT02465060", "official_title"=)"Molecular Analysis for Therapy Choice (MATCH)", "open_date"=)"12-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"EAY131", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Keith", "pi_last_name"=)"Flaherty", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"176073250", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00060", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4193C00001", "lead_org_po_id"=)"34899", "local_site_identifier"=)"Pro00059081", "nci_id"=)"NCI-2015-00060", "nct_id"=)"NCT02207530", "official_title"=)"A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "open_date"=)"13-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"176278402", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00071", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"STML-401-0214", "lead_org_po_id"=)"48419304", "local_site_identifier"=)"Pro00058309", "nci_id"=)"NCI-2015-00071", "nct_id"=)"NCT02270463", "official_title"=)"A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR", "open_date"=)"25-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"176419501", "specific_funding_source"=)"Stemline Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00128", "affiliate_total"=)"5", "affiliate_total_rp"=)"5", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-BR003", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-BR003", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"NRG-BR003", "nci_id"=)"NCI-2015-00128", "nct_id"=)"NCT02488967", "official_title"=)"A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer", "open_date"=)"26-Jun-2015", "other_ids"=)"NRG-BR1428", "other_protocol_ids"=)"NRG-BR003, NRG-BR1428", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Vicente", "pi_last_name"=)"Valero", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"177199071", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00144", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTA 408-C-1401", "lead_org_po_id"=)"212365", "local_site_identifier"=)"Pro00059068", "nci_id"=)"NCI-2015-00144", "nct_id"=)"NCT02259231", "official_title"=)"An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma", "open_date"=)"28-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"177544193", "specific_funding_source"=)"Reata Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"FLX925-01", "lead_org_po_id"=)"49121464", "local_site_identifier"=)"Pro00064219", "nci_id"=)"NCI-2015-00165", "nct_id"=)"NCT02335814", "official_title"=)"Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "open_date"=)"20-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"177778755", "specific_funding_source"=)"FLX Bio, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00188", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CP-MGD007-01", "lead_org_po_id"=)"124446", "local_site_identifier"=)"Pro00056149", "nci_id"=)"NCI-2015-00188", "nct_id"=)"NCT02248805", "official_title"=)"A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma", "open_date"=)"03-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"178092308", "specific_funding_source"=)"MacroGenics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00200", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GO29294", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00058406", "nci_id"=)"NCI-2015-00200", "nct_id"=)"NCT02302807", "official_title"=)"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy", "open_date"=)"04-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"178224194", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00230", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGI-110-04", "lead_org_po_id"=)"48735172", "local_site_identifier"=)"Pro00065300", "nci_id"=)"NCI-2015-00230", "nct_id"=)"NCT02348489", "official_title"=)"A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy", "open_date"=)"20-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"178930928", "specific_funding_source"=)"Astex Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00260", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091401", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091401", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00260", "nct_id"=)"NCT02500797", "official_title"=)"Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma", "open_date"=)"30-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"A091401", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sandra", "pi_last_name"=)"D'Angelo", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"179742778", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00277", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RU241306I", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"Pro00059332", "nci_id"=)"NCI-2015-00277", "nct_id"=)"NCT02393690", "official_title"=)"Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers", "open_date"=)"04-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Alan", "pi_last_name"=)"Ho", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"180118734", "specific_funding_source"=)"Academic and Community Cancer Research United", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00282", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CC-5013-DLC-002", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"Pro00058584", "nci_id"=)"NCI-2015-00282", "nct_id"=)"NCT02285062", "official_title"=)"Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma", "open_date"=)"23-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"180247299", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00284", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"APL-CP0514", "lead_org_po_id"=)"48927695", "local_site_identifier"=)"Pro00056364", "nci_id"=)"NCI-2015-00284", "nct_id"=)"NCT02264639", "official_title"=)"An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).", "open_date"=)"24-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"180328274", "specific_funding_source"=)"Apellis Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00285", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INO-VT-464-CL-004", "lead_org_po_id"=)"38235419", "local_site_identifier"=)"Pro00056987", "nci_id"=)"NCI-2015-00285", "nct_id"=)"NCT02361086", "official_title"=)"A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients With Castration-Resistant Prostate Cancer", "open_date"=)"24-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"180328879", "specific_funding_source"=)"Innocrin Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00297", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"23", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"44", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053325", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00297", "nct_id"=)"NCT02303678", "official_title"=)"Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally via Convection-Enhanced Delivery for Adult Patients with Recurrent Malignant Glioma", "open_date"=)"10-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"180470199", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00298", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"21", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058865", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00298", "nct_id"=)"NCT02318095", "official_title"=)"Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic Cancer", "open_date"=)"03-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Manisha", "pi_last_name"=)"Palta", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"180470823", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00320", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SARC028", "lead_org_po_id"=)"138099", "local_site_identifier"=)"Pro00061069", "nci_id"=)"NCI-2015-00320", "nct_id"=)"NCT02301039", "official_title"=)"SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas", "open_date"=)"13-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"180692573", "specific_funding_source"=)"Sarcoma Alliance for Research Through Collaboration", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00323", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A061402", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A061402", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00323", "nct_id"=)"NCT02516423", "official_title"=)"Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy", "open_date"=)"23-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"A061402", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuj", "pi_last_name"=)"Mahindra", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"180695000", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00324", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AAML1531", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAML1531", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00324", "nct_id"=)"NCT02521493", "official_title"=)"Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome", "open_date"=)"23-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"AAML1531", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jason", "pi_last_name"=)"Berman", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"180695790", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00365", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"71", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00055609", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00365", "nct_id"=)"NCT02363933", "official_title"=)"A Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients with Primary Glial Brain Tumors", "open_date"=)"24-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"181390106", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00448", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CDX011-05", "lead_org_po_id"=)"56901", "local_site_identifier"=)"Pro00065547", "nci_id"=)"NCI-2015-00448", "nct_id"=)"NCT02302339", "official_title"=)"A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma", "open_date"=)"16-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"181894045", "specific_funding_source"=)"Celldex Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00460", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-238", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00060696", "nci_id"=)"NCI-2015-00460", "nct_id"=)"NCT02388906", "official_title"=)"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)", "open_date"=)"10-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"182013653", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00484", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"18", "center_total_rp"=)"18", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-477", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00484", "nct_id"=)"NCT02337491", "official_title"=)"Phase II Study of Pembrolizumab (MK-3475) with and without Bevacizumab for Recurrent Glioblastoma", "open_date"=)"03-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Reardon", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"182591259", "specific_funding_source"=)"Merck and Company Inc, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00490", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-361", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00056953", "nci_id"=)"NCI-2015-00490", "nct_id"=)"NCT02289690", "official_title"=)"A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer", "open_date"=)"24-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"182610734", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00512", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"R2810-ONC-1423", "lead_org_po_id"=)"212669", "local_site_identifier"=)"Pro00063093", "nci_id"=)"NCI-2015-00512", "nct_id"=)"NCT02383212", "official_title"=)"A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies", "open_date"=)"02-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"182726609", "specific_funding_source"=)"Regeneron Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00538", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-ST-003", "lead_org_po_id"=)"47894204", "local_site_identifier"=)"Pro00060103", "nci_id"=)"NCI-2015-00538", "nct_id"=)"NCT02362048", "official_title"=)"A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer", "open_date"=)"20-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"182938013", "specific_funding_source"=)"Acerta Pharma BV", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00546", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A071401", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A071401", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00546", "nct_id"=)"NCT02523014", "official_title"=)"Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations", "open_date"=)"28-Aug-2015", "other_ids"=)"NCI-2015-00501", "other_protocol_ids"=)"A071401, NCI-2015-00501", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Priscilla", "pi_last_name"=)"Brastianos", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"182945798", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00547", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EA2142", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EA2142", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00547", "nct_id"=)"NCT02595424", "official_title"=)"Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinomas", "open_date"=)"06-Nov-2015", "other_ids"=)"NCI-2015-00505", "other_protocol_ids"=)"EA2142, NCI-2015-00505", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Eads", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"182946477", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00566", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NEOD001-CL002", "lead_org_po_id"=)"48419354", "local_site_identifier"=)"Pro00063420", "nci_id"=)"NCI-2015-00566", "nct_id"=)"NCT02312206", "official_title"=)"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis", "open_date"=)"27-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"183472898", "specific_funding_source"=)"Prothena Therapeutics Ltd.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00582", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"60", "center_total_rp"=)"60", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"68", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00059469", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00582", "nct_id"=)"NCT02348710", "official_title"=)"Intervention to Increase Levels of Exercise among Breast Cancer Survivors", "open_date"=)"24-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"183780586", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00591", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"06-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PCYC-1135-CA", "lead_org_po_id"=)"50366884", "local_site_identifier"=)"Pro00061881", "nci_id"=)"NCI-2015-00591", "nct_id"=)"NCT02403271", "official_title"=)"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors", "open_date"=)"07-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"183928708", "specific_funding_source"=)"Pharmacyclics LLC.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00606", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GY004", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GY004", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00606", "nct_id"=)"NCT02446600", "official_title"=)"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "open_date"=)"04-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"NRG-GY004", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Joyce", "pi_last_name"=)"Liu", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"184757108", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00611", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 54828-101", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00061567", "nci_id"=)"NCI-2015-00611", "nct_id"=)"NCT02393248", "official_title"=)"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies", "open_date"=)"13-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"184765425", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00612", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4193C00003", "lead_org_po_id"=)"34899", "local_site_identifier"=)"Pro00060939", "nci_id"=)"NCI-2015-00612", "nct_id"=)"NCT02319044", "official_title"=)"A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "open_date"=)"18-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"184768612", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00634", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCSJ148X2201", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00055551", "nci_id"=)"NCI-2015-00634", "nct_id"=)"NCT02268526", "official_title"=)"A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients", "open_date"=)"15-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"184914450", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00651", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GY005", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GY005", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00651", "nct_id"=)"NCT02502266", "official_title"=)"A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)", "open_date"=)"05-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"NRG-GY005", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Jung-min", "pi_last_name"=)"Lee", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"185067582", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00663", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-204", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00059334", "nci_id"=)"NCI-2015-00663", "nct_id"=)"NCT02320058", "official_title"=)"A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "open_date"=)"01-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"185570719", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00710", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-360", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00059908", "nci_id"=)"NCI-2015-00710", "nct_id"=)"NCT02412371", "official_title"=)"A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"30-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"186801862", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00711", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MRZ-108", "lead_org_po_id"=)"38989474", "local_site_identifier"=)"Pro00059540", "nci_id"=)"NCI-2015-00711", "nct_id"=)"NCT02330562", "official_title"=)"A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by a Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab", "open_date"=)"30-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"186802686", "specific_funding_source"=)"Triphase Research and Development I Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00733", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"20", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060174", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00733", "nct_id"=)"NCT02442583", "official_title"=)"Reducing Sedentary Behaviors among Colorectal Cancer Survivors: Cancer Survivorship Center Pilot Project", "open_date"=)"08-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"187284026", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00739", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"39", "center_total_rp"=)"39", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060925", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00739", "nct_id"=)"", "official_title"=)"Project Breathe: Smoking Cessation and Pain Management in Cancer Survivors", "open_date"=)"28-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kathryn", "pi_last_name"=)"Pollak", "pi_middle_initial"=)"I", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"187345892", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00756", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"192", "center_total_rp"=)"192", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061381", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00756", "nct_id"=)"NCT02465892", "official_title"=)"A Randomized Clinical Trial of the Pillars4Life Curriculum", "open_date"=)"21-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"187452004", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00768", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PLX108-10", "lead_org_po_id"=)"68015", "local_site_identifier"=)"Pro00061113", "nci_id"=)"NCI-2015-00768", "nct_id"=)"NCT02371369", "official_title"=)"A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath", "open_date"=)"07-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"187595579", "specific_funding_source"=)"Daiichi Sankyo Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00812", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-03-PATHOLHUM-02", "lead_org_po_id"=)"52548839", "local_site_identifier"=)"Pro00059394", "nci_id"=)"NCI-2015-00812", "nct_id"=)"NCT02338492", "official_title"=)"A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"188494005", "specific_funding_source"=)"IlluminOss Medical, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00824", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MDV3100-13", "lead_org_po_id"=)"8007919", "local_site_identifier"=)"Pro00063400", "nci_id"=)"NCI-2015-00824", "nct_id"=)"NCT02319837", "official_title"=)"A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy", "open_date"=)"18-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"188838257", "specific_funding_source"=)"Medivation Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00835", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GY006", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GY006", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00835", "nct_id"=)"NCT02466971", "official_title"=)"A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer", "open_date"=)"15-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"NRG-GY006", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Charles", "pi_last_name"=)"Leath", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"189019265", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00855", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"UTX-IB-301", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"Pro00059834", "nci_id"=)"NCI-2015-00855", "nct_id"=)"NCT02301156", "official_title"=)"A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"26-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"190236491", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00856", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"19", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054740", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00856", "nct_id"=)"NCT02366728", "official_title"=)"Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-Specific Dendritic Cell Vaccines with Adjuvant Tetanus Pre-conditioning in Patients with Newly-Diagnosed Glioblastoma", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"190243251", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00858", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1102", "lead_org_po_id"=)"249581", "local_site_identifier"=)"Pro00050652", "nci_id"=)"NCI-2015-00858", "nct_id"=)"NCT02016781", "official_title"=)"A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)", "open_date"=)"26-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"190264700", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00931", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2215-CL-0301", "lead_org_po_id"=)"48002713", "local_site_identifier"=)"Pro00064933", "nci_id"=)"NCI-2015-00931", "nct_id"=)"NCT02421939", "official_title"=)"A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation", "open_date"=)"12-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"191500813", "specific_funding_source"=)"Astellas Pharma Global Development, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00941", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Dec-2016", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PRO00023447", "lead_org_po_id"=)"249581", "local_site_identifier"=)"Pro00059830", "nci_id"=)"NCI-2015-00941", "nct_id"=)"NCT02269267", "official_title"=)"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)", "open_date"=)"03-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"191556055", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00945", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-ST-005", "lead_org_po_id"=)"47894204", "local_site_identifier"=)"Pro00060954", "nci_id"=)"NCI-2015-00945", "nct_id"=)"NCT02351739", "official_title"=)"Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)", "open_date"=)"04-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"191621962", "specific_funding_source"=)"Acerta Pharma BV", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00966", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLAG525X2101C", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00062919", "nci_id"=)"NCI-2015-00966", "nct_id"=)"NCT02460224", "official_title"=)"A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies", "open_date"=)"11-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"191799196", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01040", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CL-PTL-119", "lead_org_po_id"=)"14093834", "local_site_identifier"=)"Pro00058896", "nci_id"=)"NCI-2015-01040", "nct_id"=)"NCT02346747", "official_title"=)"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy", "open_date"=)"17-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"193106990", "specific_funding_source"=)"Gradalis Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01065", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11097", "lead_org_po_id"=)"12389987", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01065", "nct_id"=)"NCT02504359", "official_title"=)"A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma", "open_date"=)"20-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Emma", "pi_last_name"=)"Scott", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"193919501", "specific_funding_source"=)"OHSU Knight Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01075", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"130106", "lead_org_po_id"=)"130639", "local_site_identifier"=)"Pro00058699", "nci_id"=)"NCI-2015-01075", "nct_id"=)"NCT01829711", "official_title"=)"A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia", "open_date"=)"25-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Leukemia, other", "sp_id"=)"194031348", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01086", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AP24534-14-203", "lead_org_po_id"=)"30792", "local_site_identifier"=)"Pro00064341", "nci_id"=)"NCI-2015-01086", "nct_id"=)"NCT02467270", "official_title"=)"A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses", "open_date"=)"26-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"194124533", "specific_funding_source"=)"ARIAD Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01088", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLEE011F2301", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00062951", "nci_id"=)"NCI-2015-01088", "nct_id"=)"NCT02422615", "official_title"=)"A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment", "open_date"=)"17-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"194128653", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01150", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AG881-C-002", "lead_org_po_id"=)"11722315", "local_site_identifier"=)"Pro00063389", "nci_id"=)"NCI-2015-01150", "nct_id"=)"NCT02481154", "official_title"=)"A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation", "open_date"=)"07-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"195311870", "specific_funding_source"=)"Agios Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01178", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221405", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IBCSG 48-14/BIG 8-13", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01178", "nct_id"=)"NCT02308085", "official_title"=)"A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy", "open_date"=)"15-Oct-2015", "other_ids"=)"Alliance A221405/IBCSG 48-14\rIBCSG 48-14\rBIG 8-13 POSITIVE", "other_protocol_ids"=)"A221405, Alliance, A221405/IBCSG, 48-14, IBCSG, 48-14, BIG, 8-13, POSITIVE", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Ann", "pi_last_name"=)"Partridge", "pi_middle_initial"=)"H", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"195585951", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01191", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060926", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01191", "nct_id"=)"", "official_title"=)"Move 2 Health: A Couple-Based Physical Activity Intervention for Cancer Survivors", "open_date"=)"26-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"195926155", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01192", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063330", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01192", "nct_id"=)"NCT02706301", "official_title"=)"Coping Skills for Colorectal Cancer Survivors with Pain and Distress", "open_date"=)"29-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"195928314", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01209", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"131R10-001", "lead_org_po_id"=)"192780", "local_site_identifier"=)"Pro00072844", "nci_id"=)"NCI-2015-01209", "nct_id"=)"NCT02482441", "official_title"=)"A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer", "open_date"=)"01-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"196116394", "specific_funding_source"=)"OncoMed Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01235", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019B2202", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00061367", "nci_id"=)"NCI-2015-01235", "nct_id"=)"NCT02435849", "official_title"=)"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia", "open_date"=)"20-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"196755033", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01236", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1505", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1505", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01236", "nct_id"=)"NCT02562716", "official_title"=)"A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma", "open_date"=)"12-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"S1505", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Davendra", "pi_last_name"=)"Sohal", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"196755307", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01238", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019A2205B", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00061937", "nci_id"=)"NCI-2015-01238", "nct_id"=)"NCT02445222", "official_title"=)"Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy", "open_date"=)"08-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"196764826", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01245", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PR-30-5020-C", "lead_org_po_id"=)"25957265", "local_site_identifier"=)"Pro00062414", "nci_id"=)"NCI-2015-01245", "nct_id"=)"NCT02354586", "official_title"=)"A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens", "open_date"=)"21-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"196963182", "specific_funding_source"=)"Tesaro Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01262", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-227", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00064704", "nci_id"=)"NCI-2015-01262", "nct_id"=)"NCT02477826", "official_title"=)"An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"24-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"197353722", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01270", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9903", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9903", "lead_org_po_id"=)"37883561", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01270", "nct_id"=)"NCT02520778", "official_title"=)"A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor", "open_date"=)"31-Mar-2016", "other_ids"=)"16-714", "other_protocol_ids"=)"9903, 16-714", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Oxnard", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"197711705", "specific_funding_source"=)"Dana-Farber - Harvard Cancer Center LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01298", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15677", "lead_org_po_id"=)"119479", "local_site_identifier"=)"Pro00065913", "nci_id"=)"NCI-2015-01298", "nct_id"=)"NCT02451943", "official_title"=)"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma", "open_date"=)"18-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"197992315", "specific_funding_source"=)"Eli Lilly and Company", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01317", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"MCC-15-10994", "lead_org_po_id"=)"238148", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01317", "nct_id"=)"NCT02515110", "official_title"=)"Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women with Breast Cancer-“HeNRIetta”", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Douglas", "pi_last_name"=)"Arthur", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"198149539", "specific_funding_source"=)"Virginia Commonwealth University/Massey Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01321", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12751", "lead_org_po_id"=)"40350", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01321", "nct_id"=)"NCT01596751", "official_title"=)"Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients with Metastatic Breast Cancer", "open_date"=)"06-Jul-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Hope", "pi_last_name"=)"Rugo", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"198173420", "specific_funding_source"=)"UCSF Medical Center-Mount Zion", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01329", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA008-002", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00061125", "nci_id"=)"NCI-2015-01329", "nct_id"=)"NCT02341625", "official_title"=)"A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"198563373", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01334", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WO29636", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00063661", "nci_id"=)"NCI-2015-01334", "nct_id"=)"NCT02450331", "official_title"=)"A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"198612884", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01339", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00062343", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01339", "nct_id"=)"NCT02483871", "official_title"=)"Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy", "open_date"=)"30-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Kimberly", "pi_last_name"=)"Blackwell", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"198805592", "specific_funding_source"=)"Susan G Komen Breast Cancer Foundation, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01362", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-331", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00064315", "nci_id"=)"NCI-2015-01362", "nct_id"=)"NCT02481830", "official_title"=)"An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)", "open_date"=)"07-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"199581279", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01461", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019C2201", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00064804", "nci_id"=)"NCI-2015-01461", "nct_id"=)"NCT02445248", "official_title"=)"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "open_date"=)"15-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"201258325", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01477", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ374", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 52793-101", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00065008", "nci_id"=)"NCI-2015-01477", "nct_id"=)"NCT02265510", "official_title"=)"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies", "open_date"=)"25-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"201735443", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01480", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PNT2258-04-Richter's", "lead_org_po_id"=)"52548814", "local_site_identifier"=)"Pro00066902", "nci_id"=)"NCI-2015-01480", "nct_id"=)"NCT02378038", "official_title"=)"A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)", "open_date"=)"04-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"201843241", "specific_funding_source"=)"Sierra Oncology, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01489", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CR107170", "lead_org_po_id"=)"48659622", "local_site_identifier"=)"Pro00064478", "nci_id"=)"NCI-2015-01489", "nct_id"=)"NCT02426086", "official_title"=)"A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor", "open_date"=)"01-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"202085317", "specific_funding_source"=)"Janssen Research & Development, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PM1183-C-004-14", "lead_org_po_id"=)"209784", "local_site_identifier"=)"Pro00062433", "nci_id"=)"NCI-2015-01497", "nct_id"=)"NCT02421588", "official_title"=)"Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)", "open_date"=)"28-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"202112830", "specific_funding_source"=)"PharmaMar SA", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01563", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00059856", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01563", "nct_id"=)"NCT02478255", "official_title"=)"Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment", "open_date"=)"20-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Holman", "pi_last_name"=)"McAdams", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"203268867", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01565", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00064813", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01565", "nct_id"=)"NCT02510716", "official_title"=)"Addressing Tobacco Use Disparities in Rural Older Adults through an Innovative Mobile Phone Intervention: Testing the Feasibility of the Textto4gotobacco Intervention", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Devon", "pi_last_name"=)"Noonan", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"", "sp_id"=)"203269813", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01596", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15-174", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01596", "nct_id"=)"NCT02489617", "official_title"=)"The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Intraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle Biopsy", "open_date"=)"08-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Faina", "pi_last_name"=)"Nakhlis", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"203997730", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01602", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GO29537", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00062549", "nci_id"=)"NCI-2015-01602", "nct_id"=)"NCT02367781", "official_title"=)"A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer", "open_date"=)"14-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"204004236", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01623", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M13-694", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00063539", "nci_id"=)"NCI-2015-01623", "nct_id"=)"NCT02470585", "official_title"=)"A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "open_date"=)"01-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"204245799", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01625", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063936", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01625", "nct_id"=)"NCT02482389", "official_title"=)"A Phase II Study of Preoperative Boost Radiotherapy in Patients with Breast Cancer with Biomarker Analysis", "open_date"=)"08-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Janet", "pi_last_name"=)"Horton", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"204260214", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01655", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PTC596-ONC-001-AST", "lead_org_po_id"=)"211911", "local_site_identifier"=)"Pro00065884", "nci_id"=)"NCI-2015-01655", "nct_id"=)"NCT02404480", "official_title"=)"A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors", "open_date"=)"01-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"204913341", "specific_funding_source"=)"PTC Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01691", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-352-1672", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00069408", "nci_id"=)"NCI-2015-01691", "nct_id"=)"NCT02515630", "official_title"=)"A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)", "open_date"=)"22-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"205256336", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01744", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9922", "dt4_program_codes"=)"", "entire_study"=)"32", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"9922", "lead_org_po_id"=)"37888474", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01744", "nct_id"=)"NCT02581930", "official_title"=)"A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance", "open_date"=)"17-Aug-2016", "other_ids"=)"NCI9922", "other_protocol_ids"=)"9922, NCI9922", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Stergios", "pi_last_name"=)"Moschos", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"206628298", "specific_funding_source"=)"Duke University - Duke Cancer Institute LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01752", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN07LT", "lead_org_po_id"=)"159558", "local_site_identifier"=)"Pro00061078", "nci_id"=)"NCI-2015-01752", "nct_id"=)"NCT02322320", "official_title"=)"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)", "open_date"=)"07-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"206909359", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01773", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063328", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01773", "nct_id"=)"NCT02574507", "official_title"=)"Behavioral Weight and Symptom Management for Breast Cancer Survivors and Their Partners", "open_date"=)"30-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"207522579", "specific_funding_source"=)"National Institutes of Health Clinical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01809", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NYMC 564", "lead_org_po_id"=)"171496", "local_site_identifier"=)"Pro00062316", "nci_id"=)"NCI-2015-01809", "nct_id"=)"NCT02098512", "official_title"=)"A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)", "open_date"=)"19-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"208762857", "specific_funding_source"=)"New York Medical College", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01813", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1301", "lead_org_po_id"=)"159558", "local_site_identifier"=)"Pro00058005", "nci_id"=)"NCI-2015-01813", "nct_id"=)"NCT02345850", "official_title"=)"A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)", "open_date"=)"01-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"208780248", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01829", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1302", "lead_org_po_id"=)"159558", "local_site_identifier"=)"Pro00063517", "nci_id"=)"NCI-2015-01829", "nct_id"=)"NCT02440464", "official_title"=)"Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN #1302)", "open_date"=)"21-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"208939797", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01840", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-451", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00070704", "nci_id"=)"NCI-2015-01840", "nct_id"=)"NCT02538666", "official_title"=)"A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)", "open_date"=)"01-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"209137889", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01850", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3475-183", "lead_org_po_id"=)"147288", "local_site_identifier"=)"Pro00066617", "nci_id"=)"NCI-2015-01850", "nct_id"=)"NCT02576977", "official_title"=)"A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)", "open_date"=)"01-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"209370456", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01856", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063848", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01856", "nct_id"=)"NCT02482376", "official_title"=)"A Phase II Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer: Analysis of Pathologic Response", "open_date"=)"21-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Janet", "pi_last_name"=)"Horton", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"209386860", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01857", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D6070C00001", "lead_org_po_id"=)"130639", "local_site_identifier"=)"Pro00064751", "nci_id"=)"NCI-2015-01857", "nct_id"=)"NCT02503774", "official_title"=)"A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors", "open_date"=)"01-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"209398513", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01867", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGN35-025", "lead_org_po_id"=)"219916", "local_site_identifier"=)"Pro00064494", "nci_id"=)"NCI-2015-01867", "nct_id"=)"NCT02572167", "official_title"=)"A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy", "open_date"=)"16-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"209519005", "specific_funding_source"=)"Seattle Genetics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01897", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADXS001-06", "lead_org_po_id"=)"48659730", "local_site_identifier"=)"Pro00064449", "nci_id"=)"NCI-2015-01897", "nct_id"=)"NCT02399813", "official_title"=)"PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANORECTAL CANAL", "open_date"=)"01-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"209773198", "specific_funding_source"=)"Advaxis, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01916", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EA5142", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EA5142", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01916", "nct_id"=)"NCT02595944", "official_title"=)"Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers", "open_date"=)"06-May-2016", "other_ids"=)"", "other_protocol_ids"=)"EA5142", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jamie", "pi_last_name"=)"Chaft", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"209916611", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01918", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"9", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011401", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011401", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01918", "nct_id"=)"NCT02750826", "official_title"=)"Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer", "open_date"=)"29-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"A011401", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Ligibel", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"209917126", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01928", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADCT-301-002", "lead_org_po_id"=)"48498377", "local_site_identifier"=)"Pro00066343", "nci_id"=)"NCI-2015-01928", "nct_id"=)"NCT02588092", "official_title"=)"A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia", "open_date"=)"04-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"210382242", "specific_funding_source"=)"ADC Therapeutics SARL", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01929", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091304", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091304", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01929", "nct_id"=)"NCT02601209", "official_title"=)"A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma", "open_date"=)"30-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"A091304", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"William", "pi_last_name"=)"Tap", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"210412565", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01930", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-ST-004", "lead_org_po_id"=)"36776822", "local_site_identifier"=)"Pro00064897", "nci_id"=)"NCI-2015-01930", "nct_id"=)"NCT02570711", "official_title"=)"Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer", "open_date"=)"19-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"210532007", "specific_funding_source"=)"Acerta Pharma", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01931", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"23", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"61", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063483", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01931", "nct_id"=)"NCT02540161", "official_title"=)"Phase 2 Study of Sym004 for Adult Patients with Recurrent Glioblastoma", "open_date"=)"30-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"210543917", "specific_funding_source"=)"Symphogen A/S, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01945", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AG-221-AML-004", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"Pro00066615", "nci_id"=)"NCI-2015-01945", "nct_id"=)"NCT02577406", "official_title"=)"A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation", "open_date"=)"01-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"210907687", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01966", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-CL-006", "lead_org_po_id"=)"47894204", "local_site_identifier"=)"Pro00070143", "nci_id"=)"NCI-2015-01966", "nct_id"=)"NCT02477696", "official_title"=)"A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia", "open_date"=)"01-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"211425205", "specific_funding_source"=)"Acerta Pharma BV", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01967", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BR31", "lead_org_po_id"=)"47305144", "local_site_identifier"=)"Pro00062555", "nci_id"=)"NCI-2015-01967", "nct_id"=)"NCT02273375", "official_title"=)"A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer", "open_date"=)"02-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"211428013", "specific_funding_source"=)"Canadian Cancer Trials Group", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01971", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"39110-106", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00068096", "nci_id"=)"NCI-2015-01971", "nct_id"=)"NCT02559492", "official_title"=)"A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors", "open_date"=)"24-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"211434512", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02003", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IRB14833", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02003", "nct_id"=)"", "official_title"=)"Enhancing Patient-Provider Communication about Sexual Concerns in Breast Cancer", "open_date"=)"12-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Jenny", "pi_last_name"=)"Reese", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"211751857", "specific_funding_source"=)"American Cancer Society", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02004", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGN19A-003", "lead_org_po_id"=)"219916", "local_site_identifier"=)"Pro00066502", "nci_id"=)"NCI-2015-02004", "nct_id"=)"NCT02592876", "official_title"=)"A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant", "open_date"=)"01-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"211763395", "specific_funding_source"=)"Seattle Genetics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02014", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"RU221511I", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02014", "nct_id"=)"NCT02640053", "official_title"=)"Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial", "open_date"=)"23-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Charles", "pi_last_name"=)"Loprinzi", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"211856741", "specific_funding_source"=)"Academic and Community Cancer Research United", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02028", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KTE-C19-102", "lead_org_po_id"=)"25983713", "local_site_identifier"=)"Pro00066516", "nci_id"=)"NCI-2015-02028", "nct_id"=)"NCT02601313", "official_title"=)"A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)", "open_date"=)"16-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"212178143", "specific_funding_source"=)"Kite Pharma, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02046", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC1410", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02046", "nct_id"=)"NCT02328313", "official_title"=)"Impact of Physical Activity on Biomarker of Aging and Body Composition among Breast Cancer Survivors Age 65 and Older", "open_date"=)"09-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Hyman", "pi_last_name"=)"Muss", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"212325520", "specific_funding_source"=)"Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AFT-05", "lead_org_po_id"=)"43104771", "local_site_identifier"=)"Pro00067282", "nci_id"=)"NCI-2015-02057", "nct_id"=)"NCT02513394", "official_title"=)"PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer", "open_date"=)"09-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"212419111", "specific_funding_source"=)"Alliance Foundation Trials, LLC.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02074", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"21", "center_total_rp"=)"11", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047231", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02074", "nct_id"=)"NCT02036918", "official_title"=)"Evaluation of Lymph Node Metastases in Men Undergoing Treatment with Sipuleucel-T for Metastatic Castrate-Resistant Prostate Cancer", "open_date"=)"28-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Brant", "pi_last_name"=)"Inman", "pi_middle_initial"=)"A", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"212693527", "specific_funding_source"=)"Dendreon Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02086", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CDX1127-06", "lead_org_po_id"=)"56901", "local_site_identifier"=)"Pro00064766", "nci_id"=)"NCI-2015-02086", "nct_id"=)"NCT02543645", "official_title"=)"A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer", "open_date"=)"01-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213168797", "specific_funding_source"=)"Celldex Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02087", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"18", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00064227", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02087", "nct_id"=)"NCT02611063", "official_title"=)"A Phase I Trial of Fostamatinib and Chronic Graft-vs.-Host Disease Development after Allogeneic Stem Cell Transplantation", "open_date"=)"20-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Stefanie", "pi_last_name"=)"Sarantopoulos", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213171494", "specific_funding_source"=)"Rigel Pharmaceuticals, Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02113", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00039982", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02113", "nct_id"=)"", "official_title"=)"Comparison of Power Injection versus Hand Injection of Administering Contrast Media in MR Perfusion Imaging", "open_date"=)"29-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Provenzale", "pi_middle_initial"=)"M", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"213885021", "specific_funding_source"=)"Bayer Corporation, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02115", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"25", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051412", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02115", "nct_id"=)"", "official_title"=)"Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) of Bone Marrow in Acute Myeloid Leukemia: Correlation of Perfusion Parameters and Bone Marrow Biopsy", "open_date"=)"23-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rajan", "pi_last_name"=)"Gupta", "pi_middle_initial"=)"T", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"213891105", "specific_funding_source"=)"Bayer Corporation, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02147", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"17", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00055890", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02147", "nct_id"=)"NCT02439437", "official_title"=)"Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-mastectomy Pain", "open_date"=)"13-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"214167188", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02182", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"19", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063108", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02182", "nct_id"=)"NCT02457715", "official_title"=)"Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients with Cancer and Amyotrophic Lateral Sclerosis", "open_date"=)"09-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214391801", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02184", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"24", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"44", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065621", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02184", "nct_id"=)"NCT02783755", "official_title"=)"A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities", "open_date"=)"26-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"214398265", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02187", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"20", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065982", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02187", "nct_id"=)"", "official_title"=)"Usability Testing of a Web-Based Patient Financial Assistance Intervention", "open_date"=)"25-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Yousuf", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214403736", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02207", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15743", "lead_org_po_id"=)"35145", "local_site_identifier"=)"Pro00072619", "nci_id"=)"NCI-2015-02207", "nct_id"=)"NCT02610140", "official_title"=)"A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy", "open_date"=)"28-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Respiratory/Intrathoracic Organs", "sp_id"=)"215785280", "specific_funding_source"=)"Bayer Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02213", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054746", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02213", "nct_id"=)"NCT02193347", "official_title"=)"Patients with IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine", "open_date"=)"04-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"215889350", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02229", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15702", "lead_org_po_id"=)"119479", "local_site_identifier"=)"Pro00068676", "nci_id"=)"NCI-2015-02229", "nct_id"=)"NCT02423343", "official_title"=)"A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)", "open_date"=)"10-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"217365805", "specific_funding_source"=)"Eli Lilly and Company", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02241", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3475-177", "lead_org_po_id"=)"147288", "local_site_identifier"=)"Pro00070459", "nci_id"=)"NCI-2015-02241", "nct_id"=)"NCT02563002", "official_title"=)"A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)", "open_date"=)"08-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"219486596", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02250", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1507", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1507", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02250", "nct_id"=)"NCT02642042", "official_title"=)"A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease following One or Two Prior Systemic Therapies", "open_date"=)"18-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"S1507", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Shirish", "pi_last_name"=)"Gadgeel", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"220242740", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02284", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PEC001", "lead_org_po_id"=)"49575854", "local_site_identifier"=)"Pro00067600", "nci_id"=)"NCI-2015-02284", "nct_id"=)"NCT02494570", "official_title"=)"A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-rapamycin) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)", "open_date"=)"29-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"222866419", "specific_funding_source"=)"Aadi, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02285", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CR107947", "lead_org_po_id"=)"48659622", "local_site_identifier"=)"Pro00071290", "nci_id"=)"NCI-2015-02285", "nct_id"=)"NCT02598661", "official_title"=)"A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment", "open_date"=)"29-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"222870231", "specific_funding_source"=)"Janssen Research & Development, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00012", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IMDZ-C232", "lead_org_po_id"=)"40374374", "local_site_identifier"=)"Pro00069932", "nci_id"=)"NCI-2016-00012", "nct_id"=)"NCT02609984", "official_title"=)"A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1", "open_date"=)"05-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"223396241", "specific_funding_source"=)"Immune Design", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00050", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"8", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400I", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00050", "nct_id"=)"NCT02785952", "official_title"=)"A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and no Matching Biomarker (Lung-Map Sub-Study)", "open_date"=)"18-Dec-2015", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400I, NCT02154490", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"223987408", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00059", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"66", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065241", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00059", "nct_id"=)"NCT02529072", "official_title"=)"AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination with DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors", "open_date"=)"05-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"224917169", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00108", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"STML-401-0414", "lead_org_po_id"=)"48419304", "local_site_identifier"=)"Pro00069269", "nci_id"=)"NCI-2016-00108", "nct_id"=)"NCT02661022", "official_title"=)"A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma", "open_date"=)"25-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"227086938", "specific_funding_source"=)"Stemline Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00144", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-498", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00072239", "nci_id"=)"NCI-2016-00144", "nct_id"=)"NCT02617589", "official_title"=)"A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)", "open_date"=)"15-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"227589309", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00148", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-296-1080", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00069751", "nci_id"=)"NCI-2016-00148", "nct_id"=)"NCT02545504", "official_title"=)"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", "open_date"=)"29-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"227604405", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADN011", "lead_org_po_id"=)"43941037", "local_site_identifier"=)"Pro00066047", "nci_id"=)"NCI-2016-00165", "nct_id"=)"NCT02411084", "official_title"=)"Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus \"Conventional Treatment\" for Treating Steroid Resistant Acute Graft-versus Host Disease", "open_date"=)"20-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"228050027", "specific_funding_source"=)"Adienne SA", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00166", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063975", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00166", "nct_id"=)"NCT02619604", "official_title"=)"A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia", "open_date"=)"21-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Linda", "pi_last_name"=)"Sutton", "pi_middle_initial"=)"M", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"228052905", "specific_funding_source"=)"Gilead, Genentech Inc., Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00172", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-015", "lead_org_po_id"=)"24314431", "local_site_identifier"=)"Pro00069272", "nci_id"=)"NCI-2016-00172", "nct_id"=)"NCT02628704", "official_title"=)"Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug", "open_date"=)"03-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"228191486", "specific_funding_source"=)"Karyopharm Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00173", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-568", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00069822", "nci_id"=)"NCI-2016-00173", "nct_id"=)"NCT02659059", "official_title"=)"A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs. Chemotherapy Alone (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"15-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"228192257", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00207", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4190C00022", "lead_org_po_id"=)"130639", "local_site_identifier"=)"Pro00066636", "nci_id"=)"NCI-2016-00207", "nct_id"=)"NCT02519348", "official_title"=)"A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma", "open_date"=)"09-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"228945286", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00215", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SCRX001-002", "lead_org_po_id"=)"39897311", "local_site_identifier"=)"Pro00069666", "nci_id"=)"NCI-2016-00215", "nct_id"=)"NCT02674568", "official_title"=)"An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)", "open_date"=)"09-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"228968293", "specific_funding_source"=)"Stemcentrx", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00216", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INO-VT-464-CL-006", "lead_org_po_id"=)"38235419", "local_site_identifier"=)"Pro00068128", "nci_id"=)"NCI-2016-00216", "nct_id"=)"NCT02580448", "official_title"=)"A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer", "open_date"=)"10-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"229024132", "specific_funding_source"=)"Innocrin Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00233", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011502", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011502", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00233", "nct_id"=)"NCT02927249", "official_title"=)"A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial", "open_date"=)"08-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"A011502", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Wendy", "pi_last_name"=)"Chen", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"229284366", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00242", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PHP-OCM-301", "lead_org_po_id"=)"49262411", "local_site_identifier"=)"Pro00069107", "nci_id"=)"NCI-2016-00242", "nct_id"=)"NCT02678572", "official_title"=)"A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma", "open_date"=)"15-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"229777667", "specific_funding_source"=)"Delcath Systems Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NEOD001-201", "lead_org_po_id"=)"48419354", "local_site_identifier"=)"Pro00070414", "nci_id"=)"NCI-2016-00255", "nct_id"=)"NCT02632786", "official_title"=)"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction", "open_date"=)"07-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"229877126", "specific_funding_source"=)"Prothena Therapeutics Ltd.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00264", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1415CD", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1415CD", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00264", "nct_id"=)"NCT02728596", "official_title"=)"A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)", "open_date"=)"07-Oct-2016", "other_ids"=)"S1415", "other_protocol_ids"=)"S1415CD, S1415", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Ramsey", "pi_middle_initial"=)"D", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"229925660", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00288", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"BMX-HGG-001", "lead_org_po_id"=)"44564732", "local_site_identifier"=)"Pro00062660", "nci_id"=)"NCI-2016-00288", "nct_id"=)"NCT02655601", "official_title"=)"A Phase 1/2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001", "open_date"=)"05-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"230510407", "specific_funding_source"=)"BioMimetix JV, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00289", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068978", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00289", "nct_id"=)"NCT02627079", "official_title"=)"ICanSTEP: Increasing Physical Activity in Cancer Survivors through a Text-messaging Exercise Motivation Program", "open_date"=)"16-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Bridget", "pi_last_name"=)"Koontz", "pi_middle_initial"=)"F", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"230513448", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00290", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CP-MGAH22-05", "lead_org_po_id"=)"124446", "local_site_identifier"=)"Pro00068590", "nci_id"=)"NCI-2016-00290", "nct_id"=)"NCT02689284", "official_title"=)"A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer", "open_date"=)"23-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"230528681", "specific_funding_source"=)"MacroGenics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00327", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3475-119", "lead_org_po_id"=)"147288", "local_site_identifier"=)"Pro00065597", "nci_id"=)"NCI-2016-00327", "nct_id"=)"NCT02555657", "official_title"=)"A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)", "open_date"=)"01-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"231534417", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00375", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"UTX-TGR-304", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"Pro00072597", "nci_id"=)"NCI-2016-00375", "nct_id"=)"NCT02612311", "official_title"=)"A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"07-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"232529362", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00391", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Pevonedistat-2001", "lead_org_po_id"=)"138345", "local_site_identifier"=)"Pro00069276", "nci_id"=)"NCI-2016-00391", "nct_id"=)"NCT02610777", "official_title"=)"A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia", "open_date"=)"10-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"232916886", "specific_funding_source"=)"Millennium Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"B7791001", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"Pro00067872", "nci_id"=)"NCI-2016-00393", "nct_id"=)"NCT02616185", "official_title"=)"A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (VBIR) For Prostate Cancer (PF-06753512)", "open_date"=)"10-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"232925113", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00399", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MIP-1404-3301", "lead_org_po_id"=)"48834314", "local_site_identifier"=)"Pro00069229", "nci_id"=)"NCI-2016-00399", "nct_id"=)"NCT02615067", "official_title"=)"A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)", "open_date"=)"11-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"232997593", "specific_funding_source"=)"Molecular Insight Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00402", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ONT-380-206", "lead_org_po_id"=)"47103596", "local_site_identifier"=)"Pro00067720", "nci_id"=)"NCI-2016-00402", "nct_id"=)"NCT02614794", "official_title"=)"Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)", "open_date"=)"11-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"233011779", "specific_funding_source"=)"Cascadian Therapeutics Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00404", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AGS-16C3F-15-3", "lead_org_po_id"=)"24584", "local_site_identifier"=)"Pro00074533", "nci_id"=)"NCI-2016-00404", "nct_id"=)"NCT02639182", "official_title"=)"A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma", "open_date"=)"19-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"233018413", "specific_funding_source"=)"Agensys", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00428", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4190C00023", "lead_org_po_id"=)"130639", "local_site_identifier"=)"Pro00073198", "nci_id"=)"NCI-2016-00428", "nct_id"=)"NCT02549651", "official_title"=)"A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "open_date"=)"01-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"233771416", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00430", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PP LNM 01", "lead_org_po_id"=)"49831458", "local_site_identifier"=)"Pro00070716", "nci_id"=)"NCI-2016-00430", "nct_id"=)"NCT02209532", "official_title"=)"A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping", "open_date"=)"16-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"233791814", "specific_funding_source"=)"Novadaq Technologies Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00469", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M15-394", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00070425", "nci_id"=)"NCI-2016-00469", "nct_id"=)"NCT02565758", "official_title"=)"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors", "open_date"=)"25-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"235081036", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00475", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IMCgp100-201", "lead_org_po_id"=)"44247936", "local_site_identifier"=)"Pro00067271", "nci_id"=)"NCI-2016-00475", "nct_id"=)"NCT02535078", "official_title"=)"A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab in Patients With Advanced Melanoma", "open_date"=)"28-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"235460119", "specific_funding_source"=)"Immunocore Ltd", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00521", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-350-1604", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00066478", "nci_id"=)"NCI-2016-00521", "nct_id"=)"NCT02607228", "official_title"=)"A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer", "open_date"=)"31-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"235902969", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00628", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-406-1840", "lead_org_po_id"=)"88127", "local_site_identifier"=)"Pro00070562", "nci_id"=)"NCI-2016-00628", "nct_id"=)"NCT02701634", "official_title"=)"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)", "open_date"=)"19-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"239599157", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00634", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"48", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00069444", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00634", "nct_id"=)"NCT02664363", "official_title"=)"ExCeL: EGFRvIII Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for Patients with Newly-Diagnosed GBM during Lymphopenia", "open_date"=)"20-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"239637197", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00719", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"350", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00070823", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00719", "nct_id"=)"NCT02791646", "official_title"=)"Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART", "open_date"=)"03-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"242246504", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00721", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"330", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00071993", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00721", "nct_id"=)"NCT02803593", "official_title"=)"To Enhance Breast Cancer Survivorship of Asian Americans", "open_date"=)"03-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Eun-ok", "pi_last_name"=)"Im", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"242248966", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00746", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-020", "lead_org_po_id"=)"54187152", "local_site_identifier"=)"Pro00072155", "nci_id"=)"NCI-2016-00746", "nct_id"=)"NCT02606461", "official_title"=)"A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)", "open_date"=)"12-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"242548499", "specific_funding_source"=)"Karyopharm Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00815", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019B2205J", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00057441", "nci_id"=)"NCI-2016-00815", "nct_id"=)"NCT02228096", "official_title"=)"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia", "open_date"=)"24-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"246031562", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00826", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057501", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00826", "nct_id"=)"NCT02452697", "official_title"=)"A Randomized Phase II Trial to Evaluate Progression-Free Survival Rates in Patients Receiving NK Cell-Enriched Donor Cell Infusions When Administered Alone or Administered with the TLR9 Agonist, DUK-CPG-001, from a 4-6/8 HLA-Matched Related or 7-8/8 HLA-Matched Donor following Reduced Intensity or Non-ablative Allogeneic Stem Cell Transplantation", "open_date"=)"17-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Rizzieri", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"246768598", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00827", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061309", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00827", "nct_id"=)"NCT02598427", "official_title"=)"Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients with New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer", "open_date"=)"10-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Kimberly", "pi_last_name"=)"Blackwell", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"246771317", "specific_funding_source"=)"Genentech Inc., Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00846", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AC220-A-U302", "lead_org_po_id"=)"68015", "local_site_identifier"=)"Pro00071289", "nci_id"=)"NCI-2016-00846", "nct_id"=)"NCT02668653", "official_title"=)"A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia", "open_date"=)"20-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"248049297", "specific_funding_source"=)"Daiichi Sankyo Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00858", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-577", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00072847", "nci_id"=)"NCI-2016-00858", "nct_id"=)"NCT02743494", "official_title"=)"A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer", "open_date"=)"22-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"248332961", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00875", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-602", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00072528", "nci_id"=)"NCI-2016-00875", "nct_id"=)"NCT02726581", "official_title"=)"An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602", "open_date"=)"07-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"249497417", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00952", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-548", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00071737", "nci_id"=)"NCI-2016-00952", "nct_id"=)"NCT02667587", "official_title"=)"A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548", "open_date"=)"17-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"251100010", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00975", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"230", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073234", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00975", "nct_id"=)"NCT02970344", "official_title"=)"Improving Health Engagement and Lifestyle Management for Breast Cancer Survivors with Diabetes", "open_date"=)"16-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"251718483", "specific_funding_source"=)"American Cancer Society, Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00996", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1501", "lead_org_po_id"=)"249581", "local_site_identifier"=)"Pro00075321", "nci_id"=)"NCI-2016-00996", "nct_id"=)"NCT02806947", "official_title"=)"A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN #1501)", "open_date"=)"09-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"251854038", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01013", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"74", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00062304", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01013", "nct_id"=)"NCT02757326", "official_title"=)"A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients with Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated with Proteasome Inhibitors and Immunomodulatory Drugs", "open_date"=)"23-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Yubin", "pi_last_name"=)"Kang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"252470268", "specific_funding_source"=)"Apogee Biotechnology Corporation, Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WO29635", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00071053", "nci_id"=)"NCI-2016-01018", "nct_id"=)"NCT02792192", "official_title"=)"A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER", "open_date"=)"28-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"252579251", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01055", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"95", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068753", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01055", "nct_id"=)"", "official_title"=)"Improved Ultrasound Imaging Using Elevated Acoustic Output", "open_date"=)"30-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Clare", "pi_last_name"=)"Haystead", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"253520093", "specific_funding_source"=)"National Institutes of Health, National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01056", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"220", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068979", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01056", "nct_id"=)"NCT02895841", "official_title"=)"Patient-Empowered Mobile Technology in Hospitalized Patients with Pain", "open_date"=)"30-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nirmish", "pi_last_name"=)"Shah", "pi_middle_initial"=)"R", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"253522879", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01115", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-017", "lead_org_po_id"=)"54187152", "local_site_identifier"=)"Pro00069273", "nci_id"=)"NCI-2016-01115", "nct_id"=)"NCT02343042", "official_title"=)"A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma", "open_date"=)"14-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"255859868", "specific_funding_source"=)"Karyopharm Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01139", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068544", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01139", "nct_id"=)"NCT02728830", "official_title"=)"A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin", "open_date"=)"18-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"O", "phase_additional_qualifier_code"=)"", "phase_description"=)"Early Phase I", "pi_first_name"=)"Angeles", "pi_last_name"=)"Secord", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"257138885", "specific_funding_source"=)"Merck and Company Inc, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01140", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072023", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01140", "nct_id"=)"NCT02787993", "official_title"=)"Feasibility and Acceptability of a Behavioral Symptom Management Program for Patients with Advanced Breast Cancer in Singapore and the US", "open_date"=)"08-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"257140660", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01154", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SY-1425-201", "lead_org_po_id"=)"30282652", "local_site_identifier"=)"Pro00072859", "nci_id"=)"NCI-2016-01154", "nct_id"=)"NCT02807558", "official_title"=)"A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "open_date"=)"16-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"258264622", "specific_funding_source"=)"Syros Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OT-15-001", "lead_org_po_id"=)"30981925", "local_site_identifier"=)"Pro00076758", "nci_id"=)"NCI-2016-01159", "nct_id"=)"NCT02796261", "official_title"=)"A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy", "open_date"=)"20-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"258372775", "specific_funding_source"=)"Orbus Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01161", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TGR-1202-201-CLL", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"Pro00072486", "nci_id"=)"NCI-2016-01161", "nct_id"=)"NCT02742090", "official_title"=)"A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy", "open_date"=)"26-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"258390238", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01176", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"10", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00071159", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01176", "nct_id"=)"NCT02722395", "official_title"=)"Magnetic Resonance Imaging (MRI) Solely for Liver Stereotactic Body Radiation Therapy (SBRT)", "open_date"=)"27-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Brian", "pi_last_name"=)"Czito", "pi_middle_initial"=)"G", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"258685207", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01186", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ICT8", "lead_org_po_id"=)"48074332", "local_site_identifier"=)"Pro00072423", "nci_id"=)"NCI-2016-01186", "nct_id"=)"NCT02802267", "official_title"=)"Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy", "open_date"=)"29-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"259098865", "specific_funding_source"=)"Hybrigenics Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01219", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ONO-4538-24/CA209-473", "lead_org_po_id"=)"192810", "local_site_identifier"=)"Pro00070461", "nci_id"=)"NCI-2016-01219", "nct_id"=)"NCT02569242", "official_title"=)"ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Unresectable Advanced or Recurrent Esophageal Cancer", "open_date"=)"03-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Esophagus", "sp_id"=)"260699013", "specific_funding_source"=)"Ono Pharmaceutical Company Limited", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01245", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00066964", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01245", "nct_id"=)"NCT02687009", "official_title"=)"A Phase I Study of Niclosamide in Patients with Resectable Colon Cancer", "open_date"=)"05-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Michael", "pi_last_name"=)"Morse", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"261451579", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"UTX-TGR-204", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"Pro00072590", "nci_id"=)"NCI-2016-01255", "nct_id"=)"NCT02656303", "official_title"=)"A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304", "open_date"=)"10-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"261588244", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01309", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CNTX-CX-01-2015-AML-1", "lead_org_po_id"=)"48723391", "local_site_identifier"=)"Pro00073464", "nci_id"=)"NCI-2016-01309", "nct_id"=)"NCT02873338", "official_title"=)"A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia", "open_date"=)"23-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"263192301", "specific_funding_source"=)"Cantex Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01313", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WP29945", "lead_org_po_id"=)"90971", "local_site_identifier"=)"Pro00068531", "nci_id"=)"NCI-2016-01313", "nct_id"=)"NCT02650713", "official_title"=)"An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors", "open_date"=)"24-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"263255862", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01320", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"250", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00070790", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01320", "nct_id"=)"NCT02944344", "official_title"=)"The Four Conversations RCT", "open_date"=)"18-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"263361738", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01391", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"26", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00060068", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01391", "nct_id"=)"NCT02757248", "official_title"=)"A Phase 1 Trial of Volasertib plus Romidepsin in Patients with Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma", "open_date"=)"29-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Anne", "pi_last_name"=)"Beaven", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"265251523", "specific_funding_source"=)"National Comprehensive Cancer Network, Boehringer Ingelheim Pharmaceuticals Inc, National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01392", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068908", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01392", "nct_id"=)"NCT02817607", "official_title"=)"Pilot Study to Assess Breast Sensation before and after Breast Cancer Treatment", "open_date"=)"31-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Hollenbeck", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"265255472", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01425", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075558", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01425", "nct_id"=)"", "official_title"=)"The Concepts of Progression Free Survival and Maintenance Therapies in Shared Decision Making for Ovarian Cancer: An Assessment of Patients’ Understanding and Preferences", "open_date"=)"13-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Havrilesky", "pi_middle_initial"=)"J", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"267302739", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01447", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLBH589DUS106", "lead_org_po_id"=)"170150", "local_site_identifier"=)"Pro00071291", "nci_id"=)"NCI-2016-01447", "nct_id"=)"NCT02720510", "official_title"=)"A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma", "open_date"=)"21-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"267595029", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01493", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"C0591001", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"Pro00073139", "nci_id"=)"NCI-2016-01493", "nct_id"=)"NCT02764151", "official_title"=)"A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas", "open_date"=)"13-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"269880528", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01498", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"1000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075411", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01498", "nct_id"=)"NCT02986152", "official_title"=)"Cancer Distress Coach RCT", "open_date"=)"29-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"270182806", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01518", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GC P#05.01.020", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"Pro00072499", "nci_id"=)"NCI-2016-01518", "nct_id"=)"NCT02730299", "official_title"=)"A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies", "open_date"=)"14-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"271172718", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01530", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGI-110-07", "lead_org_po_id"=)"48735172", "local_site_identifier"=)"Pro00074201", "nci_id"=)"NCI-2016-01530", "nct_id"=)"NCT02907359", "official_title"=)"A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents", "open_date"=)"30-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"271206822", "specific_funding_source"=)"Astex Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01556", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075612", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01556", "nct_id"=)"NCT02922790", "official_title"=)"Feasibility and Smokers' Reactions to DNA Feedback", "open_date"=)"12-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"272278117", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01668", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7080-M000-213", "lead_org_po_id"=)"68715", "local_site_identifier"=)"Pro00074190", "nci_id"=)"NCI-2016-01668", "nct_id"=)"NCT02657369", "official_title"=)"An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)", "open_date"=)"01-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"274893186", "specific_funding_source"=)"Eisai Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01711", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"480", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068595", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01711", "nct_id"=)"NCT02707471", "official_title"=)"Improving Well-being for Breast Cancer Patients Taking Adjuvant Endocrine Therapy", "open_date"=)"24-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"276078326", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01712", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075906", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01712", "nct_id"=)"", "official_title"=)"Usability Testing of a Web-Based Tool to Prepare Patients for Palliative Care", "open_date"=)"03-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Arif", "pi_last_name"=)"Kamal", "pi_middle_initial"=)"H", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"276079781", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01807", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-031", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"Pro00071288", "nci_id"=)"NCI-2016-01807", "nct_id"=)"NCT02755597", "official_title"=)"A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors", "open_date"=)"18-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"277422447", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01936", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075429", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01936", "nct_id"=)"NCT02886572", "official_title"=)"Outcome in Patients with 4 or More Brain Metastases Treated with Single-Isocenter, Multi-target (SIMT) Stereotactic Radiosurgery: A Prospective Single-Arm Study in Adults with Brain Metastases", "open_date"=)"22-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Grace", "pi_last_name"=)"Kim", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"280901219", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01968", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00074542", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01968", "nct_id"=)"NCT02987881", "official_title"=)"Physical Activity and Nutrition Counseling Intervention in Endometrial Cancer Survivors", "open_date"=)"08-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Angeles", "pi_last_name"=)"Secord", "pi_middle_initial"=)"A", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"281316761", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-02026", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"16-439", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-02026", "nct_id"=)"NCT02975869", "official_title"=)"Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia", "open_date"=)"15-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Areej", "pi_last_name"=)"El-Jawahri", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"282590424", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-02048", "affiliate_total"=)"3", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RU011201I", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-02048", "nct_id"=)"NCT02037529", "official_title"=)"A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer", "open_date"=)"17-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Minetta", "pi_last_name"=)"Liu", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"282838394", "specific_funding_source"=)"Academic and Community Cancer Research United", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MEDI4736-MDS-001", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"Pro00075114", "nci_id"=)"NCI-2017-00018", "nct_id"=)"NCT02775903", "official_title"=)"A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly ()= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)", "open_date"=)"05-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"284114009", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00062", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"600", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072077", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00062", "nct_id"=)"NCT02501265", "official_title"=)"Randomized-Controlled Smoking Cessation Trial on Varenicline vs. Varenicline-Based Adaptive Pharmacotherapy with Cross-Randomization to High vs. Low Intensity Behavioral Therapy", "open_date"=)"05-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Davis", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"284754141", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00093", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"32", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00071629", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00093", "nct_id"=)"NCT02818920", "official_title"=)"Pembrolizumab Prior to Surgery for Stage 1B, 2, or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study", "open_date"=)"09-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Neal", "pi_last_name"=)"Ready", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"286179528", "specific_funding_source"=)"Merck and Company Inc, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"760", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057568", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00159", "nct_id"=)"NCT02483832", "official_title"=)"Effects of Message Framing and Risk Feedback on CRC Screening", "open_date"=)"03-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"", "sp_id"=)"288511692", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00168", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"115", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063791", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00168", "nct_id"=)"NCT02613689", "official_title"=)"Addressing Tobacco Use Disparities through an Innovative Mobile Phone Intervention: The Text to Forgo Smokeless Tobacco", "open_date"=)"13-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Devon", "pi_last_name"=)"Noonan", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"288524825", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00214", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"200", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00052865", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00214", "nct_id"=)"NCT02477124", "official_title"=)"A See and Treat Paradigm for Cervical Pre-cancer", "open_date"=)"22-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"289602898", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00566", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00034208", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00566", "nct_id"=)"NCT02864368", "official_title"=)"PERFORMANCE: Peptide Targets for Glioblastoma against Novel Cytomegalovirus Antigens", "open_date"=)"21-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"297448100", "specific_funding_source"=)"American Brain Tumor Association, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-01099", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"1000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00077090", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-01099", "nct_id"=)"", "official_title"=)"Nurse-Led Parent Educational Discharge Support Strategies (PEDSS) for Children Newly Diagnosed with Cancer", "open_date"=)"31-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Cheryl", "pi_last_name"=)"Rodgers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"311960488", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00331", "affiliate_total"=)"270", "affiliate_total_rp"=)"58", "center_total"=)"245", "center_total_rp"=)"19", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCRN07", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCRN07", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00331", "nct_id"=)"NCT01117168", "official_title"=)"Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)", "open_date"=)"24-Dec-2007", "other_ids"=)"CDR0000069496", "other_protocol_ids"=)"ACCRN07, CDR0000069496", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Julie", "pi_last_name"=)"Ross", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"249603", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00382", "affiliate_total"=)"5", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE05N1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE05N1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00382", "nct_id"=)"NCT00736749", "official_title"=)"Umbrella Long-Term Follow-Up Protocol", "open_date"=)"19-May-2008", "other_ids"=)"CDR0000590123\rPALTE05N1_A06PAMDREVW01", "other_protocol_ids"=)"ALTE05N1, CDR0000590123, PALTE05N1_A06PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Smita", "pi_last_name"=)"Bhatia", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74446915", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00383", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE07C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE07C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00383", "nct_id"=)"NCT00772200", "official_title"=)"Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer", "open_date"=)"15-Sep-2008", "other_ids"=)"CDR0000594326\rCOG-ALTE07C1", "other_protocol_ids"=)"ALTE07C1, CDR0000594326, COG-ALTE07C1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leanne", "pi_last_name"=)"Embry", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74447321", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02878", "affiliate_total"=)"4", "affiliate_total_rp"=)"4", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"28-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"URCC-10055", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"URCC10055", "lead_org_po_id"=)"35608105", "local_site_identifier"=)"URCC10055", "nci_id"=)"NCI-2011-02878", "nct_id"=)"NCT01382082", "official_title"=)"Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-treatment, Post-treatment, and at Six Month Follow-up", "open_date"=)"17-May-2011", "other_ids"=)"10055\rCDR0000697582\rURCC 10055", "other_protocol_ids"=)"URCC-10055, 10055, CDR0000697582, URCC, 10055", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michelle", "pi_last_name"=)"Janelsins", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74999368", "specific_funding_source"=)"University of Rochester NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01804", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"500", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00041936", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01804", "nct_id"=)"NCT01904175", "official_title"=)"REGISTRY STUDY OF T CELL DEPLETED ALLOGENEIC REDUCED INTENSITY STEM CELL TRANSPLANT RECIPIENTS", "open_date"=)"23-Jul-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"David", "pi_last_name"=)"Rizzieri", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Unknown Sites", "sp_id"=)"123195813", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"13", "clinical_research_cat"=)"OBS", "close_date"=)"04-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050297", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00502", "nct_id"=)"NCT02040155", "official_title"=)"Real Time In-Vivo Dosimetry for Gynecologic Brachytherapy", "open_date"=)"22-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"136468753", "specific_funding_source"=)"Wallace H Coulter Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01376", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"OBS", "close_date"=)"02-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-CC002", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-CC002", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01376", "nct_id"=)"NCT02315469", "official_title"=)"Pre-operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers", "open_date"=)"10-Feb-2015", "other_ids"=)"GOG-ELD1301", "other_protocol_ids"=)"NRG-CC002, GOG-ELD1301", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amina", "pi_last_name"=)"Ahmed", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"147511926", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01509", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A151216", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A151216", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01509", "nct_id"=)"NCT02194738", "official_title"=)"Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)", "open_date"=)"18-Aug-2014", "other_ids"=)"NCT02200497", "other_protocol_ids"=)"A151216, NCT02200497", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Oxnard", "pi_middle_initial"=)"R", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"149349354", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"27", "center_total_rp"=)"27", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"APEC14B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"APEC14B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02057", "nct_id"=)"NCT02402244", "official_title"=)"The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study", "open_date"=)"26-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"APEC14B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Peter", "pi_last_name"=)"Adamson", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"166725062", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02344", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-CBA", "lead_org_po_id"=)"57642", "local_site_identifier"=)"Pro00031160", "nci_id"=)"NCI-2014-02344", "nct_id"=)"NCT01351545", "official_title"=)"A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications", "open_date"=)"10-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170803013", "specific_funding_source"=)"Center for International Blood and Marrow Transplant Research", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00581", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"15", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058229", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00581", "nct_id"=)"NCT02353715", "official_title"=)"A Pilot Study PEAX: Men with Metastatic Castrate-Resistant Prostate Cancer Treated with Either Sipuleucel-T (Provenge®), Enzalutamide (Xtandi®), or Abiraterone Acetate (Zytiga®) Undergoing Cardiopulmonary Exercise Testing", "open_date"=)"19-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"183777145", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01479", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"18-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB-MA-PV-401", "lead_org_po_id"=)"109566", "local_site_identifier"=)"Pro00055580", "nci_id"=)"NCI-2015-01479", "nct_id"=)"NCT02252159", "official_title"=)"Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices", "open_date"=)"25-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"201738834", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01666", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"ADU-CL-03", "lead_org_po_id"=)"25463513", "local_site_identifier"=)"Pro00069379", "nci_id"=)"NCI-2015-01666", "nct_id"=)"", "official_title"=)"Long-Term Follow-Up of Subjects Who Have Participated in Aduro-Sponsored Protocols", "open_date"=)"", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"205006485", "specific_funding_source"=)"Aduro BioTech Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01885", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1417CD", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1417CD", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01885", "nct_id"=)"NCT02728804", "official_title"=)"Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer", "open_date"=)"05-May-2016", "other_ids"=)"S1417", "other_protocol_ids"=)"S1417CD, S1417", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Veena", "pi_last_name"=)"Shankaran", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"209690737", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02071", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00044852", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02071", "nct_id"=)"NCT02080897", "official_title"=)"Evaluating Quality of Life in Patients with Soft Tissue Sarcoma Presenting with Metastatic Lung Disease Using the ESAS-Sarcoma Modified Questionnaire ", "open_date"=)"10-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"William", "pi_last_name"=)"Eward", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"212688735", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02073", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"144", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050174", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02073", "nct_id"=)"", "official_title"=)"Using Community Based Participatory Research (CBPR) to Understand Access to Cancer Care and Research FOCUS GROUP", "open_date"=)"10-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nadine", "pi_last_name"=)"Barrett", "pi_middle_initial"=)"", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212691955", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02078", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"10", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051203", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02078", "nct_id"=)"NCT02099526", "official_title"=)"Needs of Older Caregivers of Adults with Cancer In the First 2 Weeks following Hospital Discharge", "open_date"=)"03-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Cristina", "pi_last_name"=)"Hendrix", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212697130", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02079", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"1500", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051666", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02079", "nct_id"=)"", "official_title"=)"Survey of Adult Cancer Survivors Needs and Interests in Survivorship Services", "open_date"=)"19-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Denise", "pi_last_name"=)"Spector", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212697513", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02083", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"31", "center_total_rp"=)"2", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053557", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02083", "nct_id"=)"", "official_title"=)"Hippocampal Volume as an Anatomic Correlate of Survivorship in Patients with Low Grade Glioma: Repeatability and Relationship to Cognitive Dysfunction, Exercise Behavior, and Functional Capacity", "open_date"=)"12-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"212700684", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02096", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"GC P# 04.01.020/030", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"Pro00050211", "nci_id"=)"NCI-2015-02096", "nct_id"=)"NCT02039557", "official_title"=)"Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells", "open_date"=)"01-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213291746", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02119", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"14", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"64", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053989", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02119", "nct_id"=)"NCT02150369", "official_title"=)"Investigating Cognitive/Affective/Sleep Symptoms during High-Dose Interleukin-2 Therapy", "open_date"=)"03-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Robin", "pi_last_name"=)"Knobel", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"213900771", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02124", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"59", "center_total_rp"=)"59", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"150", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054663", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02124", "nct_id"=)"", "official_title"=)"Effectiveness of a Multidisciplinary Intervention for Sexual Health in Survivors of Women’s Cancers", "open_date"=)"10-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kelly", "pi_last_name"=)"Westbrook", "pi_middle_initial"=)"E", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213905115", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02146", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"7", "clinical_research_cat"=)"OBS", "close_date"=)"05-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"25", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00055718", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02146", "nct_id"=)"NCT02235441", "official_title"=)"Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies: A Pilot Study", "open_date"=)"13-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Manisha", "pi_last_name"=)"Palta", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Other Digestive Organ", "sp_id"=)"214166591", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02152", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"75", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057117", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02152", "nct_id"=)"", "official_title"=)"Triadic Expectations: Decision-Making in Advanced Cancer", "open_date"=)"24-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Karen", "pi_last_name"=)"Steinhauser", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214184880", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02154", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"17", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057527", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02154", "nct_id"=)"", "official_title"=)"Feasibility of Transferring Health Data from Apple HealthKit to the Duke Electronic Medical Record (Maestro Care) via Epic MyChart: A Pilot Trial", "open_date"=)"20-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"214185843", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"160", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058440", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02159", "nct_id"=)"NCT02522793", "official_title"=)"Noninvasive Optical Spectroscopy for Identification of Cutaneous Cancer", "open_date"=)"21-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Charles", "pi_last_name"=)"Woodard", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Other Skin", "sp_id"=)"214200591", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02161", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"130", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058567", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02161", "nct_id"=)"", "official_title"=)"Evaluating Preferences for Alternative Genetic Testing Strategies among Women with Epithelial Ovarian Cancer", "open_date"=)"17-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Havrilesky", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"214205080", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02164", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"7", "clinical_research_cat"=)"OBS", "close_date"=)"14-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060650", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02164", "nct_id"=)"NCT02396641", "official_title"=)"Implementation of Consensus-Based Standards for Best Supportive Care in a Clinical Trial: A Pilot Study", "open_date"=)"09-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214210250", "specific_funding_source"=)"American Cancer Society, Agency for Healthcare Research and Quality, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02166", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"07-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061294", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02166", "nct_id"=)"", "official_title"=)"Assessment of Palliative Care Informational Needs", "open_date"=)"06-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Arif", "pi_last_name"=)"Kamal", "pi_middle_initial"=)"H", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214211988", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02178", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"17", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061596", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02178", "nct_id"=)"", "official_title"=)"A Pilot Study to Describe the Trajectory of Symptoms and Adaptive Challenges of Adults Living with Low Grade Gliomas", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Mary", "pi_last_name"=)"Affronti", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"214374713", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02179", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061601", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02179", "nct_id"=)"NCT02407977", "official_title"=)"Real Time In-vivo Body Surface Dosimetry for External Beam Radiation Therapy", "open_date"=)"02-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214384361", "specific_funding_source"=)"Wallace H Coulter Foundation, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02186", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"70", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065972", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02186", "nct_id"=)"", "official_title"=)"Defining Value of Cancer Care from the Patient and Caregiver Perspective", "open_date"=)"08-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214400279", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00271", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"125", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068192", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00271", "nct_id"=)"", "official_title"=)"Prognostic Understanding and Decision-Making in Acute Myeloid Leukemia (AML)", "open_date"=)"03-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Thomas", "pi_last_name"=)"Lablanc", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"229999394", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00633", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"ONC-MA-1004", "lead_org_po_id"=)"48002713", "local_site_identifier"=)"Pro00066008", "nci_id"=)"NCI-2016-00633", "nct_id"=)"NCT02380274", "official_title"=)"A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States", "open_date"=)"26-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"239623944", "specific_funding_source"=)"Astellas Pharma Global Development, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00676", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"DIV-NB-401", "lead_org_po_id"=)"50367183", "local_site_identifier"=)"Pro00069779", "nci_id"=)"NCI-2016-00676", "nct_id"=)"NCT02693171", "official_title"=)"A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients", "open_date"=)"14-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"241168990", "specific_funding_source"=)"United Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00722", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"25", "center_total_rp"=)"25", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"450", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00070017", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00722", "nct_id"=)"", "official_title"=)"Duke Cancer Institute Multidisciplinary Active Surveillance (DUCIMAS) Cohort Study", "open_date"=)"05-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Thomas", "pi_last_name"=)"Polascik", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"242250328", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00828", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209357", "lead_org_po_id"=)"36140", "local_site_identifier"=)"Pro00068641", "nci_id"=)"NCI-2016-00828", "nct_id"=)"NCT02780089", "official_title"=)"A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study", "open_date"=)"25-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"246772434", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01014", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"300", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072096", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01014", "nct_id"=)"", "official_title"=)"Preferences: An Online Survey for Women with Ovarian Cancer", "open_date"=)"21-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Havrilesky", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"252471413", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01173", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"35", "center_total_rp"=)"35", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"3000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073920", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01173", "nct_id"=)"NCT02845687", "official_title"=)"Observational Study on Smoking Cessation and Cost Outcomes in the Duke Smoking Cessation Program", "open_date"=)"01-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Davis", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"", "sp_id"=)"258683770", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01322", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075053", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01322", "nct_id"=)"", "official_title"=)"Usability Testing of a Patient Assistance Navigation Tool", "open_date"=)"19-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"263379509", "specific_funding_source"=)"National Institutes of Health, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01323", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065967", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01323", "nct_id"=)"NCT02943044", "official_title"=)"Characterization of Physiological and Morphological Features of Clinical Head & Neck Squamous Cell Carcinomas (HNSCCs) Using a Quantitative Optical Sensor", "open_date"=)"16-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Walter", "pi_last_name"=)"Lee", "pi_middle_initial"=)"T", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"263382166", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"140", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00071979", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01393", "nct_id"=)"", "official_title"=)"Communicating about Sexual Concerns and Dysfunction Effectively (CASCADE) Program", "open_date"=)"06-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kevin", "pi_last_name"=)"Weinfurt", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"265258854", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01399", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADP-0000-001", "lead_org_po_id"=)"23866637", "local_site_identifier"=)"Pro00068071", "nci_id"=)"NCI-2016-01399", "nct_id"=)"NCT02636855", "official_title"=)"A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies", "open_date"=)"12-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"266218873", "specific_funding_source"=)"Adaptimmune Limited", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073547", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01497", "nct_id"=)"NCT02906592", "official_title"=)"Using a Geriatric Oncology Assessment to Link with Services (GOAL)", "open_date"=)"28-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leah", "pi_last_name"=)"Zullig", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"270182150", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01757", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"397", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073210", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01757", "nct_id"=)"", "official_title"=)"Frailty Assessment in Patients Undergoing Oncologic Pancreatic Surgery: A NISQIP and NCI Center QI Initiative", "open_date"=)"09-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Dan", "pi_last_name"=)"Blazer", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"276878187", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01934", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"Ajinomoto 2015-01", "lead_org_po_id"=)"42081238", "local_site_identifier"=)"Pro00073162", "nci_id"=)"NCI-2016-01934", "nct_id"=)"NCT02512757", "official_title"=)"The AminoIndex™ Study - A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology", "open_date"=)"08-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"280898521", "specific_funding_source"=)"Innovis LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}],
+"data" =) [{"ad_nci_id"=)"NCI-2009-00310", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL05B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL05B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00310", "nct_id"=)"NCT00897325", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens", "open_date"=)"25-Sep-2006", "other_ids"=)"CDR0000491159\rCOG-AALL05B1", "other_protocol_ids"=)"AALL05B1, CDR0000491159, COG-AALL05B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Hunger", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74445057", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00324", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ABTR01B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ABTR01B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00324", "nct_id"=)"NCT00898079", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors", "open_date"=)"13-Oct-2003", "other_ids"=)"COG-ABTR01B1\rCDR0000271415", "other_protocol_ids"=)"ABTR01B1, COG-ABTR01B1, CDR0000271415", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nilsa", "pi_last_name"=)"Ramirez", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74441473", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00334", "affiliate_total"=)"3", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS02B3", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS02B3", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00334", "nct_id"=)"NCT00919750", "official_title"=)"A Children's Oncology Group Protocol for Collecting and Banking Pediatric Brain Tumor Research Specimens", "open_date"=)"16-Feb-2004", "other_ids"=)"CDR0000352347\rCOG-ACNS02B3", "other_protocol_ids"=)"ACNS02B3, CDR0000352347, COG-ACNS02B3", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Pomeroy", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74442841", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00370", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS07B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS07B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00370", "nct_id"=)"NCT00899990", "official_title"=)"A COG Study for collecting and Banking Ewing Sarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"CDR0000544202\rCOG-AEWS07B1", "other_protocol_ids"=)"AEWS07B1, CDR0000544202, COG-AEWS07B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Lessnick", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74446293", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00378", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"10-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHOD04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHOD04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00378", "nct_id"=)"NCT00900250", "official_title"=)"Hodgkin Disease (HD) Banking Study", "open_date"=)"23-Oct-2006", "other_ids"=)"COG-AHOD04B1\rCDR0000495369", "other_protocol_ids"=)"AHOD04B1, COG-AHOD04B1, CDR0000495369", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Meghan", "pi_last_name"=)"Higman", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"74445260", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00397", "affiliate_total"=)"44", "affiliate_total_rp"=)"4", "center_total"=)"54", "center_total_rp"=)"10", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL00B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL00B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00397", "nct_id"=)"NCT00904241", "official_title"=)"Neuroblastoma Biology Studies", "open_date"=)"06-Nov-2000", "other_ids"=)"CDR0000078642\rNCT00256763", "other_protocol_ids"=)"ANBL00B1, CDR0000078642, NCT00256763", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Hogarty", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"250582", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00406", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL04B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL04B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00406", "nct_id"=)"NCT01000753", "official_title"=)"Rare And Cutaneous Non-Hodgkin Lymphoma Registry", "open_date"=)"30-May-2005", "other_ids"=)"CDR0000404164\rCOG-ANHL04B1", "other_protocol_ids"=)"ANHL04B1, CDR0000404164, COG-ANHL04B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amanda", "pi_last_name"=)"Termuhlen", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74443210", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00410", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AOST06B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AOST06B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00410", "nct_id"=)"NCT00899275", "official_title"=)"A Children’s Oncology Group Protocol for Collecting and Banking Osteosarcoma Specimens", "open_date"=)"04-Feb-2008", "other_ids"=)"COG-AOST06B1\rCDR0000562538", "other_protocol_ids"=)"AOST06B1, COG-AOST06B1, CDR0000562538", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Richard", "pi_last_name"=)"Gorlick", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"74446542", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00416", "affiliate_total"=)"23", "affiliate_total_rp"=)"7", "center_total"=)"26", "center_total_rp"=)"7", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AREN03B2", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AREN03B2", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00416", "nct_id"=)"NCT00898365", "official_title"=)"Renal Tumors Classification, Biology, and Banking Study", "open_date"=)"27-Feb-2006", "other_ids"=)"COG-AREN03B2\rCDR0000459797", "other_protocol_ids"=)"AREN03B2, COG-AREN03B2, CDR0000459797", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Mullen", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74443978", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00494", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"01-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-8461", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 8461", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00494", "nct_id"=)"NCT00048958", "official_title"=)"Cytogenetic Studies in Acute Leukemia and Multiple Myeloma", "open_date"=)"22-Jun-1984", "other_ids"=)"CDR0000256897", "other_protocol_ids"=)"CALGB-8461, CDR0000256897", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Clara", "pi_last_name"=)"Bloomfield", "pi_middle_initial"=)"D", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74394012", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00502", "affiliate_total"=)"19", "affiliate_total_rp"=)"0", "center_total"=)"42", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"D9902", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D9902", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00502", "nct_id"=)"NCT00919269", "official_title"=)"A COG Soft Tissue Sarcoma Diagnosis, Biology and Banking Protocol", "open_date"=)"15-Mar-1999", "other_ids"=)"POG-9153\rCDR0000078602\rCOG-D9902\rCCG-B904\rIRS-D9902", "other_protocol_ids"=)"D9902, POG-9153, CDR0000078602, COG-D9902, CCG-B904, IRS-D9902", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Stephen", "pi_last_name"=)"Skapek", "pi_middle_initial"=)"X", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"74452350", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00715", "affiliate_total"=)"23", "affiliate_total_rp"=)"0", "center_total"=)"43", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Q9403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COG-4941L", "lead_org_po_id"=)"170240", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00715", "nct_id"=)"NCT00228696", "official_title"=)"National Wilms Tumor Late Effects Study", "open_date"=)"01-Oct-1995", "other_ids"=)"IRB00024842\rCDR0000069131", "other_protocol_ids"=)"Q9403, IRB00024842, CDR0000069131", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Wendy", "pi_last_name"=)"Leisenring", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"255137", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00751", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0000B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0000B", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00751", "nct_id"=)"NCT00784225", "official_title"=)"Prevention of Cataract and Age-Related Macular Degeneration with Vitamin E and Selenium - SELECT Eye Endpoints (SEE), Ancillary Study to SELECT", "open_date"=)"29-Jul-2010", "other_ids"=)"SWOG-S0000B\rCDR0000617778", "other_protocol_ids"=)"S0000B, SWOG-S0000B, CDR0000617778", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Frank", "pi_last_name"=)"Meyskens", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"74448410", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01112", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-MC083I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC083I", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01112", "nct_id"=)"NCT00967239", "official_title"=)"A Genome-Wide Association Study in Participants Experiencing Breast Cancer Events in High-Risk Postmenopausal Women Receiving Selective Estrogen Receptor Modulators on NSABP Trials P-1 and P-2", "open_date"=)"28-Apr-2009", "other_ids"=)"CDR0000638644", "other_protocol_ids"=)"NSABP-MC083I, CDR0000638644", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Ingle", "pi_middle_initial"=)"N", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"351326", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01208", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2010LSUC043", "lead_org_po_id"=)"139049", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01208", "nct_id"=)"NCT01288222", "official_title"=)"KIR Genotyping for Unrelated Donor (URD) Selection Prior to Hematopoietic Cell Transplantation (HCT) for AML: Selecting a Favorable KIR Donor", "open_date"=)"20-Jun-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Daniel", "pi_last_name"=)"Weisdorf", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74346339", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02976", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-151107", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 151107", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02976", "nct_id"=)"NCT01414595", "official_title"=)"Molecular Characterization of Lung Cancer: A Collaboration with the Cancer Genome Atlas Project (TGCA)", "open_date"=)"15-Oct-2011", "other_ids"=)"CDR0000706375", "other_protocol_ids"=)"CALGB-151107, CDR0000706375", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"75343061", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03822", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE03N1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE03N1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03822", "nct_id"=)"NCT00082745", "official_title"=)"Key Adverse Events after Childhood Cancer", "open_date"=)"22-Mar-2004", "other_ids"=)"CDR0000360708\rCOG-ALTE03N1\rNCT00228787", "other_protocol_ids"=)"ALTE03N1, CDR0000360708, COG-ALTE03N1, NCT00228787", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Smita", "pi_last_name"=)"Bhatia", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"80132371", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01996", "affiliate_total"=)"3", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A211201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A211201", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01996", "nct_id"=)"NCT01666171", "official_title"=)"Change in Mammographic Density with Metformin Use: A Companion Study to NCIC Study MA.32", "open_date"=)"22-Aug-2012", "other_ids"=)"CDR0000738328\rCALGB-A211201\rMA.32D", "other_protocol_ids"=)"A211201, CDR0000738328, CALGB-A211201, MA.32D", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Marie", "pi_last_name"=)"Wood", "pi_middle_initial"=)"E", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"100000519", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02421", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"220", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"400", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00006143", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02421", "nct_id"=)"", "official_title"=)"Malignant Melanoma Optimizing the Efficacy of Therapies thru a Better Understanding of Alkylating Drug Resistance Mechanisms, Gene Expression, Immune Responses, Pharacokinetics, and Pathologic Responses to Treatment", "open_date"=)"04-Jun-2002", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Paul", "pi_last_name"=)"Mosca", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"128724263", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00021", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"128", "center_total_rp"=)"34", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"200", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00030747", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00021", "nct_id"=)"", "official_title"=)"Evaluation of a Novel Pancreatic Cancer Biomarker", "open_date"=)"04-Oct-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rebekah", "pi_last_name"=)"White", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"130520678", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00050", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1598", "center_total_rp"=)"148", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"150", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00012010", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00050", "nct_id"=)"", "official_title"=)"Early Detection of Breast Cancer Using Circulating Markers", "open_date"=)"03-Nov-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Marks", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130563044", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01585", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9671", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9671", "lead_org_po_id"=)"16108126", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01585", "nct_id"=)"NCT02243592", "official_title"=)"Exceptional Responders Pilot Study: Molecular Profiling of Tumors from Cancer Patients Who Are Exceptional Responders", "open_date"=)"24-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"9671", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Barbara", "pi_last_name"=)"Conley", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"150767079", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00863", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9846", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9846", "lead_org_po_id"=)"37942400", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00863", "nct_id"=)"NCT02474160", "official_title"=)"Patient-Derived Models Tissue Procurement Protocol for the National Cancer Institute (NCI)", "open_date"=)"15-May-2015", "other_ids"=)"P9846_R02PAPPHOLD01\rP9846", "other_protocol_ids"=)"9846, P9846_R02PAPPHOLD01, P9846", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Doroshow", "pi_middle_initial"=)"H", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"190447033", "specific_funding_source"=)"National Cancer Institute LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02072", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"2", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047147", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02072", "nct_id"=)"NCT02026960", "official_title"=)"RNA Extraction and Amplification from Biopsy Specimens in Subjects with Metastatic Renal Cell Carcinoma", "open_date"=)"28-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212691436", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02075", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"155", "center_total_rp"=)"81", "clinical_research_cat"=)"ANC/COR", "close_date"=)"17-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"400", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050074", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02075", "nct_id"=)"", "official_title"=)"Thyroid Cancer and Polybrominated Diphenyl Ether (PBDE) Exposure ", "open_date"=)"14-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Julie", "pi_last_name"=)"Sosa", "pi_middle_initial"=)"A", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"212694580", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02077", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050745", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02077", "nct_id"=)"NCT02132182", "official_title"=)"A Canine/ Human Translational Model of Phenotypic and Functional Differences between Monocytes in Patients with and without Osteosarcoma", "open_date"=)"24-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"William", "pi_last_name"=)"Eward", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Bones and Joints", "sp_id"=)"212696664", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02081", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"60", "center_total_rp"=)"7", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"95", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00052149", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02081", "nct_id"=)"NCT02080650", "official_title"=)"Characterization of Circulating Tumor Cells captured by c-MET", "open_date"=)"18-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212699939", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02114", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"97", "center_total_rp"=)"93", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"400", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00044981", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02114", "nct_id"=)"", "official_title"=)"Acquisition of Tissue and Blood (Optional) from Patients with a History of Breast Cancer ", "open_date"=)"01-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Herbert", "pi_last_name"=)"Lyerly", "pi_middle_initial"=)"K", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"213887178", "specific_funding_source"=)"Department of Defense", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02116", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"148", "center_total_rp"=)"144", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"550", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053535", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02116", "nct_id"=)"NCT02229565", "official_title"=)"Molecular Mechanisms Underlying Prostate Cancer Disparities", "open_date"=)"16-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Steven", "pi_last_name"=)"Patierno", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"213895546", "specific_funding_source"=)"Bayer Corporation, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02118", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"15", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053925", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02118", "nct_id"=)"NCT02204943", "official_title"=)"Pharmacodynamic Study of Radium-223 in Men with Bone Metastatic Castration-Resistant Prostate Cancer (CRPC) ", "open_date"=)"28-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"213899899", "specific_funding_source"=)"Bayer Corporation, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02122", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"150", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054422", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02122", "nct_id"=)"", "official_title"=)"Identification of Novel Angiogenesis Biomarkers Correlating with Tumor Response after Hepatic Arterial Embolization for Hepatocellular Carcinoma", "open_date"=)"29-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Charles", "pi_last_name"=)"Kim", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"213903965", "specific_funding_source"=)"Radiological Society of North America, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02148", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"48", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"120", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00056936", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02148", "nct_id"=)"NCT02269982", "official_title"=)"Development of Circulating Molecular Predictors of Chemotherapy and Novel Hormonal Therapy Benefit in Men with Metastatic Castration Resistant Prostate Cancer (mCRPC)", "open_date"=)"14-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"214168377", "specific_funding_source"=)"Prostate Cancer Foundation, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02162", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"20", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"160", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00059349", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02162", "nct_id"=)"NCT02694965", "official_title"=)"Understanding Immunotherapy Resistance Mechanisms in Advanced Melanoma ", "open_date"=)"13-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Brent", "pi_last_name"=)"Hanks", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"214207553", "specific_funding_source"=)"Merck and Company Inc, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02180", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00062142", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02180", "nct_id"=)"NCT02580045", "official_title"=)"CSF Pharmacokinetics and Cell-Free DNA in Patients with Advanced Cancer", "open_date"=)"02-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Kimberly", "pi_last_name"=)"Blackwell", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214386213", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00448", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"11", "center_total_rp"=)"11", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00064629", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00448", "nct_id"=)"NCT02638818", "official_title"=)"A Pilot Study Evaluating Health-related Quality of Life Endpoints in Patients Undergoing Minimally Invasive versus Open Pancreaticoduodenectomy", "open_date"=)"14-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Dan", "pi_last_name"=)"Blazer", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"234522556", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00589", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"122", "center_total_rp"=)"122", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"2000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065084", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00589", "nct_id"=)"", "official_title"=)"Duke GI BEST: Duke Gastrointestinal Biomarkers and Epidemiology Study", "open_date"=)"05-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Qingyi", "pi_last_name"=)"Wei", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"238442455", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00829", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00069742", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00829", "nct_id"=)"NCT02848872", "official_title"=)"Evaluation of Tumor and Blood Immune Biomarkers in Resected Non-Small Cell Lung Cancer", "open_date"=)"19-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Clarke", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"246773971", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00976", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"5", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072146", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00976", "nct_id"=)"", "official_title"=)"Immune Expression in Pediatric Wilms Tumor", "open_date"=)"20-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Routh", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"251721307", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01174", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"120", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072748", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01174", "nct_id"=)"", "official_title"=)"Monitoring of Immune Profiles of Adult Patients Diagnosed with Glioma", "open_date"=)"20-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"258684301", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00063", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"ANC/COR", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00074697", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00063", "nct_id"=)"", "official_title"=)"Pilot Study to Assess Feasibility of Pleural Fluid for Tumor DNA", "open_date"=)"06-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kamran", "pi_last_name"=)"Mahmood", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"284755689", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00336", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0332", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0332", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00336", "nct_id"=)"NCT00392327", "official_title"=)"Efficacy of Carboplatin Administered Concomitantly with Radiation and Isotretinoin as a Pro-apoptotic Agent in Other than Average Risk Medulloblastoma/PNET Patients", "open_date"=)"26-Mar-2007", "other_ids"=)"CDR0000511991\rCOG-ACNS0332", "other_protocol_ids"=)"ACNS0332, CDR0000511991, COG-ACNS0332", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Olson", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74409372", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00447", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-140503", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 140503", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00447", "nct_id"=)"NCT00499330", "official_title"=)"A Phase III Randomized Trial of Lobectomy versus Sublobar Resection for Small (≤ 2 cm) Peripheral Non-small Cell Lung Cancer", "open_date"=)"15-Jun-2007", "other_ids"=)"CDR0000555324\rECOG-40503", "other_protocol_ids"=)"CALGB-140503, CDR0000555324, ECOG-40503", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Nasser", "pi_last_name"=)"Altorki", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74412640", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00470", "affiliate_total"=)"6", "affiliate_total_rp"=)"1", "center_total"=)"6", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-30610", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-30610", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00470", "nct_id"=)"NCT00632853", "official_title"=)"Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide", "open_date"=)"15-Mar-2008", "other_ids"=)"CALGB 30610/RTOG 0538\rCDR0000588879\rRTOG 0538", "other_protocol_ids"=)"CALGB-30610, CALGB, 30610/RTOG, 0538, CDR0000588879, RTOG, 0538", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Bogart", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74419665", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00496", "affiliate_total"=)"10", "affiliate_total_rp"=)"5", "center_total"=)"11", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-90203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-90203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00496", "nct_id"=)"NCT00430183", "official_title"=)"A Randomized Phase III Study of Neo-adjuvant Docetaxel and Androgen Deprivation Prior to Radical Prostatectomy versus Immediate Radical Prostatectomy in Patients with High-Risk, Clinically Localized Prostate Cancer", "open_date"=)"15-Dec-2006", "other_ids"=)"CDR0000526353", "other_protocol_ids"=)"CALGB-90203, CDR0000526353", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Eastham", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74410017", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00507", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1305", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1305", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00507", "nct_id"=)"NCT00588770", "official_title"=)"A Phase III Randomized Trial of Chemotherapy with or without Bevacizumab in Patients with Recurrent or Metastatic Head and Neck Cancer", "open_date"=)"08-Aug-2008", "other_ids"=)"CDR0000582533", "other_protocol_ids"=)"E1305, CDR0000582533", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Athanassios (Ethan)", "pi_last_name"=)"Argiris", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74416180", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00587", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0213", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00587", "nct_id"=)"NCT00565851", "official_title"=)"A Phase III Randomized Controlled Clinical Trial of Carboplatin and Paclitaxel (or Gemcitabine) Alone or in Combination with Bevacizumab (NSC #704865) Followed by Bevacizumab and Secondary Cytoreductive Surgery in Platinum-Sensitive, Recurrent Ovarian, Peritoneal Primary and Fallopian Tube Cancer. NCI-Supplied Agents: Bevacizumab (NSC #704865)", "open_date"=)"06-Dec-2007", "other_ids"=)"CDR0000546714", "other_protocol_ids"=)"GOG-0213, CDR0000546714", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Coleman", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74412058", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00595", "affiliate_total"=)"23", "affiliate_total_rp"=)"2", "center_total"=)"19", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0225", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0225", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00595", "nct_id"=)"NCT00719303", "official_title"=)"Can Diet and Physical Activity Modulate Ovarian, Fallopian Tube and Primary Peritoneal Cancer Progression-Free Survival?", "open_date"=)"18-Jun-2012", "other_ids"=)"CDR0000594600", "other_protocol_ids"=)"GOG-0225, CDR0000594600", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Alberts", "pi_middle_initial"=)"S", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74420620", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00603", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0238", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0238", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00603", "nct_id"=)"NCT00492778", "official_title"=)"A Randomized Trial of Pelvic Irradiation with or without Concurrent Weekly Cisplatin in Patients with Pelvic-Only Recurrence of Carcinoma of the Uterine Corpus", "open_date"=)"25-Feb-2008", "other_ids"=)"CDR0000550975", "other_protocol_ids"=)"GOG-0238, CDR0000550975", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jonathan", "pi_last_name"=)"Feddock", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"74412141", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00733", "affiliate_total"=)"22", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0534", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0534", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00733", "nct_id"=)"NCT00567580", "official_title"=)"A Phase III Trial of Short Term Androgen Deprivation with Pelvic Lymph Node or Prostate Bed Only Radiotherapy (SPPORT) in Prostate Cancer Patients with a Rising PSA After Radical Prostatectomy", "open_date"=)"13-Feb-2008", "other_ids"=)"CDR0000577574", "other_protocol_ids"=)"RTOG-0534, CDR0000577574", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alan", "pi_last_name"=)"Pollack", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74418627", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00926", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GE 122-008", "lead_org_po_id"=)"88518", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00926", "nct_id"=)"NCT00730444", "official_title"=)"Expanded Access Protocol for [123I]mIBG for Patients With Known or Suspected Neuroblastoma", "open_date"=)"12-Feb-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Jean", "pi_last_name"=)"De Serres, MD", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"282928", "specific_funding_source"=)"GE Healthcare", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-01064", "affiliate_total"=)"9", "affiliate_total_rp"=)"1", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL0032", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL0032", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-01064", "nct_id"=)"NCT00026312", "official_title"=)"Phase III Randomized Study of Chimeric Antibody 14.18 (Ch14.18) in High Risk Neuroblastoma following Myeloablative Therapy and Autologous Stem Cell Rescue", "open_date"=)"18-Oct-2001", "other_ids"=)"PANBL0032_A33PAMDREVW01\rCOG-ANBL0032\rCDR0000069018", "other_protocol_ids"=)"ANBL0032, PANBL0032_A33PAMDREVW01, COG-ANBL0032, CDR0000069018", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alice", "pi_last_name"=)"Yu", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74439628", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00030", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"265-101", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00030", "nct_id"=)"NCT00697632", "official_title"=)"Open-Label Dose-Escalation Trial to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Daily Oral MGCD265 Administered Without Interruption to Subjects With Advanced Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"10097024", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-00454", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"111767", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-00454", "nct_id"=)"NCT00790816", "official_title"=)"An Open-Label Phase Ib Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-Cancer Treatment in Patients With Solid Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"21019472", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-01344", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MIP-IB12B", "lead_org_po_id"=)"48834314", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-01344", "nct_id"=)"NCT00874614", "official_title"=)"A Phase II Study Evaluating the Efficacy and Safety of Ultratrace Iobenguane I 131 in Patients With Malignant Relapsed/Refractory Pheochromocytoma/Paraganglioma", "open_date"=)"01-Jun-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Endocrine System", "sp_id"=)"61642327", "specific_funding_source"=)"Molecular Insight Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02211", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"28", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-106", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02211", "nct_id"=)"NCT01208662", "official_title"=)"A Randomized Phase III Study Comparing Conventional Dose Treatment Using a Combination of Lenalidomide, Bortezomib, and Dexamethasone (RVD) to High-Dose Treatment with Peripheral Stem Cell Transplant in the Initial Management of Myeloma in Patients up to 65 Years of Age", "open_date"=)"27-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Paul", "pi_last_name"=)"Richardson", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74027624", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2010-02332", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TED10893", "lead_org_po_id"=)"214637", "local_site_identifier"=)"", "nci_id"=)"NCI-2010-02332", "nct_id"=)"NCT01084252", "official_title"=)"A Phase I/2 Dose Escalation Safety, Pharmacokinetic and Efficacy Study of Multiple Intravenous Administrations of a Humanized Monoclonal Antibody (SAR650984) Against CD38 in Patients With Selected CD38+ Hematological Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74089494", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00116", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10112", "lead_org_po_id"=)"38249", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00116", "nct_id"=)"NCT01273610", "official_title"=)"Tolerability of the Combination of Lapatinib and Trastuzumab in Adults Aged 60 or Older with HER2 Positive Locally Advanced or Metastatic Breast Cancer", "open_date"=)"13-Apr-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Arti", "pi_last_name"=)"Hurria", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74143229", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation, City of Hope Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00793", "affiliate_total"=)"23", "affiliate_total_rp"=)"3", "center_total"=)"24", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"08-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E5508", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E5508", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00793", "nct_id"=)"NCT01107626", "official_title"=)"Randomized Phase III Study of Maintenance Therapy with Bevacizumab, Pemetrexed, or a Combination of Bevacizumab and Pemetrexed following Carboplatin, Paclitaxel and Bevacizumab for Advanced Non-squamous NSCLC", "open_date"=)"12-Aug-2010", "other_ids"=)"ECOG-E5508\rPE5508_A10PAMDREVW01\rCDR0000666482", "other_protocol_ids"=)"E5508, ECOG-E5508, PE5508_A10PAMDREVW01, CDR0000666482", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Suresh", "pi_last_name"=)"Ramalingam", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74436393", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00878", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0920", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0920", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00878", "nct_id"=)"NCT00956007", "official_title"=)"A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer", "open_date"=)"05-Nov-2009", "other_ids"=)"NCT01311063\rCDR0000651536", "other_protocol_ids"=)"RTOG-0920, NCT01311063, CDR0000651536", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Machtay", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74431710", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-00883", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KB004-01", "lead_org_po_id"=)"14203561", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-00883", "nct_id"=)"NCT01211691", "official_title"=)"Study of the Anti-EphA3 Monoclonal Antibody KB004 in Subjects With EphA3-Expressing Hematologic Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74291095", "specific_funding_source"=)"KaloBios Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01164", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"VB-111-122", "lead_org_po_id"=)"242384", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01164", "nct_id"=)"NCT01260506", "official_title"=)"", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74337723", "specific_funding_source"=)"Vascular Biogenics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01190", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2533.00", "lead_org_po_id"=)"39492311", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01190", "nct_id"=)"NCT01413100", "official_title"=)"A Phase II Multi-center Study of High-Dose Cyclophosphamide and Antithymocyte Globulin Followed by Autologous Hematopoietic Cell Transplantation with Post Transplant Maintenance for the Treatment of Systemic Sclerosis", "open_date"=)"15-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"George", "pi_last_name"=)"Georges", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Skin", "sp_id"=)"74339835", "specific_funding_source"=)"Scleroderma Research Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01438", "affiliate_total"=)"31", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"06-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"SCUSF-0806", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SCUSF 0806", "lead_org_po_id"=)"36324157", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01438", "nct_id"=)"NCT01009918", "official_title"=)"Phase II Placebo-Controlled Trial of Lisinopril and Coreg CR® to Reduce Cardiotoxicity in Patients with Breast Cancer Receiving (Neo)adjuvant Chemotherapy with Trastuzumab (Herceptin®)", "open_date"=)"01-Mar-2010", "other_ids"=)"HLMCC-0806\rCDR0000654123", "other_protocol_ids"=)"SCUSF-0806, HLMCC-0806, CDR0000654123", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Maya", "pi_last_name"=)"Guglin", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74377539", "specific_funding_source"=)"SunCoast CCOP Research Base at the University of South Florida", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01745", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"06-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL09P1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL09P1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01745", "nct_id"=)"NCT01175356", "official_title"=)"A COG Pilot Study of Intensive Induction Chemotherapy and 131I-MIBG Followed by Myeloablative Busulfan/Melphalan (Bu/Mel) for Newly Diagnosed High-Risk Neuroblastoma", "open_date"=)"04-Oct-2010", "other_ids"=)"CDR0000682629", "other_protocol_ids"=)"ANBL09P1, CDR0000682629", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Brian", "pi_last_name"=)"Weiss", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74411070", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01919", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0260", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0260", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01919", "nct_id"=)"NCT00888615", "official_title"=)"A Phase II Evaluation of Elesclomol Sodium and Weekly Paclitaxel in the Treatment of Recurrent or Persistent Platinum-Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer", "open_date"=)"13-Dec-2010", "other_ids"=)"CDR0000641202", "other_protocol_ids"=)"GOG-0260, CDR0000641202", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Bradley", "pi_last_name"=)"Monk", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74427167", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01948", "affiliate_total"=)"16", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0815", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0815", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01948", "nct_id"=)"NCT00936390", "official_title"=)"A Phase III Prospective Randomized Trial of Dose-Escalated Radiotherapy with or without Short-Term Androgen Deprivation Therapy for Patients with Intermediate-Risk Prostate Cancer", "open_date"=)"14-Sep-2009", "other_ids"=)"CDR0000648194", "other_protocol_ids"=)"RTOG-0815, CDR0000648194", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alvaro", "pi_last_name"=)"Martinez", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74430433", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01973", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0724", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0724/GOG-0724", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01973", "nct_id"=)"NCT00980954", "official_title"=)"Phase III Randomized Study of Concurrent Chemotherapy and Pelvic Radiation Therapy with or without Adjuvant Chemotherapy in High-Risk Patients with Early-Stage Cervical Carcinoma following Radical Hysterectomy", "open_date"=)"15-Sep-2014", "other_ids"=)"GOG-0724\rCDR0000654709", "other_protocol_ids"=)"RTOG-0724, GOG-0724, CDR0000654709", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuja", "pi_last_name"=)"Jhingran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74432640", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01975", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHEP0731", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHEP0731", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01975", "nct_id"=)"NCT00980460", "official_title"=)"Treatment of Children with All Stages of Hepatoblastoma with Temsirolimus (NSC#683864) Added to High Risk Stratum Treatment", "open_date"=)"14-Sep-2009", "other_ids"=)"COG-AHEP0731\rNCT02265692\rCDR0000654889", "other_protocol_ids"=)"AHEP0731, COG-AHEP0731, NCT02265692, CDR0000654889", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Howard", "pi_last_name"=)"Katzenstein", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"74432842", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01987", "affiliate_total"=)"9", "affiliate_total_rp"=)"3", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0848", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-0848", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01987", "nct_id"=)"NCT01013649", "official_title"=)"A Phase II-R and a Phase III Trial Evaluating Both Erlotinib (Ph II-R) and Chemoradiation (Ph III) as Adjuvant Treatment for Patients with Resected Head of Pancreas Adenocarcinoma", "open_date"=)"17-Nov-2009", "other_ids"=)"CDR0000659092\rRTOG 0848", "other_protocol_ids"=)"RTOG-0848, CDR0000659092, RTOG, 0848", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ross", "pi_last_name"=)"Abrams", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"74433795", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01989", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80802", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80802", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01989", "nct_id"=)"NCT01015833", "official_title"=)"Phase III Randomized Study of Sorafenib plus Doxorubicin versus Sorafenib in Patients with Advanced Hepatocellular Carcinoma (HCC)", "open_date"=)"15-Feb-2010", "other_ids"=)"CDR0000659348", "other_protocol_ids"=)"CALGB-80802, CDR0000659348", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ghassan", "pi_last_name"=)"Abou-Alfa", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"74433954", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-01992", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2906", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2906", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-01992", "nct_id"=)"NCT02085408", "official_title"=)"Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age )/= 60 Years)", "open_date"=)"28-Dec-2010", "other_ids"=)"NCT01041703\rECOG-E2906\rCDR0000659585", "other_protocol_ids"=)"E2906, NCT01041703, ECOG-E2906, CDR0000659585", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"James", "pi_last_name"=)"Foran", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74434175", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02000", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0264", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0264", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02000", "nct_id"=)"NCT01042522", "official_title"=)"A Randomized Phase II Trial of Paclitaxel and Carboplatin vs. Bleomycin, Etoposide, and Cisplatin for Newly Diagnosed Advanced Stage and Recurrent Chemonaive Sex Cord-Stromal Tumors of the Ovary", "open_date"=)"08-Feb-2010", "other_ids"=)"CDR0000662814", "other_protocol_ids"=)"GOG-0264, CDR0000662814", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jubilee", "pi_last_name"=)"Brown", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"74434968", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02008", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0937", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0937", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02008", "nct_id"=)"NCT01055197", "official_title"=)"Randomized Phase II Study Comparing Prophylactic Cranial Irradiation Alone to Prophylactic Cranial Irradiation and Consolidative Extra-Cranial Irradiation for Extensive Disease Small Cell Lung Cancer (ED-SCLC)", "open_date"=)"18-Mar-2010", "other_ids"=)"CDR0000663959", "other_protocol_ids"=)"RTOG-0937, CDR0000663959", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Gore", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"74435576", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02015", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0905", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0905", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02015", "nct_id"=)"NCT01064648", "official_title"=)"A Phase I/Randomized Phase II Study of Cediranib (NSC#732208) versus Placebo in Combination with Cisplatin and Pemetrexed in Chemonaive Patients with Malignant Pleural Mesothelioma", "open_date"=)"15-Mar-2010", "other_ids"=)"CDR0000665415", "other_protocol_ids"=)"S0905, CDR0000665415", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Anne", "pi_last_name"=)"Tsao", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Respiratory/Intrathoracic Organs", "sp_id"=)"74436203", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02028", "affiliate_total"=)"9", "affiliate_total_rp"=)"2", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0931", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0931", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02028", "nct_id"=)"NCT01120249", "official_title"=)"EVEREST: EVErolimus for Renal Cancer Ensuing Surgical Therapy, A Phase III Study", "open_date"=)"01-Apr-2011", "other_ids"=)"SWOG-S0931\rCDR0000668388", "other_protocol_ids"=)"S0931, SWOG-S0931, CDR0000668388", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Christopher", "pi_last_name"=)"Ryan", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"74437329", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02029", "affiliate_total"=)"2", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0831", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0831", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02029", "nct_id"=)"NCT01096368", "official_title"=)"Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients with Newly Diagnosed Ependymoma Ages 1 to 21 Years", "open_date"=)"29-Mar-2010", "other_ids"=)"CDR0000668560\rCOG-ACNS0831", "other_protocol_ids"=)"ACNS0831, CDR0000668560, COG-ACNS0831", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Amy", "pi_last_name"=)"Smith", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74457474", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02034", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-50801", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-50801", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02034", "nct_id"=)"NCT01118026", "official_title"=)"Phase II Trial of Response-Adapted Therapy Based on Positron Emission Tomography (PET) for Bulky Stage I and Stage II Classical Hodgkin Lymphoma (HL)", "open_date"=)"15-May-2010", "other_ids"=)"CDR0000669076", "other_protocol_ids"=)"CALGB-50801, CDR0000669076", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ann", "pi_last_name"=)"LaCasce", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"74456784", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0263", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0263", "lead_org_po_id"=)"88642", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02037", "nct_id"=)"NCT01101451", "official_title"=)"Randomized Phase III Clinical Trial of Adjuvant Radiation Versus Chemoradiation in Intermediate Risk, Stage I/IIA Cervical Cancer Treated With Initial Radical Hysterectomy and Pelvic Lymphadenectomy", "open_date"=)"12-Apr-2010", "other_ids"=)"CDR0000670125", "other_protocol_ids"=)"GOG-0263, CDR0000670125", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sang", "pi_last_name"=)"Ryu", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"74437876", "specific_funding_source"=)"Gynecologic Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02050", "affiliate_total"=)"49", "affiliate_total_rp"=)"13", "center_total"=)"13", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"20-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80702", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80702", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02050", "nct_id"=)"NCT01150045", "official_title"=)"A Phase III Trial of 6 versus 12 Treatments of Adjuvant FOLFOX plus Celecoxib or Placebo for Patients with Resected Stage III Colon Cancer", "open_date"=)"22-Jun-2010", "other_ids"=)"CALGB/SWOG C80702\rCDR0000675693\rCALGB-SWOG C80702\rCALGB 80702", "other_protocol_ids"=)"CALGB-80702, CALGB/SWOG, C80702, CDR0000675693, CALGB-SWOG, C80702, CALGB, 80702", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Meyerhardt", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Colon", "sp_id"=)"74438921", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3A06", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3A06", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02057", "nct_id"=)"NCT01169337", "official_title"=)"Randomized Phase III Trial of Lenalidomide versus Observation Alone in Patients with Asymptomatic High-Risk Smoldering Multiple Myeloma", "open_date"=)"05-Oct-2010", "other_ids"=)"CDR0000682012\rECOG-E3A06", "other_protocol_ids"=)"E3A06, CDR0000682012, ECOG-E3A06", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sagar", "pi_last_name"=)"Lonial", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"74439478", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02572", "affiliate_total"=)"76", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-47", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-47", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02572", "nct_id"=)"NCT01275677", "official_title"=)"A Randomized Phase III Trial of Adjuvant Therapy Comparing Chemotherapy Alone (Six Cycles of Docetaxel plus Cyclophosphamide or Four Cycles of Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer", "open_date"=)"06-Jan-2011", "other_ids"=)"CDR0000692574", "other_protocol_ids"=)"NSABP-B-47, CDR0000692574", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Louis", "pi_last_name"=)"Fehrenbacher", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74677970", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02599", "affiliate_total"=)"24", "affiliate_total_rp"=)"6", "center_total"=)"22", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL0932", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL0932", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02599", "nct_id"=)"NCT01190930", "official_title"=)"Treatment of Patients with Newly Diagnosed Standard Risk B-Lymphoblastic Leukemia (B-ALL) or Localized B-Lineage Lymphoblastic Lymphoma (B-LLy)", "open_date"=)"09-Aug-2010", "other_ids"=)"CDR0000683227", "other_protocol_ids"=)"AALL0932, CDR0000683227", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anne", "pi_last_name"=)"Angiolillo", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74707439", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02601", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1010", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1010", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02601", "nct_id"=)"NCT01196390", "official_title"=)"A Phase III Trial Evaluating the Addition of Trastuzumab to Trimodality Treatment of HER2-Overexpressing Esophageal Adenocarcinoma", "open_date"=)"30-Dec-2010", "other_ids"=)"CDR0000683717", "other_protocol_ids"=)"RTOG-1010, CDR0000683717", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Howard", "pi_last_name"=)"Safran", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Esophagus", "sp_id"=)"74708646", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02605", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS0821", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS0821", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02605", "nct_id"=)"NCT01217437", "official_title"=)"Temozolomide With Irinotecan Versus Temozolomide, Irinotecan Plus Bevacizumab (NSC# 704865) for Recurrent/Refractory Medulloblastoma/CNS PNET of Childhood, a COG Randomized Phase II Screening Trial", "open_date"=)"22-Nov-2010", "other_ids"=)"COG-ACNS0821\rCDR0000686608", "other_protocol_ids"=)"ACNS0821, COG-ACNS0821, CDR0000686608", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Adam", "pi_last_name"=)"Levy", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74711654", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02611", "affiliate_total"=)"3", "affiliate_total_rp"=)"1", "center_total"=)"7", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS1031", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS1031", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02611", "nct_id"=)"NCT01231906", "official_title"=)"A Phase III Randomized Trial of Adding Vincristine-Topotecan-Cyclophosphamide to Standard Chemotherapy in Initial Treatment of Non-Metastatic Ewing Sarcoma", "open_date"=)"22-Nov-2010", "other_ids"=)"CDR0000687639\rCOG-AEWS1031", "other_protocol_ids"=)"AEWS1031, CDR0000687639, COG-AEWS1031", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Patrick", "pi_last_name"=)"Leavey", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74715539", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02613", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-70807", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 70807", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02613", "nct_id"=)"NCT01238172", "official_title"=)"The Men’s Eating and Living (MEAL) Study: A Randomized Trial of Diet to Alter Disease Progression in Prostate Cancer Patients on Active Surveillance", "open_date"=)"01-Dec-2010", "other_ids"=)"CDR0000687958", "other_protocol_ids"=)"CALGB-70807, CDR0000687958", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"John", "pi_last_name"=)"Parsons", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74717134", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02623", "affiliate_total"=)"15", "affiliate_total_rp"=)"1", "center_total"=)"33", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1007", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1007", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02623", "nct_id"=)"NCT01272037", "official_title"=)"A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less. RxPONDER: A Clinical Trial Rx for Positive Node, Endocrine Responsive Breast Cancer", "open_date"=)"15-Jan-2011", "other_ids"=)"SWOG-S1007\rPS1007_A11PAMDREVW01\rCDR0000692475", "other_protocol_ids"=)"S1007, SWOG-S1007, PS1007_A11PAMDREVW01, CDR0000692475", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kevin", "pi_last_name"=)"Kalinsky", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"74723280", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02625", "affiliate_total"=)"4", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-50904", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 50904", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02625", "nct_id"=)"NCT01286272", "official_title"=)"A Randomized Phase II Trial of Ofatumumab and Bendamustine vs. Ofatumumab, Bortezomib (NSC #681239) and Bendamustine in Patients with Untreated Follicular Lymphoma", "open_date"=)"08-Apr-2011", "other_ids"=)"CDR0000694298", "other_protocol_ids"=)"CALGB-50904, CDR0000694298", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Kristie", "pi_last_name"=)"Blum", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74724720", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02636", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL0934", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL0934", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02636", "nct_id"=)"NCT01371656", "official_title"=)"A Randomized Trial of Levofloxacin to Prevent Bacteremia in Children Being Treated for Acute Leukemia (AL) or Undergoing Hematopoietic Stem Cell Transplantation (HSCT)", "open_date"=)"20-Jun-2011", "other_ids"=)"CDR0000695661", "other_protocol_ids"=)"ACCL0934, CDR0000695661", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sarah", "pi_last_name"=)"Alexander", "pi_middle_initial"=)"W", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74729630", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02640", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL0933", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL0933", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02640", "nct_id"=)"NCT01307579", "official_title"=)"A Randomized Open-Label Trial of Caspofungin versus Fluconazole to Prevent Invasive Fungal Infections in Children Undergoing Chemotherapy for Acute Myeloid Leukemia (AML)", "open_date"=)"04-Apr-2011", "other_ids"=)"COG-ACCL0933\rCDR0000695748", "other_protocol_ids"=)"ACCL0933, COG-ACCL0933, CDR0000695748", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Theoklis", "pi_last_name"=)"Zaoutis", "pi_middle_initial"=)"E", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74732800", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02642", "affiliate_total"=)"6", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-80803", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-80803", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02642", "nct_id"=)"NCT01333033", "official_title"=)"Randomized Phase II Trial of PET Scan-Directed Combined Modality Therapy in Esophageal Cancer", "open_date"=)"15-Jul-2011", "other_ids"=)"CDR0000698428", "other_protocol_ids"=)"CALGB-80803, CDR0000698428", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Karyn", "pi_last_name"=)"Goodman", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74734227", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02645", "affiliate_total"=)"3", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2108", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2108", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02645", "nct_id"=)"NCT01242800", "official_title"=)"A Randomized Phase III Trial of the Value of Early Local Therapy for the Intact Primary Tumor in Patients with Metastatic Breast Cancer", "open_date"=)"08-Feb-2011", "other_ids"=)"ECOG-E2108\rCDR0000688097", "other_protocol_ids"=)"E2108, ECOG-E2108, CDR0000688097", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Seema", "pi_last_name"=)"Khan", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74736422", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02649", "affiliate_total"=)"20", "affiliate_total_rp"=)"0", "center_total"=)"11", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1609", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1609", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02649", "nct_id"=)"NCT01274338", "official_title"=)"A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy Versus High-Dose Interferon a-2b for Resected High-Risk Melanoma", "open_date"=)"25-May-2011", "other_ids"=)"ECOG-E1609\rCDR0000692568", "other_protocol_ids"=)"E1609, ECOG-E1609, CDR0000692568", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ahmad", "pi_last_name"=)"Tarhini", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"74738057", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02670", "affiliate_total"=)"4", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AAML1031", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAML1031", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02670", "nct_id"=)"NCT01371981", "official_title"=)"A Phase III Randomized Trial for Patients with De Novo AML Using Bortezomib and Sorafenib (NSC# 681239, NSC# 724772) for Patients with High Allelic Ratio FLT3/ITD", "open_date"=)"20-Jun-2011", "other_ids"=)"CDR0000701850\rCOG-AAML1031", "other_protocol_ids"=)"AAML1031, CDR0000701850, COG-AAML1031", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Richard", "pi_last_name"=)"Aplenc", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"74751754", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02673", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1001", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02673", "nct_id"=)"NCT01359592", "official_title"=)"A Phase II Trial of PET-Directed Therapy for Limited Stage Diffuse Large B-Cell Lymphoma (DLBCL)", "open_date"=)"18-Jul-2011", "other_ids"=)"SWOG-S1001\rCDR0000700624", "other_protocol_ids"=)"S1001, SWOG-S1001, CDR0000700624", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"Persky", "pi_middle_initial"=)"O", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"74754334", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02674", "affiliate_total"=)"28", "affiliate_total_rp"=)"7", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-0924", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 0924", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02674", "nct_id"=)"NCT01368588", "official_title"=)"Androgen Deprivation Therapy and High Dose Radiotherapy with or without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial", "open_date"=)"07-Jul-2011", "other_ids"=)"PRTOG-0924_A03PAMDREVW01\rCDR0000701128", "other_protocol_ids"=)"RTOG-0924, PRTOG-0924_A03PAMDREVW01, CDR0000701128", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mack", "pi_last_name"=)"Roach", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"74754892", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02676", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N107C", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N107C", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02676", "nct_id"=)"NCT01372774", "official_title"=)"A Phase III Trial of Post-Surgical Stereotactic Radiosurgery (SRS) Compared with Whole Brain Radiotherapy (WBRT) for Resected Metastatic Brain Disease", "open_date"=)"08-Jul-2011", "other_ids"=)"CDR0000701474\rNCCTG-N107C", "other_protocol_ids"=)"N107C, CDR0000701474, NCCTG-N107C", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Paul", "pi_last_name"=)"Brown", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"74756305", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02702", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-009", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02702", "nct_id"=)"NCT01340300", "official_title"=)"Randomized Phase II Study of Exercise and Metformin in Colorectal and Breast Cancer Survivors", "open_date"=)"30-Jun-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Meyerhardt", "pi_middle_initial"=)"A", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74781096", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02978", "affiliate_total"=)"16", "affiliate_total_rp"=)"5", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANZGOG-0902-GOG-0274", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANZGOG-0902-GOG-0274", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02978", "nct_id"=)"NCT01414608", "official_title"=)"A Phase III Trial of Adjuvant Chemotherapy following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial", "open_date"=)"09-Jan-2012", "other_ids"=)"ANZGOG-0902\rRTOG-1174\rGOG-0274\rCDR0000706698", "other_protocol_ids"=)"ANZGOG-0902-GOG-0274, ANZGOG-0902, RTOG-1174, GOG-0274, CDR0000706698", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kathleen", "pi_last_name"=)"Moore", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"75343881", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02980", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1411", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1411", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02980", "nct_id"=)"NCT01415752", "official_title"=)"Intergroup Randomized Phase II Four Arm Study in Patients with Previously Untreated Mantle Cell Lymphoma of Therapy with: Arm A = Rituximab+ Bendamustine Followed by Rituximab Consolidation (RB --)R); Arm B = Rituximab + Bendamustine + Bortezomib Followed by Rituximab Consolidation (RBV--) R), Arm C = Rituximab + Bendamustine Followed by Lenalidomide + Rituximab Consolidation (RB --) LR) or Arm D = Rituximab + Bendamustine + Bortezomib Followed by Lenalidomide + Rituximab Consolidation (RBV --) LR)", "open_date"=)"22-May-2012", "other_ids"=)"ECOG-E1411\rCDR0000707057", "other_protocol_ids"=)"E1411, ECOG-E1411, CDR0000707057", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Smith", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"75347136", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03059", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"02-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-321", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03059", "nct_id"=)"NCT01182350", "official_title"=)"Phase II Trial of Molecularly Determined Treatment of Children and Young Adults with Newly Diagnosed Diffuse Intrinsic Pontine Gliomas", "open_date"=)"01-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mark", "pi_last_name"=)"Kieran", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"75631011", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03132", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB18424-258", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03132", "nct_id"=)"NCT01348490", "official_title"=)"An Open Label Assessment of Safety and Efficacy of Ruxolitinib (INCB018424) in Subjects With Primary Myelofibrosis (PMF), Post Essential Thrombocythemia-myelofibrosis (PPV-MF) and Post Polycythemia Vera-myelofibrosis (PET-MF) Who Have Platelet Counts of 50 x 10^9/L to 100 x 10^9/L", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"75707169", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03452", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"25-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-40903", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB 40903", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03452", "nct_id"=)"NCT01439711", "official_title"=)"Phase II Study Neoadjuvant Letrozole for Postmenopausal Women with Estrogen Receptor Positive Ductal Carcinoma in SITU (DCIS)", "open_date"=)"15-Feb-2012", "other_ids"=)"CDR0000701992", "other_protocol_ids"=)"CALGB-40903, CDR0000701992", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Eun-Sil (Shelley)", "pi_last_name"=)"Hwang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"76642201", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03797", "affiliate_total"=)"18", "affiliate_total_rp"=)"4", "center_total"=)"18", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL1131", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03797", "nct_id"=)"NCT02883049", "official_title"=)"A Phase III Randomized Trial for Newly Diagnosed High Risk B-Lymphoblastic Leukemia (B-ALL) including a Stratum Evaluating Dasatinib (NSC#732517) in Patients with Ph-like Tyrosine Kinase Inhibitor (TKI) Sensitive Mutations", "open_date"=)"27-Feb-2012", "other_ids"=)"COG-AALL1131\rNCT01406756\rCDR0000706370", "other_protocol_ids"=)"AALL1131, COG-AALL1131, NCT01406756, CDR0000706370", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Michael", "pi_last_name"=)"Burke", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"77859432", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03837", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"65", "center_total_rp"=)"19", "clinical_research_cat"=)"INT", "close_date"=)"26-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"62", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00025164", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03837", "nct_id"=)"NCT01186978", "official_title"=)"Phase II Study of Dose-Reduced Consolidation Radiation Therapy in Patients with Diffuse Large B-Cell Lymphoma", "open_date"=)"21-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Christopher", "pi_last_name"=)"Kelsey", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"80477956", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03848", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"50", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"31-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"64", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00000581", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03848", "nct_id"=)"NCT00626483", "official_title"=)"REGULATe: REGULATory T-Cell Inhibition with Basiliximab (Simulect®) during Recovery from Therapeutic Temozolomide-Induced Lymphopenia during Antitumor Immunotherapy Targeted against Cytomegalovirus in Patients with Newly-Diagnosed Glioblastoma Multiforme", "open_date"=)"16-Apr-2007", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"80537438", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-03861", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"0", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00026864", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-03861", "nct_id"=)"", "official_title"=)"Treatment of Metastatic Liver Disease With Humanitarian Use Device:  TheraSphere® (yttrium-90 Glass Microsphere)", "open_date"=)"08-Dec-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Paul", "pi_last_name"=)"Suhocki", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"80539059", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2010-0794", "lead_org_po_id"=)"227400", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00037", "nct_id"=)"NCT01471106", "official_title"=)"Phase II Short-Term Adjuvant Therapy and Biomarker Studies with Targeted Agents in Women with Estrogen Receptor Negative Breast Cancer", "open_date"=)"21-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Banu", "pi_last_name"=)"Arun", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"80732462", "specific_funding_source"=)"Bristol-Myers Squibb, Susan G Komen Breast Cancer Foundation, M D Anderson Cancer Center CCOP Research Base", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00053", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RC1126", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00053", "nct_id"=)"NCT01532089", "official_title"=)"A Randomized Phase II Trial of Erlotinib Alone or in Combination with Bevacizumab in Patients with Non-small Cell Lung Cancer and Activating Epidermal Growth Factor Receptor Mutations", "open_date"=)"16-Mar-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Thomas", "pi_last_name"=)"Stinchcombe", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"80783694", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00082", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"29-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-033", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-033", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00082", "nct_id"=)"NCT01514201", "official_title"=)"A Phase I/II Study of ABT-888, An Oral Poly(ADP-ribose) Polymerase Inhibitor, and Concurrent Radiation Therapy, Followed by ABT-888 and Temozolomide, in Children with Newly Diagnosed Diffuse Pontine Gliomas (DIPG)", "open_date"=)"17-Nov-2011", "other_ids"=)"P12978\rNCT01507324\rCDR0000717423\r12-C-0213", "other_protocol_ids"=)"PBTC-033, P12978, NCT01507324, CDR0000717423, 12-C-0213", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Patricia", "pi_last_name"=)"Baxter", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"81059272", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00096", "affiliate_total"=)"10", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1201", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00096", "nct_id"=)"NCT01498289", "official_title"=)"A Randomized Phase II Pilot Study Prospectively Evaluating Treatment for Patients Based on ERCC1 (Excision Repair Cross-Complementing 1) for Advanced/Metastatic Esophageal, Gastric or Gastroesophageal Junction (GEJ) Cancer", "open_date"=)"08-Feb-2012", "other_ids"=)"CDR0000720255", "other_protocol_ids"=)"S1201, CDR0000720255", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Syma", "pi_last_name"=)"Iqbal", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"81066674", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00102", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL1131", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00102", "nct_id"=)"NCT01503515", "official_title"=)"A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) following Allogeneic Hematopoietic Cell Transplantation (HCT)", "open_date"=)"21-Mar-2013", "other_ids"=)"CDR0000721415", "other_protocol_ids"=)"ACCL1131, CDR0000721415", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Christopher", "pi_last_name"=)"Dvorak", "pi_middle_initial"=)"C", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"81069466", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00105", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCL1033", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCL1033", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00105", "nct_id"=)"NCT01503632", "official_title"=)"A Comprehensive Approach to Improve Medication Adherence in Pediatric ALL", "open_date"=)"21-Feb-2012", "other_ids"=)"NCT01476852\rCDR0000721559", "other_protocol_ids"=)"ACCL1033, NCT01476852, CDR0000721559", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Smita", "pi_last_name"=)"Bhatia", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"81070761", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00110", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"02-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CALGB-51101", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CALGB-51101", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00110", "nct_id"=)"NCT01511562", "official_title"=)"A Randomized Phase II Trial of Myeloablative Versus Non-Myeloablative Consolidation Chemotherapy for Newly Diagnosed Primary CNS B-cell Lymphoma", "open_date"=)"15-Jun-2012", "other_ids"=)"CDR0000721927", "other_protocol_ids"=)"CALGB-51101, CDR0000721927", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Tracy", "pi_last_name"=)"Batchelor", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"81073217", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00234", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N1048", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N1048", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00234", "nct_id"=)"NCT01515787", "official_title"=)"A Phase II/III Trial of Neoadjuvant FOLFOX, with Selective Use of Combined Modality Chemoradiation versus Preoperative Combined Modality Chemoradiation for Locally Advanced Rectal Cancer Patients Undergoing Low Anterior Resection with Total Mesorectal Excision", "open_date"=)"13-Jan-2012", "other_ids"=)"PN1048_A11PAMDREVW01\rNCCTG-N1048\rCDR0000715321", "other_protocol_ids"=)"N1048, PN1048_A11PAMDREVW01, NCCTG-N1048, CDR0000715321", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Deborah", "pi_last_name"=)"Schrag", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Rectum", "sp_id"=)"88713679", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00249", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"20-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0277", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0277", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00249", "nct_id"=)"NCT01533207", "official_title"=)"A Phase III Randomized Trial of Gemcitabine (NSC# 613327) plus Docetaxel (NSC# 628503) Followed by Doxorubicin (NSC# 123127) versus Observation for Uterus-Limited, High-Grade Uterine Leiomyosarcoma", "open_date"=)"04-Jun-2012", "other_ids"=)"IRCI 001\rCDR0000724874", "other_protocol_ids"=)"GOG-0277, IRCI, 001, CDR0000724874", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Martee", "pi_last_name"=)"Hensley", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"88721567", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11-344", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00255", "nct_id"=)"NCT01494662", "official_title"=)"A Phase II Trial of HKI-272 (Neratinib) and Capecitabine for Patients with Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Breast Cancer and Brain Metastases", "open_date"=)"02-Feb-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Rachel", "pi_last_name"=)"Freedman", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"88983658", "specific_funding_source"=)"Serenex Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00268", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MPD-RC 111", "lead_org_po_id"=)"170797", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00268", "nct_id"=)"NCT01259817", "official_title"=)"Single Arm Salvage Therapy with Pegylated Interferon Alfa-2a for Patients with High Risk Polycythemia Vera or High Risk Essential Thrombocythemia Who are Either Hydroxyurea Resistant or Intolerant or Have Had Abdominal Vein Thrombosis", "open_date"=)"13-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Lewis", "pi_last_name"=)"Silverman", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"89039847", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00269", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MPD-RC 112", "lead_org_po_id"=)"170797", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00269", "nct_id"=)"NCT01259856", "official_title"=)"Randomized Trial of Pegylated Interferon Alfa-2a versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera and High Risk Essential Thrombocythemia", "open_date"=)"13-Aug-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ronald", "pi_last_name"=)"Hoffman", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"89040826", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00350", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-012", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00350", "nct_id"=)"NCT01454102", "official_title"=)"A Multi-arm Phase I Safety Study of Nivolumab in Combination With Gemcitabine/Cisplatin, Pemetrexed/Cisplatin, Carboplatin/Paclitaxel, Bevacizumab Maintenance, Erlotinib, Ipilimumab or as Monotherapy in Subjects With Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"89554647", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00352", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M12-895", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00352", "nct_id"=)"NCT01506609", "official_title"=)"A Randomized, Phase 2 Study of the Efficacy and Tolerability of Veliparib in Combination With Temozolomide or Veliparib in Combination With Carboplatin and Paclitaxel Versus Placebo Plus Carboplatin and Paclitaxel in Subjects With BRCA1 or BRCA2 Mutation and Metastatic Breast Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"89555034", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00578", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TTX404", "lead_org_po_id"=)"219099", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00578", "nct_id"=)"NCT01439347", "official_title"=)"Phase 3 Study of Study to Evaluate Marqibo® in the Combination Chemotherapy in the Treatment of Subjects )or=60 Years Old With Newly Diagnosed Acute Lymphoblastic Leukemia (ALL)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"90998490", "specific_funding_source"=)"Spectrum Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00703", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS1022", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS1022", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00703", "nct_id"=)"NCT01553149", "official_title"=)"A Phase II Randomized Trial of Lenalidomide (NSC # 703813) in Pediatric Patients with Recurrent, Refractory or Progressive Juvenile Pilocytic Astrocytomas and Optic Pathway Gliomas", "open_date"=)"19-Mar-2012", "other_ids"=)"COG-ACNS1022\rCDR0000728296", "other_protocol_ids"=)"ACNS1022, COG-ACNS1022, CDR0000728296", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Katherine", "pi_last_name"=)"Warren", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"91624546", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00707", "affiliate_total"=)"5", "affiliate_total_rp"=)"3", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"Z11102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Z11102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00707", "nct_id"=)"NCT01556243", "official_title"=)"Impact of Breast Conservation Surgery on Surgical Outcomes and Cosmesis in Patients with Multiple Ipsilateral Breast Cancers (MIBC)", "open_date"=)"23-Jul-2012", "other_ids"=)"CDR0000728605\rACOSOG-Z11102", "other_protocol_ids"=)"Z11102, CDR0000728605, ACOSOG-Z11102", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Judy", "pi_last_name"=)"Boughey", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"91626441", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00719", "affiliate_total"=)"11", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00719", "nct_id"=)"NCT01573442", "official_title"=)"Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women with Aromatase Inhibitor Induced Arthralgias", "open_date"=)"07-Sep-2012", "other_ids"=)"CDR0000730083", "other_protocol_ids"=)"A221102, CDR0000730083", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Charles", "pi_last_name"=)"Loprinzi", "pi_middle_initial"=)"L", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"91632684", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-00723", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2810", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2810", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-00723", "nct_id"=)"NCT01575548", "official_title"=)"Randomized, Double-Blind Phase III Study of Pazopanib vs. Placebo in Patients with Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease following Metastatectomy", "open_date"=)"08-Aug-2012", "other_ids"=)"ECOG-E2810\rCDR0000730383", "other_protocol_ids"=)"E2810, ECOG-E2810, CDR0000730383", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Leonard", "pi_last_name"=)"Appleman", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"91635101", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01153", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PRI-724-201", "lead_org_po_id"=)"45912155", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01153", "nct_id"=)"NCT01606579", "official_title"=)"An Open-Label, Dose-Escalation Phase I/II Study of PRI-724 for Patients With Advanced Myeloid Malignancies", "open_date"=)"01-Jul-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"96334408", "specific_funding_source"=)"Prism Pharma Co., Ltd.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01279", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMyC 10-MM-01", "lead_org_po_id"=)"25978205", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01279", "nct_id"=)"NCT01464034", "official_title"=)"A Multi-Center Phase I/II, Open-Label, Dose-Finding Pilot Study of the Combination of Carfilzomib and Pomalidomide With Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"97037167", "specific_funding_source"=)"Academic Myeloma Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Neogenix 0901", "lead_org_po_id"=)"49385246", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01393", "nct_id"=)"NCT01040000", "official_title"=)"A Phase 1/2 Therapeutic, Open Label, Multi-Center Clinical Trial of NPC-1C, a Chimeric Monoclonal Antibody, in Adults With Recurrent, Locally Advanced Unresectable or Metastatic Pancreatic and Colorectal Cancer After Standard Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"97619580", "specific_funding_source"=)"Precision Biologics, Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01513", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"201209135", "lead_org_po_id"=)"143971", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01513", "nct_id"=)"NCT01670877", "official_title"=)"A Phase II Study of Neratinib Alone and in Combination with Fulvestrant in Metastatic HER2 Non-amplified but HER2 Mutant Breast Cancer", "open_date"=)"11-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Cynthia", "pi_last_name"=)"Ma", "pi_middle_initial"=)"X", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"97860423", "specific_funding_source"=)"Siteman Cancer Center at Washington University", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01572", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2603.00", "lead_org_po_id"=)"39492311", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01572", "nct_id"=)"NCT01690520", "official_title"=)"Multi-center, Open-Label Randomized Study of Single or Double Myeloablative Cord Blood Transplantation with or without Infusion of Off–the-Shelf Ex Vivo Expanded Cryopreserved Cord Blood Progenitor Cells in Patients with Hematologic Malignancies", "open_date"=)"11-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Filippo", "pi_last_name"=)"Milano", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"98013008", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01732", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1205", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1205", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01732", "nct_id"=)"NCT01730950", "official_title"=)"Randomized Phase II Trial of Concurrent Bevacizumab and Re-irradiation versus Bevacizumab Alone as Treatment for Recurrent Glioblastoma", "open_date"=)"20-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1205", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Christina", "pi_last_name"=)"Tsien", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"99195295", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01960", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1202", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1202", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01960", "nct_id"=)"NCT01598298", "official_title"=)"A Randomized Placebo-Controlled Phase III Study of Duloxetine for Treatment of Aromatase Inhibitor (AI)-Associated Musculoskeletal Symptoms in Women With Early Stage Breast Cancer", "open_date"=)"10-Jun-2013", "other_ids"=)"SWOG-S1202\rCDR0000730691", "other_protocol_ids"=)"S1202, SWOG-S1202, CDR0000730691", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Norah", "pi_last_name"=)"Henry", "pi_middle_initial"=)"L", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"99948386", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01963", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL1131", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01963", "nct_id"=)"NCT01595048", "official_title"=)"Intergroup Trial for Children or Adolescents with B-Cell NHL or B-AL: Evaluation of Rituximab Efficacy and Safety in High Risk Patients", "open_date"=)"11-Jun-2012", "other_ids"=)"2010-019224-31\rIGR2009/1593\rCDR0000732604", "other_protocol_ids"=)"ANHL1131, 2010-019224-31, IGR2009/1593, CDR0000732604", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Thomas", "pi_last_name"=)"Gross", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"99950089", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01964", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0279", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0279", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01964", "nct_id"=)"NCT01595061", "official_title"=)"A Phase II Trial Evaluating Cisplatin (NSC #119875) and Gemcitabine (NSC #613327) Concurrent with Intensity-Modulated Radiation Therapy (IMRT) in the Treatment of Locally Advanced Squamous Cell Carcinoma of the Vulva (NCT #01595061)", "open_date"=)"02-Jul-2012", "other_ids"=)"CDR0000732793", "other_protocol_ids"=)"GOG-0279, CDR0000732793", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Neil", "pi_last_name"=)"Horowitz", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Female Genital", "sp_id"=)"99950723", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01967", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS1123", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS1123", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01967", "nct_id"=)"NCT01602666", "official_title"=)"Phase 2 Trial of Response-Based Radiation Therapy for Patients with Localized Central Nervous System Germ Cell Tumors (CNS GCT)", "open_date"=)"29-May-2012", "other_ids"=)"CDR0000734032", "other_protocol_ids"=)"ACNS1123, CDR0000734032", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ute", "pi_last_name"=)"Bartels", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"99952246", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01977", "affiliate_total"=)"3", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1119", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1119", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01977", "nct_id"=)"NCT01622868", "official_title"=)"Phase II Randomized Study of Whole Brain Radiotherapy/Stereotactic Radiosurgery in Combination with Concurrent Lapatinib in Patients with Brain Metastasis from HER2-Positive Breast Cancer: A Collaborative Study of NRG Oncology and KROG", "open_date"=)"26-Jul-2012", "other_ids"=)"CDR0000735353", "other_protocol_ids"=)"RTOG-1119, CDR0000735353", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"In", "pi_last_name"=)"Kim", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"99987387", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01985", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2511", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2511", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01985", "nct_id"=)"NCT01642251", "official_title"=)"Phase I and Randomized Phase II Double Blind Clinical Trial of Cisplatin and Etoposide in Combination with Veliparib (ABT-888) or Placebo as Frontline Therapy for Extensive Stage Small Cell Lung Cancer", "open_date"=)"28-Sep-2012", "other_ids"=)"CDR0000736704\rECOG-E2511", "other_protocol_ids"=)"E2511, CDR0000736704, ECOG-E2511", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Taofeek", "pi_last_name"=)"Owonikoko", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"99992668", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01989", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"N1174", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"N1174", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01989", "nct_id"=)"NCT01648348", "official_title"=)"Phase I/Comparative Randomized Phase II Trial of TRC105 plus Bevacizumab versus Bevacizumab in Bevacizumab-Naive Patients with Recurrent Glioblastoma Multiforme", "open_date"=)"09-Nov-2012", "other_ids"=)"NCCTG-N1174\rCDR0000737109", "other_protocol_ids"=)"N1174, NCCTG-N1174, CDR0000737109", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Evanthia", "pi_last_name"=)"Galanis", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"99995576", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01995", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1207", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1207", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01995", "nct_id"=)"NCT01674140", "official_title"=)"Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High-risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer. e^3 Breast Cancer Study-Evaluating Everolimus with Endocrine Therapy.", "open_date"=)"04-Sep-2013", "other_ids"=)"S1207/NSABP B-53\rSWOG-S1207\rCDR0000738280", "other_protocol_ids"=)"S1207, S1207/NSABP, B-53, SWOG-S1207, CDR0000738280", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mariana", "pi_last_name"=)"Chavez Mac Gregor", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"99999640", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-01998", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1211", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1211", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-01998", "nct_id"=)"NCT01668719", "official_title"=)"A Randomized Phase I/II Study of Optimal Induction Therapy of Bortezomib, Dexamethasone and Lenalidomide with or without Elotuzumab (NSC-764479) for Newly Diagnosed High Risk Multiple Myeloma (HRMM)", "open_date"=)"09-Nov-2012", "other_ids"=)"CDR0000738512\rPS1211_A12PAMDREVW01", "other_protocol_ids"=)"S1211, CDR0000738512, PS1211_A12PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Saad", "pi_last_name"=)"Usmani", "pi_middle_initial"=)"Z", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"100002105", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02001", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 1203", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02001", "nct_id"=)"NCT01672892", "official_title"=)"A Randomized Phase III Study of Standard vs. IMRT Pelvic Radiation for Post-Operative Treatment of Endometrial and Cervical Cancer (TIME-C)", "open_date"=)"28-Nov-2012", "other_ids"=)"CDR0000738944", "other_protocol_ids"=)"RTOG-1203, CDR0000738944", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ann", "pi_last_name"=)"Klopp", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"100004132", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02020", "affiliate_total"=)"8", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221101", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221101", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02020", "nct_id"=)"NCT01781468", "official_title"=)"A Phase III Randomized, Double-blind Placebo Controlled Study of Armodafinil (Nuvigil) to\r\nReduce Cancer-Related Fatigue in Patients with High Grade Glioma", "open_date"=)"03-Jun-2013", "other_ids"=)"N10C3", "other_protocol_ids"=)"A221101, N10C3", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Alyx", "pi_last_name"=)"Umphrey", "pi_middle_initial"=)"B", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"100223340", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02037", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAA-III-01", "lead_org_po_id"=)"25119592", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02037", "nct_id"=)"NCT01578239", "official_title"=)"A Multicentre, Stratified, Open, Randomized, Comparator-controlled, Parallel-group Phase III Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"100428078", "specific_funding_source"=)"Advanced Accelerator Applications SA", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02045", "affiliate_total"=)"4", "affiliate_total_rp"=)"3", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011104", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011104", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02045", "nct_id"=)"NCT01805076", "official_title"=)"Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women with Breast Cancer", "open_date"=)"21-Feb-2014", "other_ids"=)"ACRIN 6694", "other_protocol_ids"=)"A011104, ACRIN, 6694", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Isabelle", "pi_last_name"=)"Bedrosian", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"100479303", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02067", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S0820", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S0820", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02067", "nct_id"=)"NCT01349881", "official_title"=)"A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients with Stage 0-III Colon or Rectal Cancer, Phase III- Preventing Adenomas of the Colon with Eflornithine and Sulindac (PACES)", "open_date"=)"01-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"S0820", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jason", "pi_last_name"=)"Zell", "pi_middle_initial"=)"A", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"100639166", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02078", "affiliate_total"=)"34", "affiliate_total_rp"=)"34", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"SCUSF-1102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"SCUSF 1102", "lead_org_po_id"=)"36324157", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02078", "nct_id"=)"NCT01789684", "official_title"=)"A Cluster Randomized Controlled Trial Comparing Interventions to Enhance Utilization of Genetics\r\nServices Among Breast Cancer Patients", "open_date"=)"21-Feb-2013", "other_ids"=)"RSB002", "other_protocol_ids"=)"SCUSF-1102, RSB002", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Sutphen", "pi_middle_initial"=)"", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"100741021", "specific_funding_source"=)"SunCoast CCOP Research Base at the University of South Florida", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02213", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"17-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9197", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9197", "lead_org_po_id"=)"38249", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02213", "nct_id"=)"NCT01729806", "official_title"=)"A Phase I Study of Ipilimumab in Combination with Rituximab in Patients with Relapsed/Refractory CD20+ B-Cell Lymphoma", "open_date"=)"19-Nov-2012", "other_ids"=)"NCI# 9197\rCDR0000743246\rPHI-69", "other_protocol_ids"=)"9197, NCI#, 9197, CDR0000743246, PHI-69", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Joseph", "pi_last_name"=)"Tuscano", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"101579366", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02217", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-258", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02217", "nct_id"=)"NCT01670500", "official_title"=)"Randomized Phase II Trial of Neoadjuvant Cisplatin vs. Doxorubicin/Cyclophosphamide (“AC”) in Women with Newly Diagnosed Breast Cancer and Germline BRCA Mutations", "open_date"=)"25-Oct-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Nadine", "pi_last_name"=)"Tung", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"101844827", "specific_funding_source"=)"Myriad Genetics Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02228", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2011-155", "lead_org_po_id"=)"131559", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02228", "nct_id"=)"NCT01728259", "official_title"=)"Phase I Study of Pomalidomide, Bortezomib, and Dexamethasone (PVD) as First-Line Treatment of AL Amyloidosis or Light Chain Deposition Disease", "open_date"=)"05-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jeffrey", "pi_last_name"=)"Zonder", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"101973429", "specific_funding_source"=)"Wayne State University/Karmanos Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02289", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PRLX93936-0002", "lead_org_po_id"=)"211513", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02289", "nct_id"=)"NCT01695590", "official_title"=)"Phase 1/2, Multi-center, Open Label, Dose Escalation, Safety, Efficacy and PK Study of PRLX 93936 Administered IV 3 Days a Week for 3 Weeks Followed by a 9 Day Rest Period in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"102088358", "specific_funding_source"=)"Prolexys Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02608", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1A11", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1A11", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02608", "nct_id"=)"NCT01863550", "official_title"=)"Randomized Phase III Trial of Bortezomib, LENalidomide and Dexamethasone (VRd) versus Carfilzomib, Lenalidomide, Dexamethasone (CRd) Followed by Limited or Indefinite DURation Lenalidomide MaintenANCE in Patients with Newly Diagnosed Symptomatic Multiple Myeloma (ENDURANCE)", "open_date"=)"02-Dec-2013", "other_ids"=)"ECOG-E1A11", "other_protocol_ids"=)"E1A11, ECOG-E1A11", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Shaji", "pi_last_name"=)"Kumar", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"102651560", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02876", "affiliate_total"=)"4", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1216", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1216", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02876", "nct_id"=)"NCT01809691", "official_title"=)"A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 with Androgen Deprivation Therapy + Bicalutamide in Patients with Newly Diagnosed Metastatic Hormone Sensitive Prostate Cancer", "open_date"=)"06-Mar-2013", "other_ids"=)"SWOG-S1216", "other_protocol_ids"=)"S1216, SWOG-S1216", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Neeraj", "pi_last_name"=)"Agarwal", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"103688308", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02880", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EPZ-5676-12-001", "lead_org_po_id"=)"69406", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02880", "nct_id"=)"NCT01684150", "official_title"=)"A Phase 1, Open-Label, Dose-Escalation & Expanded Cohort, Continuous IV Infusion, Multi-center Study of the Safety, Tolerability,PK & PD of EPZ-5676 in Treatment Relapsed/Refractory Patients With Leukemias Involving Translocation of the MLL Gene at 11q23 or Advanced Hematologic Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"103727036", "specific_funding_source"=)"Epizyme, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02990", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"22-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9214", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9214", "lead_org_po_id"=)"125217", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02990", "nct_id"=)"NCT01757639", "official_title"=)"A Phase 1 Study of Ipilimumab in Relapsed and Refractory High Risk Myelodysplastic Syndrome and Acute Myeloid Leukemia with Minimal Residual Disease", "open_date"=)"14-Dec-2012", "other_ids"=)"CDR0000744584\rJ1276\rNA_00076038", "other_protocol_ids"=)"9214, CDR0000744584, J1276, NA_00076038", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"B.", "pi_last_name"=)"Smith", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"104010930", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-02996", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"297", "center_total_rp"=)"82", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"320", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00033339", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-02996", "nct_id"=)"NCT01908504", "official_title"=)"FDG-PET for the Delivery of Adaptive Radiation Therapy", "open_date"=)"", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"104029591", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03085", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GO27826", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03085", "nct_id"=)"NCT01667419", "official_title"=)"A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of Vemurafenib (RO5185426) Adjuvant Therapy in Patients With Surgically Resected, Cutaneous BRAF Mutant Melanoma at High Risk for Recurrence", "open_date"=)"01-Sep-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"104391310", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03125", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL1221", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03125", "nct_id"=)"NCT01767194", "official_title"=)"A Phase II Randomized Trial of Irinotecan/Temozolomide with Temsirolimus (NSC# 683864) or Chimeric 14.18 Antibody (Ch14.18) (NSC# 764038) in Children with Refractory, Relapsed or Progressive Neuroblastoma", "open_date"=)"12-Feb-2013", "other_ids"=)"CDR0000745188\rCOG-ANBL1221\rPANBL1221_A08PAMDREVW01", "other_protocol_ids"=)"ANBL1221, CDR0000745188, COG-ANBL1221, PANBL1221_A08PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Rajen", "pi_last_name"=)"Mody", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"104622123", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03130", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-187", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03130", "nct_id"=)"NCT01751451", "official_title"=)"A Phase 2, Randomized, 3-Arm Study of Abiraterone Acetate Alone, Abiraterone Acetate plus Degarelix, a GnRH Antagonist, and Degarelix Alone for Patients with Prostate Cancer with a Rising PSA or a Rising PSA and Nodal Disease following Definitive Radical Prostatectomy", "open_date"=)"20-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Howard", "pi_last_name"=)"Scher", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"104641990", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03142", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M13-367", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03142", "nct_id"=)"NCT01794520", "official_title"=)"A Phase I Study Evaluating the Safety and Pharmacokinetics of ABT-199 in Subjects With Relapsed or Refractory Multiple Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"104715958", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2012-03198", "affiliate_total"=)"16", "affiliate_total_rp"=)"10", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-51", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-51", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2012-03198", "nct_id"=)"NCT01872975", "official_title"=)"A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy", "open_date"=)"22-Aug-2013", "other_ids"=)"NSABP-B-51/RTOG-1304", "other_protocol_ids"=)"NSABP-B-51, NSABP-B-51/RTOG-1304", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Eleftherios (Terry)", "pi_last_name"=)"Mamounas", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"105039873", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00084", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CC-486-AML-001", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00084", "nct_id"=)"NCT01757535", "official_title"=)"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Compare Efficacy and Safety of Oral Azacitidine Plus Best-supportive Care Versus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia in Complete Remission", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"105601593", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00426", "affiliate_total"=)"5", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1Z11", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1Z11", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00426", "nct_id"=)"NCT01824836", "official_title"=)"A Cohort Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)", "open_date"=)"21-May-2013", "other_ids"=)"", "other_protocol_ids"=)"E1Z11", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Vered", "pi_last_name"=)"Stearns", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"107120237", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00444", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A071101", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A071101", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00444", "nct_id"=)"NCT01814813", "official_title"=)"A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex-96 (HSPPC-96) (NSC #725085) Vaccine Given with Bevacizumab versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)", "open_date"=)"22-May-2013", "other_ids"=)"", "other_protocol_ids"=)"A071101", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ian", "pi_last_name"=)"Parney", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"107427299", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00454", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"24-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00033820", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00454", "nct_id"=)"NCT01627288", "official_title"=)"Integrated Dose Escalation for Advanced, Localized Gynecologic Cancer (The IDEAL – Gyn Trial)", "open_date"=)"04-Jun-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"107625696", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00455", "affiliate_total"=)"5", "affiliate_total_rp"=)"3", "center_total"=)"15", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"56", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00033060", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00455", "nct_id"=)"NCT01669798", "official_title"=)"Phase II Evaluation of Nintedanib (BIBF 1120) in the Treatment of Bevacizumab-Resistant Persistent or Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma", "open_date"=)"09-Oct-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Angeles", "pi_last_name"=)"Secord", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"107629271", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00472", "affiliate_total"=)"22", "affiliate_total_rp"=)"10", "center_total"=)"75", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"20-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"62", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00037688", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00472", "nct_id"=)"NCT01661972", "official_title"=)"X-TRAP: Phase I/II Study of Capecitabine plus Ziv-Aflibercept in Metastatic Colorectal Cancer", "open_date"=)"27-Aug-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"John", "pi_last_name"=)"Strickler", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"107830678", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00475", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"6", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"31-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"X05397", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00475", "nct_id"=)"NCT01729338", "official_title"=)"Phase II Study of Subcutaneous VELCADE and Oral Cyclophosphamide-Based Induction Followed by Sequential Maintenance Therapy with VELCADE and Revlimid (Lenalidomide) for Newly Diagnosed Multiple Myeloma in Non-transplant Candidates: An Entirely Non-intravenous Regimen", "open_date"=)"09-Nov-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Gwynn", "pi_last_name"=)"Long", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"107833188", "specific_funding_source"=)"Takeda", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00480", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"27", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"56", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00040206", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00480", "nct_id"=)"NCT01754402", "official_title"=)"A Phase I-II Study of the Combination of Bendamustine and Pomalidomide with Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma", "open_date"=)"18-Dec-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Gwynn", "pi_last_name"=)"Long", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"107845226", "specific_funding_source"=)"Celgene Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00490", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"04-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1203", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00490", "nct_id"=)"NCT01802333", "official_title"=)"A Randomized Phase III Study of Standard Cytarabine plus Daunorubicin (7+3) Therapy or Idarubicin with High Dose Cytarabine (IA) versus IA with Vorinostat (NSC-701852) (IA + V) in Younger Patients with Previously Untreated Acute Myeloid Leukemia (AML)", "open_date"=)"12-Feb-2013", "other_ids"=)"SWOG-S1203\rPS1203_A06PAMDREVW01", "other_protocol_ids"=)"S1203, SWOG-S1203, PS1203_A06PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Guillermo", "pi_last_name"=)"Garcia-Manero", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"107909826", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00494", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"30", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"16153", "lead_org_po_id"=)"238118", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00494", "nct_id"=)"NCT01610206", "official_title"=)"A Randomized Open Label Phase II Study of Weekly Gemcitabine Plus Pazopanib Versus Weekly Gemcitabine Alone in the Treatment of Patients With Persistent or Relapsed Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Carcinoma", "open_date"=)"06-Aug-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Linda", "pi_last_name"=)"Duska", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"107958249", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00500", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1216", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1216", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00500", "nct_id"=)"NCT01810913", "official_title"=)"Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered with Concurrent Cisplatin versus Docetaxel versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck", "open_date"=)"18-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1216", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Paul", "pi_last_name"=)"Harari", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"108017957", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00503", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"52M51-001", "lead_org_po_id"=)"192780", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00503", "nct_id"=)"NCT01703572", "official_title"=)"A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Lymphoid Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"108055339", "specific_funding_source"=)"OncoMed Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00509", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GP28328", "lead_org_po_id"=)"87945", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00509", "nct_id"=)"NCT01633970", "official_title"=)"A Study of Atezolizumab Administered in Combination With Bevacizumab and/or With Chemotherapy in Participants With Locally Advanced or Metastatic Solid Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"108103137", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00520", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"136", "center_total_rp"=)"85", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"136", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00031206", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00520", "nct_id"=)"NCT01450826", "official_title"=)"A Randomized Open Label Phase II Trial of Aprepitant (Emend) in Combination with Ondansetron Compared to Standard 5HT3 Serotonin Antagonist (Ondansetron) in the Prevention of Acute and Delayed Chemotherapy Induced Nausea and Vomiting (CINV) in Glioma Patients Receiving a Temozolomide Based Regimen", "open_date"=)"31-Oct-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Mary", "pi_last_name"=)"Affronti", "pi_middle_initial"=)"L", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"108390307", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00525", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"26", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"19-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00034612", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00525", "nct_id"=)"NCT01526473", "official_title"=)"A Phase I Study to Evaluate the Antitumor Activity and Safety of DUKE-002-VRP(HUHER2-ECD+TM), an Alphaviral Vector Encoding the HER2 Extracellular Domain and Transmembrane Region, in Patients with Locally Advanced or Metastatic Human Epidermal Growth Factor Receptor 2-Positive (HER2+) Cancers Including Breast Cancer", "open_date"=)"20-Apr-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Michael", "pi_last_name"=)"Morse", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"108486062", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00526", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-037", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-037", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00526", "nct_id"=)"NCT02031965", "official_title"=)"A Phase I Study of Intratumoral/Peritumoral Herpes Simplex Virus-1 Mutant HSV1716 in Patients with Refractory or Recurrent High Grade Gliomas (HGG)", "open_date"=)"02-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"PBTC-037", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Mariko", "pi_last_name"=)"DeWire", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"108487103", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00567", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"39", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"42", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00003975", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00567", "nct_id"=)"NCT01627275", "official_title"=)"Naive T-Cell Depleted Donor Lymphocyte Infusion following Allogeneic Stem Cell Transplantation", "open_date"=)"02-Apr-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Mitchell", "pi_last_name"=)"Horwitz", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"110456299", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00572", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMyC 11-MM-01", "lead_org_po_id"=)"25978205", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00572", "nct_id"=)"NCT01660750", "official_title"=)"A Multi-Center Phase Ib, Open-Label, Dose-Finding Pilot Study to Evaluate the Combination of Carfilzomib and Cyclophosphamide With Dexamethasone Prior to ASCT in Patients With Transplant Eligible Newly Diagnosed Myeloma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"110463278", "specific_funding_source"=)"Academic Myeloma Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00579", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"10", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00013947", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00579", "nct_id"=)"NCT01274377", "official_title"=)"A Pilot Trial of CMV Specific Donor Lymphocyte Infusions From 3-6/6 HLA Matched Family Member following Nonmyeloablative Allogeneic Stem Cell Transplantation", "open_date"=)"22-Feb-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nelson", "pi_last_name"=)"Chao", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"110865425", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00581", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00041857", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00581", "nct_id"=)"NCT01763944", "official_title"=)"A Randomized Controlled Clinical Trial of Carbohydrate Restriction among Men with a Rising PSA after Failed Primary Therapy for Prostate Cancer", "open_date"=)"17-Jan-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Pao-Hwa", "pi_last_name"=)"Lin", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"110865842", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00583", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"59R5-002", "lead_org_po_id"=)"192780", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00583", "nct_id"=)"NCT01647828", "official_title"=)"A Phase 1b/2 Study of OMP-59R5 in Combination With Nab-Paclitaxel and Gemcitabine in Subjects With Previously Untreated Stage IV Pancreatic Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"110888127", "specific_funding_source"=)"OncoMed Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00630", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"115523", "lead_org_po_id"=)"88367", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00630", "nct_id"=)"NCT01610414", "official_title"=)"Observer-blind Study to Evaluate Efficacy, Safety, and Immunogenicity of GSK Biologicals' Herpes Zoster Vaccine GSK1437173A", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"111790172", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00666", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MI-CP216", "lead_org_po_id"=)"130639", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00666", "nct_id"=)"NCT01284231", "official_title"=)"A Phase 1, Open-Label Study to Evaluate the Safety and Tolerability of MEDI-565 in Adults With Gastrointestinal Adenocarcinomas", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"112660251", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00717", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AGS-003-007", "lead_org_po_id"=)"52548764", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00717", "nct_id"=)"NCT01582672", "official_title"=)"An International Phase 3 Randomized Trial of Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"113083363", "specific_funding_source"=)"Argos Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00721", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"25-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00038093", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00721", "nct_id"=)"NCT01820754", "official_title"=)"Evaluation of Circulating T Cells and Tumor Infiltrating Lymphocytes with Specificities against Tumor Associated Antigens during and after Neoadjuvant Chemotherapy and Phased Ipilimumab in Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"28-Feb-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Neal", "pi_last_name"=)"Ready", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"113092477", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00737", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1306", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG-1306", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00737", "nct_id"=)"NCT01822496", "official_title"=)"A Randomized Phase II Study of Individualized Combined Modality Therapy for Stage III Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"04-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1306", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"113220963", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00796", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1304", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1304", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00796", "nct_id"=)"NCT01903811", "official_title"=)"A Phase II Randomized Study Comparing Two Doses of Carfilzomib (NSC-756640) with Dexamethasone for Multiple Myeloma Patients with Relapsed or Refractory Disease", "open_date"=)"18-Oct-2013", "other_ids"=)"SWOG-S1304\rPS1304_A07PAMDREVW01", "other_protocol_ids"=)"S1304, SWOG-S1304, PS1304_A07PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sikander", "pi_last_name"=)"Ailawadhi", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"114031091", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00810", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MM-111-13-02-04", "lead_org_po_id"=)"9346107", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00810", "nct_id"=)"NCT01774851", "official_title"=)"Randomized, Open Label, Phase 2 Study of MM-111 and Paclitaxel With Trastuzumab in Patients With HER2 Positive Carcinomas of the Distal Esophagus, Gastroesophageal (GE) Junction and Stomach Who Have Failed Front Line Metastatic or Locally Advanced Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"114331856", "specific_funding_source"=)"Merrimack Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00814", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E3311", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E3311", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00814", "nct_id"=)"NCT01898494", "official_title"=)"Phase II Randomized Trial of Transoral Surgical Resection Followed by Low-Dose or Standard-Dose IMRT in Resectable p16+ Locally Advanced Oropharynx Cancer", "open_date"=)"08-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"E3311", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Robert", "pi_last_name"=)"Ferris", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"114430323", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00820", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"06-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A031203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A031203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00820", "nct_id"=)"NCT01835158", "official_title"=)"Randomized Phase II Study Comparing Cabozantinib  (NSC #761968) with Commercially Supplied Sunitinib in Patients with Previously Untreated Locally Advanced or Metastatic Renal Cell Carcinoma", "open_date"=)"08-Jul-2013", "other_ids"=)"", "other_protocol_ids"=)"A031203", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Toni", "pi_last_name"=)"Choueiri", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"114537758", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00821", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"06-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091201", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00821", "nct_id"=)"NCT01835145", "official_title"=)"Randomized Phase II Study Comparing the MET Inhibitor Cabozantinib to Temozolomide/Dacarbazine in Ocular Melanoma", "open_date"=)"31-Jul-2013", "other_ids"=)"CALGB-A091201", "other_protocol_ids"=)"A091201, CALGB-A091201", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jason", "pi_last_name"=)"Luke", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"114539182", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00875", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011202", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011202", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00875", "nct_id"=)"NCT01901094", "official_title"=)"A Randomized Phase III Trial Comparing Axillary Lymph Node Dissection to Axillary Radiation in Breast Cancer Patients (cT1-3 N1) Who Have Positive Sentinel Lymph Node Disease after Neoadjuvant Chemotherapy", "open_date"=)"07-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"A011202", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Judy", "pi_last_name"=)"Boughey", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"115873799", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00894", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"1012007786", "lead_org_po_id"=)"62311", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00894", "nct_id"=)"NCT01367002", "official_title"=)"Randomized Phase II Evaluation of Carboplatin/Paclitaxel with and without Trastuzumab (Herceptin) in HER2/neu+ Patients with Advanced/Recurrent Uterine Serous Papillary Carcinoma", "open_date"=)"29-Apr-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Alessandro", "pi_last_name"=)"Santin", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"116035552", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00939", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"RTOG-1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTOG 1221", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00939", "nct_id"=)"NCT01953952", "official_title"=)"Randomized Phase II Trial of Transoral Endoscopic Head and Neck Surgery Followed by Risk-Based IMRT and Weekly Cisplatin versus IMRT and Weekly Cisplatin for HPV Negative Oropharynx Cancer", "open_date"=)"30-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"RTOG-1221", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Floyd", "pi_last_name"=)"Holsinger", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"116502962", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00943", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1028", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00943", "nct_id"=)"NCT01361113", "official_title"=)"Neoadjuvant Pazopanib: A Phase II Study to Evaluate the Effect on Disease Response and Recurrence and to Report on Possible Predictive Biomarkers of Drug Activity in Renal Cell Carcinoma", "open_date"=)"15-Feb-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Kimryn", "pi_last_name"=)"Rathmell", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"116519078", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00951", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"07-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1024", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00951", "nct_id"=)"NCT01300962", "official_title"=)"A Four Part, Phase I Dose-Escalation Study of the Combinations of Concurrent BKM120 and Capecitabine, or Concurrent BYL719 and Capecitabine, or Concurrent BKM120 and Capecitabine and Trastuzumab, or Concurrent BKM120 and Capecitabine and Lapatinib in Patients with Metastatic Breast Cancer", "open_date"=)"25-Jul-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Elizabeth", "pi_last_name"=)"Dees", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"116522888", "specific_funding_source"=)"UNC Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00954", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1029", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00954", "nct_id"=)"NCT01298570", "official_title"=)"A Multi-Center, Randomized, Placebo-Controlled Phase II Study of Regorafenib in Combination with FOLFIRI (Irinotecan, 5-Fluorouracil, and Leucovorin) versus Placebo with FOLFIRI as Second-Line Therapy in Patients with Metastatic Colorectal Cancer", "open_date"=)"02-Mar-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Hanna", "pi_last_name"=)"Sanoff", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"116524303", "specific_funding_source"=)"UNC Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00959", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"17-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1412", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1412", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00959", "nct_id"=)"NCT01856192", "official_title"=)"Randomized Phase II Open Label Study of Lenalidomide R-CHOP (R2CHOP) vs. RCHOP (Rituximab, Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) in Patients with Newly Diagnosed Diffuse Large B Cell Lymphoma", "open_date"=)"27-Aug-2013", "other_ids"=)"ECOG-E1412", "other_protocol_ids"=)"E1412, ECOG-E1412", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Grzegorz", "pi_last_name"=)"Nowakowski", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"116534699", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-00995", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A211102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A211102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-00995", "nct_id"=)"NCT01905046", "official_title"=)"Testing for Atypia in Random Periareolar Fine Needle Aspiration (RPFNA) Cytology after 12 Months Metformin (1, 1-Dimethylbiguanide Hydrochloride) Chemoprevention versus Placebo Control in Premenopausal Women", "open_date"=)"01-Feb-2015", "other_ids"=)"CALGB-A211102", "other_protocol_ids"=)"A211102, CALGB-A211102", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Victoria", "pi_last_name"=)"Seewaldt", "pi_middle_initial"=)"L", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"116815020", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01099", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LX1606.1-301-CS", "lead_org_po_id"=)"9774850", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01099", "nct_id"=)"NCT01677910", "official_title"=)"A Phase 3, Randomized, Placebo-controlled, Parallel Group, Multicenter, Double-blind Study to Evaluate the Efficacy and Safety of Telotristat Etiprate (LX1606) in Patients With Carcinoid Syndrome Not Adequately Controlled by Somatostatin Analog (SSA) Therapy", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Stomach", "sp_id"=)"117928518", "specific_funding_source"=)"Lexicon Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01125", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SJMB12", "lead_org_po_id"=)"221716", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01125", "nct_id"=)"NCT01878617", "official_title"=)"A Clinical and Molecular Risk-Directed Therapy for Newly Diagnosed Medulloblastoma (SJMB12)", "open_date"=)"17-Jun-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Amar", "pi_last_name"=)"Gajjar", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"118027628", "specific_funding_source"=)"St. Jude Children's Research Hospital, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01139", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MC1221", "lead_org_po_id"=)"139137", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01139", "nct_id"=)"NCT01880528", "official_title"=)"A Double-Blind Pilot Study to Measure the Effect of Lisinopril vs. Placebo on Pulmonary Distress in Patients Receiving External Beam Radiotherapy to the Lung", "open_date"=)"31-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Steven", "pi_last_name"=)"Schild", "pi_middle_initial"=)"E", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"118140347", "specific_funding_source"=)"Mayo Clinic", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01220", "affiliate_total"=)"3", "affiliate_total_rp"=)"2", "center_total"=)"10", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"28-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A041202", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A041202", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01220", "nct_id"=)"NCT01886872", "official_title"=)"A Randomized Phase III Study of Bendamustine plus Rituximab versus Ibrutinib plus Rituximab versus Ibrutinib Alone in Untreated Older Patients ()/= 65 Years of Age) with Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"09-Dec-2013", "other_ids"=)"ALLIANCE A041202", "other_protocol_ids"=)"A041202, ALLIANCE, A041202", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Woyach", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"118981555", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01221", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"COVLARL0287", "lead_org_po_id"=)"61194", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01221", "nct_id"=)"NCT01706822", "official_title"=)"Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Laparoscopic Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Rectum", "sp_id"=)"118982229", "specific_funding_source"=)"Covidien", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01245", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00010324", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01245", "nct_id"=)"NCT00849745", "official_title"=)"Nonmyeloablative Allogeneic Peripheral Blood Stem Cell Transplantation for Severe Autoimmune Diseases", "open_date"=)"15-Sep-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Keith", "pi_last_name"=)"Sullivan", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Unknown Sites", "sp_id"=)"119098725", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01259", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"10", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045700", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01259", "nct_id"=)"NCT01881334", "official_title"=)"A Compassionate Release Protocol: Expanded Access to T-Cell Depleted Haplo-identical Stem Cells for Patients Receiving Allogeneic Transplantation Using a Related Haplo-identical Donor and Unrelated, Umbilical Cord Blood Donor(s) for the Treatment of High Risk Malignancies or Non-malignant Disorders Requiring Allogeneic Transplantation", "open_date"=)"30-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Joanne", "pi_last_name"=)"Kurtzberg", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"119122334", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AMyC 11MM02", "lead_org_po_id"=)"25978205", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01324", "nct_id"=)"NCT01789242", "official_title"=)"A Phase I Dose Escalation Study of Carfilzomib in Patients With Previously-Treated Systemic Light-Chain (AL) Amyloidosis", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"119917356", "specific_funding_source"=)"Academic Myeloma Consortium", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01411", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PB1201", "lead_org_po_id"=)"49385246", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01411", "nct_id"=)"NCT01834235", "official_title"=)"A Multicenter Phase I/II Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel With or Without NPC-1C in Patients With Metastatic or Locally Advanced Pancreatic Cancer Previously Treated With FOLFIRINOX", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"120949386", "specific_funding_source"=)"Precision Biologics, Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01605", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"10-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CITN-04", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CITN-04", "lead_org_po_id"=)"12715537", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01605", "nct_id"=)"NCT01961115", "official_title"=)"A Phase II Pilot Trial of an Indoleamine 2,3, Dioxygenase-1 (IDO1) Inhibitor (INCB024360) plus a Multipeptide Melanoma Vaccine (MELITAC 12.1) in Patients with Advanced Melanoma", "open_date"=)"13-Sep-2013", "other_ids"=)"", "other_protocol_ids"=)"CITN-04", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Craig", "pi_last_name"=)"Slingluff", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"121133684", "specific_funding_source"=)"Cancer Immunotherapy Trials Network", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01639", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-039", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-039", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01639", "nct_id"=)"NCT01964300", "official_title"=)"Phase II Study of Peginterferon Alfa-2b (SYLATRON) for Pediatric Patients with Unresectable or Recurrent Craniopharyngioma", "open_date"=)"05-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"PBTC-039", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Stewart", "pi_last_name"=)"Goldman", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"121531092", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01642", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-266", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01642", "nct_id"=)"NCT01920737", "official_title"=)"A Novel “Pediatric-Inspired” Regimen with Reduced Myelosuppressive Drugs for Adults (Aged 18-60) with Newly Diagnosed Ph Negative Acute Lymphoblastic Leukemia", "open_date"=)"07-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jae", "pi_last_name"=)"Park", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"121599898", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01684", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GC P#03.01.020", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01684", "nct_id"=)"NCT01816230", "official_title"=)"Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells, in Adolescent and Adult Patients With Hematological Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122076406", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01689", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"114271", "lead_org_po_id"=)"88367", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01689", "nct_id"=)"NCT01328054", "official_title"=)"A Phase IV, Placebo-controlled Single Sequence Crossover Study to Evaluate the Effect of Repeat Oral Doses of Lapatinib on Cardiac Repolarization in Patients With Advanced Cancer", "open_date"=)"01-Dec-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122079865", "specific_funding_source"=)"GlaxoSmithKline", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01692", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"A8851008", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01692", "nct_id"=)"NCT00761267", "official_title"=)"A Prospective, Open-label Study To Assess The Pharmacokinetics, Safety & Efficacy Of Anidulafungin When Used To Treat Children With Invasive Candidiasis, Including Candidemia", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122081600", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01694", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TGR-1202-101 (HEMREF 31)", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01694", "nct_id"=)"NCT01767766", "official_title"=)"A Phase I Dose Escalation Study Evaluating the Safety and Efficacy of TGR 1202 in Patients With Relapsed or Refractory Hematologic Malignancies", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"122086019", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01696", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"0517-029", "lead_org_po_id"=)"147288", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01696", "nct_id"=)"NCT01697579", "official_title"=)"A Phase IIb, Partially-Blinded, Randomized, Active Comparator-Controlled Study to Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated With Emetogenic Chemotherapy Sub-title: Open-Label Cohort to Further Evaluate the Pharmacokinetics/Pharmacodynamics, Safety, and Tolerability of Fosaprepitant in Pediatric Patients Birth to (12 Years Old", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122096319", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01697", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12PLK02", "lead_org_po_id"=)"211483", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01697", "nct_id"=)"NCT01856023", "official_title"=)"Open-Label, Randomized, Multi-Center Study Comparing the Sequence of High Dose Aldesleukin (Interleukin-2) and Ipilimumab (Yervoy) in Patients With Metastatic Melanoma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"122096697", "specific_funding_source"=)"Prometheus", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01737", "affiliate_total"=)"9", "affiliate_total_rp"=)"8", "center_total"=)"10", "center_total_rp"=)"10", "clinical_research_cat"=)"INT", "close_date"=)"31-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A031201", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A031201", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01737", "nct_id"=)"NCT01949337", "official_title"=)"Phase III Trial of Enzalutamide (NSC # 766085) versus Enzalutamide, Abiraterone and Prednisone for Castration Resistant Metastatic Prostate Cancer", "open_date"=)"22-Jan-2014", "other_ids"=)"CALGB-A031201", "other_protocol_ids"=)"A031201, CALGB-A031201", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Michael", "pi_last_name"=)"Morris", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"122379619", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01760", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"WF-98213", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"98213", "lead_org_po_id"=)"213850", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01760", "nct_id"=)"NCT01988571", "official_title"=)"Preventing Anthracycline Cardiovascular Toxicity with Statins (PREVENT)", "open_date"=)"05-Feb-2014", "other_ids"=)"WFU-98213\rWF 98213\rCCCWFU 98213\rWFU 98213\r00024197", "other_protocol_ids"=)"WF-98213, WFU-98213, WF, 98213, CCCWFU, 98213, WFU, 98213, 00024197", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"William", "pi_last_name"=)"Hundley", "pi_middle_initial"=)"G", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"122741869", "specific_funding_source"=)"Wake Forest NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01776", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1313", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1313", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01776", "nct_id"=)"NCT01959139", "official_title"=)"A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) versus Modified FOLFIRINOX Alone in Patients with Good Performance Status Metastatic Pancreatic Adenocarcinoma", "open_date"=)"06-Jan-2014", "other_ids"=)"PS1313_A09PAMDREVW01", "other_protocol_ids"=)"S1313, PS1313_A09PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Ramesh", "pi_last_name"=)"Ramanathan", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"122968436", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01793", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CAMN107AUS37", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01793", "nct_id"=)"NCT01744665", "official_title"=)"A Phase II Randomized, Multicenter Study of Treatment-free Remission in Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Patients Who Achieve and Sustain MR4.5 After Switching to Nilotinib", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"123134376", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01803", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"29", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"37", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00044071", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01803", "nct_id"=)"NCT01717053", "official_title"=)"A Phase II Trial of Abiraterone Acetate, Radiotherapy, and Short-Term Androgen Deprivation in Men with Unfavorable Risk Localized Prostate Cancer", "open_date"=)"09-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Bridget", "pi_last_name"=)"Koontz", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"123195451", "specific_funding_source"=)"Janssen Pharmaceuticals", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01818", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"16-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"13-048", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01818", "nct_id"=)"NCT01853748", "official_title"=)"A Randomized Phase II Study of Adjuvant Trastuzumab Emtansine (T-DM1) vs. Paclitaxel in Combination with Trastuzumab for Stage I HER2-Positive Breast Cancer (ATEMPT Trial)", "open_date"=)"17-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sara", "pi_last_name"=)"Tolaney", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"123421842", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01874", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"29", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"130", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00010519", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01874", "nct_id"=)"NCT00932672", "official_title"=)"Randomized Controlled Clinical Trial of Carbohydrate Restriction among Men on Androgen Deprivation Therapy for Prostate Cancer", "open_date"=)"08-Jun-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Brant", "pi_last_name"=)"Inman", "pi_middle_initial"=)"A", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"124092244", "specific_funding_source"=)"Abbott Laboratories", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01899", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"51", "center_total_rp"=)"30", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"110", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00031169", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01899", "nct_id"=)"NCT01491893", "official_title"=)"Dose-Finding and Safety Study of an Oncolytic Polio/Rhinovirus Recombinant against Recurrent WHO Grade IV Malignant Glioma", "open_date"=)"11-Jan-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"124218874", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01900", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"22-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"38", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00032421", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01900", "nct_id"=)"NCT01513733", "official_title"=)"The CATCH Prostate Cancer Trial: Cabazitaxel and Tasquinimod in Men with Castration-Resistant Heavily Pre-treated Prostate Cancer", "open_date"=)"01-Dec-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"124247368", "specific_funding_source"=)"Sanofi Aventis", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01904", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"URCC-13059", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"URCC#13059", "lead_org_po_id"=)"35608105", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01904", "nct_id"=)"NCT02054741", "official_title"=)"A Geriatric Assessment Intervention for Patients Aged 70 and Over Receiving Chemotherapy or Similar Agents for Advanced Cancer: Reducing Toxicity in Older Adults", "open_date"=)"15-May-2014", "other_ids"=)"NCT02066168\r13059", "other_protocol_ids"=)"URCC-13059, NCT02066168, 13059", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Supriya", "pi_last_name"=)"Mohile", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124262014", "specific_funding_source"=)"University of Rochester NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01922", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SPI-BEL-12-104", "lead_org_po_id"=)"219099", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01922", "nct_id"=)"NCT01839097", "official_title"=)"Phase 1 Dose Finding Study of Belinostat Plus Cyclophosphamide/Vincristine/Doxorubicin/Prednisone (CHOP) Regimen (BelCHOP) for Treatment of Patients With Peripheral T-cell Lymphoma(PTCL)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"124309674", "specific_funding_source"=)"Spectrum Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01934", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CFZ002", "lead_org_po_id"=)"28076", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01934", "nct_id"=)"NCT01949545", "official_title"=)"An Open-Label, Single Arm, Phase 1 Study of the Pharmacokinetics and Safety of Carfilzomib in Subjects With Advanced Malignancies and Varying Degrees of Hepatic Impairment", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124435016", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01951", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D0818C00001", "lead_org_po_id"=)"34899", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01951", "nct_id"=)"NCT01844986", "official_title"=)"A Phase III, Randomised, Double Blind, Placebo Controlled, Multicentre Study of Olaparib Maintenance Monotherapy in Patients With BRCA Mutated Advanced (FIGO Stage III-IV) Ovarian Cancer Following First Line Platinum Based Chemotherapy.", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"124605008", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01952", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CR100845", "lead_org_po_id"=)"48659622", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01952", "nct_id"=)"NCT01703481", "official_title"=)"A Phase 1 Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of JNJ-42756493, a Pan-Fibroblast Growth Factor Receptor (FGFR) Tyrosine Kinase Inhibitor, in Subjects With Advanced or Refractory Solid Tumors or Lymphoma", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124614363", "specific_funding_source"=)"Janssen Research & Development, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01964", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Jul-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CMX001-301", "lead_org_po_id"=)"46747919", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01964", "nct_id"=)"NCT01769170", "official_title"=)"A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter, Phase 3 Study of the Safety, Tolerability, and Efficacy of CMX001 for the Prevention of Cytomegalovirus (CMV) Infection in CMV-seropositive (R+) Hematopoietic Stem Cell Transplant Recipients", "open_date"=)"23-Aug-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"124648643", "specific_funding_source"=)"Chimerix", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01983", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D1532C00065", "lead_org_po_id"=)"34899", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01983", "nct_id"=)"NCT01843062", "official_title"=)"A Randomised, Double Blind Study to Compare the Complete Remission Rate Following a 5-Week Course of Selumetinib or Placebo and Single Dose Adjuvant Radioactive Iodine Therapy in Patients With Differentiated Thyroid Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"124821826", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02008", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"07-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"13-262", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02008", "nct_id"=)"NCT01965353", "official_title"=)"A Phase I Open Label Study of Panobinostat in Combination with Lenalidomide, Bortezomib, and Dexamethasone in Patients with Relapsed and Relapsed/Refractory Multiple Myeloma", "open_date"=)"18-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jacob", "pi_last_name"=)"Laubach", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"125066661", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02087", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"0103-014", "lead_org_po_id"=)"33540028", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02087", "nct_id"=)"NCT02018926", "official_title"=)"A Phase I/II, Multi-Center Study of Mocetinostat (MGCD0103) in Combination With Azacitidine in Subjects With Intermediate or High Risk Myelodysplastic Syndrome (MDS)", "open_date"=)"01-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"125232573", "specific_funding_source"=)"Mirati Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02164", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"32", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Apr-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00012947", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02164", "nct_id"=)"NCT00978432", "official_title"=)"A Phase 2 Study to Evaluate the Efficacy of Epigenetic Modulation in Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL)", "open_date"=)"24-Aug-2009", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Anne", "pi_last_name"=)"Beaven", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"125808014", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02167", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANHL12P1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANHL12P1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02167", "nct_id"=)"NCT01979536", "official_title"=)"A Randomized Phase 2 Trial of Brentuximab Vedotin (SGN35, NSC# 749710), or Crizotinib (NSC#749005, Commercially Labeled) in Combination with Chemotherapy for Newly Diagnosed Patients with Anaplastic Large Cell Lymphoma (ALCL)", "open_date"=)"08-Nov-2013", "other_ids"=)"COG-ANHL12P1", "other_protocol_ids"=)"ANHL12P1, COG-ANHL12P1", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Eric", "pi_last_name"=)"Lowe", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"125817960", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02192", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"60", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00021317", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02192", "nct_id"=)"NCT01061788", "official_title"=)"A Phase I Trial of the IGF-1R Antibody AMG 479 in Combination with Everolimus (RAD001) and Panitumumab in Patients with Advanced Cancer (The RAP Trial)", "open_date"=)"09-Apr-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Herbert", "pi_last_name"=)"Hurwitz", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"125933484", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02201", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"11-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00030834", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02201", "nct_id"=)"NCT01491841", "official_title"=)"Phase I/II Study of the Combination of Bendamustine, Rituximab, and Pixantrone in Patients with Relapsed/Refractory B Cell Non-Hodgkin Lymphoma", "open_date"=)"21-Sep-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Anne", "pi_last_name"=)"Beaven", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"125963365", "specific_funding_source"=)"Cell Therapeutics Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02221", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PR-30-5011-C", "lead_org_po_id"=)"25957265", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02221", "nct_id"=)"NCT01847274", "official_title"=)"A Phase 3 Randomized Double-blind Trial of Maintenance With Niraparib Versus Placebo in Patients With Platinum Sensitive Ovarian Cancer.", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"126125207", "specific_funding_source"=)"Tesaro Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02228", "affiliate_total"=)"4", "affiliate_total_rp"=)"4", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-52", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-52", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02228", "nct_id"=)"NCT02003209", "official_title"=)"A Randomized Phase III Trial Evaluating Pathologic Complete Response Rates in Patients with Hormone Receptor-Positive, HER2-Positive, Large Operable and Locally Advanced Breast Cancer Treated with Neoadjuvant Therapy of Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab (TCHP) with or without Estrogen Deprivation", "open_date"=)"15-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"NSABP-B-52", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mothaffar", "pi_last_name"=)"Rimawi", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"126184536", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02284", "affiliate_total"=)"2", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0286B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0286B", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02284", "nct_id"=)"NCT02065687", "official_title"=)"A Randomized Phase II/III Study of Paclitaxel/Carboplatin/Metformin (NSC#91485) versus Paclitaxel/Carboplatin/Placebo as Initial Therapy for Measurable Stage III or IVA, Stage IVB, or Recurrent Endometrial Cancer", "open_date"=)"17-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"GOG-0286B", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Victoria", "pi_last_name"=)"Bae-Jump", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"126986253", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02333", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"COVLARO0286", "lead_org_po_id"=)"61194", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02333", "nct_id"=)"NCT01717014", "official_title"=)"Evaluating the Radial Reload Stapler With Tri-Staple TM Technology During Open Low Anterior Resection for Rectal Cancer: A Prospective Multicenter Case Series", "open_date"=)"09-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Rectum", "sp_id"=)"127743842", "specific_funding_source"=)"Covidien", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02335", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"10-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7080-G000-304", "lead_org_po_id"=)"41888289", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02335", "nct_id"=)"NCT01761266", "official_title"=)"A Multicenter, Randomized, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-Line Treatment of Subjects With Unresectable Hepatocellular Carcinoma", "open_date"=)"01-May-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"127744200", "specific_funding_source"=)"Eisai Limited", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02336", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"117146", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02336", "nct_id"=)"NCT01890746", "official_title"=)"A Randomized, Blinded, Placebo-Controlled, Dose Finding Study to Assess the Safety and Efficacy of the Oral Thrombopoietin Receptor Agonist, Eltrombopag, Administered to Subjects With Acute Myelogenous Leukaemia (AML) Receiving Induction Chemotherapy", "open_date"=)"01-Sep-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"127744403", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02337", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-032", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02337", "nct_id"=)"NCT01928394", "official_title"=)"A Phase 1/2, Open-label Study of Nivolumab Monotherapy or Nivolumab Combined With Ipilimumab in Subjects With Advanced or Metastatic Solid Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"127744599", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02377", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"20120216", "lead_org_po_id"=)"28076", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02377", "nct_id"=)"NCT02000427", "official_title"=)"A Phase 2 Single Arm, Multicenter Trial to Evaluate the Efficacy of the BiTE Antibody Blinatumomab in Adult Subjects With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia (Alcantara Study)", "open_date"=)"20-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"128309956", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02379", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACNS1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACNS1221", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02379", "nct_id"=)"NCT02017964", "official_title"=)"A Phase II Study for the Treatment of Non-metastatic Nodular Desmoplastic Medulloblastoma in Children Less Than 4 Years of Age", "open_date"=)"23-Dec-2013", "other_ids"=)"COG-ACNS1221", "other_protocol_ids"=)"ACNS1221, COG-ACNS1221", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Lucie", "pi_last_name"=)"Lafay-Cousin", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"128364006", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MDV3100-14", "lead_org_po_id"=)"8007919", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02393", "nct_id"=)"NCT02003924", "official_title"=)"A Multinational, Phase 3, Randomized, Double Blind, Placebo Controlled, Efficacy and Safety Study of Enzalutamide in Patients With Nonmetastatic Castration Resistant Prostate Cancer", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"128499368", "specific_funding_source"=)"Medivation Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02398", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-352-0101", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02398", "nct_id"=)"NCT01969838", "official_title"=)"A Phase 3, Randomized, Double-blind Active-controlled Study Evaluating Momelotinib vs. Ruxolitinib in Subjects With Primary Myelofibrosis (PMF) or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"128574413", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02429", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"407", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"530", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00007857", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02429", "nct_id"=)"NCT00734955", "official_title"=)"An Optical Assay System for Intra Operative Assessment of Tumor Margins in Patients with Breast Cancer", "open_date"=)"25-May-2006", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"128749625", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02435", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CMEK162AUS11", "lead_org_po_id"=)"23609", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02435", "nct_id"=)"NCT01885195", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 3 - MEK162 for Patients With RAS/RAF/MEK Activated Tumors", "open_date"=)"24-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"128859925", "specific_funding_source"=)"Array Biopharma Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-02485", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1310", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1310", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-02485", "nct_id"=)"NCT02042443", "official_title"=)"Randomized Phase II Trial of Single Agent MEK Inhibitor Trametinib (GSK1120212) Vs 5-Fluorouracil or Capecitabine in Refractory Advanced Biliary Cancer", "open_date"=)"15-Feb-2014", "other_ids"=)"SWOG-S1310", "other_protocol_ids"=)"S1310, SWOG-S1310", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Richard", "pi_last_name"=)"Kim", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"129078990", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00012", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBSC", "lead_org_po_id"=)"57642", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00012", "nct_id"=)"NCT00785525", "official_title"=)"Filgrastim-Mobilized Peripheral Blood Stem Cells for Allogeneic Transplantation With Unrelated Donors", "open_date"=)"02-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"", "sp_id"=)"130377858", "specific_funding_source"=)"Center for International Blood and Marrow Transplant Research", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00024", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"50", "center_total_rp"=)"22", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00032263", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00024", "nct_id"=)"NCT01725022", "official_title"=)"A Controlled Study of Stem Cell Transplantation Medical Home Care Compared to Standard Hospital Care", "open_date"=)"13-Mar-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nelson", "pi_last_name"=)"Chao", "pi_middle_initial"=)"J", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"130521819", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00025", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"26", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"17-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00032595", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00025", "nct_id"=)"NCT02019199", "official_title"=)"Magnetic Resonance Imaging (MRI) for Radiation Therapy Treatment Planning Evaluation of Lung, Liver, and Pancreatic Motion", "open_date"=)"", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Brian", "pi_last_name"=)"Czito", "pi_middle_initial"=)"G", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"130525824", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00028", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00038021", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00028", "nct_id"=)"", "official_title"=)"Local Modulation of Immune Receptor Function to Enhance Immune Responses to Dendritic Cell Vaccination in Subjects with Triple Negative Breast Cancer", "open_date"=)"23-Feb-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Eun-Sil (Shelley)", "pi_last_name"=)"Hwang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"130530540", "specific_funding_source"=)"Susan G Komen Breast Cancer Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00031", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"19-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00044274", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00031", "nct_id"=)"NCT01954030", "official_title"=)"A Phase 1/2 Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Bevacizumab for Adult Patients with Recurrent Malignant Glioma Post-Bevacizumab Failure", "open_date"=)"21-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"130533897", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00032", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00044446", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00032", "nct_id"=)"NCT01927081", "official_title"=)"Self-Management Interventions for Living Well with Breast Cancer", "open_date"=)"03-Sep-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130534160", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00033", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"92", "center_total_rp"=)"51", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"138", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045975", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00033", "nct_id"=)"NCT01905397", "official_title"=)"A Randomized Phase II Evaluation of Negative Pressure Wound Therapy for Reduction of Postoperative Surgical Site Infection in Patients Undergoing Colorectal and Hepatopancreatobiliary Surgery", "open_date"=)"08-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Dan", "pi_last_name"=)"Blazer", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"130534504", "specific_funding_source"=)"Kinetic Concepts Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00036", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"43", "center_total_rp"=)"15", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047214", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00036", "nct_id"=)"NCT01947166", "official_title"=)"Pancreatic Resection, Malnutrition, and Readmission: Assessment and Prevention", "open_date"=)"30-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kara", "pi_last_name"=)"Penne", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"130536291", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00041", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"55", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"165", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00006458", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00041", "nct_id"=)"", "official_title"=)"Acoustic Radiation Force Impulse (ARFI) Imaging of the Prostate in Vivo", "open_date"=)"27-Jul-2008", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Kathryn", "pi_last_name"=)"Nightingale", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"130545763", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00042", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"83", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"245", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00008173", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00042", "nct_id"=)"NCT00900575", "official_title"=)"Cervical Cancer Detection Using Optical Spectroscopy", "open_date"=)"09-Jun-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"130548162", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00058", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"130", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"14-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"250", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00022895", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00058", "nct_id"=)"NCT02189278", "official_title"=)"Improving Adherence to Recommended Surveillance in Breast Cancer Survivors", "open_date"=)"03-Sep-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130609152", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00059", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"120", "center_total_rp"=)"61", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"220", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00028284", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00059", "nct_id"=)"NCT01372631", "official_title"=)"Spectral and High Resolution Measurements for Improved Optical Margin Assessment", "open_date"=)"25-Feb-2011", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130610179", "specific_funding_source"=)"National Institutes of Health Clinical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00061", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"36", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047952", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00061", "nct_id"=)"NCT01984671", "official_title"=)"Home-Based Tablet Computer Pain Coping Skills Following Stem Cell Transplant", "open_date"=)"08-Oct-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"130611263", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00075", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"467", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"900", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00008472", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00075", "nct_id"=)"", "official_title"=)"Breast MRI Screening and Prevention for High-Risk Women", "open_date"=)"27-Jun-2005", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Victoria", "pi_last_name"=)"Seewaldt", "pi_middle_initial"=)"L", "primary_purpose"=)"Scr", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130623860", "specific_funding_source"=)"Susan G Komen Breast Cancer Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00079", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-170", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00079", "nct_id"=)"NCT01725633", "official_title"=)"Safety and Tolerability of Nonlinear Aerobic Training in Women with Metastatic Breast Cancer", "open_date"=)"17-Nov-2010", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Lee", "pi_last_name"=)"Jones", "pi_middle_initial"=)"W", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"130626319", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00118", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E1912", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E1912", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00118", "nct_id"=)"NCT02048813", "official_title"=)"A Randomized Phase III Study of Ibrutinib (PCI-32765)-Based Therapy vs Standard Fludarabine, Cyclophosphamide, and Rituximab (FCR) Chemoimmunotherapy in Untreated Younger Patients with Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"20-Feb-2014", "other_ids"=)"ECOG-E1912", "other_protocol_ids"=)"E1912, ECOG-E1912", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Tait", "pi_last_name"=)"Shanafelt", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"131086466", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00149", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBYL719A2201", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00149", "nct_id"=)"NCT01923168", "official_title"=)"A Phase II Randomized, Double-blind Placebo Controlled, Study of Letrozole With or Without BYL719 or Buparlisib, for the Neoadjuvant Treatment of Postmenopausal Women With Hormone Receptor-positive HER2-negative Breast Cancer", "open_date"=)"15-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"132477774", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00156", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CINC280X2204", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00156", "nct_id"=)"NCT01870726", "official_title"=)"A Phase Ib/II, Multi-center, Open-label Study of INC280 in Combination With Buparlisib in Patients With Recurrent Glioblastoma", "open_date"=)"16-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"132793633", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00162", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Feb-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBKM120ZUS40", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00162", "nct_id"=)"NCT01833169", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 1 - BKM120 for Patients With PI3K-activated Tumors", "open_date"=)"16-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"132818427", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00185", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADU-CL-04", "lead_org_po_id"=)"48498433", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00185", "nct_id"=)"NCT02004262", "official_title"=)"A Phase 2B, Randomized, Controlled, Multicenter, Open-Label Study of the Efficacy and Immune Response of GVAX Pancreas Vaccine (With Cyclophosphamide) and CRS 207 Compared to Chemotherapy or to CRS-207 Alone in Adults With Previously-Treated Metastatic Pancreatic Adenocarcinoma", "open_date"=)"28-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"133067112", "specific_funding_source"=)"Aduro Biotech, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00209", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0283", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0283", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00209", "nct_id"=)"NCT02059265", "official_title"=)"A Phase II Trial of DCTD-Sponsored Dasatinib in Recurrent/Persistent Ovary, Fallopian Tube, Primary Peritoneal, and Endometrial Clear Cell Carcinoma Characterized for the Retention or Loss of BAF250a Expression", "open_date"=)"03-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"GOG-0283", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Hyman", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"133353493", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00222", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AC220-007", "lead_org_po_id"=)"68015", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00222", "nct_id"=)"NCT02039726", "official_title"=)"A Phase 3 Open-label Randomized Study of Quizartinib (AC220) Monotherapy Versus Salvage Chemotherapy in Subjects With Tyrosine Kinase 3 - Internal Tandem Duplication (FLT3-ITD) Positive Acute Myeloid Leukemia (AML) Refractory to or Relapsed After First-line Treatment With or Without Hematopoietic Stem Cell Transplantation (HSCT) Consolidation", "open_date"=)"29-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"133987772", "specific_funding_source"=)"Daiichi Sankyo Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00229", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INO-VT-464-CL-001", "lead_org_po_id"=)"38235419", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00229", "nct_id"=)"NCT02012920", "official_title"=)"A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VT-464 in Patients With Castration-Resistant Prostate Cancer", "open_date"=)"29-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"134164225", "specific_funding_source"=)"Innocrin Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00256", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15983", "lead_org_po_id"=)"35145", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00256", "nct_id"=)"NCT01939223", "official_title"=)"A Randomized, Double-blind, Placebo-controlled Phase-III Study of Adjuvant Regorafenib Versus Placebo for Patients With Stage IV Colorectal Cancer After Curative Treatment of Liver Metastases", "open_date"=)"31-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"134482660", "specific_funding_source"=)"Bayer Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00257", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-006", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00257", "nct_id"=)"NCT01946074", "official_title"=)"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABT-165, a Dual Variable Domain Immunoglobulin in Subjects With Advanced Solid Tumors", "open_date"=)"31-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"134482921", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00258", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"31", "center_total_rp"=)"15", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045042", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00258", "nct_id"=)"NCT01996202", "official_title"=)"A Pilot Study of Ipilimumab and Radiation in Poor Prognosis Melanoma", "open_date"=)"05-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"April", "pi_last_name"=)"Salama", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"134483914", "specific_funding_source"=)"Bristol-Myers Squibb, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00259", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"11", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00045976", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00259", "nct_id"=)"NCT01890213", "official_title"=)"A Pilot Study of Active Immunotherapy With CEA(6D) VRP Vaccine (AVX701) in Patients With Stage III Colorectal Cancer", "open_date"=)"13-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Morse", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"134484461", "specific_funding_source"=)"AlphaVax Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00260", "affiliate_total"=)"5", "affiliate_total_rp"=)"5", "center_total"=)"45", "center_total_rp"=)"37", "clinical_research_cat"=)"INT", "close_date"=)"03-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00046383", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00260", "nct_id"=)"NCT01940276", "official_title"=)"A Phase II Open-Label, Parallel Group Study of Abiraterone Acetate plus Prednisone in African American and Caucasian Men with Metastatic Castrate-Resistant Prostate Cancer", "open_date"=)"21-Nov-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Daniel", "pi_last_name"=)"George", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"134484910", "specific_funding_source"=)"Janssen Pharmaceuticals", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00264", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"01-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091105", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091105", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00264", "nct_id"=)"NCT02066181", "official_title"=)"A Phase III, Double Blind, Randomized, Placebo-Controlled Trial of Sorafenib in Desmoid Tumors or Aggressive Fibromatosis (DT/DF)", "open_date"=)"21-Mar-2014", "other_ids"=)"1 R01 FD005105-01A1\rPA091105_A04PAMDREVW01", "other_protocol_ids"=)"A091105, 1, R01, FD005105-01A1, PA091105_A04PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Mrinal", "pi_last_name"=)"Gounder", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"134524399", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00304", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"20-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"159", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047969", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00304", "nct_id"=)"NCT01989052", "official_title"=)"A Phase 1/2 Unblinded Trial of Carboxyamidotriazole Orotate (CTO) Alone or in Combination with Lomustine for Bevacizumab-Naïve Adult Patients with Recurrent Malignant Glioma", "open_date"=)"10-Dec-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"134747525", "specific_funding_source"=)"Tactical Therapeutics Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00305", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"105SAR101", "lead_org_po_id"=)"23305594", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00305", "nct_id"=)"NCT01975519", "official_title"=)"A Phase 1B Dose-escalation and Phase 2a Study of TRC105 in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma", "open_date"=)"04-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"134747813", "specific_funding_source"=)"TRACON Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00307", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1101", "lead_org_po_id"=)"249581", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00307", "nct_id"=)"NCT01597778", "official_title"=)"A Multi-Center, Phase III, Randomized Trial of Reduced Intensity Conditioning (RIC) and Transplantation of Double Unrelated Umbilical Cord Blood (dUCB) Versus HLA-Haploidentical Related Bone Marrow (Haplo) for Patients With Hematologic Malignancies (BMT CTN #1101)", "open_date"=)"04-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"134752051", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00328", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-143", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00328", "nct_id"=)"NCT02017717", "official_title"=)"A Randomized Phase 3 Open Label Study of Nivolumab Versus Bevacizumab and Multiple Phase 1 Safety Cohorts of Nivolumab or Nivolumab in Combination With Ipilimumab Across Different Lines of Glioblastoma", "open_date"=)"12-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"134880805", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00365", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-026", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00365", "nct_id"=)"NCT02041533", "official_title"=)"An Open-Label, Randomized, Phase 3 Trial of Nivolumab Versus Investigator's Choice Chemotherapy as First-Line Therapy for Stage IV or Recurrent PD-L1+ Non-Small Cell Lung Cancer", "open_date"=)"28-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"135357538", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00373", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CDX011-04", "lead_org_po_id"=)"56901", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00373", "nct_id"=)"NCT01997333", "official_title"=)"A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)", "open_date"=)"11-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"135380274", "specific_funding_source"=)"Celldex Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00422", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D1532C00079", "lead_org_po_id"=)"34899", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00422", "nct_id"=)"NCT01933932", "official_title"=)"A Phase III, Double-Blind, Randomised, Placebo-Controlled Study to Assess the Efficacy and Safety of Selumetinib (AZD6244; ARRY-142886) (Hyd-Sulfate) in Combination With Docetaxel, in Patients Receiving Second Line Treatment for KRAS Mutation-Positive Locally Advanced or Metastatic Non Small Cell Lung Cancer (Stage IIIB - IV) (SELECT 1)", "open_date"=)"18-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"135895289", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00446", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221301", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221301", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00446", "nct_id"=)"NCT02116530", "official_title"=)"Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC);  A Randomized, Double-Blind, Placebo-Controlled Trial", "open_date"=)"05-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"A221301", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Rudolph", "pi_last_name"=)"Navari", "pi_middle_initial"=)"M", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"136123867", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00483", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SCRX16-001", "lead_org_po_id"=)"39897311", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00483", "nct_id"=)"NCT01901653", "official_title"=)"Phase I/II Open Label Dose Escalation Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of SC16LD6.5 as a Single Agent in Patients With Recurrent Small Cell Lung Cancer", "open_date"=)"25-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"136442914", "specific_funding_source"=)"Stemcentrx", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00491", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLEE011A2301", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00491", "nct_id"=)"NCT01958021", "official_title"=)"A Randomized Double-blind, Placebo-controlled Study of LEE011 in Combination With Letrozole for the Treatment of Postmenopausal Women With Hormone Receptor Positive, HER2 Negative, Advanced Breast Cancer Who Received no Prior Therapy for Advanced Disease", "open_date"=)"25-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"136454680", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00616", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A071102", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A071102", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00616", "nct_id"=)"NCT02152982", "official_title"=)"A Phase II/III Randomized Trial of Veliparib or Placebo in Combination with Adjuvant Temozolomide in Newly Diagnosed Glioblastoma with MGMT Promoter Hypermethylation", "open_date"=)"15-Dec-2014", "other_ids"=)"CALGB-A071102", "other_protocol_ids"=)"A071102, CALGB-A071102", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Jann", "pi_last_name"=)"Sarkaria", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"137447064", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00619", "affiliate_total"=)"8", "affiliate_total_rp"=)"8", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"URCC-13070", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"URCC# 13070", "lead_org_po_id"=)"35608105", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00619", "nct_id"=)"NCT02107443", "official_title"=)"Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers", "open_date"=)"26-Jun-2014", "other_ids"=)"URCC13070", "other_protocol_ids"=)"URCC-13070, URCC13070", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Supriya", "pi_last_name"=)"Mohile", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"137481249", "specific_funding_source"=)"University of Rochester NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00627", "affiliate_total"=)"11", "affiliate_total_rp"=)"9", "center_total"=)"23", "center_total_rp"=)"23", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00627", "nct_id"=)"NCT02154490", "official_title"=)"A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)", "open_date"=)"16-Jun-2014", "other_ids"=)"S1400B\rS1400D\rS1400C\rS1400I\rS1400A\rS1400E", "other_protocol_ids"=)"S1400, S1400B, S1400D, S1400C, S1400I, S1400A, S1400E", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"137570059", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00629", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"GOG-0281", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GOG-0281", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00629", "nct_id"=)"NCT02101788", "official_title"=)"A Randomized Phase II/III Study to Assess the Efficacy of Trametinib (GSK 1120212) in Patients with Recurrent or Progressive Low-Grade Serous Ovarian Cancer or Peritoneal Cancer", "open_date"=)"27-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"GOG-0281", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"David", "pi_last_name"=)"Gershenson", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"137589214", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00631", "affiliate_total"=)"4", "affiliate_total_rp"=)"4", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL1331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL1331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00631", "nct_id"=)"NCT02101853", "official_title"=)"Risk-Stratified Randomized Phase III Testing of Blinatumomab (NSC#765986) in First Relapse of Childhood B-Lymphoblastic Leukemia (B-ALL)", "open_date"=)"08-Dec-2014", "other_ids"=)"COG-AALL1331", "other_protocol_ids"=)"AALL1331, COG-AALL1331", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Patrick", "pi_last_name"=)"Brown", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"137592455", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00635", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-HN001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-HN001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00635", "nct_id"=)"NCT02135042", "official_title"=)"Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)", "open_date"=)"21-Apr-2014", "other_ids"=)"NCT02179164\rRTOG-1305", "other_protocol_ids"=)"NRG-HN001, NCT02179164, RTOG-1305", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Nancy", "pi_last_name"=)"Lee", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"137650585", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00640", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-042", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-042", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00640", "nct_id"=)"NCT02255461", "official_title"=)"Phase I Study of CDK 4-6 Inhibitor PD-0332991 in Children with Recurrent, Progressive or Refractory Central Nervous System Tumors", "open_date"=)"05-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"PBTC-042", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Sridharan", "pi_last_name"=)"Gururangan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"137710132", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00644", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NSABP-B-55", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NSABP-B-55", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00644", "nct_id"=)"NCT02032823", "official_title"=)"A Randomised, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy", "open_date"=)"03-Jul-2014", "other_ids"=)"NSABP B-55/BIG 6-13\rNSABP B-55\rBIG 6-13\rB-55/BIG 6-13\rD081CC00006", "other_protocol_ids"=)"NSABP-B-55, NSABP, B-55/BIG, 6-13, NSABP, B-55, BIG, 6-13, B-55/BIG, 6-13, D081CC00006", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Charles", "pi_last_name"=)"Geyer", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"137744148", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00660", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PCYC-1119-CA", "lead_org_po_id"=)"50366884", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00660", "nct_id"=)"NCT01962792", "official_title"=)"A Multicenter Phase 1/2b Study of the Bruton's Tyrosine Kinase Inhibitor, Ibrutinib (PCI-32765), in Combination With Carfilzomib (Kyprolis™) in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma", "open_date"=)"10-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"139054283", "specific_funding_source"=)"Pharmacyclics LLC.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00663", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"38", "center_total_rp"=)"33", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00043247", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00663", "nct_id"=)"NCT02046122", "official_title"=)"A Phase 1/2 Study of the Safety and Efficacy of Chemotherapy Combined with Adoptive Transfer of HLA-Haploidentical Donor Lymphocyte Infusion in Older Patients with High-Risk Acute Myeloid Leukemia and Myelodysplastic Syndrome", "open_date"=)"11-Feb-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Anthony", "pi_last_name"=)"Sung", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"139061297", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00677", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ANBL1232", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ANBL1232", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00677", "nct_id"=)"NCT02176967", "official_title"=)"Utilizing Response- and Biology-Based Risk Factors to Guide Therapy in Patients with Non-high-risk Neuroblastoma", "open_date"=)"28-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"ANBL1232", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Holly", "pi_last_name"=)"Meany", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"139231605", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00679", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GRASPALL 2012-09", "lead_org_po_id"=)"38740143", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00679", "nct_id"=)"NCT01910428", "official_title"=)"A Phase I Study of L-asparaginase Encapsulated in Red Blood Cells (Eryaspase) in Combination With the CALGB Regimen During Induction and Consolidation Phases in the Treatment of Adult Patients With Acute Lymphoblastic Leukemia and Lymphoma", "open_date"=)"09-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"139241091", "specific_funding_source"=)"ERYtech Pharma", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00702", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-BR001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-BR001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00702", "nct_id"=)"NCT02206334", "official_title"=)"A Phase 1 Study of Stereotactic Body Radiotherapy (SBRT) for the Treatment of Multiple Metastases", "open_date"=)"04-Aug-2014", "other_ids"=)"NRG BR001", "other_protocol_ids"=)"NRG-BR001, NRG, BR001", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Steven", "pi_last_name"=)"Chmura", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"139634803", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00704", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"DEK-Dkk1-P102", "lead_org_po_id"=)"48834287", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00704", "nct_id"=)"NCT02013154", "official_title"=)"A Five Part, Phase 1, Multi-center, Open-label Study of DKN-01 in Combination With Weekly Paclitaxel; Part A: A Dose-Escalation Study in Patients With Relapsed or Refractory (R/R) Esophageal Cancer (EC) or Gastro-esophageal Junction (GEJ) Tumors; Part B: An Expansion Cohort in Patients With R/R EC or GEJ Tumors; Part C: An Expansion Cohort in Patients With R/R Esophageal or GEJ Adenocarcinoma; Part D: An Expansion Cohort in Patients With R/R Esophageal Squamous Cell Cancer; Part E: An Expansion Cohort in Patients With R/R Gastric Adenocarcinoma With Wnt Signaling Alterations", "open_date"=)"17-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"139649872", "specific_funding_source"=)"Leap Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00712", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AALL1231", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AALL1231", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00712", "nct_id"=)"NCT02112916", "official_title"=)"A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)", "open_date"=)"30-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"AALL1231", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Teachey", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"139737692", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00746", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E2112", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E2112", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00746", "nct_id"=)"NCT02115282", "official_title"=)"A Randomized Phase III Trial of Endocrine Therapy plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer", "open_date"=)"29-Mar-2014", "other_ids"=)"ECOG-E2112", "other_protocol_ids"=)"E2112, ECOG-E2112", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Roisin", "pi_last_name"=)"Connolly", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"140237851", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00793", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-142", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00793", "nct_id"=)"NCT02060188", "official_title"=)"A Phase 2 Clinical Trial of Nivolumab, or Nivolumab Combinations in Recurrent and Metastatic Microsatellite High (MSI-H) and Non-MSI-H Colon Cancer", "open_date"=)"27-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"140585092", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00814", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1406", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1406", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00814", "nct_id"=)"NCT02164916", "official_title"=)"Randomized Phase II Study of Irinotecan and Cetuximab with or without Vemurafenib in BRAF Mutant Metastatic Colorectal Cancer", "open_date"=)"13-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"S1406", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Edmund", "pi_last_name"=)"Kopetz", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"140750017", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00820", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-008", "lead_org_po_id"=)"54187152", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00820", "nct_id"=)"NCT02088541", "official_title"=)"A Randomized, Open Label, Phase 2 Study of the Selective Inhibitor of Nuclear Export (Sine) Selinexor (KPT-330) Versus Specified Physician's Choice in Patients ≥ 60 Years Old With Relapsed/Refractory Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy and/or Transplantation", "open_date"=)"16-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"140817612", "specific_funding_source"=)"Karyopharm Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00848", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CITN-09", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CITN-09", "lead_org_po_id"=)"12715537", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00848", "nct_id"=)"NCT02267603", "official_title"=)"A Phase II Study of MK-3475 in Patients with Advanced Merkel Cell Carcinoma (MCC)", "open_date"=)"25-Nov-2014", "other_ids"=)"MK-3475", "other_protocol_ids"=)"CITN-09, MK-3475", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Paul", "pi_last_name"=)"Nghiem", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Skin", "sp_id"=)"141089497", "specific_funding_source"=)"Cancer Immunotherapy Trials Network", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00853", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BO28407", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00853", "nct_id"=)"NCT01966471", "official_title"=)"A Randomized, Multicenter, Open-Label, Phase III Trial Comparing Trastuzumab Plus Pertuzumab Plus a Taxane Following Anthracyclines Versus Trastuzumab Emtansine Plus Pertuzumab Following Anthracyclines as Adjuvant Therapy in Patients With Operable HER2-Positive Primary Breast Cancer", "open_date"=)"04-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"141157002", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00869", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"02-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TL32711-POC-0090-PTL", "lead_org_po_id"=)"220676", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00869", "nct_id"=)"NCT01940172", "official_title"=)"A Phase 1b, Open-label, Non-randomized Multicenter Study of Birinapant in Combination With Conatumumab in Subjects With Relapsed Epithelial Ovarian Cancer, Primary Peritoneal Cancer or Fallopian Tube Cancer", "open_date"=)"08-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"141404892", "specific_funding_source"=)"TetraLogic Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00898", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"03-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"CITN-07-FLT3L", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CITN-07-FLT3L", "lead_org_po_id"=)"12715537", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00898", "nct_id"=)"NCT02129075", "official_title"=)"A Phase II, Open-Label, Multicenter, Randomized Study of CDX-1401, a Dendritic Cell Targeting NY-ESO-1 Vaccine, in Patients with Malignant Melanoma Pre-treated with Recombinant CDX-301, a Recombinant Human Flt3 Ligand", "open_date"=)"09-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"CITN-07-FLT3L", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Nina", "pi_last_name"=)"Bhardwaj", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"141728259", "specific_funding_source"=)"Cancer Immunotherapy Trials Network", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00909", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GC P#02.01.020", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00909", "nct_id"=)"NCT01590628", "official_title"=)"Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells, in Combination With a Second, Unmanipulated Cord Blood Unit in Patients With Hemoglobinopathies", "open_date"=)"11-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"141780481", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00926", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-237", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00926", "nct_id"=)"NCT02099058", "official_title"=)"A Multicenter, Phase 1/1b, Open-Label, Dose-Escalation Study of ABBV-399, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors", "open_date"=)"14-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"141902803", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00948", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"47", "center_total_rp"=)"27", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"182", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00052239", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00948", "nct_id"=)"NCT02090582", "official_title"=)"Pilot Study on H.O.P.E: Helping Ovarian Cancer Patients Cope during Disease Recurrence ", "open_date"=)"19-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Paula", "pi_last_name"=)"Lee", "pi_middle_initial"=)"S", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"141997240", "specific_funding_source"=)"Foundation for Women's Cancer, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00955", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"13-383", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00955", "nct_id"=)"NCT01982448", "official_title"=)"A Randomized Phase II Study of Preoperative Cisplatin versus Paclitaxel in Patients with Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker", "open_date"=)"29-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Erica", "pi_last_name"=)"Mayer", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"142006183", "specific_funding_source"=)"Myriad Genetics Inc, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00956", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MCC-17651", "lead_org_po_id"=)"71815", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00956", "nct_id"=)"NCT02115542", "official_title"=)"Multi Institutional Phase II Trial of Single Agent Regorafenib in Refractory Advanced Biliary Cancers", "open_date"=)"10-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Richard", "pi_last_name"=)"Kim", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"142006505", "specific_funding_source"=)"Bayer Corporation, Moffitt Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00985", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TSP0147", "lead_org_po_id"=)"35215944", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00985", "nct_id"=)"NCT02066103", "official_title"=)"Broncho-Adventitial Delivery of Paclitaxel to Extend Airway Patency in Malignant Airway Obstruction Patients", "open_date"=)"17-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"142201599", "specific_funding_source"=)"Mercator MedSystems Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01071", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-LU001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-LU001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01071", "nct_id"=)"NCT02186847", "official_title"=)"Randomized Phase II Trial of Concurrent Chemoradiotherapy +/- Metformin HCL in Locally Advanced NSCLC", "open_date"=)"25-Aug-2014", "other_ids"=)"PNRG-LU001_A01PAMDREVW01", "other_protocol_ids"=)"NRG-LU001, PNRG-LU001_A01PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Theodoros", "pi_last_name"=)"Tsakiridis", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"143526473", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01104", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"JDI2007-01", "lead_org_po_id"=)"3890853", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01104", "nct_id"=)"NCT01590680", "official_title"=)"An Open Label, Expanded Access Protocol Using 131I-metaiodobenzylguanidine (131I-MIBG)Therapy in Patients With Refractory Neuroblastoma, Pheochromocytoma, or Paraganglioma", "open_date"=)"07-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"143984691", "specific_funding_source"=)"DRAXIMAGE", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01146", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"STML-401-0114", "lead_org_po_id"=)"10912561", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01146", "nct_id"=)"NCT02113982", "official_title"=)"SL-401 in Patients With Acute Myeloid Leukemia (AML) and Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)", "open_date"=)"17-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"144365298", "specific_funding_source"=)"Stemline Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053306", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01159", "nct_id"=)"", "official_title"=)"Cancer Distress Coach Pilot Study  ", "open_date"=)"14-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"144527155", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01160", "affiliate_total"=)"2", "affiliate_total_rp"=)"2", "center_total"=)"23", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00049983", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01160", "nct_id"=)"NCT02008383", "official_title"=)"Cabozantinib (XL184) with Panitumumab in Subjects with RAS Wild-Type Metastatic Colorectal Cancer and Cabozantinib Monotherapy in Subjects with MET Amplified Treatment-Refractory Colorectal Cancer", "open_date"=)"29-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"John", "pi_last_name"=)"Strickler", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"144527719", "specific_funding_source"=)"Exelixis Inc", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01161", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"21", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"38", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00049865", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01161", "nct_id"=)"NCT02057939", "official_title"=)"Salvage Therapeutic Radiation with Enzalutamide and ADT in Men with Recurrent Prostate Cancer (STREAM) ", "open_date"=)"15-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Andrew", "pi_last_name"=)"Armstrong", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"144528010", "specific_funding_source"=)"Astellas Pharma US Inc, Medivation Inc, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01167", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-140", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01167", "nct_id"=)"NCT02038946", "official_title"=)"A Single Arm, Open-Label Phase 2 Study of Nivolumab (BMS-936558) in Subjects With Relapsed or Refractory Follicular Lymphoma (FL)", "open_date"=)"13-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"144552329", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01193", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9785-CL-0403", "lead_org_po_id"=)"48002713", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01193", "nct_id"=)"NCT01977651", "official_title"=)"A Multicenter, Single-Arm, Open-Label, Post-Marketing Safety Study to Evaluate the Risk of Seizure Among Subjects With Metastatic Castration-Resistant Prostate Cancer (mCRPC) Treated With Enzalutamide Who Are at Potential Increased Risk of Seizure", "open_date"=)"19-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"144964314", "specific_funding_source"=)"Astellas Pharma Global Development, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01220", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"35", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"25-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"66", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00053588", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01220", "nct_id"=)"", "official_title"=)"Usability Testing and Development of a Web-Based Patient Distress Intervention ", "open_date"=)"13-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"145515592", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01223", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AHOD1331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AHOD1331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01223", "nct_id"=)"NCT02166463", "official_title"=)"A Randomized Phase III Study of Brentuximab Vedotin (SGN-35) for Newly Diagnosed High-Risk Classical Hodgkin Lymphoma (cHL) in Children and Adolescents", "open_date"=)"16-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"AHOD1331", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Sharon", "pi_last_name"=)"Castellino", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"145528769", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01237", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Mar-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-312-0123", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01237", "nct_id"=)"NCT01980888", "official_title"=)"A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Untreated Chronic Lymphocytic Leukemia", "open_date"=)"28-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"145713075", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01253", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Sep-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AV001", "lead_org_po_id"=)"38736123", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01253", "nct_id"=)"NCT02130557", "official_title"=)"A Multicenter Phase 3 Randomized, Open-Label Study of Bosutinib Versus Imatinib in Adult Patients With Newly Diagnosed Chronic Phase (CP) Chronic Myelogenous Leukemia (CML)", "open_date"=)"08-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"145960736", "specific_funding_source"=)"Avillion LLP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01261", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E4112", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E4112", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01261", "nct_id"=)"NCT02352883", "official_title"=)"Prospective Study of Magnetic Resonance Imaging (MRI) and Multiparameter Gene Expression Assay in Ductal Carcinoma In Situ (DCIS)", "open_date"=)"17-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"E4112", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Constance", "pi_last_name"=)"Lehman", "pi_middle_initial"=)"D", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"146207180", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01268", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-141", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01268", "nct_id"=)"NCT02105636", "official_title"=)"An Open Label, Randomized Phase 3 Clinical Trial of Nivolumab vs Therapy of Investigator's Choice in Recurrent or Metastatic Platinum-refractory Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "open_date"=)"03-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"146224627", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01279", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-HN002", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-HN002", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01279", "nct_id"=)"NCT02254278", "official_title"=)"A Randomized Phase II Trial for Patients with p16 Positive, Non-Smoking Associated, Locoregionally Advanced Oropharyngeal Cancer", "open_date"=)"27-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"NRG-HN002", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sue", "pi_last_name"=)"Yom", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"146409149", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01282", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BP29262", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01282", "nct_id"=)"NCT02141295", "official_title"=)"A Phase II, Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of RO5520985 (Vanucizumab) Plus FOLFOX Versus Bevacizumab Plus FOLFOX in Patients With Previously Untreated Metastatic Colorectal Cancer", "open_date"=)"01-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"146439394", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01321", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-352-1214", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01321", "nct_id"=)"NCT02101268", "official_title"=)"A Phase 3, Randomized Study To Evaluate the Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, or Post-essential Thrombocythemia Myelofibrosis Who Were Treated With Ruxolitinib", "open_date"=)"12-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"146897244", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01324", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"15-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 18424-362", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01324", "nct_id"=)"NCT02117479", "official_title"=)"A Randomized, Double-Blind, Phase 3 Study of the Janus Kinase (JAK) 1/2 Inhibitor, Ruxolitinib, or Placebo in Combination With Capecitabine in Subjects With Advanced or Metastatic Adenocarcinoma of the Pancreas Who Have Failed or Are Intolerant to First-Line Chemotherapy (The JANUS 1 Study)", "open_date"=)"13-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"146948597", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01340", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ARST1321", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ARST1321", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01340", "nct_id"=)"NCT02180867", "official_title"=)"Pazopanib Neoadjuvant Trial in Non-rhabdomyosarcoma Soft Tissue Sarcomas (PAZNTIS): A Phase II/III Randomized Trial of Preoperative Chemoradiation or Preoperative Radiation plus or minus Pazopanib (NSC# 737754)", "open_date"=)"11-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"ARST1321", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Aaron", "pi_last_name"=)"Weiss", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"147120168", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01345", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12-287", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01345", "nct_id"=)"NCT02164019", "official_title"=)"A Randomized Trial to Assess Patient Quality of Life and Function after Alternative Surgeries for Pathologic Fractures of the Femur", "open_date"=)"11-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"John", "pi_last_name"=)"Healey", "pi_middle_initial"=)"H", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"147199543", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01350", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OPZ007", "lead_org_po_id"=)"28076", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01350", "nct_id"=)"NCT01999335", "official_title"=)"Phase 1b/3 Multicenter Study of Oprozomib, Pomalidomide, and Dexamethasone in Primary Refractory or Relapsed and Refractory Multiple Myeloma Subjects", "open_date"=)"17-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"147213560", "specific_funding_source"=)"Amgen, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01378", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"18-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400A", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400A", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01378", "nct_id"=)"NCT02766335", "official_title"=)"A Phase II Study of MEDI4736 for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers (Lung- Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400A, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147525658", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01379", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"13-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400B", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400B", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01379", "nct_id"=)"NCT02785913", "official_title"=)"A Phase II Study of GDC-0032 (Taselisib) for Previously Treated PI3K Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400B, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147527145", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01380", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400C", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400C", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01380", "nct_id"=)"NCT02785939", "official_title"=)"A Phase II Study of Palbociclib for Prevoiusly Treated Cell Cycle Gene Alteration Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400C, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147527427", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01381", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400D", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400D", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01381", "nct_id"=)"NCT02965378", "official_title"=)"A Phase II Study of AZD4547 for Previously Treated FGFR-Positive Patients with Stage IV Squamous Cell Lung Cancer (Lung-Map Sub-Study)", "open_date"=)"16-Jun-2014", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400D, NCT02154490", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"147528449", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01403", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RF-3501", "lead_org_po_id"=)"214245", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01403", "nct_id"=)"NCT01711658", "official_title"=)"TRYHARD: A Phase II, Randomized, Double Blind, Placebo-Controlled Study of Lapatinib (Tykerb®) for Non-HPV Locally Advanced Head and Neck Cancer With Concurrent Chemoradiation", "open_date"=)"20-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"147628364", "specific_funding_source"=)"Radiation Therapy Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01408", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC 1317", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01408", "nct_id"=)"NCT02138617", "official_title"=)"GENIC, A Genotype-Directed Phase II Study of Irinotecan Dosing in Metastatic Colorectal Cancer (mCRC) Patients Receiving FOLFIRI + Bevacizumab", "open_date"=)"06-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Hanna Kelly", "pi_last_name"=)"Sanoff", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"147708807", "specific_funding_source"=)"UNC Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01416", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"44", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00046479", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01416", "nct_id"=)"NCT02115243", "official_title"=)"A Phase I Trial of Neoadjuvant Ipilimumab Followed by Melphalan via Isolated Limb Infusion for Patients with Unresectable In-Transit Extremity Melanoma", "open_date"=)"09-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"April", "pi_last_name"=)"Salama", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"147782013", "specific_funding_source"=)"Bristol-Myers Squibb, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01434", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALN-TTR02-004", "lead_org_po_id"=)"27710", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01434", "nct_id"=)"NCT01960348", "official_title"=)"APOLLO: A Phase 3 Multicenter, Multinational, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Patisiran (ALN-TTR02) in Transthyretin (TTR)-Mediated Polyneuropathy (Familial Amyloidotic Polyneuropathy-FAP)", "open_date"=)"26-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"148149370", "specific_funding_source"=)"Alnylam Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01442", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M12-914", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01442", "nct_id"=)"NCT02163694", "official_title"=)"A Phase 3 Randomized, Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the PARP Inhibitor Veliparib (ABT-888) in HER2 Negative Metastatic or Locally Advanced Unresectable BRCA-Associated Breast Cancer", "open_date"=)"21-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"148449851", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01443", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB18424-267", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01443", "nct_id"=)"NCT02119676", "official_title"=)"A Randomized, Double-Blind Study of Ruxolitinib or Placebo in Combination With Regorafenib in Subjects With Relapsed or Refractory Metastatic Colorectal Cancer", "open_date"=)"30-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"148451762", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01470", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1320", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1320", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01470", "nct_id"=)"NCT02196181", "official_title"=)"A Randomized Phase II Trial of Intermittent versus Continuous Dosing of Dabrafenib (NSC-763760) and Trametinib (NSC-763093) in BRAF V600E/K Mutant Melanoma", "open_date"=)"22-Jul-2014", "other_ids"=)"NCT02199730\rS1221", "other_protocol_ids"=)"S1320, NCT02199730, S1221", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Alain", "pi_last_name"=)"Algazi", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"148768613", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1316", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1316", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01497", "nct_id"=)"NCT02270450", "official_title"=)"Prospective Comparative Effectiveness Trial for Malignant Bowel Obstruction", "open_date"=)"09-Mar-2015", "other_ids"=)"SWOG/S1316", "other_protocol_ids"=)"S1316, SWOG/S1316", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Krouse", "pi_middle_initial"=)"S", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"149112389", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01507", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"E4512", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E4512", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01507", "nct_id"=)"NCT02201992", "official_title"=)"A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein", "open_date"=)"18-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"E4512", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"David", "pi_last_name"=)"Gerber", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"149348456", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01508", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A081105", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A081105", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01508", "nct_id"=)"NCT02193282", "official_title"=)"Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"18-Aug-2014", "other_ids"=)"CALGB A081105", "other_protocol_ids"=)"A081105, CALGB, A081105", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ramaswamy", "pi_last_name"=)"Govindan", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"149348877", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01526", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CP-MGD006-01", "lead_org_po_id"=)"124446", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01526", "nct_id"=)"NCT02152956", "official_title"=)"A Phase 1, First in Human, Dose Escalation Study of MGD006, a CD123 x CD3 Dual Affinity Re-Targeting (DART®) Bi-Specific Antibody Based Molecule, in Patients With Relapsed or Refractory AML or Intermediate-2/High Risk MDS", "open_date"=)"11-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"150008789", "specific_funding_source"=)"MacroGenics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01549", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TL32711-RAN-0094-PTL", "lead_org_po_id"=)"220676", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01549", "nct_id"=)"NCT02147873", "official_title"=)"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study of Azacitidine With or Without Birinapant With a Single Arm Open-Label Run-In Phase in Subjects With Higher Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia", "open_date"=)"15-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"150265234", "specific_funding_source"=)"TetraLogic Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01550", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ARRAY-520-215", "lead_org_po_id"=)"23609", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01550", "nct_id"=)"NCT02092922", "official_title"=)"A Phase 2 Trial of Filanesib in Relapsed/Refractory Multiple Myeloma (AfFIRM)", "open_date"=)"15-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"150265850", "specific_funding_source"=)"Array Biopharma Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01598", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-Jun-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D6011C00001", "lead_org_po_id"=)"34899", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01598", "nct_id"=)"NCT02087176", "official_title"=)"A Lead-in Phase II Multicentre, Randomised, Double-Blind Study Comparing AZD1775 Plus Docetaxel and Placebo Plus Docetaxel in Previously Treated Non-Small-Cell Lung Cancer Patients", "open_date"=)"22-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"150966665", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01689", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Sep-2015", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"1210013164", "lead_org_po_id"=)"170710", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01689", "nct_id"=)"NCT01799278", "official_title"=)"A Phase II Trial of the Aurora Kinase A Inhibitor MLN8237 in Patients With Metastatic Castrate Resistant and Neuroendocrine Prostate Cancer", "open_date"=)"30-Jul-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"152564286", "specific_funding_source"=)"Weill Medical College of Cornell University", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01763", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-358", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01763", "nct_id"=)"NCT02203773", "official_title"=)"A Phase 1b Study of ABT-199 (GDC-0199) in Combination With Azacitidine or Decitabine in Treatment-Naive Subjects With Acute Myelogenous Leukemia Who Are ≥ 60 Years of Age and Who Are Not Eligible for Standard Induction Therapy", "open_date"=)"23-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"155068080", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01785", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MP-001", "lead_org_po_id"=)"51968392", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01785", "nct_id"=)"NCT02160106", "official_title"=)"First-in-Human Dose-Escalation Study of TEW-7197 Monotherapy in Subjects With Advanced Stage Solid Tumors", "open_date"=)"06-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"155599090", "specific_funding_source"=)"MedPacto, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01810", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-BR002", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-BR002", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01810", "nct_id"=)"NCT02364557", "official_title"=)"A Phase IIR/III Trial of  Standard of Care Therapy with or without Stereotactic Body Radiotherapy (SBRT) and/or Surgical Ablation for Newly Oligometastatic Breast Cancer", "open_date"=)"24-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"NRG-BR002", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Steven", "pi_last_name"=)"Chmura", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"157824532", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01811", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ML28897", "lead_org_po_id"=)"87945", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01811", "nct_id"=)"NCT02091141", "official_title"=)"My Pathway: An Open-Label Phase IIa Study Evaluating Trastuzumab/Pertuzumab, Erlotinib, Vemurafenib/Cobimetinib, Vismodegib, Alectinib, and Atezolizumab in Patients Who Have Advanced Solid Tumors With Mutations or Gene Expression Abnormalities Predictive of Response to One of These Agents", "open_date"=)"12-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"158322232", "specific_funding_source"=)"Genentech Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01820", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EA1131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EA1131", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01820", "nct_id"=)"NCT02445391", "official_title"=)"A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients with Residual Triple-Negative Basal-Like Breast Cancer following Neoadjuvant Chemotherapy", "open_date"=)"29-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"EA1131", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Ingrid", "pi_last_name"=)"Mayer", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"158867277", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01844", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"21-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-312-0133", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01844", "nct_id"=)"NCT02044822", "official_title"=)"A Phase 2, Single Arm Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Rituximab in Patients With Previously Untreated Chronic Lymphocytic Leukemia With 17p Deletion", "open_date"=)"15-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"159576742", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01877", "affiliate_total"=)"26", "affiliate_total_rp"=)"26", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221304", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221304", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01877", "nct_id"=)"NCT02229539", "official_title"=)"A Phase III Placebo-Controlled, Randomized Three-Arm Study of Doxepin and a Topical Rinse in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy with or without Chemotherapy", "open_date"=)"01-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"A221304", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Robert", "pi_last_name"=)"Miller", "pi_middle_initial"=)"C", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Lip, Oral Cavity and Pharynx", "sp_id"=)"160735744", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01894", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-046", "lead_org_po_id"=)"170680", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01894", "nct_id"=)"NCT02218606", "official_title"=)"An Exploratory Randomized Phase II Multicenter Trial of Abiraterone Acetate with or without Cabazitaxel in Treatment of Metastatic Castration Resistant Prostate Cancer", "open_date"=)"19-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Susan", "pi_last_name"=)"Slovin", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"162573305", "specific_funding_source"=)"Memorial Sloan-Kettering Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01899", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"J13161", "lead_org_po_id"=)"125217", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01899", "nct_id"=)"NCT02120157", "official_title"=)"A Pediatric Blood and Marrow Transplant Consortium (PBMTC) Multi-Center Phase II Pilot Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched T Cell Replete Bone Marrow with Post-Transplantation Cyclophosphamide for Children and Young Adults with Hematologic Malignancies", "open_date"=)"18-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Heather", "pi_last_name"=)"Symons", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"162943523", "specific_funding_source"=)"Johns Hopkins University/Sidney Kimmel Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01939", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CD-ON-CAT-8015-1036", "lead_org_po_id"=)"130639", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01939", "nct_id"=)"NCT02227108", "official_title"=)"A Phase 2, Multicenter, Single-arm Study of Moxetumomab Pasudotox in Pediatric Subjects With Relapsed or Refractory Pediatric Acute Lymphoblastic Leukemia (pALL) or Lymphoblastic Lymphoma of B-cell Origin", "open_date"=)"08-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"165176224", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01940", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"04-May-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"00035055", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01940", "nct_id"=)"", "official_title"=)"Feasibility of a Couple-Based Intervention for Parents of Children with Cancer", "open_date"=)"11-Jun-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"", "sp_id"=)"165178177", "specific_funding_source"=)"National Institutes of Health Clinical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01942", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"90", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051024", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01942", "nct_id"=)"NCT02218151", "official_title"=)"Patient-Centered Home-Based Hematopoietic Stem Cell Transplantation", "open_date"=)"03-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Nelson", "pi_last_name"=)"Chao", "pi_middle_initial"=)"J", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"165179580", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01943", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"41", "center_total_rp"=)"41", "clinical_research_cat"=)"INT", "close_date"=)"10-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221303", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A221303", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01943", "nct_id"=)"NCT02349412", "official_title"=)"Randomized Study of Early Palliative Care Integrated with Standard Oncology Care versus Standard Oncology Care Alone in Patients with Incurable Lung or Non-colorectal Gastrointestinal Malignancies", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"A221303", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Temel", "pi_middle_initial"=)"G", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"165180052", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01945", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"04-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051541", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01945", "nct_id"=)"NCT02116894", "official_title"=)"Phase Ib Study of the Combination Regorafenib with PF-03446962 in Patients with Refractory Metastatic Colorectal Cancer (REGAL-1 Trial) ", "open_date"=)"19-Aug-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Herbert", "pi_last_name"=)"Hurwitz", "pi_middle_initial"=)"I", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"165181249", "specific_funding_source"=)"Pfizer, Inc., National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01948", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CAMN107A2203", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01948", "nct_id"=)"NCT01844765", "official_title"=)"A Multi-center, Open Label, Non-controlled Phase II Study to Evaluate Efficacy and Safety of Oral Nilotinib in Pediatric Patients With Newly Diagnosed Ph+ Chronic Myelogenous Leukemia (CML) in Chronic Phase (CP) or With Ph+ CML in CP or Accelerated Phase (AP) Resistant or Intolerant to Either Imatinib or Dasatinib", "open_date"=)"08-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"165216571", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01955", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-007790", "lead_org_po_id"=)"139137", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01955", "nct_id"=)"NCT01500304", "official_title"=)"Feasibility and Safety of Minimally Invasive Inguinal Lymph Node Dissection in Patients with Melanoma", "open_date"=)"01-Apr-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"James", "pi_last_name"=)"Jakub", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"165254108", "specific_funding_source"=)"Mayo Clinic", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01993", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-214", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01993", "nct_id"=)"NCT02231749", "official_title"=)"A Phase 3, Randomized, Open-Label Study of Nivolumab Combined With Ipilimumab Versus Sunitinib Monotherapy in Subjects With Previously Untreated, Advanced or Metastatic Renal Cell Carcinoma", "open_date"=)"17-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"165825224", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01999", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CBGJ398XUS04", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01999", "nct_id"=)"NCT02160041", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module 6 - BGJ398 for Patients With Tumors With FGFR Genetic Alterations", "open_date"=)"17-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"165959400", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02023", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SARC024", "lead_org_po_id"=)"138099", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02023", "nct_id"=)"NCT02048371", "official_title"=)"A Blanket Protocol to Study Oral Regorafenib in Patients With Refractory Liposarcoma, Osteogenic Sarcoma, and Ewing/Ewing-like Sarcomas", "open_date"=)"23-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"166576226", "specific_funding_source"=)"Sarcoma Alliance for Research Through Collaboration", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02047", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OX4218s", "lead_org_po_id"=)"47617319", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02047", "nct_id"=)"NCT02132468", "official_title"=)"A Ph 2 Study to Investigate the Safety and Activity of Fosbretabulin Tromethamine (CA4P) in the Treatment of Well-Differentiated, Low-to-Intermediate-Grade Unresectable, Recurrent or Metastatic PNET or GI-NET Neuroendocrine Tumors/Carcinoid With Elevated Biomarkers", "open_date"=)"06-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"166697582", "specific_funding_source"=)"Mateon Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02061", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GU001", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GU001", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02061", "nct_id"=)"NCT02316548", "official_title"=)"Randomized Phase II Trial of Postoperative Adjuvant IMRT Following Cystectomy for pT3/pT4 Urothelial Bladder Cancer", "open_date"=)"23-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"NRG-GU001", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Libni", "pi_last_name"=)"Eapen", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"166730293", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02066", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"147", "center_total_rp"=)"137", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054792", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02066", "nct_id"=)"NCT02266017", "official_title"=)"An Accessible Mobile Health Behavioral Intervention for Cancer Pain", "open_date"=)"03-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"166982497", "specific_funding_source"=)"American Cancer Society, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02093", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MM-302-02-02-03", "lead_org_po_id"=)"9346107", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02093", "nct_id"=)"NCT02213744", "official_title"=)"A Randomized, Multicenter, Open Label Study of MM-302 Plus Trastuzumab vs. Chemotherapy of Physician's Choice Plus Trastuzumab in Anthracycline Naive Patients With Locally Advanced/Metastatic HER2-Positive Breast Cancer", "open_date"=)"01-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"167248394", "specific_funding_source"=)"Merrimack Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02128", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"30-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLDK378AUS23", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02128", "nct_id"=)"NCT02186821", "official_title"=)"Modular Phase II Study to Link Targeted Therapy to Patients With Pathway Activated Tumors: Module - 7 Ceritinib (LDK378) for Patients Whose Tumors Have Aberrations in ALK or ROS1", "open_date"=)"07-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"167638558", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02143", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PNT2258-03-DLBCL", "lead_org_po_id"=)"52548814", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02143", "nct_id"=)"NCT02226965", "official_title"=)"A Phase II Study of PNT2258 in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma", "open_date"=)"24-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"168112999", "specific_funding_source"=)"Sierra Oncology, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02182", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"PBTC-043", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PBTC-043", "lead_org_po_id"=)"208502", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02182", "nct_id"=)"NCT02415153", "official_title"=)"A Phase I Trial of Pomalidomide for Children with Recurrent, Progressive, or Refractory CNS Tumors", "open_date"=)"14-Jul-2015", "other_ids"=)"CC-4047-PBTC-043\rPPBTC-043_R04PAPP01", "other_protocol_ids"=)"PBTC-043, CC-4047-PBTC-043, PPBTC-043_R04PAPP01", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Jason", "pi_last_name"=)"Fangusaro", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"168646433", "specific_funding_source"=)"Pediatric Brain Tumor Consortium", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02266", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AAML1331", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAML1331", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02266", "nct_id"=)"NCT02339740", "official_title"=)"A Phase III Study for Patients with Newly Diagnosed Acute Promyelocytic Leukemia (APL) Using Arsenic Trioxide and All-Trans Retinoic Acid", "open_date"=)"29-Jun-2015", "other_ids"=)"PAAML1331_A01PAMDREVW0", "other_protocol_ids"=)"AAML1331, PAAML1331_A01PAMDREVW0", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Matthew", "pi_last_name"=)"Kutny", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"169771226", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02300", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"18-Feb-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CO-1686-022 (TIGER-1)", "lead_org_po_id"=)"30178935", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02300", "nct_id"=)"NCT02186301", "official_title"=)"TIGER 1: A Randomized, Open-Label, Phase 2/3 Study of CO-1686 or Erlotinib as First-Line Treatment of Patients With EGFR-Mutant Advanced/Metastatic NSCLC", "open_date"=)"18-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"170298784", "specific_funding_source"=)"Clovis Oncology", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02316", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00051736", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02316", "nct_id"=)"NCT02215070", "official_title"=)"A Phase II Trial for the Prevention of Gastrointestinal Toxicity from Total Body Irradiation or High Dose Chemotherapy with Pasireotide", "open_date"=)"22-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Anthony", "pi_last_name"=)"Sung", "pi_middle_initial"=)"D", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170513635", "specific_funding_source"=)"Duke University Medical Center, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02317", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"29", "center_total_rp"=)"29", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"472", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00057512", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02317", "nct_id"=)"NCT02430467", "official_title"=)"Caregiver-Guided Pain Management in Palliative Care", "open_date"=)"27-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170514411", "specific_funding_source"=)"NIH - National Institute of Nursing Research, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02364", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"01-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-296", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02364", "nct_id"=)"NCT02251548", "official_title"=)"A Phase II Study of Ibrutinib in Combination with Fludarabine, Cyclophosphamide, and Rituximab (iFCR) in Previously Untreated, Younger Patients with Chronic Lymphocytic Leukemia", "open_date"=)"03-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Matthew", "pi_last_name"=)"Davids", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"170965178", "specific_funding_source"=)"Pharmacyclics Inc, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02380", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AEWS1221", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AEWS1221", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02380", "nct_id"=)"NCT02306161", "official_title"=)"Randomized Phase 3 Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479, NSC# 750008) to Multiagent Chemotherapy for Patients with Newly Diagnosed Metastatic Ewing Sarcoma", "open_date"=)"08-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"AEWS1221", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Steven", "pi_last_name"=)"DuBois", "pi_middle_initial"=)"G", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"171266659", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02405", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1403", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1403", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02405", "nct_id"=)"NCT02438722", "official_title"=)"A Randomized Phase II/III Trial of Afatinib plus Cetuximab versus Afatinib Alone in Treatment-Naive Patients with Advanced, EGFR Mutation Positive Non-small Cell Lung Cancer (NSCLC) (BI 1200.124)", "open_date"=)"25-Mar-2015", "other_ids"=)"BI 1200.124", "other_protocol_ids"=)"S1403, BI, 1200.124", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Sarah", "pi_last_name"=)"Goldberg", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"171640719", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02409", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"17-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011203", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011203", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02409", "nct_id"=)"NCT02311933", "official_title"=)"A Randomized Phase II Trial of Tamoxifen versus Z-Endoxifen HCL in Postmenopausal Women with Metastatic Estrogen Receptor Positive, HER2 Negative Breast Cancer", "open_date"=)"06-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"A011203", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Matthew", "pi_last_name"=)"Goetz", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"171656120", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02418", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PIN-PHO1201", "lead_org_po_id"=)"41861741", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02418", "nct_id"=)"NCT02082522", "official_title"=)"Multicenter, Open-label, Randomized, Controlled Phase III Clinical Study of the Efficacy and Safety of Photodynamic Therapy Using Porfimer Sodium for Injection as Treatment for Unresectable Advanced Perihilar Cholangiocarcinoma", "open_date"=)"21-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"171830703", "specific_funding_source"=)"Concordia Laboratories Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02420", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"03-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9673", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9673", "lead_org_po_id"=)"37888781", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02420", "nct_id"=)"NCT02314169", "official_title"=)"A Multi-Institutional Phase 2 Study of Nivolumab in Refractory Metastatic Squamous Cell Carcinoma of the Anal Canal", "open_date"=)"01-May-2015", "other_ids"=)"P9673_R03PAPPHOLD01\rNCI9673", "other_protocol_ids"=)"9673, P9673_R03PAPPHOLD01, NCI9673", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Cathy", "pi_last_name"=)"Eng", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Anus", "sp_id"=)"171839627", "specific_funding_source"=)"University of Texas MD Anderson Cancer Center LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02508", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLEE011E2301", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02508", "nct_id"=)"NCT02278120", "official_title"=)"A Phase III Randomized, Double-blind, Placebo-controlled Study of LEE011 or Placebo in Combination With Tamoxifen and Goserelin or a Non-steroidal Aromatase Inhibitor (NSAI) and Goserelin for the Treatment of Premenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer", "open_date"=)"12-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"172608877", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02541", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"13", "center_total_rp"=)"13", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00053924", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02541", "nct_id"=)"NCT02256111", "official_title"=)"EXTEND: Safety and Efficacy of Exercise Training in Men Receiving Enzalutamide in Combination with Conventional Androgen Deprivation Therapy for Hormone Naïve Prostate Cancer", "open_date"=)"26-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"173217129", "specific_funding_source"=)"National Institutes of Health Clinical Center, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02585", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WIRB Protocol: 20141932", "lead_org_po_id"=)"38724643", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02585", "nct_id"=)"NCT02301611", "official_title"=)"A Prospective, Randomized, Blinded, Placebo-controlled, Phase IIb Trial of an Autologous Tumor Lysate (TL) + Yeast Cell Wall Particles (YCWP) + Dendritic Cells (DC) Vaccine vs Unloaded YCWP + DC in Stage III and Stage IV (Resected) Melanoma to Prevent Recurrence.", "open_date"=)"19-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"173952351", "specific_funding_source"=)"Cancer Insight, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02596", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"27-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA001-030", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02596", "nct_id"=)"NCT02247349", "official_title"=)"A Phase 1/2 Multicenter Study of BMS-986012 in Subjects With Relapsed/Refractory Small Cell Lung Cancer", "open_date"=)"17-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"174039443", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02676", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1404", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1404", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02676", "nct_id"=)"NCT02506153", "official_title"=)"A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma", "open_date"=)"15-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"S1404", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Kenneth", "pi_last_name"=)"Grossmann", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"175010868", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00025", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 24360-203 / ECHO-203", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00025", "nct_id"=)"NCT02318277", "official_title"=)"A Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of Epacadostat (INCB024360) in Combination With Durvalumab (MEDI4736) in Subjects With Selected Advanced Solid Tumors (ECHO-203)", "open_date"=)"29-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"175684036", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00040", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 24360-204 / ECHO-204", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00040", "nct_id"=)"NCT02327078", "official_title"=)"A Phase 1/2 Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)", "open_date"=)"08-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"175932339", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00051", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9825", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9825", "lead_org_po_id"=)"37883561", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00051", "nct_id"=)"NCT02345265", "official_title"=)"A Phase 2 Study of Olaparib and Cediranib for the Treatment of Recurrent Ovarian Cancer", "open_date"=)"04-Dec-2015", "other_ids"=)"16-700", "other_protocol_ids"=)"9825, 16-700", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Joyce", "pi_last_name"=)"Liu", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"176071830", "specific_funding_source"=)"Dana-Farber - Harvard Cancer Center LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00054", "affiliate_total"=)"29", "affiliate_total_rp"=)"29", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EAY131", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EAY131", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00054", "nct_id"=)"NCT02465060", "official_title"=)"Molecular Analysis for Therapy Choice (MATCH)", "open_date"=)"12-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"EAY131", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Keith", "pi_last_name"=)"Flaherty", "pi_middle_initial"=)"T", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"176073250", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00060", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"26-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4193C00001", "lead_org_po_id"=)"34899", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00060", "nct_id"=)"NCT02207530", "official_title"=)"A Phase II, Multi-Center, Single-Arm, Global Study of MEDI4736 Monotherapy in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "open_date"=)"13-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"176278402", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00071", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"STML-401-0214", "lead_org_po_id"=)"48419304", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00071", "nct_id"=)"NCT02270463", "official_title"=)"A Phase 1/2 Study of SL-401 as Consolidation Therapy for Adult Patients With Adverse Risk Acute Myeloid Leukemia in First CR, and/or Evidence of Minimal Residual Disease (MRD) in First CR", "open_date"=)"25-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"176419501", "specific_funding_source"=)"Stemline Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00128", "affiliate_total"=)"5", "affiliate_total_rp"=)"5", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-BR003", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-BR003", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00128", "nct_id"=)"NCT02488967", "official_title"=)"A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin plus Cyclophosphamide Followed by Weekly Paclitaxel with or without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer", "open_date"=)"26-Jun-2015", "other_ids"=)"NRG-BR1428", "other_protocol_ids"=)"NRG-BR003, NRG-BR1428", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Vicente", "pi_last_name"=)"Valero", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"177199071", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00144", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RTA 408-C-1401", "lead_org_po_id"=)"212365", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00144", "nct_id"=)"NCT02259231", "official_title"=)"An Open-label, Multicenter, Dose-escalation, Phase 1b/2 Study of the Safety, Efficacy, Pharmacodynamics, and Pharmacokinetics of RTA 408 in Combination With Ipilimumab or Nivolumab in the Treatment of Patients With Unresectable or Metastatic Melanoma", "open_date"=)"28-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"177544193", "specific_funding_source"=)"Reata Pharmaceuticals Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"FLX925-01", "lead_org_po_id"=)"49121464", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00165", "nct_id"=)"NCT02335814", "official_title"=)"Phase 1/1b, First-in-Human, Dose-Escalation and Expansion Study of FLX925 Administered Orally to Subjects With Relapsed or Refractory Acute Myeloid Leukemia", "open_date"=)"20-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"177778755", "specific_funding_source"=)"FLX Bio, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00188", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CP-MGD007-01", "lead_org_po_id"=)"124446", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00188", "nct_id"=)"NCT02248805", "official_title"=)"A Phase 1, First-in-Human, Open Label, Dose Escalation Study of MGD007, A Humanized gpA33 x CD3 Dual-Affinity Re-Targeting (DART®) Protein in Patients With Relapsed/Refractory Metastatic Colorectal Carcinoma", "open_date"=)"03-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"178092308", "specific_funding_source"=)"MacroGenics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00200", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GO29294", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00200", "nct_id"=)"NCT02302807", "official_title"=)"A Phase III, Open-Label, Multicenter, Randomized Study to Investigate the Efficacy and Safety of Atezolizumab (Anti-PD-L1 Antibody) Compared With Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Bladder Cancer After Failure With Platinum-Containing Chemotherapy", "open_date"=)"04-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"178224194", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00230", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGI-110-04", "lead_org_po_id"=)"48735172", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00230", "nct_id"=)"NCT02348489", "official_title"=)"A Phase 3, Multicenter, Open-label, Randomized Study of SGI-110 Versus Treatment Choice (TC) in Adults With Previously Untreated Acute Myeloid Leukemia (AML) Who Are Not Considered Candidates for Intensive Remission Induction Chemotherapy", "open_date"=)"20-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"178930928", "specific_funding_source"=)"Astex Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00260", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091401", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091401", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00260", "nct_id"=)"NCT02500797", "official_title"=)"Randomized Phase II Study of Nivolumab with or without Ipilimumab in Patients with Metastatic or Unresectable Sarcoma", "open_date"=)"30-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"A091401", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Sandra", "pi_last_name"=)"D'Angelo", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"179742778", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00277", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RU241306I", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00277", "nct_id"=)"NCT02393690", "official_title"=)"Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination with Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers", "open_date"=)"04-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Alan", "pi_last_name"=)"Ho", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"180118734", "specific_funding_source"=)"Academic and Community Cancer Research United", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00282", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CC-5013-DLC-002", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00282", "nct_id"=)"NCT02285062", "official_title"=)"Phase 3 Randomized, Double-Blind, Placebo Controlled, Multicenter Study to Compare the Efficacy and Safety of Lenalidomide (CC-5013) Plus R-CHOP Chemotherapy (R2-CHOP) Versus Placebo Plus R-CHOP Chemotherapy in Subjects With Previously Untreated Activated B-cell Type Diffuse Large B-cell Lymphoma", "open_date"=)"23-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"180247299", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00284", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"APL-CP0514", "lead_org_po_id"=)"48927695", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00284", "nct_id"=)"NCT02264639", "official_title"=)"An Open Label, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of APL-2 as an Add-On to Standard of Care in Subjects With Paroxysmal Nocturnal Hemoglobinuria (PNH).", "open_date"=)"24-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"180328274", "specific_funding_source"=)"Apellis Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00285", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"08-Sep-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INO-VT-464-CL-004", "lead_org_po_id"=)"38235419", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00285", "nct_id"=)"NCT02361086", "official_title"=)"A Phase 1/2 Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Once-Daily VT-464 in Patients With Castration-Resistant Prostate Cancer", "open_date"=)"24-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"180328879", "specific_funding_source"=)"Innocrin Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00297", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"23", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"44", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053325", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00297", "nct_id"=)"NCT02303678", "official_title"=)"Phase I Single-Center, Dose Escalation Study of D2C7-IT Administered Intratumorally via Convection-Enhanced Delivery for Adult Patients with Recurrent Malignant Glioma", "open_date"=)"10-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"180470199", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00298", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"21", "center_total_rp"=)"21", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058865", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00298", "nct_id"=)"NCT02318095", "official_title"=)"Feasibility Study of Neoadjuvant Gemcitabine/Nab-Paclitaxel and Hypofractionated Image-Guided Intensity Modulated Radiotherapy in Resectable and Borderline Resectable Pancreatic Cancer", "open_date"=)"03-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Manisha", "pi_last_name"=)"Palta", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"180470823", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00320", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"22-Mar-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SARC028", "lead_org_po_id"=)"138099", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00320", "nct_id"=)"NCT02301039", "official_title"=)"SARC028: A Phase II Study of the Anti-PD1 Antibody Pembrolizumab (MK-3475) in Patients With Advanced Sarcomas", "open_date"=)"13-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"180692573", "specific_funding_source"=)"Sarcoma Alliance for Research Through Collaboration", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00323", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A061402", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A061402", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00323", "nct_id"=)"NCT02516423", "official_title"=)"Solitary Plasmacytoma of Bone: Randomized Phase III Trial to Evaluate Treatment with Adjuvant Systemic Treatment and Zoledronic Acid versus Zoledronic Acid after Definite Radiation Therapy", "open_date"=)"23-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"A061402", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Anuj", "pi_last_name"=)"Mahindra", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"180695000", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00324", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"AAML1531", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AAML1531", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00324", "nct_id"=)"NCT02521493", "official_title"=)"Risk-Stratified Therapy for Acute Myeloid Leukemia in Down Syndrome", "open_date"=)"23-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"AAML1531", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jason", "pi_last_name"=)"Berman", "pi_middle_initial"=)"N", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"180695790", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00365", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"9", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"71", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00055609", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00365", "nct_id"=)"NCT02363933", "official_title"=)"A Feasibility Study to Evaluate the Efficacy and Safety of Perampanel in Seizure Patients with Primary Glial Brain Tumors", "open_date"=)"24-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"IV", "phase_additional_qualifier_code"=)"", "phase_description"=)"IV", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"181390106", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00448", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CDX011-05", "lead_org_po_id"=)"56901", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00448", "nct_id"=)"NCT02302339", "official_title"=)"A Phase 2 Study of Glembatumumab Vedotin, an Anti-gpNMB Antibody-drug Conjugate, as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma", "open_date"=)"16-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"181894045", "specific_funding_source"=)"Celldex Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00460", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-238", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00460", "nct_id"=)"NCT02388906", "official_title"=)"A Phase 3, Randomized, Double-blind Study of Adjuvant Immunotherapy With Nivolumab Versus Ipilimumab After Complete Resection of Stage IIIb/c or Stage IV Melanoma in Subjects Who Are at High Risk for Recurrence (CheckMate 238: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 238)", "open_date"=)"10-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"182013653", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00484", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"18", "center_total_rp"=)"18", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-477", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00484", "nct_id"=)"NCT02337491", "official_title"=)"Phase II Study of Pembrolizumab (MK-3475) with and without Bevacizumab for Recurrent Glioblastoma", "open_date"=)"03-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Reardon", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"182591259", "specific_funding_source"=)"Merck and Company Inc, Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00490", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-361", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00490", "nct_id"=)"NCT02289690", "official_title"=)"A Phase 1 Dose Escalation and Phase 2 Randomized Double-Blind Study of Veliparib in Combination With Carboplatin and Etoposide as a Therapy of Treatment-Naïve Extensive Stage Disease Small Cell Lung Cancer", "open_date"=)"24-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"182610734", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00512", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"R2810-ONC-1423", "lead_org_po_id"=)"212669", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00512", "nct_id"=)"NCT02383212", "official_title"=)"A First-in-Human Study of Repeat Dosing With REGN2810, a Monoclonal, Fully Human Antibody to Programmed Death - 1 (PD-1), as Single Therapy and in Combination With Other Anti-Cancer Therapies in Patients With Advanced Malignancies", "open_date"=)"02-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"182726609", "specific_funding_source"=)"Regeneron Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00538", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Dec-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-ST-003", "lead_org_po_id"=)"47894204", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00538", "nct_id"=)"NCT02362048", "official_title"=)"A Phase 2 Proof-of-Concept Study of ACP-196 Alone and in Combination With Pembrolizumab in Subjects With Advanced or Metastatic Pancreatic Cancer", "open_date"=)"20-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"182938013", "specific_funding_source"=)"Acerta Pharma BV", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00546", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A071401", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A071401", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00546", "nct_id"=)"NCT02523014", "official_title"=)"Phase II Trial of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations", "open_date"=)"28-Aug-2015", "other_ids"=)"NCI-2015-00501", "other_protocol_ids"=)"A071401, NCI-2015-00501", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Priscilla", "pi_last_name"=)"Brastianos", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"182945798", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00547", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EA2142", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EA2142", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00547", "nct_id"=)"NCT02595424", "official_title"=)"Randomized Phase II Study of Cisplatin and Etoposide versus Temozolomide and Capecitabine in Patients with Advanced G3 Non-small Cell Gastroenteropancreatic  Neuroendocrine Carcinomas", "open_date"=)"06-Nov-2015", "other_ids"=)"NCI-2015-00505", "other_protocol_ids"=)"EA2142, NCI-2015-00505", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Eads", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"182946477", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00566", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NEOD001-CL002", "lead_org_po_id"=)"48419354", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00566", "nct_id"=)"NCT02312206", "official_title"=)"A Phase 3, Randomized, Multicenter, Double-Blind, Placebo-Controlled, 2-Arm, Efficacy and Safety Study of NEOD001 Plus Standard of Care Versus Placebo Plus Standard of Care in Subjects With Light Chain (AL) Amyloidosis", "open_date"=)"27-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"183472898", "specific_funding_source"=)"Prothena Therapeutics Ltd.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00582", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"60", "center_total_rp"=)"60", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"68", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00059469", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00582", "nct_id"=)"NCT02348710", "official_title"=)"Intervention to Increase Levels of Exercise among Breast Cancer Survivors", "open_date"=)"24-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"183780586", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00591", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"06-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PCYC-1135-CA", "lead_org_po_id"=)"50366884", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00591", "nct_id"=)"NCT02403271", "official_title"=)"A Multi-Center Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Durvalumab (MEDI4736), in Subjects With Relapsed or Refractory Solid Tumors", "open_date"=)"07-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"183928708", "specific_funding_source"=)"Pharmacyclics LLC.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00606", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GY004", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GY004", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00606", "nct_id"=)"NCT02446600", "official_title"=)"A Phase III Study Comparing Single-Agent Olaparib or the Combination of Cediranib and Olaparib to Standard Platinum-Based Chemotherapy in Women with Recurrent Platinum-Sensitive Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "open_date"=)"04-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"NRG-GY004", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Joyce", "pi_last_name"=)"Liu", "pi_middle_initial"=)"F", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"184757108", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00611", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 54828-101", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00611", "nct_id"=)"NCT02393248", "official_title"=)"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB054828 in Subjects With Advanced Malignancies", "open_date"=)"13-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"184765425", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00612", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-May-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4193C00003", "lead_org_po_id"=)"34899", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00612", "nct_id"=)"NCT02319044", "official_title"=)"A Phase II, Randomized, Open-Label, Multi-Center, Global Study of MEDI4736 Monotherapy, Tremelimumab Monotherapy, and MEDI4736 in Combination With Tremelimumab in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)", "open_date"=)"18-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"184768612", "specific_funding_source"=)"AstraZeneca Pharmaceuticals LP", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00634", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCSJ148X2201", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00634", "nct_id"=)"NCT02268526", "official_title"=)"A Multi-center, Randomized, Double-blind, Placebo Controlled, Study to Evaluate the Efficacy and Safety of CSJ148 Compared to Placebo to Prevent Human Cytomegalovirus (HCMV) Replication in Stem Cell Transplant Patients", "open_date"=)"15-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"184914450", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00651", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"4", "center_total_rp"=)"4", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GY005", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GY005", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00651", "nct_id"=)"NCT02502266", "official_title"=)"A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or -Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS)", "open_date"=)"05-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"NRG-GY005", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"Jung-min", "pi_last_name"=)"Lee", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"185067582", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00663", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-204", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00663", "nct_id"=)"NCT02320058", "official_title"=)"A Multi-Center Phase 2 Open-Label Study to Evaluate Safety and Efficacy in Subjects With Melanoma Metastatic to the Brain Treated With Nivolumab in Combination With Ipilimumab Followed by Nivolumab Monotherapy", "open_date"=)"01-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"185570719", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00710", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-360", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00710", "nct_id"=)"NCT02412371", "official_title"=)"A Phase 1 Dose Escalation and Phase 2 Randomized, Placebo-Controlled Study of the Efficacy and Tolerability of Veliparib in Combination With Paclitaxel/Carboplatin-Based Chemoradiotherapy Followed by Veliparib and Paclitaxel/Carboplatin Consolidation in Subjects With Stage III Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"30-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"186801862", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00711", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MRZ-108", "lead_org_po_id"=)"38989474", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00711", "nct_id"=)"NCT02330562", "official_title"=)"A Phase 1, Multicenter, Open-label, Dose-escalation, Combination Study of Marizomib and Bevacizumab in Bevacizumab-Naïve Subjects With WHO Grade IV Malignant Glioma Followed by a Phase 2 Studies of Single Agent Marizomib and Combination Marizomib and Bevacizumab", "open_date"=)"30-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"186802686", "specific_funding_source"=)"Triphase Research and Development I Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00733", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"20", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060174", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00733", "nct_id"=)"NCT02442583", "official_title"=)"Reducing Sedentary Behaviors among Colorectal Cancer Survivors: Cancer Survivorship Center Pilot Project", "open_date"=)"08-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"187284026", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00739", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"39", "center_total_rp"=)"39", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060925", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00739", "nct_id"=)"", "official_title"=)"Project Breathe: Smoking Cessation and Pain Management in Cancer Survivors", "open_date"=)"28-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kathryn", "pi_last_name"=)"Pollak", "pi_middle_initial"=)"I", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"187345892", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00756", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"192", "center_total_rp"=)"192", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061381", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00756", "nct_id"=)"NCT02465892", "official_title"=)"A Randomized Clinical Trial of the Pillars4Life Curriculum", "open_date"=)"21-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"187452004", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00768", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"24-Oct-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PLX108-10", "lead_org_po_id"=)"68015", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00768", "nct_id"=)"NCT02371369", "official_title"=)"A Double-blind, Randomized, Placebo-controlled Phase 3 Study of Orally Administered PLX3397 in Subjects With Pigmented Villonodular Synovitis or Giant Cell Tumor of the Tendon Sheath", "open_date"=)"07-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"187595579", "specific_funding_source"=)"Daiichi Sankyo Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00812", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"29-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"14-03-PATHOLHUM-02", "lead_org_po_id"=)"52548839", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00812", "nct_id"=)"NCT02338492", "official_title"=)"A Prospective, Multi-Center Study of the IlluminOss® Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Humerus From Metastatic Bone Disease", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"188494005", "specific_funding_source"=)"IlluminOss Medical, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00824", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MDV3100-13", "lead_org_po_id"=)"8007919", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00824", "nct_id"=)"NCT02319837", "official_title"=)"A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monotherapy, and Placebo Plus Leuprolide in Men With High-Risk Nonmetastatic Prostate Cancer Progressing After Definitive Therapy", "open_date"=)"18-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"188838257", "specific_funding_source"=)"Medivation Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00835", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-GY006", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-GY006", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00835", "nct_id"=)"NCT02466971", "official_title"=)"A Randomized Phase II Trial of Radiation Therapy and Cisplatin Alone or in Combination with Intravenous Triapine in Women with Newly Diagnosed Bulky Stage IB2, Stage II, IIIB, or IVA Cancer of the Uterine Cervix or Stage II-IVA Vaginal Cancer", "open_date"=)"15-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"NRG-GY006", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Charles", "pi_last_name"=)"Leath", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"189019265", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00855", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"16-Dec-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"UTX-IB-301", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00855", "nct_id"=)"NCT02301156", "official_title"=)"A Phase 3, Randomized, Study to Assess the Efficacy and Safety of Ublituximab in Combination With Ibrutinib Compared to Ibrutinib Alone, in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"26-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"190236491", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00856", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"19", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054740", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00856", "nct_id"=)"NCT02366728", "official_title"=)"Evaluation of Overcoming Limited Migration and Enhancing Cytomegalovirus-Specific Dendritic Cell Vaccines with Adjuvant Tetanus Pre-conditioning in Patients with Newly-Diagnosed Glioblastoma", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"190243251", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00858", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1102", "lead_org_po_id"=)"249581", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00858", "nct_id"=)"NCT02016781", "official_title"=)"A Multi-Center Biologic Assignment Trial Comparing Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients w/Intermediate-2 & High Risk Myelodysplastic Syndrome (BMT CTN #1102)", "open_date"=)"26-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"190264700", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00931", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"2215-CL-0301", "lead_org_po_id"=)"48002713", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00931", "nct_id"=)"NCT02421939", "official_title"=)"A Phase 3 Open-Label, Multicenter, Randomized Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation", "open_date"=)"12-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"191500813", "specific_funding_source"=)"Astellas Pharma Global Development, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00941", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"14-Dec-2016", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PRO00023447", "lead_org_po_id"=)"249581", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00941", "nct_id"=)"NCT02269267", "official_title"=)"The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)", "open_date"=)"03-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"191556055", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00945", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"11-Jan-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-ST-005", "lead_org_po_id"=)"47894204", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00945", "nct_id"=)"NCT02351739", "official_title"=)"Randomized Phase 2 Trial of ACP-196 and Pembrolizumab Immunotherapy Dual CHECKpoint Inhibition In Platinum Resistant Metastatic Urothelial Carcinoma (RAPID CHECK Study)", "open_date"=)"04-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"191621962", "specific_funding_source"=)"Acerta Pharma BV", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00966", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLAG525X2101C", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00966", "nct_id"=)"NCT02460224", "official_title"=)"A Phase I/II, Open Label, Multicenter Study of the Safety and Efficacy of LAG525 Single Agent and in Combination With PDR001 Administered to Patients With Advanced Malignancies", "open_date"=)"11-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"191799196", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01040", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"28-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CL-PTL-119", "lead_org_po_id"=)"14093834", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01040", "nct_id"=)"NCT02346747", "official_title"=)"A Randomized, Double-Blind, Placebo-Controlled Phase 3 Trial of Vigil Engineered Autologous Tumor Cell Immunotherapy in Subjects With Stage IIIb-IV Ovarian Cancer in Clinical Complete Response Following Surgery and Primary Chemotherapy", "open_date"=)"17-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"193106990", "specific_funding_source"=)"Gradalis Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01065", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"11097", "lead_org_po_id"=)"12389987", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01065", "nct_id"=)"NCT02504359", "official_title"=)"A Feasibility Study of Myeloablative BEAM Allogeneic Transplantation Followed by Oral Ixazomib Maintenance Therapy in Patients with Relapsed High-Risk Multiple Myeloma", "open_date"=)"20-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Emma", "pi_last_name"=)"Scott", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"193919501", "specific_funding_source"=)"OHSU Knight Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01075", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"12-Jul-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"130106", "lead_org_po_id"=)"130639", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01075", "nct_id"=)"NCT01829711", "official_title"=)"A Pivotal Multicenter Trial of Moxetumomab Pasudotox in Relapsed/ Refractory Hairy Cell Leukemia", "open_date"=)"25-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Leukemia, other", "sp_id"=)"194031348", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01086", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AP24534-14-203", "lead_org_po_id"=)"30792", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01086", "nct_id"=)"NCT02467270", "official_title"=)"A Randomized, Open-label, Phase 2 Trial of Ponatinib in Patients With Resistant Chronic Phase Chronic Myeloid Leukemia to Characterize the Efficacy and Safety of a Range of Doses", "open_date"=)"26-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"194124533", "specific_funding_source"=)"ARIAD Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01088", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-Nov-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLEE011F2301", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01088", "nct_id"=)"NCT02422615", "official_title"=)"A Randomized Double-blind, Placebo-controlled Study of Ribociclib in Combination With Fulvestrant for the Treatment of Men and Postmenopausal Women With Hormone Receptor Positive, HER2-negative, Advanced Breast Cancer Who Have Received no or Only One Line of Prior Endocrine Treatment", "open_date"=)"17-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"194128653", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01150", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AG881-C-002", "lead_org_po_id"=)"11722315", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01150", "nct_id"=)"NCT02481154", "official_title"=)"A Phase 1, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-881 in Patients With Advanced Solid Tumors, Including Gliomas, With an IDH1 and/or IDH2 Mutation", "open_date"=)"07-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"195311870", "specific_funding_source"=)"Agios Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01178", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A221405", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IBCSG 48-14/BIG 8-13", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01178", "nct_id"=)"NCT02308085", "official_title"=)"A Study Evaluating the Pregnancy Outcomes and Safety of Interrupting Endocrine Therapy for Young Women with Endocrine Responsive Breast Cancer Who Desire Pregnancy", "open_date"=)"15-Oct-2015", "other_ids"=)"Alliance A221405/IBCSG 48-14\rIBCSG 48-14\rBIG 8-13 POSITIVE", "other_protocol_ids"=)"A221405, Alliance, A221405/IBCSG, 48-14, IBCSG, 48-14, BIG, 8-13, POSITIVE", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Ann", "pi_last_name"=)"Partridge", "pi_middle_initial"=)"H", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"195585951", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01191", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060926", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01191", "nct_id"=)"", "official_title"=)"Move 2 Health: A Couple-Based Physical Activity Intervention for Cancer Survivors", "open_date"=)"26-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Porter", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"195926155", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01192", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063330", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01192", "nct_id"=)"NCT02706301", "official_title"=)"Coping Skills for Colorectal Cancer Survivors with Pain and Distress", "open_date"=)"29-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"195928314", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01209", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"131R10-001", "lead_org_po_id"=)"192780", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01209", "nct_id"=)"NCT02482441", "official_title"=)"A Phase 1a/b Dose Escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of OMP-131R10 in Advanced Solid Tumors and in Combination With FOLFIRI for Patients With Previously Treated Metastatic Colorectal Cancer", "open_date"=)"01-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"196116394", "specific_funding_source"=)"OncoMed Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01235", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019B2202", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01235", "nct_id"=)"NCT02435849", "official_title"=)"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia", "open_date"=)"20-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"196755033", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01236", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1505", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1505", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01236", "nct_id"=)"NCT02562716", "official_title"=)"A Randomized Phase II Study of Perioperative mFOLFIRINOX versus Gemcitabine/Nab-Paclitaxel as Therapy for Resectable Pancreatic Adenocarcinoma", "open_date"=)"12-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"S1505", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Davendra", "pi_last_name"=)"Sohal", "pi_middle_initial"=)"P", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"196755307", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01238", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019A2205B", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01238", "nct_id"=)"NCT02445222", "official_title"=)"Long Term Follow-Up of Patients Exposed to Lentiviral-Based CD19 Directed CAR T-Cell Therapy", "open_date"=)"08-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"196764826", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01245", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PR-30-5020-C", "lead_org_po_id"=)"25957265", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01245", "nct_id"=)"NCT02354586", "official_title"=)"A Phase 2, Open-Label, Single-Arm Study to Evaluate the Safety and Efficacy of Niraparib in Patients With Advanced, Relapsed, High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Who Have Received Three or Four Previous Chemotherapy Regimens", "open_date"=)"21-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"196963182", "specific_funding_source"=)"Tesaro Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01262", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-227", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01262", "nct_id"=)"NCT02477826", "official_title"=)"An Open-Label, Randomized Phase 3 Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum Doublet Chemotherapy Versus Platinum Doublet Chemotherapy in Subjects With Chemotherapy-Naïve Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"24-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"197353722", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01270", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9903", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"9903", "lead_org_po_id"=)"37883561", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01270", "nct_id"=)"NCT02520778", "official_title"=)"A Phase 1B Study of AZD9291 in Combination with Navitoclax in EGFR-Mutant Non-small Cell Lung Cancer following Resistance to Initial EGFR Kinase Inhibitor", "open_date"=)"31-Mar-2016", "other_ids"=)"16-714", "other_protocol_ids"=)"9903, 16-714", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Oxnard", "pi_middle_initial"=)"R", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"197711705", "specific_funding_source"=)"Dana-Farber - Harvard Cancer Center LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01298", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"03-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15677", "lead_org_po_id"=)"119479", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01298", "nct_id"=)"NCT02451943", "official_title"=)"A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial of Doxorubicin Plus Olaratumab Versus Doxorubicin Plus Placebo in Patients With Advanced or Metastatic Soft Tissue Sarcoma", "open_date"=)"18-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"197992315", "specific_funding_source"=)"Eli Lilly and Company", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01317", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"MCC-15-10994", "lead_org_po_id"=)"238148", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01317", "nct_id"=)"NCT02515110", "official_title"=)"Hypofractionated Regional Nodal Irradiation Phase 2 Clinical Trial for Women with Breast Cancer-“HeNRIetta”", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Douglas", "pi_last_name"=)"Arthur", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"198149539", "specific_funding_source"=)"Virginia Commonwealth University/Massey Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01321", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"12751", "lead_org_po_id"=)"40350", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01321", "nct_id"=)"NCT01596751", "official_title"=)"Enhancing Efficacy of Chemotherapy in Triple Negative/Basal-Like Breast Cancer by Targeting Macrophages: A Multicenter Phase Ib/II Study of PLX 3397 and Eribulin in Patients with Metastatic Breast Cancer", "open_date"=)"06-Jul-2012", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Hope", "pi_last_name"=)"Rugo", "pi_middle_initial"=)"S", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"198173420", "specific_funding_source"=)"UCSF Medical Center-Mount Zion", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01329", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA008-002", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01329", "nct_id"=)"NCT02341625", "official_title"=)"A Phase I/IIa Study of BMS-986148, a Mesothelin Directed Antibody Drug Conjugate, in Subjects With Select Advanced Solid Tumors", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"198563373", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01334", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WO29636", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01334", "nct_id"=)"NCT02450331", "official_title"=)"A Phase III, Open-Label, Multicenter, Randomized Study of Atezolizumab (Anti-PD-L1 Antibody) Versus Observation as Adjuvant Therapy in Patients With High-Risk Muscle-Invasive Urothelial Carcinoma After Surgical Resection", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"198612884", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01339", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00062343", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01339", "nct_id"=)"NCT02483871", "official_title"=)"Dose Optimization of Rosuvastatin in Early Stage and Metastatic Estrogen Receptor Positive Breast Cancer Patients on Endocrine Therapy", "open_date"=)"30-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Kimberly", "pi_last_name"=)"Blackwell", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"198805592", "specific_funding_source"=)"Susan G Komen Breast Cancer Foundation, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01362", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"31-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-331", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01362", "nct_id"=)"NCT02481830", "official_title"=)"An Open-label, Randomized, Phase 3 Study of Nivolumab or Chemotherapy in Subjects With Relapsed Small-cell Lung Cancer After Platinum-based First Line Chemotherapy (CheckMate 331: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 331)", "open_date"=)"07-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"199581279", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01461", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019C2201", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01461", "nct_id"=)"NCT02445248", "official_title"=)"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Adult Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)", "open_date"=)"15-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"201258325", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01477", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ374", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB 52793-101", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01477", "nct_id"=)"NCT02265510", "official_title"=)"A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCB052793 in Subjects With Advanced Malignancies", "open_date"=)"25-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"201735443", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01480", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Jun-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PNT2258-04-Richter's", "lead_org_po_id"=)"52548814", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01480", "nct_id"=)"NCT02378038", "official_title"=)"A Phase II Study of PNT2258 in Patients With Richter's Transformation (RT)", "open_date"=)"04-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"201843241", "specific_funding_source"=)"Sierra Oncology, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01489", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CR107170", "lead_org_po_id"=)"48659622", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01489", "nct_id"=)"NCT02426086", "official_title"=)"A Randomized, Single-Blind, Multicenter Phase 2 Study to Evaluate the Activity of 2 Dose Levels of Imetelstat in Subjects With Intermediate-2 or High-Risk Myelofibrosis (MF) Relapsed/Refractory to Janus Kinase (JAK) Inhibitor", "open_date"=)"01-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"202085317", "specific_funding_source"=)"Janssen Research & Development, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PM1183-C-004-14", "lead_org_po_id"=)"209784", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01497", "nct_id"=)"NCT02421588", "official_title"=)"Phase III Randomized Clinical Trial of Lurbinectedin (PM01183) Versus Pegylated Liposomal Doxorubicin or Topotecan in Patients With Platinum-resistant Ovarian Cancer (CORAIL Trial)", "open_date"=)"28-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"202112830", "specific_funding_source"=)"PharmaMar SA", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01563", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00059856", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01563", "nct_id"=)"NCT02478255", "official_title"=)"Longitudinal MR Imaging of Pulmonary Function in Patients Receiving Thoracic Radiation Treatment", "open_date"=)"20-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Holman", "pi_last_name"=)"McAdams", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"203268867", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01565", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00064813", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01565", "nct_id"=)"NCT02510716", "official_title"=)"Addressing Tobacco Use Disparities in Rural Older Adults through an Innovative Mobile Phone Intervention: Testing the Feasibility of the Textto4gotobacco Intervention", "open_date"=)"04-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Devon", "pi_last_name"=)"Noonan", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"", "sp_id"=)"203269813", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01596", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15-174", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01596", "nct_id"=)"NCT02489617", "official_title"=)"The Incidence of Adjacent Synchronous Ipsilateral Infiltrating Carcinoma and/or DCIS in Patients Diagnosed with Intraductal Papilloma without Atypia or Flat Epithelial Atypia by Core Needle Biopsy", "open_date"=)"08-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Faina", "pi_last_name"=)"Nakhlis", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"203997730", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01602", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GO29537", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01602", "nct_id"=)"NCT02367781", "official_title"=)"A Phase III Multicenter, Randomized, Open-Label Study Evaluating the Efficacy and Safety of Atezolizumab (MPDL3280A, Anti-PD-L1 Antibody) in Combination With Carboplatin+Nab-Paclitaxel for Chemotherapy-Naive Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer", "open_date"=)"14-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"204004236", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01623", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M13-694", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01623", "nct_id"=)"NCT02470585", "official_title"=)"A Phase 3 Placebo-Controlled Study of Carboplatin/Paclitaxel With or Without Concurrent and Continuation Maintenance Veliparib (PARP Inhibitor) in Subjects With Previously Untreated Stages III or IV High-Grade Serous Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer", "open_date"=)"01-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"204245799", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01625", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063936", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01625", "nct_id"=)"NCT02482389", "official_title"=)"A Phase II Study of Preoperative Boost Radiotherapy in Patients with Breast Cancer with Biomarker Analysis", "open_date"=)"08-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Janet", "pi_last_name"=)"Horton", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"204260214", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01655", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PTC596-ONC-001-AST", "lead_org_po_id"=)"211911", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01655", "nct_id"=)"NCT02404480", "official_title"=)"A Phase 1 Study of PTC596 in Patients With Advanced Solid Tumors", "open_date"=)"01-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"204913341", "specific_funding_source"=)"PTC Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01691", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"20-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-352-1672", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01691", "nct_id"=)"NCT02515630", "official_title"=)"A Phase 2, Open-label, Translational Biology Study of Momelotinib in Transfusion-Dependent Subjects With Primary Myelofibrosis (PMF) or Post-polycythemia Vera or Post-essential Thrombocythemia Myelofibrosis (Post-PV/ET MF)", "open_date"=)"22-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"205256336", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01744", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"9922", "dt4_program_codes"=)"", "entire_study"=)"32", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"9922", "lead_org_po_id"=)"37888474", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01744", "nct_id"=)"NCT02581930", "official_title"=)"A Phase 2 Study of Ibrutinib (PCI-32765) in Refractory Distant Metastatic Cutaneous Melanoma: Correlation of Biomarkers with Response and Resistance", "open_date"=)"17-Aug-2016", "other_ids"=)"NCI9922", "other_protocol_ids"=)"9922, NCI9922", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Stergios", "pi_last_name"=)"Moschos", "pi_middle_initial"=)"J", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"206628298", "specific_funding_source"=)"Duke University - Duke Cancer Institute LAO", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01752", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN07LT", "lead_org_po_id"=)"159558", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01752", "nct_id"=)"NCT02322320", "official_title"=)"Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN #07LT)", "open_date"=)"07-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"206909359", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01773", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063328", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01773", "nct_id"=)"NCT02574507", "official_title"=)"Behavioral Weight and Symptom Management for Breast Cancer Survivors and Their Partners", "open_date"=)"30-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"207522579", "specific_funding_source"=)"National Institutes of Health Clinical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01809", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NYMC 564", "lead_org_po_id"=)"171496", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01809", "nct_id"=)"NCT02098512", "official_title"=)"A Multicenter Pilot Study of Reduced Intensity Conditioning and Allogeneic Stem Cell Transplantation Followed by Targeted Immunotherapy in Children, Adolescents and Young Adults With Poor Risk CD30+ Hodgkin Lymphoma (HL)", "open_date"=)"19-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"208762857", "specific_funding_source"=)"New York Medical College", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01813", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1301", "lead_org_po_id"=)"159558", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01813", "nct_id"=)"NCT02345850", "official_title"=)"A Randomized, Multi-Center, Phase III Trial of Calcineurin Inhibitor-Free Interventions for Prevention of Graft-versus-Host Disease (BMT CTN #1301; Progress II)", "open_date"=)"01-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"208780248", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01829", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1302", "lead_org_po_id"=)"159558", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01829", "nct_id"=)"NCT02440464", "official_title"=)"Multicenter Phase II, Double-blind Placebo Controlled Trial of Maintenance Ixazomib After Allogeneic Hematopoietic Stem Cell Transplantation for High Risk Multiple Myeloma (BMT CTN #1302)", "open_date"=)"21-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"208939797", "specific_funding_source"=)"National Heart Lung and Blood Institute", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01840", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-451", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01840", "nct_id"=)"NCT02538666", "official_title"=)"A Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination With Ipilimumab, or Placebo as Maintenance Therapy in Subjects With Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) After Completion of Platinum-based First Line Chemotherapy (CheckMate 451: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 451)", "open_date"=)"01-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"209137889", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01850", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3475-183", "lead_org_po_id"=)"147288", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01850", "nct_id"=)"NCT02576977", "official_title"=)"A Phase III Study of Pomalidomide and Low Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Refractory or Relapsed and Refractory Multiple Myeloma (rrMM) (KEYNOTE 183)", "open_date"=)"01-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"209370456", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01856", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063848", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01856", "nct_id"=)"NCT02482376", "official_title"=)"A Phase II Preoperative Single-Fraction Partial Breast Radiotherapy in Early Stage Breast Cancer: Analysis of Pathologic Response", "open_date"=)"21-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Janet", "pi_last_name"=)"Horton", "pi_middle_initial"=)"K", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"209386860", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01857", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D6070C00001", "lead_org_po_id"=)"130639", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01857", "nct_id"=)"NCT02503774", "official_title"=)"A Phase 1 Multicenter, Open-label, Dose-escalation and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Antitumor Activity of MEDI9447 Alone and in Combination With MEDI4736 in Adult Subjects With Select Advanced Solid Tumors", "open_date"=)"01-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"209398513", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01867", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGN35-025", "lead_org_po_id"=)"219916", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01867", "nct_id"=)"NCT02572167", "official_title"=)"A Phase 1/2 Study Evaluating Brentuximab Vedotin in Combination With Nivolumab in Patients With Relapsed or Refractory Hodgkin Lymphoma After Failure of Frontline Therapy", "open_date"=)"16-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Hodgkin's Lymphoma", "sp_id"=)"209519005", "specific_funding_source"=)"Seattle Genetics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01897", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"01-May-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADXS001-06", "lead_org_po_id"=)"48659730", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01897", "nct_id"=)"NCT02399813", "official_title"=)"PHASE 2 STUDY OF ADXS11-001 IN SUBJECTS WITH PERSISTENT/RECURRENT, LOCO-REGIONAL OR METASTATIC SQUAMOUS CELL CARCINOMA OF THE ANORECTAL CANAL", "open_date"=)"01-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"209773198", "specific_funding_source"=)"Advaxis, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01916", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"EA5142", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"EA5142", "lead_org_po_id"=)"35276564", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01916", "nct_id"=)"NCT02595944", "official_title"=)"Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers", "open_date"=)"06-May-2016", "other_ids"=)"", "other_protocol_ids"=)"EA5142", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jamie", "pi_last_name"=)"Chaft", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"209916611", "specific_funding_source"=)"ECOG-ACRIN Cancer Research Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01918", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"9", "center_total_rp"=)"9", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011401", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011401", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01918", "nct_id"=)"NCT02750826", "official_title"=)"Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer", "open_date"=)"29-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"A011401", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Jennifer", "pi_last_name"=)"Ligibel", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"209917126", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01928", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADCT-301-002", "lead_org_po_id"=)"48498377", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01928", "nct_id"=)"NCT02588092", "official_title"=)"A Phase 1, Open-label, Dose-escalation, Multicenter Study to Evaluate the Tolerability, Safety, Pharmacokinetics, and Activity of ADCT 301 in Patients With Relapsed or Refractory CD25-positive Acute Myeloid Leukemia (AML) or CD25-positive Acute Lymphoblastic Leukemia", "open_date"=)"04-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"210382242", "specific_funding_source"=)"ADC Therapeutics SARL", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01929", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A091304", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A091304", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01929", "nct_id"=)"NCT02601209", "official_title"=)"A Phase I/Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib in Patients with Locally Advanced/Unresectable and/or Metastatic Sarcoma", "open_date"=)"30-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"A091304", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"William", "pi_last_name"=)"Tap", "pi_middle_initial"=)"D", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"210412565", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01930", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-ST-004", "lead_org_po_id"=)"36776822", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01930", "nct_id"=)"NCT02570711", "official_title"=)"Study of Nab Paclitaxel/Gemcitabine Alone and in Combination With ACP-196 in Subjects With Previously Untreated Metastatic Pancreatic Cancer", "open_date"=)"19-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"210532007", "specific_funding_source"=)"Acerta Pharma", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01931", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"23", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"61", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063483", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01931", "nct_id"=)"NCT02540161", "official_title"=)"Phase 2 Study of Sym004 for Adult Patients with Recurrent Glioblastoma", "open_date"=)"30-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"210543917", "specific_funding_source"=)"Symphogen A/S, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01945", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AG-221-AML-004", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01945", "nct_id"=)"NCT02577406", "official_title"=)"A Phase 3, Multicenter, Open-label, Randomized Study Comparing the Efficacy and Safety of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation", "open_date"=)"01-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"210907687", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01966", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACE-CL-006", "lead_org_po_id"=)"47894204", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01966", "nct_id"=)"NCT02477696", "official_title"=)"A Randomized, Multicenter, Open-Label, Non-Inferiority, Phase III Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Subjects With High Risk Chronic Lymphocytic Leukemia", "open_date"=)"01-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"211425205", "specific_funding_source"=)"Acerta Pharma BV", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01967", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BR31", "lead_org_po_id"=)"47305144", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01967", "nct_id"=)"NCT02273375", "official_title"=)"A Phase III Prospective Double Blind Placebo Controlled Randomized Study of Adjuvant MEDI4736 In Completely Resected Non-Small Cell Lung Cancer", "open_date"=)"02-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"211428013", "specific_funding_source"=)"Canadian Cancer Trials Group", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01971", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"39110-106", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01971", "nct_id"=)"NCT02559492", "official_title"=)"A Platform Study Exploring the Safety, Tolerability, Effect on the Tumor Microenvironment, and Efficacy of INCB Combinations in Advanced Solid Tumors", "open_date"=)"24-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"211434512", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02003", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IRB14833", "lead_org_po_id"=)"199035", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02003", "nct_id"=)"", "official_title"=)"Enhancing Patient-Provider Communication about Sexual Concerns in Breast Cancer", "open_date"=)"12-Feb-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Jenny", "pi_last_name"=)"Reese", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"211751857", "specific_funding_source"=)"American Cancer Society", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02004", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGN19A-003", "lead_org_po_id"=)"219916", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02004", "nct_id"=)"NCT02592876", "official_title"=)"A Randomized, Open-Label Phase 2 Study of Denintuzumab Mafodotin (SGN-CD19A) Plus Rituximab, Ifosfamide, Carboplatin, and Etoposide (19A+RICE) Chemotherapy vs. RICE in the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Who Are Candidates for Autologous Stem Cell Transplant", "open_date"=)"01-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"211763395", "specific_funding_source"=)"Seattle Genetics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02014", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"RU221511I", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02014", "nct_id"=)"NCT02640053", "official_title"=)"Pilot Clinical Trial Evaluating the Utility of Topical Cryotherapy to Decrease Chemotherapy-Induced Peripheral Neuropathy (CIPN) and Paclitaxel-Induced Acute Pain Syndrome (P-APS): A Randomized Controlled Trial", "open_date"=)"23-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Charles", "pi_last_name"=)"Loprinzi", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"211856741", "specific_funding_source"=)"Academic and Community Cancer Research United", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02028", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KTE-C19-102", "lead_org_po_id"=)"25983713", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02028", "nct_id"=)"NCT02601313", "official_title"=)"A Phase 2 Multicenter Study Evaluating the Efficacy of KTE-C19 in Subjects With Relapsed/Refractory Mantle Cell Lymphoma (r/r MCL) (ZUMA-2)", "open_date"=)"16-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"212178143", "specific_funding_source"=)"Kite Pharma, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02046", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"LCCC1410", "lead_org_po_id"=)"149190", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02046", "nct_id"=)"NCT02328313", "official_title"=)"Impact of Physical Activity on Biomarker of Aging and Body Composition among Breast Cancer Survivors Age 65 and Older", "open_date"=)"09-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Hyman", "pi_last_name"=)"Muss", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"212325520", "specific_funding_source"=)"Lineberger Comprehensive Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AFT-05", "lead_org_po_id"=)"43104771", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02057", "nct_id"=)"NCT02513394", "official_title"=)"PALbociclib CoLlaborative Adjuvant Study: A Randomized Phase III Trial of Palbociclib With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone for Hormone Receptor Positive (HR+) / Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Early Breast Cancer", "open_date"=)"09-Sep-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"212419111", "specific_funding_source"=)"Alliance Foundation Trials, LLC.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02074", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"21", "center_total_rp"=)"11", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00047231", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02074", "nct_id"=)"NCT02036918", "official_title"=)"Evaluation of Lymph Node Metastases in Men Undergoing Treatment with Sipuleucel-T for Metastatic Castrate-Resistant Prostate Cancer", "open_date"=)"28-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Brant", "pi_last_name"=)"Inman", "pi_middle_initial"=)"A", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"212693527", "specific_funding_source"=)"Dendreon Corporation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02086", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CDX1127-06", "lead_org_po_id"=)"56901", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02086", "nct_id"=)"NCT02543645", "official_title"=)"A Phase l/ll, Open Label, Dose-escalation Study of Varlilumab (CDX-1127) in Combination With Atezolizumab (MPDL3280A, Anti-PD-L1) in Patients With Advanced Cancer", "open_date"=)"01-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213168797", "specific_funding_source"=)"Celldex Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02087", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"18", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00064227", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02087", "nct_id"=)"NCT02611063", "official_title"=)"A Phase I Trial of Fostamatinib and Chronic Graft-vs.-Host Disease Development after Allogeneic Stem Cell Transplantation", "open_date"=)"20-Nov-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Stefanie", "pi_last_name"=)"Sarantopoulos", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213171494", "specific_funding_source"=)"Rigel Pharmaceuticals, Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02113", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00039982", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02113", "nct_id"=)"", "official_title"=)"Comparison of Power Injection versus Hand Injection of Administering Contrast Media in MR Perfusion Imaging", "open_date"=)"29-Sep-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Provenzale", "pi_middle_initial"=)"M", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"213885021", "specific_funding_source"=)"Bayer Corporation, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02115", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"25", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051412", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02115", "nct_id"=)"", "official_title"=)"Quantitative Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) of Bone Marrow in Acute Myeloid Leukemia: Correlation of Perfusion Parameters and Bone Marrow Biopsy", "open_date"=)"23-Dec-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rajan", "pi_last_name"=)"Gupta", "pi_middle_initial"=)"T", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"213891105", "specific_funding_source"=)"Bayer Corporation, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02147", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"17", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00055890", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02147", "nct_id"=)"NCT02439437", "official_title"=)"Targeted Pain Coping Skills Training (PCST) for Prevention and Treatment of Persistent Post-mastectomy Pain", "open_date"=)"13-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"214167188", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02182", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"19", "center_total_rp"=)"19", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063108", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02182", "nct_id"=)"NCT02457715", "official_title"=)"Feasibility of a Consumer Based Accelerometer in Monitoring Outpatient Physical Activity: A Study in Patients with Cancer and Amyotrophic Lateral Sclerosis", "open_date"=)"09-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214391801", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02184", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"24", "center_total_rp"=)"24", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"44", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065621", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02184", "nct_id"=)"NCT02783755", "official_title"=)"A mHealth Behavioral Cancer Pain Protocol for Medically Underserved Communities", "open_date"=)"26-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"214398265", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02187", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"20", "center_total_rp"=)"20", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065982", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02187", "nct_id"=)"", "official_title"=)"Usability Testing of a Web-Based Patient Financial Assistance Intervention", "open_date"=)"25-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Yousuf", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214403736", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02207", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"13-Jan-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15743", "lead_org_po_id"=)"35145", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02207", "nct_id"=)"NCT02610140", "official_title"=)"A Randomized, Open-label, Active-controlled, Phase II Study of Intravenous Anetumab Ravtansine (BAY 94-9343) or Vinorelbine in Patients With Advanced or Metastatic Malignant Pleural Mesothelioma Overexpressing Mesothelin and Progressed on First Line Platinum/Pemetrexed-based Chemotherapy", "open_date"=)"28-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Respiratory/Intrathoracic Organs", "sp_id"=)"215785280", "specific_funding_source"=)"Bayer Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02213", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"14", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054746", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02213", "nct_id"=)"NCT02193347", "official_title"=)"Patients with IDH1 Positive Recurrent Grade II Glioma Enrolled in a Safety and Immunogenicity Study of Tumor-Specific Peptide Vaccine", "open_date"=)"04-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"215889350", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02229", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"15702", "lead_org_po_id"=)"119479", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02229", "nct_id"=)"NCT02423343", "official_title"=)"A Phase 1b/2 Dose Escalation and Cohort Expansion Study of the Safety, Tolerability and Efficacy of a Novel Transforming Growth Factor-beta Receptor I Kinase Inhibitor (Galunisertib) Administered in Combination With Anti-PD-1 (Nivolumab) in Advanced Refractory Solid Tumors (Phase 1b) and in Recurrent or Refractory Non-small Cell Lung Cancer or Hepatocellular Carcinoma (Phase 2)", "open_date"=)"10-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"217365805", "specific_funding_source"=)"Eli Lilly and Company", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02241", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3475-177", "lead_org_po_id"=)"147288", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02241", "nct_id"=)"NCT02563002", "official_title"=)"A Phase III Study of Pembrolizumab (MK-3475) vs. Chemotherapy in Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Stage IV Colorectal Carcinoma (KEYNOTE-177)", "open_date"=)"08-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"219486596", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02250", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1507", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1507", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02250", "nct_id"=)"NCT02642042", "official_title"=)"A Phase II Trial of Trametinib with Docetaxel in Patients with KRAS Mutation Positive Non-small Cell Lung Cancer (NSCLC) and Progressive Disease following One or Two Prior Systemic Therapies", "open_date"=)"18-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"S1507", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Shirish", "pi_last_name"=)"Gadgeel", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"220242740", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02284", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PEC001", "lead_org_po_id"=)"49575854", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02284", "nct_id"=)"NCT02494570", "official_title"=)"A Phase 2 Multi-center Investigation of Efficacy of ABI-009 (Nab-rapamycin) in Patients With Advanced Malignant Perivascular Epithelioid Cell Tumors (PEComa)", "open_date"=)"29-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"222866419", "specific_funding_source"=)"Aadi, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02285", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CR107947", "lead_org_po_id"=)"48659622", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02285", "nct_id"=)"NCT02598661", "official_title"=)"A Study to Evaluate Imetelstat (JNJ-63935937) in Transfusion-Dependent Subjects With IPSS Low or Intermediate-1 Risk Myelodysplastic Syndrome (MDS) That is Relapsed/Refractory to Erythropoiesis-Stimulating Agent (ESA) Treatment", "open_date"=)"29-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"222870231", "specific_funding_source"=)"Janssen Research & Development, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00012", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IMDZ-C232", "lead_org_po_id"=)"40374374", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00012", "nct_id"=)"NCT02609984", "official_title"=)"A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1", "open_date"=)"05-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"223396241", "specific_funding_source"=)"Immune Design", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00050", "affiliate_total"=)"1", "affiliate_total_rp"=)"1", "center_total"=)"8", "center_total_rp"=)"8", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1400I", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1400I", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00050", "nct_id"=)"NCT02785952", "official_title"=)"A Phase III Randomized Study of Nivolumab plus Ipilimumab versus Nivolumab for Previously Treated Patients with Stage IV Squamous Cell Lung Cancer and no Matching Biomarker (Lung-Map Sub-Study)", "open_date"=)"18-Dec-2015", "other_ids"=)"NCT02154490", "other_protocol_ids"=)"S1400I, NCT02154490", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Vassiliki", "pi_last_name"=)"Papadimitrakopoulou", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"223987408", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00059", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"5", "center_total_rp"=)"5", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"66", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065241", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00059", "nct_id"=)"NCT02529072", "official_title"=)"AVeRT: Anti-PD-1 Monoclonal Antibody (Nivolumab) in Combination with DC Vaccines for the Treatment of Recurrent Grade III and Grade IV Brain Tumors", "open_date"=)"05-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"224917169", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00108", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"STML-401-0414", "lead_org_po_id"=)"48419304", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00108", "nct_id"=)"NCT02661022", "official_title"=)"A Phase 1/2 Open Label Study of SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma", "open_date"=)"25-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"227086938", "specific_funding_source"=)"Stemline Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00144", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-498", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00144", "nct_id"=)"NCT02617589", "official_title"=)"A Randomized Phase 3 Open Label Study of Nivolumab vs Temozolomide Each in Combination With Radiation Therapy in Newly Diagnosed Adult Subjects With Unmethylated MGMT (Tumor O-6-methylguanine DNA Methyltransferase) Glioblastoma (CheckMate 498: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 498)", "open_date"=)"15-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"227589309", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00148", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"09-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-296-1080", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00148", "nct_id"=)"NCT02545504", "official_title"=)"A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GS-5745 Combined With mFOLFOX6 as First Line Treatment in Patients With Advanced Gastric or Gastroesophageal Junction Adenocarcinoma", "open_date"=)"29-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"227604405", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00165", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"23-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADN011", "lead_org_po_id"=)"43941037", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00165", "nct_id"=)"NCT02411084", "official_title"=)"Prospective, Phase II/III, Randomized Clinical Study to Compare BEGEDINA® Versus \"Conventional Treatment\" for Treating Steroid Resistant Acute Graft-versus Host Disease", "open_date"=)"20-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"228050027", "specific_funding_source"=)"Adienne SA", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00166", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063975", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00166", "nct_id"=)"NCT02619604", "official_title"=)"A Quality Improvement Approach to the Management of Chronic Lymphocytic Leukemia", "open_date"=)"21-Jan-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Linda", "pi_last_name"=)"Sutton", "pi_middle_initial"=)"M", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"228052905", "specific_funding_source"=)"Gilead, Genentech Inc., Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00172", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-015", "lead_org_po_id"=)"24314431", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00172", "nct_id"=)"NCT02628704", "official_title"=)"Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Selinexor (KPT-330), Carfilzomib, and Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma Previously Treated With a Proteasome Inhibitor and an Immunomodulatory Drug", "open_date"=)"03-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"228191486", "specific_funding_source"=)"Karyopharm Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00173", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-568", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00173", "nct_id"=)"NCT02659059", "official_title"=)"A Study of Nivolumab in Combination With Ipilimumab (Part 1); and Nivolumab Plus Ipilimumab in Combination With Chemotherapy vs. Chemotherapy Alone (Part 2) as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)", "open_date"=)"15-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"228192257", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00207", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4190C00022", "lead_org_po_id"=)"130639", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00207", "nct_id"=)"NCT02519348", "official_title"=)"A Study of Safety, Tolerability, and Clinical Activity of MEDI4736 and Tremelimumab Administered as Monotherapy and in Combination to Subjects With Unresectable Hepatocellular Carcinoma", "open_date"=)"09-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"228945286", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00215", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"19-Jun-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SCRX001-002", "lead_org_po_id"=)"39897311", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00215", "nct_id"=)"NCT02674568", "official_title"=)"An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)", "open_date"=)"09-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"228968293", "specific_funding_source"=)"Stemcentrx", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00216", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INO-VT-464-CL-006", "lead_org_po_id"=)"38235419", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00216", "nct_id"=)"NCT02580448", "official_title"=)"A Phase 1/2 Open-Label Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Efficacy of Seviteronel in Subjects With Advanced Breast Cancer", "open_date"=)"10-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"229024132", "specific_funding_source"=)"Innocrin Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00233", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A011502", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A011502", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00233", "nct_id"=)"NCT02927249", "official_title"=)"A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial", "open_date"=)"08-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"A011502", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Wendy", "pi_last_name"=)"Chen", "pi_middle_initial"=)"Y", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"229284366", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00242", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PHP-OCM-301", "lead_org_po_id"=)"49262411", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00242", "nct_id"=)"NCT02678572", "official_title"=)"A Randomized, Controlled, Phase 3 Study to Evaluate the Efficacy, Safety and Pharmacokinetics of Melphalan/HDS Treatment in Patients With Hepatic-Dominant Ocular Melanoma", "open_date"=)"15-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Eye and Orbit", "sp_id"=)"229777667", "specific_funding_source"=)"Delcath Systems Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"05-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NEOD001-201", "lead_org_po_id"=)"48419354", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00255", "nct_id"=)"NCT02632786", "official_title"=)"A Phase 2b, Randomized, Double-blind, Placebo-controlled Study of NEOD001 in Previously Treated Subjects With Light Chain (AL) Amyloidosis Who Have Persistent Cardiac Dysfunction", "open_date"=)"07-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"229877126", "specific_funding_source"=)"Prothena Therapeutics Ltd.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00264", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1415CD", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1415CD", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00264", "nct_id"=)"NCT02728596", "official_title"=)"A Pragmatic Trial to Evaluate a Guideline-Based Colony Stimulating Factor Standing Order Intervention and to Determine the Effectiveness of Colony Stimulating Factor Use as Prophylaxis for Patients Receiving Chemotherapy with Intermediate Risk for Febrile Neutropenia-Trial Assessing CSF Prescribing Effectiveness and Risk (TrACER)", "open_date"=)"07-Oct-2016", "other_ids"=)"S1415", "other_protocol_ids"=)"S1415CD, S1415", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Ramsey", "pi_middle_initial"=)"D", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"229925660", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00288", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"BMX-HGG-001", "lead_org_po_id"=)"44564732", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00288", "nct_id"=)"NCT02655601", "official_title"=)"A Phase 1/2 Trial for Patients With Newly Diagnosed High Grade Glioma Treated With Concurrent Radiation Therapy, Temozolomide, and BMX-001", "open_date"=)"05-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"230510407", "specific_funding_source"=)"BioMimetix JV, LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00289", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"16", "center_total_rp"=)"16", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068978", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00289", "nct_id"=)"NCT02627079", "official_title"=)"ICanSTEP: Increasing Physical Activity in Cancer Survivors through a Text-messaging Exercise Motivation Program", "open_date"=)"16-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Bridget", "pi_last_name"=)"Koontz", "pi_middle_initial"=)"F", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"230513448", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00290", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CP-MGAH22-05", "lead_org_po_id"=)"124446", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00290", "nct_id"=)"NCT02689284", "official_title"=)"A Phase 1b/2, Open Label, Dose Escalation Study of Margetuximab in Combination With Pembrolizumab in Patients With Relapsed/Refractory Advanced HER2+ Gastroesophageal Junction or Gastric Cancer", "open_date"=)"23-Feb-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"230528681", "specific_funding_source"=)"MacroGenics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00327", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"07-Mar-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"3475-119", "lead_org_po_id"=)"147288", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00327", "nct_id"=)"NCT02555657", "official_title"=)"A Randomized Open-Label Phase III Study of Single Agent Pembrolizumab Versus Single Agent Chemotherapy Per Physician's Choice for Metastatic Triple Negative Breast Cancer (mTNBC) - (KEYNOTE-119)", "open_date"=)"01-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"231534417", "specific_funding_source"=)"Merck and Company Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00375", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"UTX-TGR-304", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00375", "nct_id"=)"NCT02612311", "official_title"=)"A Phase 3, Randomized Study to Assess the Efficacy and Safety of Ublituximab in Combination With TGR-1202 Compared to Obinutuzumab in Combination With Chlorambucil in Patients With Chronic Lymphocytic Leukemia (CLL)", "open_date"=)"07-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"232529362", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00391", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"Pevonedistat-2001", "lead_org_po_id"=)"138345", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00391", "nct_id"=)"NCT02610777", "official_title"=)"A Phase 2, Randomized, Controlled, Open-Label, Clinical Study of the Efficacy and Safety of Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine in Patients With Higher-Risk Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia and Low-Blast Acute Myelogenous Leukemia", "open_date"=)"10-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"232916886", "specific_funding_source"=)"Millennium Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"B7791001", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00393", "nct_id"=)"NCT02616185", "official_title"=)"A Phase 1 Study To Evaluate The Safety, Pharmacokinetics And Pharmacodynamics Of Escalating Doses Of A Vaccine-based Immunotherapy Regimen (VBIR) For Prostate Cancer (PF-06753512)", "open_date"=)"10-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"232925113", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00399", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MIP-1404-3301", "lead_org_po_id"=)"48834314", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00399", "nct_id"=)"NCT02615067", "official_title"=)"A Phase 3 Study to Evaluate the Safety and Efficacy of 99mTc-MIP-1404 SPECT/CT Imaging to Detect Clinically Significant Prostate Cancer in Men With Biopsy Proven Low-Grade Prostate Cancer Who Are Candidates for Active Surveillance (proSPECT-AS)", "open_date"=)"11-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"232997593", "specific_funding_source"=)"Molecular Insight Pharmaceuticals, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00402", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ONT-380-206", "lead_org_po_id"=)"47103596", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00402", "nct_id"=)"NCT02614794", "official_title"=)"Phase 2 Randomized, Double-Blinded, Controlled Study of Tucatinib vs Placebo in Combination With Capecitabine and Trastuzumab in Patients With Pretreated Unresectable Locally Advanced or Metastatic HER2+ Breast Carcinoma (HER2CLIMB)", "open_date"=)"11-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"233011779", "specific_funding_source"=)"Cascadian Therapeutics Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00404", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AGS-16C3F-15-3", "lead_org_po_id"=)"24584", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00404", "nct_id"=)"NCT02639182", "official_title"=)"A Multi-Center, Open Label, Randomized Phase 2 Study of AGS-16C3F vs. Axitinib in Metastatic Renal Cell Carcinoma", "open_date"=)"19-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Kidney", "sp_id"=)"233018413", "specific_funding_source"=)"Agensys", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00428", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"D4190C00023", "lead_org_po_id"=)"130639", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00428", "nct_id"=)"NCT02549651", "official_title"=)"A Phase 1b Study to Evaluate the Safety and Efficacy of MEDI4736 as Monotherapy and in Combination With Tremelimumab or AZD9150 in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma", "open_date"=)"01-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"233771416", "specific_funding_source"=)"MedImmune Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00430", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"PP LNM 01", "lead_org_po_id"=)"49831458", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00430", "nct_id"=)"NCT02209532", "official_title"=)"A Randomized, Prospective, Open Label, Multicenter Study Assessing the Safety and Utility of PINPOINT® Near Infrared Fluorescence Imaging in the Identification of Lymph Nodes in Patients With Uterine and Cervical Malignancies Who Are Undergoing Lymph Node Mapping", "open_date"=)"16-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"233791814", "specific_funding_source"=)"Novadaq Technologies Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00469", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M15-394", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00469", "nct_id"=)"NCT02565758", "official_title"=)"A Multicenter, Phase 1, Open-Label, Dose-Escalation Study of ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors", "open_date"=)"25-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"235081036", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00475", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"IMCgp100-201", "lead_org_po_id"=)"44247936", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00475", "nct_id"=)"NCT02535078", "official_title"=)"A Phase Ib/II Open-label, Multi-center Study of the Safety and Efficacy of IMCgp100 in Combination With Durvalumab (MEDI4736) or Tremelimumab or the Combination of Durvalumab and Tremelimumab in Patients With Advanced Melanoma", "open_date"=)"28-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"235460119", "specific_funding_source"=)"Immunocore Ltd", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00521", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-350-1604", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00521", "nct_id"=)"NCT02607228", "official_title"=)"A Phase 1b/2 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of GS-5829 as a Single Agent and In Combination With Enzalutamide in Subjects With Metastatic Castrate-Resistant Prostate Cancer", "open_date"=)"31-Mar-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"235902969", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00628", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GS-US-406-1840", "lead_org_po_id"=)"88127", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00628", "nct_id"=)"NCT02701634", "official_title"=)"A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Tolerability of Entospletinib, a Selective SYK Inhibitor, in Combination With Systemic Corticosteroids as First-Line Therapy in Subjects With Chronic Graft Versus Host Disease (cGVHD)", "open_date"=)"19-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"239599157", "specific_funding_source"=)"Gilead", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00634", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"48", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00069444", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00634", "nct_id"=)"NCT02664363", "official_title"=)"ExCeL: EGFRvIII Chimeric Antigen Receptor (CAR) Gene-Modified T Cells for Patients with Newly-Diagnosed GBM during Lymphopenia", "open_date"=)"20-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Annick", "pi_last_name"=)"Desjardins", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"239637197", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00719", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"350", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00070823", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00719", "nct_id"=)"NCT02791646", "official_title"=)"Optimizing Delivery of a Behavioral Cancer Pain Intervention Using a SMART", "open_date"=)"03-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"242246504", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00721", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"330", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00071993", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00721", "nct_id"=)"NCT02803593", "official_title"=)"To Enhance Breast Cancer Survivorship of Asian Americans", "open_date"=)"03-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Eun-ok", "pi_last_name"=)"Im", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"242248966", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00746", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-020", "lead_org_po_id"=)"54187152", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00746", "nct_id"=)"NCT02606461", "official_title"=)"A Phase 2-3, Multicenter, Randomized, Double-blind Study of Selinexor (KPT-330) Versus Placebo in Patients With Advanced Unresectable Dedifferentiated Liposarcoma (DDLS)", "open_date"=)"12-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II_III", "phase_additional_qualifier_code"=)"", "phase_description"=)"II/III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"242548499", "specific_funding_source"=)"Karyopharm Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00815", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CCTL019B2205J", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00815", "nct_id"=)"NCT02228096", "official_title"=)"A Phase II, Single Arm, Multicenter Trial to Determine the Efficacy and Safety of CTL019 in Pediatric Patients With Relapsed and Refractory B-cell Acute Lymphoblastic Leukemia", "open_date"=)"24-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"246031562", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00826", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057501", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00826", "nct_id"=)"NCT02452697", "official_title"=)"A Randomized Phase II Trial to Evaluate Progression-Free Survival Rates in Patients Receiving NK Cell-Enriched Donor Cell Infusions When Administered Alone or Administered with the TLR9 Agonist, DUK-CPG-001, from a 4-6/8 HLA-Matched Related or 7-8/8 HLA-Matched Donor following Reduced Intensity or Non-ablative Allogeneic Stem Cell Transplantation", "open_date"=)"17-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"David", "pi_last_name"=)"Rizzieri", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"246768598", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00827", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061309", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00827", "nct_id"=)"NCT02598427", "official_title"=)"Phase I Dose Escalation Trial of Intrathecal Pertuzumab and Trastuzumab in Patients with New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer", "open_date"=)"10-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Kimberly", "pi_last_name"=)"Blackwell", "pi_middle_initial"=)"L", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"246771317", "specific_funding_source"=)"Genentech Inc., Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00846", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"AC220-A-U302", "lead_org_po_id"=)"68015", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00846", "nct_id"=)"NCT02668653", "official_title"=)"A Phase 3, Double-Blind, Placebo-controlled Study of Quizartinib (AC220) Administered in Combination With Induction and Consolidation Chemotherapy, and Administered as Maintenance Therapy in Subjects 18 to 75 Years Old With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia", "open_date"=)"20-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"248049297", "specific_funding_source"=)"Daiichi Sankyo Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00858", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-577", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00858", "nct_id"=)"NCT02743494", "official_title"=)"A Randomized, Multicenter, Double Blind, Phase III Study of Adjuvant Nivolumab or Placebo in Subjects With Resected Esophageal, or Gastroesophageal Junction Cancer", "open_date"=)"22-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"248332961", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00875", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-602", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00875", "nct_id"=)"NCT02726581", "official_title"=)"An Open-Label, Randomized Phase 3 Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma- CheckMate 602: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 602", "open_date"=)"07-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"249497417", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00952", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209-548", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00952", "nct_id"=)"NCT02667587", "official_title"=)"A Randomized Phase 2 Single Blind Study of Temozolomide Plus Radiation Therapy Combined With Nivolumab or Placebo in Newly Diagnosed Adult Subjects With MGMT-Methylated (Tumor O6-methylguanine DNA Methyltransferase) Glioblastoma - CheckMate 548: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 548", "open_date"=)"17-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"251100010", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00975", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"230", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073234", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00975", "nct_id"=)"NCT02970344", "official_title"=)"Improving Health Engagement and Lifestyle Management for Breast Cancer Survivors with Diabetes", "open_date"=)"16-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"251718483", "specific_funding_source"=)"American Cancer Society, Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00996", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"NATIONAL", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"BMTCTN1501", "lead_org_po_id"=)"249581", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00996", "nct_id"=)"NCT02806947", "official_title"=)"A Randomized, Phase II, Multicenter, Open Label, Study Evaluating Sirolimus and Prednisone in Patients With Refined Minnesota Standard Risk, Ann Arbor 1/2 Confirmed Acute Graft-Versus-Host Disease (BMT CTN #1501)", "open_date"=)"09-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"251854038", "specific_funding_source"=)"Wisconsin Clinical Cancer Center", "study_source"=)"N", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01013", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"74", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00062304", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01013", "nct_id"=)"NCT02757326", "official_title"=)"A Phase Ib/II Safety and Efficacy Study of ABC294640 in Patients with Refractory or Relapsed Multiple Myeloma Who Have Previously Been Treated with Proteasome Inhibitors and Immunomodulatory Drugs", "open_date"=)"23-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"Yubin", "pi_last_name"=)"Kang", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"252470268", "specific_funding_source"=)"Apogee Biotechnology Corporation, Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WO29635", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01018", "nct_id"=)"NCT02792192", "official_title"=)"A PHASE Ib/II, OPEN-LABEL STUDY OF THE SAFETY AND PHARMACOLOGY OF ATEZOLIZUMAB ADMINISTERED WITH OR WITHOUT BACILLE CALMETTE-GUÉRIN IN PATIENTS WITH HIGH-RISK NON-MUSCLE-INVASIVE BLADDER CANCER", "open_date"=)"28-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Urinary Bladder", "sp_id"=)"252579251", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01055", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"95", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068753", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01055", "nct_id"=)"", "official_title"=)"Improved Ultrasound Imaging Using Elevated Acoustic Output", "open_date"=)"30-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Clare", "pi_last_name"=)"Haystead", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"253520093", "specific_funding_source"=)"National Institutes of Health, National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01056", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"220", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068979", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01056", "nct_id"=)"NCT02895841", "official_title"=)"Patient-Empowered Mobile Technology in Hospitalized Patients with Pain", "open_date"=)"30-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nirmish", "pi_last_name"=)"Shah", "pi_middle_initial"=)"R", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"253522879", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01115", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"KCP-330-017", "lead_org_po_id"=)"54187152", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01115", "nct_id"=)"NCT02343042", "official_title"=)"A Phase 1b/2 Study of Selinexor (KPT-330) in Combination With Backbone Treatments for Relapsed/Refractory Multiple Myeloma", "open_date"=)"14-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I_II", "phase_additional_qualifier_code"=)"", "phase_description"=)"I/II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"255859868", "specific_funding_source"=)"Karyopharm Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01139", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068544", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01139", "nct_id"=)"NCT02728830", "official_title"=)"A Pilot Study Investigating the Effect of Pembrolizumab on the Tumoral Immunoprofile of Gynecologic Cancers of Mullerian Origin", "open_date"=)"18-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"O", "phase_additional_qualifier_code"=)"", "phase_description"=)"Early Phase I", "pi_first_name"=)"Angeles", "pi_last_name"=)"Secord", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"257138885", "specific_funding_source"=)"Merck and Company Inc, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01140", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"7", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072023", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01140", "nct_id"=)"NCT02787993", "official_title"=)"Feasibility and Acceptability of a Behavioral Symptom Management Program for Patients with Advanced Breast Cancer in Singapore and the US", "open_date"=)"08-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Tamara", "pi_last_name"=)"Somers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"257140660", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01154", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SY-1425-201", "lead_org_po_id"=)"30282652", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01154", "nct_id"=)"NCT02807558", "official_title"=)"A Biomarker-Directed Phase 2 Trial of SY-1425, a Selective Retinoic Acid Receptor Alpha Agonist, in Adult Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)", "open_date"=)"16-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"258264622", "specific_funding_source"=)"Syros Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"OT-15-001", "lead_org_po_id"=)"30981925", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01159", "nct_id"=)"NCT02796261", "official_title"=)"A Randomized Phase 3 Open-Label Study To Evaluate the Efficacy and Safety of Eflornithine With Lomustine Compared to Lomustine Alone in Patients With AA That Progress/Recur After Irradiation and Adjuvant Temozolomide Chemotherapy", "open_date"=)"20-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"258372775", "specific_funding_source"=)"Orbus Therapeutics, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01161", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"TGR-1202-201-CLL", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01161", "nct_id"=)"NCT02742090", "official_title"=)"A Phase 2 Study to Assess the Safety and Efficacy of TGR-1202 in Patients With Chronic Lymphocytic Leukemia (CLL) Who Are Intolerant to Prior BTK (Bruton Tyrosine Kinase) or PI3K-Delta (Phosphoinositide-3-kinase) Inhibitor Therapy", "open_date"=)"26-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"258390238", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01176", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"10", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00071159", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01176", "nct_id"=)"NCT02722395", "official_title"=)"Magnetic Resonance Imaging (MRI) Solely for Liver Stereotactic Body Radiation Therapy (SBRT)", "open_date"=)"27-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Brian", "pi_last_name"=)"Czito", "pi_middle_initial"=)"G", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Liver", "sp_id"=)"258685207", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01186", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ICT8", "lead_org_po_id"=)"48074332", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01186", "nct_id"=)"NCT02802267", "official_title"=)"Efficacy Study of Inecalcitol in Combination With Decitabine in Acute Myeloid Leukemia Patients Unfit for Standard Chemotherapy", "open_date"=)"29-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"259098865", "specific_funding_source"=)"Hybrigenics Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01219", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ONO-4538-24/CA209-473", "lead_org_po_id"=)"192810", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01219", "nct_id"=)"NCT02569242", "official_title"=)"ONO-4538 Phase III Study A Multicenter, Randomized, Open-label Study in Patients With Unresectable Advanced or Recurrent Esophageal Cancer", "open_date"=)"03-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Esophagus", "sp_id"=)"260699013", "specific_funding_source"=)"Ono Pharmaceutical Company Limited", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01245", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"24", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00066964", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01245", "nct_id"=)"NCT02687009", "official_title"=)"A Phase I Study of Niclosamide in Patients with Resectable Colon Cancer", "open_date"=)"05-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Michael", "pi_last_name"=)"Morse", "pi_middle_initial"=)"A", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"261451579", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01255", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"UTX-TGR-204", "lead_org_po_id"=)"31042847", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01255", "nct_id"=)"NCT02656303", "official_title"=)"A Multi-Center, Open-Label, Study to Evaluate the Safety and Efficacy of Ublituximab (TG-1101) in Combination With TGR-1202 for Patients Previously Enrolled in Protocol UTX-TGR-304", "open_date"=)"10-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lymphoid Leukemia", "sp_id"=)"261588244", "specific_funding_source"=)"TG Therapeutics Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01309", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CNTX-CX-01-2015-AML-1", "lead_org_po_id"=)"48723391", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01309", "nct_id"=)"NCT02873338", "official_title"=)"A Randomized, Phase II Study of CX-01 Combined With Standard Induction Therapy for Newly Diagnosed Acute Myeloid Leukemia", "open_date"=)"23-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"263192301", "specific_funding_source"=)"Cantex Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01313", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"WP29945", "lead_org_po_id"=)"90971", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01313", "nct_id"=)"NCT02650713", "official_title"=)"An Open-Label, Multicenter, Dose Escalation and Expansion Phase Ib Study to Evaluate the Safety, Pharmacokinetics, and Therapeutic Activity of RO6958688 in Combination With Atezolizumab in Patients With Locally Advanced and/or Metastatic CEA-Positive Solid Tumors", "open_date"=)"24-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"263255862", "specific_funding_source"=)"Hoffmann-La Roche", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01320", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"3", "center_total_rp"=)"3", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"250", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00070790", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01320", "nct_id"=)"NCT02944344", "official_title"=)"The Four Conversations RCT", "open_date"=)"18-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"263361738", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01391", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"26", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00060068", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01391", "nct_id"=)"NCT02757248", "official_title"=)"A Phase 1 Trial of Volasertib plus Romidepsin in Patients with Relapsed/Refractory Peripheral T Cell and Cutaneous T Cell Lymphoma", "open_date"=)"29-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Anne", "pi_last_name"=)"Beaven", "pi_middle_initial"=)"W", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Non-Hodgkin's Lymphoma", "sp_id"=)"265251523", "specific_funding_source"=)"National Comprehensive Cancer Network, Boehringer Ingelheim Pharmaceuticals Inc, National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01392", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068908", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01392", "nct_id"=)"NCT02817607", "official_title"=)"Pilot Study to Assess Breast Sensation before and after Breast Cancer Treatment", "open_date"=)"31-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Scott", "pi_last_name"=)"Hollenbeck", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"265255472", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01425", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075558", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01425", "nct_id"=)"", "official_title"=)"The Concepts of Progression Free Survival and Maintenance Therapies in Shared Decision Making for Ovarian Cancer: An Assessment of Patients’ Understanding and Preferences", "open_date"=)"13-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Havrilesky", "pi_middle_initial"=)"J", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"267302739", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01447", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CLBH589DUS106", "lead_org_po_id"=)"170150", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01447", "nct_id"=)"NCT02720510", "official_title"=)"A Randomized, Phase II Trial Evaluating the Efficacy and Safety of Lenalidomide, Bortezomib and Dexamethasone (RVD) With or Without Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma", "open_date"=)"21-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"267595029", "specific_funding_source"=)"Novartis Pharmaceuticals Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01493", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ325", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"C0591001", "lead_org_po_id"=)"41749415", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01493", "nct_id"=)"NCT02764151", "official_title"=)"A Phase 1 Dose Escalation Study Evaluating The Safety And Tolerability Of Pf-06840003 In Patients With Malignant Gliomas", "open_date"=)"13-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"269880528", "specific_funding_source"=)"Pfizer", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01498", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"1000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075411", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01498", "nct_id"=)"NCT02986152", "official_title"=)"Cancer Distress Coach RCT", "open_date"=)"29-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Sophia", "pi_last_name"=)"Smith", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"270182806", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01518", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"GC P#05.01.020", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01518", "nct_id"=)"NCT02730299", "official_title"=)"A Multicenter, Randomized, Phase III Registration Trial of Transplantation of NiCord®, Ex Vivo Expanded, UCB-derived, Stem and Progenitor Cells, vs. Unmanipulated UCB for Patients With Hematological Malignancies", "open_date"=)"14-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"271172718", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01530", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"SGI-110-07", "lead_org_po_id"=)"48735172", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01530", "nct_id"=)"NCT02907359", "official_title"=)"A Phase 3, Multicenter, Randomized, Open-Label Study of Guadecitabine (SGI-110) Versus Treatment Choice in Adults With Myelodysplastic Syndromes (MDS) or Chronic Myelomonocytic Leukemia (CMML) Previously Treated With Hypomethylating Agents", "open_date"=)"30-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"271206822", "specific_funding_source"=)"Astex Pharmaceuticals", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01556", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075612", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01556", "nct_id"=)"NCT02922790", "official_title"=)"Feasibility and Smokers' Reactions to DNA Feedback", "open_date"=)"12-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"272278117", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01668", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"E7080-M000-213", "lead_org_po_id"=)"68715", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01668", "nct_id"=)"NCT02657369", "official_title"=)"An Open-Label, Single-Arm, Multicenter, Phase 2 Trial of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer (ATC)", "open_date"=)"01-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Thyroid", "sp_id"=)"274893186", "specific_funding_source"=)"Eisai Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01711", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"480", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068595", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01711", "nct_id"=)"NCT02707471", "official_title"=)"Improving Well-being for Breast Cancer Patients Taking Adjuvant Endocrine Therapy", "open_date"=)"24-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Rebecca", "pi_last_name"=)"Shelby", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Breast - Female", "sp_id"=)"276078326", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01712", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075906", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01712", "nct_id"=)"", "official_title"=)"Usability Testing of a Web-Based Tool to Prepare Patients for Palliative Care", "open_date"=)"03-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Arif", "pi_last_name"=)"Kamal", "pi_middle_initial"=)"H", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"276079781", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01807", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"M14-031", "lead_org_po_id"=)"25971641", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01807", "nct_id"=)"NCT02755597", "official_title"=)"A Phase 3, Multicenter, Randomized, Double Blind Study of Bortezomib and Dexamethasone in Combination With Either Venetoclax or Placebo in Subjects With Relapsed or Refractory Multiple Myeloma Who Are Sensitive or Naïve to Proteasome Inhibitors", "open_date"=)"18-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple Myeloma", "sp_id"=)"277422447", "specific_funding_source"=)"Abbvie", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01936", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"40", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075429", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01936", "nct_id"=)"NCT02886572", "official_title"=)"Outcome in Patients with 4 or More Brain Metastases Treated with Single-Isocenter, Multi-target (SIMT) Stereotactic Radiosurgery: A Prospective Single-Arm Study in Adults with Brain Metastases", "open_date"=)"22-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Grace", "pi_last_name"=)"Kim", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"280901219", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01968", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00074542", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01968", "nct_id"=)"NCT02987881", "official_title"=)"Physical Activity and Nutrition Counseling Intervention in Endometrial Cancer Survivors", "open_date"=)"08-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Angeles", "pi_last_name"=)"Secord", "pi_middle_initial"=)"A", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Corpus Uteri", "sp_id"=)"281316761", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-02026", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"16-439", "lead_org_po_id"=)"3456936", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-02026", "nct_id"=)"NCT02975869", "official_title"=)"Randomized Trial of a Collaborative Palliative and Oncology Care Model for Patients with Acute Myeloid Leukemia", "open_date"=)"15-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Areej", "pi_last_name"=)"El-Jawahri", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"282590424", "specific_funding_source"=)"Dana-Farber Harvard Cancer Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-02048", "affiliate_total"=)"3", "affiliate_total_rp"=)"2", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"RU011201I", "lead_org_po_id"=)"23611857", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-02048", "nct_id"=)"NCT02037529", "official_title"=)"A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast Cancer", "open_date"=)"17-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"III", "phase_additional_qualifier_code"=)"", "phase_description"=)"III", "pi_first_name"=)"Minetta", "pi_last_name"=)"Liu", "pi_middle_initial"=)"C", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"282838394", "specific_funding_source"=)"Academic and Community Cancer Research United", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00018", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ373", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"MEDI4736-MDS-001", "lead_org_po_id"=)"48385871", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00018", "nct_id"=)"NCT02775903", "official_title"=)"A Randomized, Multicenter, Open-label, Phase 2 Study Evaluating the Efficacy and Safety of Azacitidine Subcutaneous in Combination With Durvalumab (MEDI4736) in Previously Untreated Subjects With Higher-Risk Myelodysplastic Syndromes (MDS) or in Elderly ()= 65 Years) Acute Myeloid Leukemia (AML) Subjects Not Eligible for Hematopoietic Stem Cell Transplantation (HSCT)", "open_date"=)"05-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"284114009", "specific_funding_source"=)"Celgene", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00062", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"600", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072077", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00062", "nct_id"=)"NCT02501265", "official_title"=)"Randomized-Controlled Smoking Cessation Trial on Varenicline vs. Varenicline-Based Adaptive Pharmacotherapy with Cross-Randomization to High vs. Low Intensity Behavioral Therapy", "open_date"=)"05-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Davis", "pi_middle_initial"=)"", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"284754141", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00093", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"32", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00071629", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00093", "nct_id"=)"NCT02818920", "official_title"=)"Pembrolizumab Prior to Surgery for Stage 1B, 2, or 3A Non-small Cell Lung Cancer (NSCLC): A Phase II Study", "open_date"=)"09-Jan-2017", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"II", "phase_additional_qualifier_code"=)"", "phase_description"=)"II", "pi_first_name"=)"Neal", "pi_last_name"=)"Ready", "pi_middle_initial"=)"E", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"286179528", "specific_funding_source"=)"Merck and Company Inc, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"760", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057568", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00159", "nct_id"=)"NCT02483832", "official_title"=)"Effects of Message Framing and Risk Feedback on CRC Screening", "open_date"=)"03-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Isaac", "pi_last_name"=)"Lipkus", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"", "sp_id"=)"288511692", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00168", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"115", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00063791", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00168", "nct_id"=)"NCT02613689", "official_title"=)"Addressing Tobacco Use Disparities through an Innovative Mobile Phone Intervention: The Text to Forgo Smokeless Tobacco", "open_date"=)"13-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Devon", "pi_last_name"=)"Noonan", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"288524825", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00214", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ170", "entire_study"=)"200", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00052865", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00214", "nct_id"=)"NCT02477124", "official_title"=)"A See and Treat Paradigm for Cervical Pre-cancer", "open_date"=)"22-Jan-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nimmi", "pi_last_name"=)"Ramanujam", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Cervix", "sp_id"=)"289602898", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-00566", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"45", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00034208", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-00566", "nct_id"=)"NCT02864368", "official_title"=)"PERFORMANCE: Peptide Targets for Glioblastoma against Novel Cytomegalovirus Antigens", "open_date"=)"21-Mar-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"I", "phase_additional_qualifier_code"=)"", "phase_description"=)"I", "pi_first_name"=)"Dina", "pi_last_name"=)"Randazzo", "pi_middle_initial"=)"M", "primary_purpose"=)"Tre", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"297448100", "specific_funding_source"=)"American Brain Tumor Association, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2017-01099", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"INT", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"1000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00077090", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2017-01099", "nct_id"=)"", "official_title"=)"Nurse-Led Parent Educational Discharge Support Strategies (PEDSS) for Children Newly Diagnosed with Cancer", "open_date"=)"31-Oct-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Cheryl", "pi_last_name"=)"Rodgers", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"311960488", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00331", "affiliate_total"=)"270", "affiliate_total_rp"=)"58", "center_total"=)"245", "center_total_rp"=)"19", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ACCRN07", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ACCRN07", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00331", "nct_id"=)"NCT01117168", "official_title"=)"Protocol for the Enrollment on the Official COG Registry, The Childhood Cancer Research Network (CCRN)", "open_date"=)"24-Dec-2007", "other_ids"=)"CDR0000069496", "other_protocol_ids"=)"ACCRN07, CDR0000069496", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Julie", "pi_last_name"=)"Ross", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"249603", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00382", "affiliate_total"=)"5", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE05N1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE05N1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00382", "nct_id"=)"NCT00736749", "official_title"=)"Umbrella Long-Term Follow-Up Protocol", "open_date"=)"19-May-2008", "other_ids"=)"CDR0000590123\rPALTE05N1_A06PAMDREVW01", "other_protocol_ids"=)"ALTE05N1, CDR0000590123, PALTE05N1_A06PAMDREVW01", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Smita", "pi_last_name"=)"Bhatia", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74446915", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2009-00383", "affiliate_total"=)"1", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"ALTE07C1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ALTE07C1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2009-00383", "nct_id"=)"NCT00772200", "official_title"=)"Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children with Cancer", "open_date"=)"15-Sep-2008", "other_ids"=)"CDR0000594326\rCOG-ALTE07C1", "other_protocol_ids"=)"ALTE07C1, CDR0000594326, COG-ALTE07C1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leanne", "pi_last_name"=)"Embry", "pi_middle_initial"=)"M", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"74447321", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2011-02878", "affiliate_total"=)"4", "affiliate_total_rp"=)"4", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"28-Apr-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"URCC-10055", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"URCC10055", "lead_org_po_id"=)"35608105", "local_site_identifier"=)"", "nci_id"=)"NCI-2011-02878", "nct_id"=)"NCT01382082", "official_title"=)"Assessment of Cognitive Function in Breast Cancer and Lymphoma Patients Receiving Chemotherapy at Pre-treatment, Post-treatment, and at Six Month Follow-up", "open_date"=)"17-May-2011", "other_ids"=)"10055\rCDR0000697582\rURCC 10055", "other_protocol_ids"=)"URCC-10055, 10055, CDR0000697582, URCC, 10055", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Michelle", "pi_last_name"=)"Janelsins", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"74999368", "specific_funding_source"=)"University of Rochester NCORP Research Base", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2013-01804", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"48", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"500", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00041936", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2013-01804", "nct_id"=)"NCT01904175", "official_title"=)"REGISTRY STUDY OF T CELL DEPLETED ALLOGENEIC REDUCED INTENSITY STEM CELL TRANSPLANT RECIPIENTS", "open_date"=)"23-Jul-2013", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"David", "pi_last_name"=)"Rizzieri", "pi_middle_initial"=)"A", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Unknown Sites", "sp_id"=)"123195813", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-00502", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"13", "clinical_research_cat"=)"OBS", "close_date"=)"04-Aug-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"20", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050297", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-00502", "nct_id"=)"NCT02040155", "official_title"=)"Real Time In-Vivo Dosimetry for Gynecologic Brachytherapy", "open_date"=)"22-Jan-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"136468753", "specific_funding_source"=)"Wallace H Coulter Foundation", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01376", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"6", "center_total_rp"=)"6", "clinical_research_cat"=)"OBS", "close_date"=)"02-Nov-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"NRG-CC002", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"NRG-CC002", "lead_org_po_id"=)"35274463", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01376", "nct_id"=)"NCT02315469", "official_title"=)"Pre-operative Assessment and Post-Operative Outcomes of Elderly Women with Gynecologic Cancers", "open_date"=)"10-Feb-2015", "other_ids"=)"GOG-ELD1301", "other_protocol_ids"=)"NRG-CC002, GOG-ELD1301", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Amina", "pi_last_name"=)"Ahmed", "pi_middle_initial"=)"", "primary_purpose"=)"Pre", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"147511926", "specific_funding_source"=)"NRG Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-01509", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"A151216", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"A151216", "lead_org_po_id"=)"35276867", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-01509", "nct_id"=)"NCT02194738", "official_title"=)"Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)", "open_date"=)"18-Aug-2014", "other_ids"=)"NCT02200497", "other_protocol_ids"=)"A151216, NCT02200497", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Geoffrey", "pi_last_name"=)"Oxnard", "pi_middle_initial"=)"R", "primary_purpose"=)"Bas", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"149349354", "specific_funding_source"=)"Alliance for Clinical Trials in Oncology", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02057", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"27", "center_total_rp"=)"27", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"APEC14B1", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"APEC14B1", "lead_org_po_id"=)"60948", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02057", "nct_id"=)"NCT02402244", "official_title"=)"The Project: Every Child Protocol: A Registry, Eligibility Screening, Biology and Outcome Study", "open_date"=)"26-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"APEC14B1", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Peter", "pi_last_name"=)"Adamson", "pi_middle_initial"=)"C", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"166725062", "specific_funding_source"=)"Childrens Oncology Group", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2014-02344", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"EXTERNALLY_PEER_REVIEWED", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"10-CBA", "lead_org_po_id"=)"57642", "local_site_identifier"=)"", "nci_id"=)"NCI-2014-02344", "nct_id"=)"NCT01351545", "official_title"=)"A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) for Transplantation in Pediatric and Adult Patients With Hematologic Malignancies and Other Indications", "open_date"=)"10-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"170803013", "specific_funding_source"=)"Center for International Blood and Marrow Transplant Research", "study_source"=)"E", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-00581", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"15", "center_total_rp"=)"15", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"36", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058229", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-00581", "nct_id"=)"NCT02353715", "official_title"=)"A Pilot Study PEAX: Men with Metastatic Castrate-Resistant Prostate Cancer Treated with Either Sipuleucel-T (Provenge®), Enzalutamide (Xtandi®), or Abiraterone Acetate (Zytiga®) Undergoing Cardiopulmonary Exercise Testing", "open_date"=)"19-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"183777145", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01479", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"18-Aug-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"INCB-MA-PV-401", "lead_org_po_id"=)"109566", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01479", "nct_id"=)"NCT02252159", "official_title"=)"Prospective, Non-interventional Study of Disease Progression and Treatment of Patients With Polycythemia Vera in United States Academic or Community Clinical Practices", "open_date"=)"25-Aug-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Other Hematopoietic", "sp_id"=)"201738834", "specific_funding_source"=)"Incyte Corporation", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01666", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"ADU-CL-03", "lead_org_po_id"=)"25463513", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01666", "nct_id"=)"", "official_title"=)"Long-Term Follow-Up of Subjects Who Have Participated in Aduro-Sponsored Protocols", "open_date"=)"", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"205006485", "specific_funding_source"=)"Aduro BioTech Inc", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-01885", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"S1417CD", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"S1417CD", "lead_org_po_id"=)"220068", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-01885", "nct_id"=)"NCT02728804", "official_title"=)"Implementation of a Prospective Financial Impact Assessment Tool in Patients with Metastatic Colorectal Cancer", "open_date"=)"05-May-2016", "other_ids"=)"S1417", "other_protocol_ids"=)"S1417CD, S1417", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Veena", "pi_last_name"=)"Shankaran", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"209690737", "specific_funding_source"=)"SWOG", "study_source"=)"N", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02071", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"100", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"Y", "islead"=)"True", "lead_org_id"=)"Pro00044852", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02071", "nct_id"=)"NCT02080897", "official_title"=)"Evaluating Quality of Life in Patients with Soft Tissue Sarcoma Presenting with Metastatic Lung Disease Using the ESAS-Sarcoma Modified Questionnaire ", "open_date"=)"10-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"William", "pi_last_name"=)"Eward", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Soft Tissue / Sarcoma", "sp_id"=)"212688735", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02073", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"144", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00050174", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02073", "nct_id"=)"", "official_title"=)"Using Community Based Participatory Research (CBPR) to Understand Access to Cancer Care and Research FOCUS GROUP", "open_date"=)"10-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Nadine", "pi_last_name"=)"Barrett", "pi_middle_initial"=)"", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212691955", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02078", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"23", "center_total_rp"=)"10", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051203", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02078", "nct_id"=)"NCT02099526", "official_title"=)"Needs of Older Caregivers of Adults with Cancer In the First 2 Weeks following Hospital Discharge", "open_date"=)"03-Apr-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Cristina", "pi_last_name"=)"Hendrix", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212697130", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02079", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"1500", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00051666", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02079", "nct_id"=)"", "official_title"=)"Survey of Adult Cancer Survivors Needs and Interests in Survivorship Services", "open_date"=)"19-May-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Denise", "pi_last_name"=)"Spector", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"212697513", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02083", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"31", "center_total_rp"=)"2", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"35", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053557", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02083", "nct_id"=)"", "official_title"=)"Hippocampal Volume as an Anatomic Correlate of Survivorship in Patients with Low Grade Glioma: Repeatability and Relationship to Cognitive Dysfunction, Exercise Behavior, and Functional Capacity", "open_date"=)"12-Jun-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Katherine", "pi_last_name"=)"Peters", "pi_middle_initial"=)"B", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"212700684", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02096", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"GC P# 04.01.020/030", "lead_org_po_id"=)"10251865", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02096", "nct_id"=)"NCT02039557", "official_title"=)"Long Term Follow Up for Patients Who Have Received Allogeneic Stem Cell Transplantation of NiCord®, Umbilical Cord Blood-derived Ex Vivo Expanded Stem and Progenitor Cells", "open_date"=)"01-Mar-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213291746", "specific_funding_source"=)"Gamida Cell", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02119", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"14", "center_total_rp"=)"14", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"64", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00053989", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02119", "nct_id"=)"NCT02150369", "official_title"=)"Investigating Cognitive/Affective/Sleep Symptoms during High-Dose Interleukin-2 Therapy", "open_date"=)"03-Oct-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Robin", "pi_last_name"=)"Knobel", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"213900771", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02124", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"59", "center_total_rp"=)"59", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"150", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00054663", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02124", "nct_id"=)"", "official_title"=)"Effectiveness of a Multidisciplinary Intervention for Sexual Health in Survivors of Women’s Cancers", "open_date"=)"10-Jul-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kelly", "pi_last_name"=)"Westbrook", "pi_middle_initial"=)"E", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"213905115", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02146", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"8", "center_total_rp"=)"7", "clinical_research_cat"=)"OBS", "close_date"=)"05-Apr-2016", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"25", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00055718", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02146", "nct_id"=)"NCT02235441", "official_title"=)"Effects of Chemoradiation and Surgery on Cardiopulmonary Fitness and Tumor Neoplastic Phenotype in Gastrointestinal Malignancies: A Pilot Study", "open_date"=)"13-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Manisha", "pi_last_name"=)"Palta", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Other Digestive Organ", "sp_id"=)"214166591", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02152", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"75", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057117", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02152", "nct_id"=)"", "official_title"=)"Triadic Expectations: Decision-Making in Advanced Cancer", "open_date"=)"24-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Karen", "pi_last_name"=)"Steinhauser", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214184880", "specific_funding_source"=)"National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02154", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"2", "center_total_rp"=)"2", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"17", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00057527", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02154", "nct_id"=)"", "official_title"=)"Feasibility of Transferring Health Data from Apple HealthKit to the Duke Electronic Medical Record (Maestro Care) via Epic MyChart: A Pilot Trial", "open_date"=)"20-Nov-2014", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Michael", "pi_last_name"=)"Harrison", "pi_middle_initial"=)"R", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"214185843", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02159", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"160", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058440", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02159", "nct_id"=)"NCT02522793", "official_title"=)"Noninvasive Optical Spectroscopy for Identification of Cutaneous Cancer", "open_date"=)"21-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Charles", "pi_last_name"=)"Woodard", "pi_middle_initial"=)"", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Other Skin", "sp_id"=)"214200591", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02161", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"130", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00058567", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02161", "nct_id"=)"", "official_title"=)"Evaluating Preferences for Alternative Genetic Testing Strategies among Women with Epithelial Ovarian Cancer", "open_date"=)"17-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Havrilesky", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Ovary", "sp_id"=)"214205080", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02164", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"7", "center_total_rp"=)"7", "clinical_research_cat"=)"OBS", "close_date"=)"14-Oct-2015", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"80", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00060650", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02164", "nct_id"=)"NCT02396641", "official_title"=)"Implementation of Consensus-Based Standards for Best Supportive Care in a Clinical Trial: A Pilot Study", "open_date"=)"09-Mar-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214210250", "specific_funding_source"=)"American Cancer Society, Agency for Healthcare Research and Quality, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02166", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"07-Feb-2017", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"60", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061294", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02166", "nct_id"=)"", "official_title"=)"Assessment of Palliative Care Informational Needs", "open_date"=)"06-Apr-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Arif", "pi_last_name"=)"Kamal", "pi_middle_initial"=)"H", "primary_purpose"=)"Hsr", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214211988", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02178", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"17", "center_total_rp"=)"17", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"15", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061596", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02178", "nct_id"=)"", "official_title"=)"A Pilot Study to Describe the Trajectory of Symptoms and Adaptive Challenges of Adults Living with Low Grade Gliomas", "open_date"=)"15-May-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Mary", "pi_last_name"=)"Affronti", "pi_middle_initial"=)"L", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"214374713", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02179", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00061601", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02179", "nct_id"=)"NCT02407977", "official_title"=)"Real Time In-vivo Body Surface Dosimetry for External Beam Radiation Therapy", "open_date"=)"02-Jun-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Junzo", "pi_last_name"=)"Chino", "pi_middle_initial"=)"P", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214384361", "specific_funding_source"=)"Wallace H Coulter Foundation, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2015-02186", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"70", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065972", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2015-02186", "nct_id"=)"", "official_title"=)"Defining Value of Cancer Care from the Patient and Caregiver Perspective", "open_date"=)"08-Oct-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"214400279", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00271", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"12", "center_total_rp"=)"12", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"125", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00068192", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00271", "nct_id"=)"", "official_title"=)"Prognostic Understanding and Decision-Making in Acute Myeloid Leukemia (AML)", "open_date"=)"03-Dec-2015", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Thomas", "pi_last_name"=)"Lablanc", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Myeloid and Monocytic Leukemia", "sp_id"=)"229999394", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00633", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"ONC-MA-1004", "lead_org_po_id"=)"48002713", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00633", "nct_id"=)"NCT02380274", "official_title"=)"A Prospective Observational Cohort Study of Patients With Castration-Resistant Prostate Cancer (CRPC) in the United States", "open_date"=)"26-Apr-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"239623944", "specific_funding_source"=)"Astellas Pharma Global Development, Inc.", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00676", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"DIV-NB-401", "lead_org_po_id"=)"50367183", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00676", "nct_id"=)"NCT02693171", "official_title"=)"A Post-Marketing Study to Further Assess the Immunogenicity and Safety of Unituxin™ in High-Risk Neuroblastoma Patients", "open_date"=)"14-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Brain and Nervous System", "sp_id"=)"241168990", "specific_funding_source"=)"United Therapeutics", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00722", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"25", "center_total_rp"=)"25", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"450", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00070017", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00722", "nct_id"=)"", "official_title"=)"Duke Cancer Institute Multidisciplinary Active Surveillance (DUCIMAS) Cohort Study", "open_date"=)"05-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Thomas", "pi_last_name"=)"Polascik", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Prostate", "sp_id"=)"242250328", "specific_funding_source"=)"Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-00828", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"CA209357", "lead_org_po_id"=)"36140", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-00828", "nct_id"=)"NCT02780089", "official_title"=)"A US Multi-Site Observational Study in Patients With Unresectable And Metastatic Melanoma: The OPTIMIzE Study", "open_date"=)"25-May-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Melanoma, Skin", "sp_id"=)"246772434", "specific_funding_source"=)"Bristol-Myers Squibb", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01014", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ135", "entire_study"=)"300", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00072096", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01014", "nct_id"=)"", "official_title"=)"Preferences: An Online Survey for Women with Ovarian Cancer", "open_date"=)"21-Jun-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Laura", "pi_last_name"=)"Havrilesky", "pi_middle_initial"=)"J", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"252471413", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01173", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"35", "center_total_rp"=)"35", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"3000", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073920", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01173", "nct_id"=)"NCT02845687", "official_title"=)"Observational Study on Smoking Cessation and Cost Outcomes in the Duke Smoking Cessation Program", "open_date"=)"01-Jul-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"James", "pi_last_name"=)"Davis", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"", "sp_id"=)"258683770", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"E", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01322", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"", "entire_study"=)"30", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00075053", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01322", "nct_id"=)"", "official_title"=)"Usability Testing of a Patient Assistance Navigation Tool", "open_date"=)"19-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Syed", "pi_last_name"=)"Zafar", "pi_middle_initial"=)"Y", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"263379509", "specific_funding_source"=)"National Institutes of Health, Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01323", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"50", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00065967", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01323", "nct_id"=)"NCT02943044", "official_title"=)"Characterization of Physiological and Morphological Features of Clinical Head & Neck Squamous Cell Carcinomas (HNSCCs) Using a Quantitative Optical Sensor", "open_date"=)"16-Aug-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Walter", "pi_last_name"=)"Lee", "pi_middle_initial"=)"T", "primary_purpose"=)"Dia", "prog_code"=)"", "site"=)"multiple", "sp_id"=)"263382166", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01393", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"140", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00071979", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01393", "nct_id"=)"", "official_title"=)"Communicating about Sexual Concerns and Dysfunction Effectively (CASCADE) Program", "open_date"=)"06-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"PILOT", "phase_description"=)"NA", "pi_first_name"=)"Kevin", "pi_last_name"=)"Weinfurt", "pi_middle_initial"=)"", "primary_purpose"=)"Sup", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"265258854", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01399", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"Y", "islead"=)"False", "lead_org_id"=)"ADP-0000-001", "lead_org_po_id"=)"23866637", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01399", "nct_id"=)"NCT02636855", "official_title"=)"A Screening Protocol to Determine Tumor Antigen Expression and HLA Sub-Type for Eligibility Determination for Clinical Trials Evaluating the Safety and Efficacy of Autologous T Cells Expressing Enhanced TCRs in Subjects With Solid and Hematological Malignancies", "open_date"=)"12-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"266218873", "specific_funding_source"=)"Adaptimmune Limited", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01497", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ318", "entire_study"=)"180", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073547", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01497", "nct_id"=)"NCT02906592", "official_title"=)"Using a Geriatric Oncology Assessment to Link with Services (GOAL)", "open_date"=)"28-Sep-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Leah", "pi_last_name"=)"Zullig", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Multiple", "sp_id"=)"270182150", "specific_funding_source"=)"National Cancer Institute, Duke University Medical Center", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01757", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"1", "center_total_rp"=)"1", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"397", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"False", "is_multiinstitutional"=)"N", "islead"=)"True", "lead_org_id"=)"Pro00073210", "lead_org_po_id"=)"149280", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01757", "nct_id"=)"", "official_title"=)"Frailty Assessment in Patients Undergoing Oncologic Pancreatic Surgery: A NISQIP and NCI Center QI Initiative", "open_date"=)"09-Nov-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"Dan", "pi_last_name"=)"Blazer", "pi_middle_initial"=)"G", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Pancreas", "sp_id"=)"276878187", "specific_funding_source"=)"Duke University Medical Center, National Cancer Institute", "study_source"=)"I", "summary_level_accrual"=)"False", "your_center_total"=)"0"}, {"ad_nci_id"=)"NCI-2016-01934", "affiliate_total"=)"0", "affiliate_total_rp"=)"0", "center_total"=)"0", "center_total_rp"=)"0", "clinical_research_cat"=)"OBS", "close_date"=)"", "comments"=)"", "consortia_trial_category"=)"", "ctep_dcp_id"=)"", "dt4_program_codes"=)"ZZZ370", "entire_study"=)"", "inv_f_nm"=)"", "inv_l_nm"=)"", "inv_m_init"=)"", "is_industrial"=)"True", "is_multiinstitutional"=)"N", "islead"=)"False", "lead_org_id"=)"Ajinomoto 2015-01", "lead_org_po_id"=)"42081238", "local_site_identifier"=)"", "nci_id"=)"NCI-2016-01934", "nct_id"=)"NCT02512757", "official_title"=)"The AminoIndex™ Study - A Case-Control Study to Verify Diagnostic Performance of AminoIndex™ Technology", "open_date"=)"08-Dec-2016", "other_ids"=)"", "other_protocol_ids"=)"", "p30grant"=)"CA014236", "phase"=)"NA", "phase_additional_qualifier_code"=)"", "phase_description"=)"NA", "pi_first_name"=)"", "pi_last_name"=)"", "pi_middle_initial"=)"", "primary_purpose"=)"Oth", "prog_code"=)"", "site"=)"Lung", "sp_id"=)"280898521", "specific_funding_source"=)"Innovis LLC", "study_source"=)"D", "summary_level_accrual"=)"True", "your_center_total"=)"0"}],
 "paging" =) {"items_per_page"=)674, "page"=)1, "pages"=)1, "sort"=)[["clinical_research_cat", "ASC"], ["nci_id", "ASC"]], "total"=)674},
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:206:in `/^I want to verify DT4 response contains the correct data for "([^"]*)" parameters in the "([^"]*)" json file$/'
features/strap_api/report_data_table_4.feature:732:in `Then I want to verify DT4 response contains the correct data for "item_per_page_all" parameters in the "duke_cancer_dt4" json file'

Scenario:#34 mime type "CSV" GET endpoint response code should return 200 2

Given the "DT4" service is called by providing following parameters 2s

Then service status code should return "200" 0s

Scenario:#35 verify exported CSV content type is "text/CSV" 3

Given the "DT4" service is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#36 mime type "PDF" GET endpoint response code should return 200 2

Given the "DT4" service is called by providing following parameters 12s

Then service status code should return "200" 0s

Scenario:#37 verify exported PDF content type is "application/pdf" 3

Given the "DT4" service is called by providing following parameters 11s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#38 mime type "JSON" GET GET endpoint response code should return 200 2

Given the "DT4" service is called by providing following parameters 1s

Then service status code should return "200" 0s

Scenario:#39 verify exported JSON content type is "application/json" 3

Given the "DT4" service is called by providing following parameters 1s

And service should return response with headers for json 0s

Then the exported file content type is "application/json" 0s

Scenario:#40 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" for Dana-Farber/Harvard Cancer Center 6

Given the "DT4" service is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#41 verify exported PDF content type is "application/pdf" for Dana-Farber/Harvard Cancer Center and PDF download is successful 6

Given the "DT4" service is called by providing following parameters 15s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 17s

Then verify PDF file downloaded successfully 0s

Scenario:#42 verify Local Trial ID key exists in the service GET call response body 3

Given the "DT4" service is called by providing following parameters 4s

Then service status code should return "200" 0s

And I want to verify DT4 response has the Local Trial ID column key as: "local_site_identifier" 0s

Scenario:#43 verify Pilot key exists in the service GET call response body 3

Given the "DT4" service is called by providing following parameters 4s

Then service status code should return "200" 0s

Then I want to verify DT4 response has the Pilot column key as: "phase_additional_qualifier_code" 0s

Scenario:#45 verify "end_date" should not be less than "start_date" 3

Given the "DT4" service is called by providing following parameters 0s

Then service status code should return "400" 0s

And service should return failed message: "end_date_less_than_start_date" due to missing required parameter 0s

Feature:Data Table 4 report: Verifying trial type in dt4 report 2

This feature scenarios verifying trials type "INTERVENTIONAL" and "NON-INTERVENTIONAL"

Scenario:#1 Verifying the trial type is "INTERVENTIONAL" based on the trial type criteria in the DT4 report 4

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify response has the trial types: "clinical_research_cat" key 0s

And trial type is "INTERVENTIONAL" 0s

Scenario:#2 Verifying the trial type is "NON-INTERVENTIONAL" based on the trial type criteria in the DT4 report 4

Given the "DT4" service is called by providing following criteria: 1s

Then service status code should return "200" 0s

Then I want to verify response has the trial types: "clinical_research_cat" key 0s

And trial type is "NON-INTERVENTIONAL" 0s

Feature:Search for Accrual counts against the disease and anatomic site endpoint 15 1

Scenario:#01 Get all participating accrual counts by NEOPLASM disease and the total analytic_accrual count should not be null 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 3s

Then accruals analytics service status code should return "200" 0s

And "" the analytic accrual counts is not null 0s

Scenario:#02 Get all participating accrual counts by NEOPLASM disease and the total analytic_accrual count should not be null for the parimary purpose chart 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 3s

Then accruals analytics service status code should return "200" 0s

And "" the analytic accrual counts is not null 0s

Scenario:#03 Get accrual details by trial category 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 16s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "accrual_detial_by_trial_category" parameters data 0s

Scenario:#04 Get accrual details by primary_purpose 1 1 1

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 32s

Then accruals analytics service status code should return "200" 0s + Show Error 

expected: "200"
     got: "502"

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/accrual_analytics.rb:59:in `/^accruals analytics service status code should return "([^"]*)"$/'
features/strap_api/accrual_analytics_anatomic_site.feature:81:in `Then accruals analytics service status code should return "200"'

And one of the data element from the accrual analytics RESPONSE should match with the "accrual_detial_by_primary_purpose" parameters data

Scenario:#05 Get all participating accrual counts by NEOPLASM disease and the total analytic_accrual count should not be null for GENDER chart 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 3s

Then accruals analytics service status code should return "200" 0s

And "" the analytic accrual counts is not null 0s

Scenario:#06 Get accrual details by Gender 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 19s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "accrual_detial_by_gender" parameters data 0s

Scenario:#07 Get all participating accrual counts by NEOPLASM disease and the total analytic_accrual count should not be null for anatomic_site chart 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 2s

Then accruals analytics service status code should return "200" 0s

And "" the analytic accrual counts is not null 0s

Scenario:#08 Get accrual details by Anatomic Site 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 1s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "accrual_detial_by_anatomic_site" parameters data 0s

Scenario:#09 Get all participating accrual counts by NEOPLASM disease and the total analytic_accrual count should not be null for nci_division_or_program chart 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 2s

Then accruals analytics service status code should return "200" 0s

And "" the analytic accrual counts is not null 0s

Scenario:#10 Get accrual details by NCI Division or Program Code 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 13s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "accrual_detial_by_nci_division_or_program" parameters data 0s

Scenario:#11 Get accrual details by Anatomic Site for Bones and Joints 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 0s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "anatomic_site_Bones_and_Joints" parameters data 0s

Scenario:#12 Get accrual details by Anatomic Site for Brain and Nervous System 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 1s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "anatomic_site_Brain_and_Nervous_System" parameters data 0s

Scenario:#13 Get accrual details by Anatomic Site for Breast - Female 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 3s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "anatomic_site_Breast_Female" parameters data 0s

Scenario:#14 Get accrual details by Anatomic Site for Breast - Male 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 1s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "anatomic_site_Breast_Male" parameters data 0s

Scenario:#15 Get accrual details by Anatomic Site for Cervix 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 1s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "anatomic_site_Cervix" parameters data 0s

Scenario:#16 Get accrual details by Anatomic Site for Colon 3

Given the "ACCRUALS_ANALYTIC" service endpoint is called by providing following filter parameters 1s

Then accruals analytics service status code should return "200" 0s

And one of the data element from the accrual analytics RESPONSE should match with the "anatomic_site_Colon" parameters data 0s

Feature:Improvement: CTRPSTRAP-116: Split out NCI ID from Other IDs in the DT4 report 9

1. Split out the 'NCI ID' from the 'Other Protocol IDs' column and put it in its own column.
2. Create a new column for 'NCI ID' between the “NCT ID” and “Protocol ID” columns.
3. Display the 'NCI ID' in the new column
4. Delete the 'NCI ID' in the “Other Protocol IDs” column

Scenario:#1 NCI ID should display as separate column and nci id should not exists in "other_protocol_ids" 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

And NCI ID "NCI-2011-02978" as a separate column: "nci_id" 0s

Scenario Outline:#2 Other Protocol IDs cloumn should not display NCI ID 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then Other protocol column: "other_protocol_ids" should not display NCI ID "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "nci_id" and it's corresponding values as "NCI-2011-02978" are correct for the nci id "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "nct_id" and it's corresponding values as "NCT01414608" are correct for the nci id "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "lead_org_id" and it's corresponding values as "ANZGOG-0902-GOG-0274" are correct for the nci id "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "lead_org_po_id" and it's corresponding values as "35274463" are correct for the nci id "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "other_ids" and it's corresponding values as "ANZGOG-0902\rRTOG-1174\rGOG-0274\rCDR0000706698" are correct for the nci id "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "other_protocol_ids" and it's corresponding values as "ANZGOG-0902-GOG-0274, ANZGOG-0902, RTOG-1174, GOG-0274, CDR0000706698" are correct for the nci id "NCI-2011-02978" 0s

Scenario Outline:#3 Other Protocol IDs cloumn should display other ID's 2

Given the "DT4" api service is called to verify NCI ID column by providing following criteria: 0s

Then I want to verify for the column as: "sp_id" and it's corresponding values as "75343881" are correct for the nci id "NCI-2011-02978" 0s

Feature:A set of API tests to get report of duplicate po persons 15

Scenario:valid prs verification GET endpoint response code should return 200 status code and contains 200 items with valid keys 4

Given the "DUPLICATE_PO" endpoint is called 2s

Then the service status code should return "200" 0s

And the response for duplicate-po-persons is not null 0s

And the response from duplicate-po-persons contains correct data 0s

Scenario Outline:valid DUPLICATE-PO-PERSONS GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "DUPLICATE_PO" report endpoint is called called with "csv" parameter 2s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Scenario Outline:valid DUPLICATE-PO-PERSONS GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "DUPLICATE_PO" report endpoint is called called with "pdf" parameter 7s

Then the service status code should return "200" 0s

And check Content-Type header is "application/pdf" 0s

And check Content-Length header is greater than zero 0s

Scenario:#3 valid DUPLICATE_PO GET endpoint response code should return 200 with parameters 2

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

Scenario:#4 GET endpoint response code should return 200 for DUPLICATE_PO service endpoint with Start Date and End Date parameters 2

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

Scenario:#5 malformed DUPLICATE_PO trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#6 DUPLICATE_PO report should be sort by "person1_fn" as ascending order by default 3

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

And I want to verify DUPLICATE_PO response sorted by: "person1_fn" as "ASC" 0s

Scenario:#7 DUPLICATE_PO report should be sort by "person1_fn" as ASC 3

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

And I want to verify DUPLICATE_PO response sorted by: "person1_fn" as "ASC" 0s

Scenario:#8 DUPLICATE_PO report should be sort by "person1_fn" as DESC 3

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

And I want to verify DUPLICATE_PO response sorted by: "person1_fn" as "DESC" 0s

Scenario:#9 mime type "CSV" GET endpoint response code should return 200 2

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

Scenario:#10 verify exported CSV content type is "text/CSV" 3

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#11 mime type "PDF" GET endpoint response code should return 200 2

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 6s

Then service status code should return "200" 0s

Scenario:#12 verify exported PDF content type is "application/pdf" 3

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 6s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#13 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "DUPLICATE_PO" service endpoint 6

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#14 verify exported PDF content type is "application/pdf" and PDF file download is successful "DUPLICATE_PO" service endpoint 6

Given the "DUPLICATE_PO" service GET endpoint is called by providing following parameters 6s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 6s

Then verify PDF file downloaded successfully 0s

Feature:A set of API tests to get report of trials sponsored by the NCI 2

Scenario:valid nci-as-sponsor-trials GET endpoint response code should return 200 status code and contains 200 items with valid keys 4

Given the "NCI_AS_SPONSOR" endpoint is called 6s

Then the service status code should return "200" 0s

And the response for nci-as-sponsor-trials is not null 0s

And the response from nci-as-sponsor-trials contains correct data 0s

Scenario Outline:valid nci-as-sponsor-trials GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "NCI_AS_SPONSOR" report endpoint is called called with "csv" parameter 8s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Feature:Search for trial funding type 1

Scenario:valid funding type GET endpoint response code should return 200 2

Given the "TRIALS_ANALYTIC" funding type service is called by providing following filter parameters 0s

Then trial analytics funding type service status code should return "200" 0s

Feature:CTRPSTRAP-128: Person Information missing for some trials in DT4 report 126

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 3s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "ad_nci_id" the corresponding values as "NCI-2011-02978" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "affiliate_total" the corresponding values as "3" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "affiliate_total_rp" the corresponding values as "0" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "center_total" the corresponding values as "0" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "center_total_rp" the corresponding values as "0" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "clinical_research_cat" the corresponding values as "INT" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "close_date" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "comments" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "consortia_trial_category" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "ctep_dcp_id" the corresponding values as "ANZGOG-0902-GOG-0274" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "dt4_program_codes" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "entire_study" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "inv_f_nm" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "inv_l_nm" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "inv_m_init" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "is_industrial" the corresponding values as "False" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "is_multiinstitutional" the corresponding values as "Y" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "islead" the corresponding values as "False" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "lead_org_id" the corresponding values as "ANZGOG-0902-GOG-0274" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "lead_org_po_id" the corresponding values as "35274463" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "local_site_identifier" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "nci_id" the corresponding values as "NCI-2011-02978" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "nct_id" the corresponding values as "NCT01414608" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "official_title" the corresponding values as "A Phase III Trial of Adjuvant Chemotherapy following Chemoradiation as Primary Treatment for Locally Advanced Cervical Cancer Compared to Chemoradiation Alone: The OUTBACK Trial" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "open_date" the corresponding values as "09-Jan-2012" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "other_ids" the corresponding values as "ANZGOG-0902\rRTOG-1174\rGOG-0274\rCDR0000706698" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "other_protocol_ids" the corresponding values as "ANZGOG-0902-GOG-0274, ANZGOG-0902, RTOG-1174, GOG-0274, CDR0000706698" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "p30grant" the corresponding values as "CA072720" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "phase" the corresponding values as "III" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "phase_additional_qualifier_code" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "phase_description" the corresponding values as "III" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "pi_first_name" the corresponding values as "Kathleen" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "pi_last_name" the corresponding values as "Moore" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "pi_middle_initial" the corresponding values as "N" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "primary_purpose" the corresponding values as "Tre" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "prog_code" the corresponding values as "" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "site" the corresponding values as "Cervix" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "sp_id" the corresponding values as "75343881" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "specific_funding_source" the corresponding values as "NRG Oncology" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "study_source" the corresponding values as "N" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "summary_level_accrual" the corresponding values as "False" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#1 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT01414608" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01414608" 0s

Then I want to verify for the fields as "your_center_total" the corresponding values as "0" are correct for the nct id "NCT01414608" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "ad_nci_id" the corresponding values as "NCI-2009-00310" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "affiliate_total" the corresponding values as "2" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "affiliate_total_rp" the corresponding values as "0" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "center_total" the corresponding values as "7" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "center_total_rp" the corresponding values as "0" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "clinical_research_cat" the corresponding values as "ANC/COR" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "close_date" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "comments" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "consortia_trial_category" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "ctep_dcp_id" the corresponding values as "AALL05B1" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "dt4_program_codes" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "entire_study" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "inv_f_nm" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "inv_l_nm" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "inv_m_init" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "is_industrial" the corresponding values as "False" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "is_multiinstitutional" the corresponding values as "Y" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "islead" the corresponding values as "False" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "lead_org_id" the corresponding values as "AALL05B1" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "lead_org_po_id" the corresponding values as "60948" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "local_site_identifier" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "nci_id" the corresponding values as "NCI-2009-00310" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "nct_id" the corresponding values as "NCT00897325" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "official_title" the corresponding values as "A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "open_date" the corresponding values as "25-Sep-2006" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "other_ids" the corresponding values as "CDR0000491159\rCOG-AALL05B1" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "other_protocol_ids" the corresponding values as "AALL05B1, CDR0000491159, COG-AALL05B1" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "p30grant" the corresponding values as "CA072720" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "phase" the corresponding values as "NA" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "phase_additional_qualifier_code" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "phase_description" the corresponding values as "NA" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "pi_first_name" the corresponding values as "Stephen" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "pi_last_name" the corresponding values as "Hunger" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "pi_middle_initial" the corresponding values as "P" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "primary_purpose" the corresponding values as "Oth" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "prog_code" the corresponding values as "" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "site" the corresponding values as "multiple" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "sp_id" the corresponding values as "74445057" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "specific_funding_source" the corresponding values as "Childrens Oncology Group" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "study_source" the corresponding values as "N" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "summary_level_accrual" the corresponding values as "False" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#2 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02065687" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT00897325" 0s

Then I want to verify for the fields as "your_center_total" the corresponding values as "0" are correct for the nct id "NCT00897325" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "ad_nci_id" the corresponding values as "NCI-2014-00627" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "affiliate_total" the corresponding values as "3" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "affiliate_total_rp" the corresponding values as "1" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "center_total" the corresponding values as "0" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "center_total_rp" the corresponding values as "0" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "clinical_research_cat" the corresponding values as "INT" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "close_date" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "comments" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "consortia_trial_category" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "ctep_dcp_id" the corresponding values as "S1400" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "dt4_program_codes" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "entire_study" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "inv_f_nm" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "inv_l_nm" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "inv_m_init" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "is_industrial" the corresponding values as "False" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "is_multiinstitutional" the corresponding values as "Y" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "islead" the corresponding values as "False" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "lead_org_id" the corresponding values as "S1400" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "lead_org_po_id" the corresponding values as "220068" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "local_site_identifier" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "nci_id" the corresponding values as "NCI-2014-00627" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "nct_id" the corresponding values as "NCT02154490" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "official_title" the corresponding values as "A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "open_date" the corresponding values as "16-Jun-2014" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "other_ids" the corresponding values as "S1400B\rS1400D\rS1400C\rS1400I\rS1400A\rS1400E" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "other_protocol_ids" the corresponding values as "S1400, S1400B, S1400D, S1400C, S1400I, S1400A, S1400E" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "p30grant" the corresponding values as "CA072720" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "phase" the corresponding values as "II_III" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "phase_additional_qualifier_code" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "phase_description" the corresponding values as "II/III" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "pi_first_name" the corresponding values as "Vassiliki" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "pi_last_name" the corresponding values as "Papadimitrakopoulou" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "pi_middle_initial" the corresponding values as "A" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "primary_purpose" the corresponding values as "Tre" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "prog_code" the corresponding values as "" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "site" the corresponding values as "Lung" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "sp_id" the corresponding values as "137570059" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "specific_funding_source" the corresponding values as "SWOG" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "study_source" the corresponding values as "N" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "summary_level_accrual" the corresponding values as "False" are correct for the nct id "NCT02154490" 0s

Scenario Outline:#3 Person information should be accurate for the Rutgers Cancer Institute of New Jersey for the nct id "NCT02154490" 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT02154490" 0s

Then I want to verify for the fields as "your_center_total" the corresponding values as "0" are correct for the nct id "NCT02154490" 0s

Feature:CTRPSTRAP-129: Fix DT4 report to exclude trials that have no accrual and are not open at any site within the family during the reporting period 42 1

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 4s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "ad_nci_id" the corresponding values as "NCI-2011-00940" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "affiliate_total" the corresponding values as "0" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "affiliate_total_rp" the corresponding values as "0" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "center_total" the corresponding values as "0" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "center_total_rp" the corresponding values as "0" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "clinical_research_cat" the corresponding values as "INT" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "close_date" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "comments" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "consortia_trial_category" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "ctep_dcp_id" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "dt4_program_codes" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "entire_study" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "inv_f_nm" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "inv_l_nm" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "inv_m_init" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "is_industrial" the corresponding values as "True" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "is_multiinstitutional" the corresponding values as "Y" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "islead" the corresponding values as "False" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "lead_org_id" the corresponding values as "8109-002" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "lead_org_po_id" the corresponding values as "69198" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 2 1

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "local_site_identifier" the corresponding values as "EC-FV-06" are correct for the nct id "NCT01170650" 0s + Show Error 

expected: "EC-FV-06"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/bug_fix_tracker_128.rb:46:in `/^I want to verify for the fields as "([^"]*)" the corresponding values as "([^"]*)" are correct for the nct id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_129.feature:32:in `Then I want to verify for the fields as "local_site_identifier" the corresponding values as "EC-FV-06" are correct for the nct id "NCT01170650"'
features/strap_api/bug_fix_tracker_129.feature:9:in `Then I want to verify for the fields as "(fields)" the corresponding values as "(values)" are correct for the nct id "NCT01170650"'

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "nci_id" the corresponding values as "NCI-2011-00940" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "nct_id" the corresponding values as "NCT01170650" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "official_title" the corresponding values as "A Randomized Double-Blind Phase 3 Trial Comparing EC145 and Pegylated Liposomal Doxorubicin (PLD/Doxil®/Caelyx®) in Combination Versus PLD in Participants With Platinum-Resistant Ovarian Cancer" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "open_date" the corresponding values as "01-May-2011" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "other_ids" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "other_protocol_ids" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "p30grant" the corresponding values as "CA015083" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "phase" the corresponding values as "III" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "phase_additional_qualifier_code" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "phase_description" the corresponding values as "III" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "pi_first_name" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "pi_last_name" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "pi_middle_initial" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "primary_purpose" the corresponding values as "Tre" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "prog_code" the corresponding values as "" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "site" the corresponding values as "multiple" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "sp_id" the corresponding values as "74297487" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "specific_funding_source" the corresponding values as "Endocyte Inc" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "study_source" the corresponding values as "D" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "summary_level_accrual" the corresponding values as "True" are correct for the nct id "NCT01170650" 0s

Scenario Outline:#1 For the open site within the family during the reporting period accrual count should displayed and the report should be included in the report 3

Given the "DT4" api service is called by providing criteria: 0s

And It shall return the response which should include nct id "NCT01170650" 0s

Then I want to verify for the fields as "your_center_total" the corresponding values as "0" are correct for the nct id "NCT01170650" 0s

Scenario:#2 For the not open site within the family during the reporting period the trial NCI-2011-00940 should not be included in the DT4 report 2

Given the "DT4" api service is called by providing following criteria: 4s

And It shall return the response which should NOT include nci id "NCI-2011-00940" 0s

Feature:CTRPSTRAP-89: DT4- Protocol ID Column (Formatting) 5

STRAP seems to remove the leading 0(s) or any 0s after a period (.). In the program itself, it has the correct Protocol ID, but when it is converted to Excel, it removes it.

Scenario:#1 Download the CSV file is successful 6

Given the "DT4" service is called by providing following parameters 5s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#2 Verify Protocol ID column in DT4 report 7

Given the "DT4" service is called by providing following parameters 5s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

And verify the "Protocol ID" column value is present 0s

Scenario:#3 Verify the leading 0(s) are not removed from the protocol ID column 7

Given the "DT4" service is called by providing following parameters 5s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

And the protocol ID's: "097517" leading ZERO(s) value should not be removed for the "NCI-2015-00014" in the csv file 0s

Scenario:#4 Verify the 0(s) after period are not removed from the protocol ID column for the trial NCI-2012-00743 7

Given the "DT4" service is called by providing following parameters 4s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

And the protocol ID's: "2605.00" ZERO(s) or OTHER value after period should not be removed for the "NCI-2012-00743" in the csv file 0s

Scenario:#5 Verify the values(s) after period are not removed from the protocol ID column for the trial NCI-2009-00696 7

Given the "DT4" service is called by providing following parameters 4s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

And the protocol ID's: "IRB11-008059" ZERO(s) or OTHER value after period should not be removed for the "NCI-2014-01647" in the csv file 0s

Feature:A set of API tests to get report of monthly milestones 17

Scenario:#1 valid MONTHLY_MILESTONE GET endpoint response code should return 400 status code and contains correct data in response 3

Given the "MONTHLY_MILESTONE" report endpoint is called called with "" parameters 1s

Then the service status code should return "400" 0s

And the response for 'MONTHLY_MILESTONE' contains the correct data for "endpoint_no_params" parameters 0s

Scenario:#2 valid MONTHLY_MILESTONE GET endpoint response code should return 200 status code with "?action=cols" parameters and contains correct data in response 3

Given the "MONTHLY_MILESTONE" report endpoint is called called with "?action=cols" parameters 0s

Then the service status code should return "200" 0s

And the response for 'MONTHLY_MILESTONE' contains the correct data for "?action=cols" parameters 0s

Scenario:#3 valid MONTHLY_MILESTONE GET endpoint response code should return 200 status code with "?start_date=2017-01-01&end_datetime=2017-02-01" parameters and contains correct data in response 3

Given the "MONTHLY_MILESTONE" report endpoint is called called with "?start_date=2017-01-01&end_datetime=2017-02-01" parameters 5s

Then the service status code should return "200" 0s

And the response for 'MONTHLY_MILESTONE' contains the correct data for "endpoint_1_month" parameters 0s

Scenario:#4 valid MONTHLY_MILESTONE GET endpoint response code should return 200 with parameters 2

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#5 GET endpoint response code should return 200 for MONTHLY_MILESTONE service endpoint with Start Date and End Date parameters 2

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#6 malformed MONTHLY_MILESTONE trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#7 MONTHLY_MILESTONE report should be sort by "nci_id" as ascending order by default 4

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify MONTHLY_MILESTONE response sorted by: "nci_id" as "ASC" 0s

And I want to verify MONTHLY_MILESTONE response sorted by: "milestone_date" as "ASC" 0s

Scenario:#8 MONTHLY_MILESTONE report should be sort by "nci_id" as ASC 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify MONTHLY_MILESTONE response sorted by: "nci_id" as "ASC" 0s

Scenario:#9 MONTHLY_MILESTONE report should be sort by "nci_id" as DESC 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify MONTHLY_MILESTONE response sorted by: "nci_id" as "DESC" 0s

Scenario:#10 MONTHLY_MILESTONE report should be sort by "milestone_date" as ASC 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify MONTHLY_MILESTONE response sorted by: "milestone_date" as "ASC" 0s

Scenario:#11 MONTHLY_MILESTONE report should be sort by "milestone_date" as DESC 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify MONTHLY_MILESTONE response sorted by: "milestone_date" as "DESC" 0s

Scenario:#12 mime type "CSV" GET endpoint response code should return 200 2

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#13 verify exported CSV content type is "text/CSV" 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#14 mime type "PDF" GET endpoint response code should return 200 2

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

Scenario:#15 verify exported PDF content type is "application/pdf" 3

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#16 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "MONTHLY_MILESTONE" service endpoint 6

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 0s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#17 verify exported PDF content type is "application/pdf" and PDF file download is successful "MONTHLY_MILESTONE" service endpoint 6

Given the "MONTHLY_MILESTONE" service GET endpoint is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 2s

Then verify PDF file downloaded successfully 0s

Feature:A set of API tests to get report of trial verification dates 16

Scenario:#1 valid TRIAL_VERIFICATION GET endpoint response code should return 200 with parameters 2

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#2 GET endpoint response code should return 200 for TRIAL_VERIFICATION service endpoint without any params 2

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#3 malformed TRIAL_VERIFICATION trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#4 valid trial verification GET endpoint response code should return 200 status code and contains correct data 4

Given the "TRIAL_VERIFICATION" endpoint is called 0s

Then the service status code should return "200" 0s

And the response for trial-verification is not null 0s

And one of the data element from the trial verification date's RESPONSE should match with the "trial_verification_date_data" parameters data 0s

Scenario:#5 valid trial verification GET endpoint with INTERVAL PARAMETER response code should return 200 status code and contains correct data 3

Given the "TRIAL_VERIFICATION" report endpoint is called called with "?interval_month=6" parameters 0s

Then the service status code should return "200" 0s

And one of the data element from the trial verification date's RESPONSE should match with the "interval_month" parameters data 0s

Scenario Outline:#6 valid trial verification GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "TRIAL_VERIFICATION" report endpoint is called called with "csv" parameter 0s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Scenario Outline:#6 valid trial verification GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "TRIAL_VERIFICATION" report endpoint is called called with "pdf" parameter 3s

Then the service status code should return "200" 0s

And check Content-Type header is "application/pdf" 0s

And check Content-Length header is greater than zero 0s

Scenario:#7 TRIAL_VERIFICATION report should be sort by "nci_id" as ascending order by default 3

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify TRIAL_VERIFICATION response sorted by: "nci_id" as "ASC" 0s

Scenario:#8 TRIAL_VERIFICATION report should be sort by "nci_id" as ASC 3

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify TRIAL_VERIFICATION response sorted by: "nci_id" as "ASC" 0s

Scenario:#9 TRIAL_VERIFICATION report should be sort by "nci_id" as DESC 3

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify TRIAL_VERIFICATION response sorted by: "nci_id" as "DESC" 0s

Scenario:#10 mime type "CSV" GET endpoint response code should return 200 2

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#11 verify exported CSV content type is "text/CSV" 3

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#12 mime type "PDF" GET endpoint response code should return 200 2

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

Scenario:#13 verify exported PDF content type is "application/pdf" 3

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 3s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#14 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "TRIAL_VERIFICATION" service endpoint 6

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 0s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#15 verify exported PDF content type is "application/pdf" and PDF file download is successful "TRIAL_VERIFICATION" service endpoint 6

Given the "TRIAL_VERIFICATION" service endpoint is called by providing following parameters 3s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 3s

Then verify PDF file downloaded successfully 0s

Feature:A set of APIs tests to verify Trial Types 4

Scenario:Get valid TRIAL TYPES service endpoint response is 200 2

Given the "TRIAL_TYPES" service is called by providing trial types filter parameters 0s

Then the service status code should return "200" 0s

Scenario Outline:Get TRIAL TYPES using the filter parameters trial-types 2

Given the "TRIAL_TYPES" service is called by providing trial types filter parameters 0s

Then the trial-types matching the query "All" is returned 0s

Scenario Outline:Get TRIAL TYPES using the filter parameters trial-types 2

Given the "TRIAL_TYPES" service is called by providing trial types filter parameters 0s

Then the trial-types matching the query "Interventional" is returned 0s

Scenario Outline:Get TRIAL TYPES using the filter parameters trial-types 2

Given the "TRIAL_TYPES" service is called by providing trial types filter parameters 0s

Then the trial-types matching the query "Non-interventional" is returned 0s

Feature:CTRPSTRAP-111: DT4 Report - Missing accrual for organizations no longer in the family 14

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 4s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "nci_id" and it's corresponding values: "NCI-2009-01112" for the trial 0s

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "entire_study" and it's corresponding values: "" for the trial 0s

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "your_center_total" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "center_total_rp" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "center_total" and it's corresponding values: "9" for the trial 0s

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "affiliate_total_rp" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#13 CTRPSTRAP-111 Other to date should return all the accrual count for trial NCI-2009-01112 even though Saint Barnabas Medical Center relationship ended with the family prior to the reporting period 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure Accrual Counts are accurate for column: "affiliate_total" and it's corresponding values: "16" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "nci_id" and it's corresponding values: "NCI-2009-01112" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "entire_study" and it's corresponding values: "400" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "your_center_total" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "center_total_rp" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "center_total" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "affiliate_total_rp" and it's corresponding values: "0" for the trial 0s

Scenario Outline:#14 CTRPSTRAP-111 Entire study field should return targeted enrollment value as the cancer center is the lead org for the trial NCI-2009-01112 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And ensure "NRG Oncology" is the lead org for the trial "NCI-2009-01112" 1s

And ensure Accrual Counts are accurate for column: "affiliate_total" and it's corresponding values: "0" for the trial 0s

Feature:A set of APIs tests to get list of dieseases name 2

Scenario:valid diseases GET endpoint response code should return 200 2

Given the nci-strap-api service is called by providing valid diseases: "DISEASES" filter parameters 0s

Then the service status code should return "200" 0s

Scenario:invalid diseases GET endpoint response code should return 404 NOT FOUND 2

Given the nci-strap-api service is called by providing invalid diseases: "DISEASES" filter parameters 0s

Then the service status code should return "404" 0s

Feature:New Feature: Tracker-130: Create Export to Excel functionality for DT4 Report 2

Scenario:#1 Download the EXCEL file is successful 6

Given the "DT4" service is called by providing following parameters to download excel file 5s

And service should return response with headers along with the file attributes 0s

Then the exported EXCEL file content type is "application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" 0s

Then the exported EXCEL file content length is grater than zero 0s

And download the EXCEL file 6s

Then verify the EXCEL file downloaded successfully 0s

Scenario:#2 Verify Protocol ID column presents in the exported DT4 report 7

Given the "DT4" service is called by providing following parameters to download excel file 5s

And service should return response with headers along with the file attributes 0s

Then the exported EXCEL file content type is "application/vnd.openxmlformats-officedocument.spreadsheetml.sheet" 0s

Then the exported EXCEL file content length is grater than zero 0s

And download the EXCEL file 5s

Then verify the EXCEL file downloaded successfully 0s

And verify the "Protocol ID" column value is present in the exported DT4 excel file 2s

Feature:A set of API tests to get report of CTEP trials with expired PCD 14

Scenario:#1 valid CTEP_EXPIRED GET endpoint response code should return 200 2

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 16s

Then service status code should return "200" 0s

Scenario:#2 malformed CTEP_EXPIRED trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return failed message: "msg_not_found" due to missing parameter 0s

Scenario:#3 valid CTEP_EXPIRED GET endpoint response code should return 200 status code and contains correct data in response 3

Given the "CTEP_EXPIRED" report endpoint is called called with "" parameters 16s

Then the service status code should return "200" 0s

And one of the data element from the CTEP TRIALS WITH EXPIRE PCD RESPONSE should match with the "expire_pcd_no_prams" parameters data 0s

Scenario Outline:#4 valid CTEP_EXPIRED GET endpoint response code should return 200 status code and returns pdf document 4

Given the "CTEP_EXPIRED" report endpoint is called called with "csv" parameter 16s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Scenario Outline:#4 valid CTEP_EXPIRED GET endpoint response code should return 200 status code and returns pdf document 4

Given the "CTEP_EXPIRED" report endpoint is called called with "pdf" parameter 17s

Then the service status code should return "200" 0s

And check Content-Type header is "application/pdf" 0s

And check Content-Length header is greater than zero 0s

Scenario:#5 CTEP_EXPIRED report should be sort by "expire_order" as ascending order by default 3

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 17s

Then service status code should return "200" 0s

And I want to verify CTEP_EXPIRED response sorted by: "expire_order" as "ASC" 0s

Scenario:#6 CTEP_EXPIRED report should be sort by "expire_order" as ASC 3

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 17s

Then service status code should return "200" 0s

And I want to verify CTEP_EXPIRED response sorted by: "expire_order" as "ASC" 0s

Scenario:#7 CTEP_EXPIRED report should be sort by "expire_order" as DESC 3

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 16s

Then service status code should return "200" 0s

And I want to verify CTEP_EXPIRED response sorted by: "expire_order" as "DESC" 0s

Scenario:#8 mime type "CSV" GET endpoint response code should return 200 2

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 16s

Then service status code should return "200" 0s

Scenario:#9 verify exported CSV content type is "text/CSV" 3

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 16s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#10 mime type "PDF" GET endpoint response code should return 200 2

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 17s

Then service status code should return "200" 0s

Scenario:#11 verify exported PDF content type is "application/pdf" 3

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 17s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#12 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully 6

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 16s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#13 verify exported PDF content type is "application/pdf" and PDF file download is successful 6

Given the "CTEP_EXPIRED" service endpoint is called by providing following parameters 17s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 17s

Then verify PDF file downloaded successfully 0s

Feature:A set of API tests to get report of ctrp biomarkers 18 3

Scenario:#1 valid CTRP_BIOMARKER GET endpoint response code should return 200 status code and contains correct data in response 2 1

Given the "CTRP_BIOMARKER" report endpoint is called called with "" parameters 31s + Show Error 

765: unexpected token at '(html)
(head)(title)502 Bad Gateway(/title)(/head)
(body bgcolor="white")
(center)(h1)502 Bad Gateway(/h1)(/center)
(/body)
(/html)
' (JSON::ParserError)
./features/step_definitions/report_monthly_milestone.rb:13:in `/^the "([^"]*)" report endpoint is called called with "([^"]*)" parameters$/'
features/strap_api/report_ctrp_biomarker.feature:6:in `Given the "CTRP_BIOMARKER" report endpoint is called called with "" parameters'

Then the service status code should return "200"

And the response for 'CTRP_BIOMARKER' contains the correct data for "endpoint_no_params" parameters

Scenario:#2 valid CTRP_BIOMARKER GET endpoint response code should return 200 status code with "?biomarker=brca&intervention=celecoxib" parameters and contains correct data in response 3

Given the "CTRP_BIOMARKER" report endpoint is called called with "?biomarker=brca&intervention=celecoxib" parameters 2s

Then the service status code should return "200" 0s

And the response for 'CTRP_BIOMARKER' contains the correct data for "endpoint_brca_celecoxib" parameters 0s

Scenario:#3 valid CTRP_BIOMARKER GET endpoint response code should return 200 status code with "?biomarker=brca2&intervention=" parameters and contains correct data in response 3

Given the "CTRP_BIOMARKER" report endpoint is called called with "?biomarker=brca2&intervention=" parameters 3s

Then the service status code should return "200" 0s

And the response for 'CTRP_BIOMARKER' contains the correct data for "endpoint_brca2" parameters 0s

Scenario Outline:#4 valid CTRP_BIOMARKER GET endpoint response code should return 200 status code and returns valid pdf and csvdocument 4

Given the "CTRP_BIOMARKER" report endpoint is called called with "csv" parameter for brca and celecoxib 2s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Scenario Outline:#4 valid CTRP_BIOMARKER GET endpoint response code should return 200 status code and returns valid pdf and csvdocument 4

Given the "CTRP_BIOMARKER" report endpoint is called called with "pdf" parameter for brca and celecoxib 2s

Then the service status code should return "200" 0s

And check Content-Type header is "application/pdf" 0s

And check Content-Length header is greater than zero 0s

Scenario:#5 valid CTRP_BIOMARKER GET endpoint response code should return 200 with parameters 2

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 2s

Then service status code should return "200" 0s

Scenario:#6 GET endpoint response code should return 200 for CTRP_BIOMARKER service endpoint without any params 1 1

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 31s

Then service status code should return "200" 0s + Show Error 

expected: "200"
     got: "502"

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:158:in `/^service status code should return "([^"]*)"$/'
features/strap_api/report_ctrp_biomarker.feature:61:in `Then service status code should return "200"'

Scenario:#7 malformed CTRP_BIOMARKER trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#8 CTRP_BIOMARKER report should be sort by "nci_id" as ascending order by default 1 3 1

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 32s

Then service status code should return "200" 0s + Show Error 

expected: "200"
     got: "502"

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:158:in `/^service status code should return "([^"]*)"$/'
features/strap_api/report_ctrp_biomarker.feature:87:in `Then service status code should return "200"'

And I want to verify CTRP_BIOMARKER response sorted by: "name" as "ASC"

And I want to verify CTRP_BIOMARKER response sorted by: "use" as "ASC"

And I want to verify CTRP_BIOMARKER response sorted by: "nci_id" as "ASC"

Scenario:#9 CTRP_BIOMARKER report should be sort by "nci_id" as ASC 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 4s

Then service status code should return "200" 0s

And I want to verify CTRP_BIOMARKER response sorted by: "nci_id" as "ASC" 0s

Scenario:#10 CTRP_BIOMARKER report should be sort by "nci_id" as DESC 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 4s

Then service status code should return "200" 0s

And I want to verify CTRP_BIOMARKER response sorted by: "nci_id" as "DESC" 0s

Scenario:#11 CTRP_BIOMARKER report should be sort by "name" as ASC 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

And I want to verify CTRP_BIOMARKER response sorted by: "name" as "ASC" 0s

Scenario:#12 CTRP_BIOMARKER report should be sort by "name" as DESC 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

And I want to verify CTRP_BIOMARKER response sorted by: "name" as "DESC" 0s

Scenario:#13 CTRP_BIOMARKER report should be sort by "use" as ASC 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

And I want to verify CTRP_BIOMARKER response sorted by: "use" as "ASC" 0s

Scenario:#14 CTRP_BIOMARKER report should be sort by "use" as DESC 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

And I want to verify CTRP_BIOMARKER response sorted by: "use" as "DESC" 0s

Scenario:#15 mime type "CSV" GET endpoint response code should return 200 2

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

Scenario:#16 verify exported CSV content type is "text/CSV" 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#17 mime type "PDF" GET endpoint response code should return 200 2

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

Then service status code should return "200" 0s

Scenario:#18 verify exported PDF content type is "application/pdf" 3

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#19 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "CTRP_BIOMARKER" service endpoint 6

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#20 verify exported PDF content type is "application/pdf" and PDF file download is successful "CTRP_BIOMARKER" service endpoint 6

Given the "CTRP_BIOMARKER" service endpoint is called by providing following parameters 3s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 3s

Then verify PDF file downloaded successfully 0s

Feature:Verifying DT4 report does not include any trial which has processing status as 'Rejected' and 'Submission Terminated' 8

Scenario Outline:#1 Verify processing status "Submission Terminated" trials are not included in the DT4 report for City of Hope National Medical Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 3s

And service call status code returned "200" 0s

And the trial: "NCI-2010-01976" lead org org family is: "City of Hope National Medical Center" 0s

And the trial: "NCI-2010-01976" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2010-01976" in the response 0s

Scenario Outline:#2 Verify processing status "Rejected" trials are not included in the DT4 report for University of New Mexico Cancer Research & Treatment Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

And service call status code returned "200" 0s

And the trial: "NCI-2011-02688" lead org org family is: "University of New Mexico Cancer Research & Treatment Center" 0s

And the trial: "NCI-2011-02688" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2011-02688" in the response 0s

Scenario Outline:#3 Verify processing status "Rejected" trials are not included in the DT4 report for Masonic Cancer Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

And service call status code returned "200" 0s

And the trial: "NCI-2012-00866" lead org org family is: "Masonic Cancer Center" 0s

And the trial: "NCI-2012-00866" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2012-00866" in the response 0s

Scenario Outline:#4 Verify processing status "Rejected" trials are not included in the DT4 report for University of UT MD Anderson Cancer Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 5s

And service call status code returned "200" 0s

And the trial: "NCI-2013-01730" lead org org family is: "UT MD Anderson Cancer Center" 0s

And the trial: "NCI-2013-01730" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2013-01730" in the response 0s

Scenario Outline:#5 Verify processing status "Rejected" trials are not included in the DT4 report for Masonic Cancer Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

And service call status code returned "200" 0s

And the trial: "NCI-2014-02309" lead org org family is: "Masonic Cancer Center" 0s

And the trial: "NCI-2014-02309" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2014-02309" in the response 0s

Scenario Outline:#6 Verify processing status "Rejected" trials are not included in the DT4 report for Moores Comprehensive Cancer Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

And service call status code returned "200" 0s

And the trial: "NCI-2015-02185" lead org org family is: "Moores Comprehensive Cancer Center" 0s

And the trial: "NCI-2015-02185" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2015-02185" in the response 0s

Scenario Outline:#7 Verify processing status "Rejected" trials are not included in the DT4 report for UC Davis Comprehensive Cancer Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

And service call status code returned "200" 0s

And the trial: "NCI-2016-00078" lead org org family is: "UC Davis Comprehensive Cancer Center" 0s

And the trial: "NCI-2016-00078" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2016-00078" in the response 0s

Scenario Outline:#8 Verify processing status "Rejected" trials are not included in the DT4 report for Albert Einstein Cancer Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

And service call status code returned "200" 0s

And the trial: "NCI-2017-01154" lead org org family is: "Albert Einstein Cancer Center" 0s

And the trial: "NCI-2017-01154" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2017-01154" in the response 0s

Feature:A set of API tests to get report of family org details 2

Scenario:valid FAMILY_ORG_DETAILS GET endpoint response code should return 400 status code and contains correct data in response 3

Given the "FAMILY_ORG_DETAILS" report endpoint is called called with "" parameters 0s

Then the service status code should return "400" 0s

And the response for 'FAMILY_ORG_DETAILS' contains the correct data for "endpoint_no_params" parameters 0s

Scenario:valid FAMILY_ORG_DETAILS GET endpoint response code should return 200 status code and contains correct data in response 3

Given the "FAMILY_ORG_DETAILS" report endpoint is called called with "?center=Abramson Cancer Center¢er=Albert Einstein Cancer Center&start_date=2017-01-01&end_date=2017-06-01" parameters 0s

Then the service status code should return "200" 0s

And the response for 'FAMILY_ORG_DETAILS' contains the correct data for "endpoint_1_month" parameters 0s

Feature:Search for trial count by trial age group 1

Scenario:valid tiral analytics age GET endpoint response code should return 200 2

Given the "TRIALS_ANALYTIC" age service endpoint is called by providing following filter parameters 1s

Then trial analytics age service status code should return "200" 0s

Feature:A set of APIs tests to verify analytic types for the DT4 report 9

Scenario:valid analytic-types GET endpoint response code should return 200 2

Given the nci-strap-api service is called by providing valid analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the service status code should return "200" 0s

Scenario:invalid analytic-types GET endpoint response code should return 404 NOT FOUND 2

Given the nci-strap-api service is called by providing invalid analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the service status code should return "404" 0s

Scenario:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 3

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

Scenario Outline:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 4

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

And the analytic type: "Phase" is one from the list in the response body 0s

Scenario Outline:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 4

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

And the analytic type: "Funding Type" is one from the list in the response body 0s

Scenario Outline:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 4

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

And the analytic type: "Status" is one from the list in the response body 0s

Scenario Outline:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 4

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

And the analytic type: "Age" is one from the list in the response body 0s

Scenario Outline:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 4

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

And the analytic type: "Race" is one from the list in the response body 0s

Scenario Outline:Get analytic types using GET to nci-strap service using the filter parameters analytic-types 4

Given the nci-strap-api service is called by providing analytic types: "ANALYTIC_TYPE" filter parameters 0s

Then the list of analytic types returned 0s

And analytic types "label" attributes cannot be null 0s

And the analytic type: "Primary Purpose" is one from the list in the response body 0s

Feature:Authorization header is required for automated reports 25

Scenario:#1 ensure "DT4" GET endpoint requires Authorization 3

Given the "DT4" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "DT4" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#2 ensure "CTRP_BIOMARKER" GET endpoint requires Authorization 3

Given the "CTRP_BIOMARKER" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "CTRP_BIOMARKER" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#3 ensure "CTEP_EXPIRED" GET endpoint requires Authorization 3

Given the "CTEP_EXPIRED" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "CTEP_EXPIRED" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#4 ensure "CTRP_DAILY_OVERRIDE" GET endpoint requires Authorization 3

Given the "CTRP_DAILY_OVERRIDE" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "CTRP_DAILY_OVERRIDE" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#5 ensure "CTRP_TRIALS_COUNT" GET endpoint requires Authorization 3

Given the "CTRP_TRIALS_COUNT" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "CTRP_TRIALS_COUNT" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#6 ensure "CTRP_USERS" GET endpoint requires Authorization 3

Given the "CTRP_USERS" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "CTRP_USERS" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#7 ensure "DUPLICATE_PO" GET endpoint requires Authorization 3

Given the "DUPLICATE_PO" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "DUPLICATE_PO" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#8 ensure "FAMILY_ORG_DETAILS" GET endpoint requires Authorization 3

Given the "FAMILY_ORG_DETAILS" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "FAMILY_ORG_DETAILS" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#9 ensure "MONTHLY_MILESTONE" GET endpoint requires Authorization 3

Given the "MONTHLY_MILESTONE" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "MONTHLY_MILESTONE" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#10 ensure "NCI_AS_SPONSOR" GET endpoint requires Authorization 3

Given the "NCI_AS_SPONSOR" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "NCI_AS_SPONSOR" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#11 ensure "TRIAL_PROCESSING_ACTIVITY" GET endpoint requires Authorization 3

Given the "TRIAL_PROCESSING_ACTIVITY" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "TRIAL_PROCESSING_ACTIVITY" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#12 ensure "TRIAL_VERIFICATION" GET endpoint requires Authorization 3

Given the "TRIAL_VERIFICATION" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "TRIAL_VERIFICATION" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#13 ensure "CTRP_DAILY_OVERRIDE" GET endpoint requires Authorization 3

Given the "CTRP_DAILY_OVERRIDE" service is called by providing following parameters without Authorization Header 0s

Then service status code should return "401" UNAUTHORIZED 0s

And I want to verify "CTRP_DAILY_OVERRIDE" response matches with authentication failure message for "authentication_failure" parameters in the "authorization_msg" json file 0s

Scenario:#14 ensure "DT4" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "DT4" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "DT4" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#15 ensure "CTRP_BIOMARKER" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "CTRP_BIOMARKER" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "CTRP_BIOMARKER" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#16 ensure "CTEP_EXPIRED" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "CTEP_EXPIRED" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "CTEP_EXPIRED" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#17 ensure "CTRP_DAILY_OVERRIDE" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "CTRP_DAILY_OVERRIDE" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "CTRP_DAILY_OVERRIDE" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#18 ensure "CTRP_TRIALS_COUNT" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "CTRP_TRIALS_COUNT" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "CTRP_TRIALS_COUNT" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#19 ensure "DUPLICATE_PO" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "DUPLICATE_PO" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "DUPLICATE_PO" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#20 ensure "FAMILY_ORG_DETAILS" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "FAMILY_ORG_DETAILS" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "FAMILY_ORG_DETAILS" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#21 ensure "MONTHLY_MILESTONE" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "MONTHLY_MILESTONE" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "MONTHLY_MILESTONE" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#22 ensure "NCI_AS_SPONSOR" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "NCI_AS_SPONSOR" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "NCI_AS_SPONSOR" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#23 ensure "TRIAL_PROCESSING_ACTIVITY" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "TRIAL_PROCESSING_ACTIVITY" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "TRIAL_PROCESSING_ACTIVITY" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#24 ensure "TRIAL_VERIFICATION" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "TRIAL_VERIFICATION" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "TRIAL_VERIFICATION" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Scenario:#25 ensure "CTRP_DAILY_OVERRIDE" GET endpoint service return 403 FORBIDDEN status with Expired TOKEN 4

Given I know the authorization TOKEN is expired 0s

And the "CTRP_DAILY_OVERRIDE" service is called by providing following parameters with Expired TOKEN 0s

Then the service status code should return "403" FORBIDDEN 0s

And I want to verify "CTRP_DAILY_OVERRIDE" response matches with permission denied message for "expired_token" parameters in the "authorization_msg" json file 0s

Feature:CTRPSTRAP-149: Add new local_center_trial_id to DT4 report 2 45

Verifying Local Trial ID for the cancer center trial(s)

Scenario Outline:#1 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Mayo Clinic Cancer Center 4

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 5s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00008" 0s

And the local center trial ID: "" is correct for the cancer center: "Mayo Clinic Cancer Center" for the trial NCI ID: "NCI-2009-00008" 0s

Scenario Outline:#1 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Mayo Clinic Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00015" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:15:in `And It shall return the response which should include nci id "NCI-2009-00015"'
features/strap_api/bug_fix_tracker_149.feature:10:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "MC998C" is correct for the cancer center: "Mayo Clinic Cancer Center" for the trial NCI ID: "NCI-2009-00015"

Scenario Outline:#1 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Mayo Clinic Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00008" 0s

And the local center trial ID: "MC0112" is correct for the cancer center: "Mayo Clinic Cancer Center" for the trial NCI ID: "NCI-2009-00008" 0s + Show Error 

expected: "MC0112"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:16:in `And the local center trial ID: "MC0112" is correct for the cancer center: "Mayo Clinic Cancer Center" for the trial NCI ID: "NCI-2009-00008"'
features/strap_api/bug_fix_tracker_149.feature:11:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#1 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Mayo Clinic Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00021" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:17:in `And It shall return the response which should include nci id "NCI-2009-00021"'
features/strap_api/bug_fix_tracker_149.feature:10:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "U1701" is correct for the cancer center: "Mayo Clinic Cancer Center" for the trial NCI ID: "NCI-2009-00021"

Scenario Outline:#2 CTRPSTRAP-149 Verifying new local_center_trial_id matches for University of Colorado Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 4s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2016-01807" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:29:in `And It shall return the response which should include nci id "NCI-2016-01807"'
features/strap_api/bug_fix_tracker_149.feature:25:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "16-1341, 16-2290" is correct for the cancer center: "University of Colorado Cancer Center" for the trial NCI ID: "NCI-2016-01807"

Scenario Outline:#2 CTRPSTRAP-149 Verifying new local_center_trial_id matches for University of Colorado Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2017-01771" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:30:in `And It shall return the response which should include nci id "NCI-2017-01771"'
features/strap_api/bug_fix_tracker_149.feature:25:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "" is correct for the cancer center: "University of Colorado Cancer Center" for the trial NCI ID: "NCI-2017-01771"

Scenario Outline:#2 CTRPSTRAP-149 Verifying new local_center_trial_id matches for University of Colorado Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2016-01660" 0s

And the local center trial ID: "16-1002" is correct for the cancer center: "University of Colorado Cancer Center" for the trial NCI ID: "NCI-2016-01660" 0s + Show Error 

expected: "16-1002"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:31:in `And the local center trial ID: "16-1002" is correct for the cancer center: "University of Colorado Cancer Center" for the trial NCI ID: "NCI-2016-01660"'
features/strap_api/bug_fix_tracker_149.feature:26:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#3 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Abramson Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 5s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And the local center trial ID: "MC083I" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2009-01112" 0s + Show Error 

expected: "MC083I"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:43:in `And the local center trial ID: "MC083I" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2009-01112"'
features/strap_api/bug_fix_tracker_149.feature:40:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#3 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Abramson Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00338" 0s

And the local center trial ID: "ACNS0334" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2009-00338" 0s + Show Error 

expected: "ACNS0334"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:44:in `And the local center trial ID: "ACNS0334" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2009-00338"'
features/strap_api/bug_fix_tracker_149.feature:40:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#3 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Abramson Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2010-00822" 0s

And the local center trial ID: "P30" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2010-00822" 0s + Show Error 

expected: "P30"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:45:in `And the local center trial ID: "P30" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2010-00822"'
features/strap_api/bug_fix_tracker_149.feature:40:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#3 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Abramson Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2010-01344" 0s

And the local center trial ID: "UPCC 02307" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2010-01344" 0s + Show Error 

expected: "UPCC 02307"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:46:in `And the local center trial ID: "UPCC 02307" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2010-01344"'
features/strap_api/bug_fix_tracker_149.feature:40:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#3 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Abramson Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2015-02094" 0s

And the local center trial ID: "UPCC 03315" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2015-02094" 0s + Show Error 

expected: "UPCC 03315"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:47:in `And the local center trial ID: "UPCC 03315" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2015-02094"'
features/strap_api/bug_fix_tracker_149.feature:40:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#3 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Abramson Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2015-00584" 0s

And the local center trial ID: "811722" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2015-00584" 0s + Show Error 

expected: "811722"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:48:in `And the local center trial ID: "811722" is correct for the cancer center: "Abramson Cancer Center" for the trial NCI ID: "NCI-2015-00584"'
features/strap_api/bug_fix_tracker_149.feature:40:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#4 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Albert Einstein Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 4s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2011-02590" 0s

And the local center trial ID: "11-02-068, PENDING" is correct for the cancer center: "Albert Einstein Cancer Center" for the trial NCI ID: "NCI-2011-02590" 0s + Show Error 

expected: "11-02-068, PENDING"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:60:in `And the local center trial ID: "11-02-068, PENDING" is correct for the cancer center: "Albert Einstein Cancer Center" for the trial NCI ID: "NCI-2011-02590"'
features/strap_api/bug_fix_tracker_149.feature:57:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#4 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Albert Einstein Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00059" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:61:in `And It shall return the response which should include nci id "NCI-2009-00059"'
features/strap_api/bug_fix_tracker_149.feature:56:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "C-2802" is correct for the cancer center: "Albert Einstein Cancer Center" for the trial NCI ID: "NCI-2009-00059"

Scenario Outline:#4 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Albert Einstein Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2015-01489" 0s

And the local center trial ID: "15-06-165-01" is correct for the cancer center: "Albert Einstein Cancer Center" for the trial NCI ID: "NCI-2015-01489" 0s + Show Error 

expected: "15-06-165-01"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:62:in `And the local center trial ID: "15-06-165-01" is correct for the cancer center: "Albert Einstein Cancer Center" for the trial NCI ID: "NCI-2015-01489"'
features/strap_api/bug_fix_tracker_149.feature:57:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#5 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Alliance for Clinical Trials in Oncology 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00452" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:74:in `And It shall return the response which should include nci id "NCI-2009-00452"'
features/strap_api/bug_fix_tracker_149.feature:70:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "CALGB-150705-ICSC" is correct for the cancer center: "Alliance for Clinical Trials in Oncology" for the trial NCI ID: "NCI-2009-00452"

Scenario Outline:#5 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Alliance for Clinical Trials in Oncology 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2016-00456" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:75:in `And It shall return the response which should include nci id "NCI-2016-00456"'
features/strap_api/bug_fix_tracker_149.feature:70:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "A021501" is correct for the cancer center: "Alliance for Clinical Trials in Oncology" for the trial NCI ID: "NCI-2016-00456"

Scenario Outline:#5 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Alliance for Clinical Trials in Oncology 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2017-00740" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:76:in `And It shall return the response which should include nci id "NCI-2017-00740"'
features/strap_api/bug_fix_tracker_149.feature:70:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "A071601" is correct for the cancer center: "Alliance for Clinical Trials in Oncology" for the trial NCI ID: "NCI-2017-00740"

Scenario Outline:#6 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Alvin J. Siteman Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 7s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00019" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:88:in `And It shall return the response which should include nci id "NCI-2009-00019"'
features/strap_api/bug_fix_tracker_149.feature:84:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "201109281" is correct for the cancer center: "Alvin J. Siteman Cancer Center" for the trial NCI ID: "NCI-2009-00019"

Scenario Outline:#6 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Alvin J. Siteman Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 7s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00063" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:89:in `And It shall return the response which should include nci id "NCI-2009-00063"'
features/strap_api/bug_fix_tracker_149.feature:84:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "201012750" is correct for the cancer center: "Alvin J. Siteman Cancer Center" for the trial NCI ID: "NCI-2009-00063"

Scenario Outline:#6 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Alvin J. Siteman Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00109" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:90:in `And It shall return the response which should include nci id "NCI-2009-00109"'
features/strap_api/bug_fix_tracker_149.feature:84:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "05-0120" is correct for the cancer center: "Alvin J. Siteman Cancer Center" for the trial NCI ID: "NCI-2009-00109"

Scenario Outline:#7 CTRPSTRAP-149 Verifying new local_center_trial_id matches for City of Hope National Medical Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 4s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And the local center trial ID: "MC083I" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01112" 0s + Show Error 

expected: "MC083I"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:102:in `And the local center trial ID: "MC083I" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01112"'
features/strap_api/bug_fix_tracker_149.feature:99:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#7 CTRPSTRAP-149 Verifying new local_center_trial_id matches for City of Hope National Medical Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01209" 0s

And the local center trial ID: "07045" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01209" 0s + Show Error 

expected: "07045"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:103:in `And the local center trial ID: "07045" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01209"'
features/strap_api/bug_fix_tracker_149.feature:99:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#7 CTRPSTRAP-149 Verifying new local_center_trial_id matches for City of Hope National Medical Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01221" 0s

And the local center trial ID: "08220, H3E-MC-JMHD" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01221" 0s + Show Error 

expected: "08220, H3E-MC-JMHD"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:104:in `And the local center trial ID: "08220, H3E-MC-JMHD" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01221"'
features/strap_api/bug_fix_tracker_149.feature:99:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#8 CTRPSTRAP-149 Verifying new local_center_trial_id matches for City of Hope National Medical Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And the local center trial ID: "MC083I" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01112" 0s + Show Error 

expected: "MC083I"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:116:in `And the local center trial ID: "MC083I" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01112"'
features/strap_api/bug_fix_tracker_149.feature:113:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#8 CTRPSTRAP-149 Verifying new local_center_trial_id matches for City of Hope National Medical Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01209" 0s

And the local center trial ID: "07045" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01209" 0s + Show Error 

expected: "07045"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:117:in `And the local center trial ID: "07045" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01209"'
features/strap_api/bug_fix_tracker_149.feature:113:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#8 CTRPSTRAP-149 Verifying new local_center_trial_id matches for City of Hope National Medical Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01221" 0s

And the local center trial ID: "08220, H3E-MC-JMHD" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01221" 0s + Show Error 

expected: "08220, H3E-MC-JMHD"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:118:in `And the local center trial ID: "08220, H3E-MC-JMHD" is correct for the cancer center: "City of Hope National Medical Center" for the trial NCI ID: "NCI-2009-01221"'
features/strap_api/bug_fix_tracker_149.feature:113:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#9 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Duke Cancer Institute 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 7s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00073" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:130:in `And It shall return the response which should include nci id "NCI-2009-00073"'
features/strap_api/bug_fix_tracker_149.feature:126:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "UCI 04-04" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00073"

Scenario Outline:#9 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Duke Cancer Institute 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00281" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:131:in `And It shall return the response which should include nci id "NCI-2009-00281"'
features/strap_api/bug_fix_tracker_149.feature:126:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "1232" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00281"

Scenario Outline:#9 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Duke Cancer Institute 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00338" 0s

And the local center trial ID: "ACNS0334" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00338" 0s + Show Error 

expected: "ACNS0334"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:132:in `And the local center trial ID: "ACNS0334" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00338"'
features/strap_api/bug_fix_tracker_149.feature:127:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#10 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Duke Cancer Institute 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00073" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:144:in `And It shall return the response which should include nci id "NCI-2009-00073"'
features/strap_api/bug_fix_tracker_149.feature:140:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "UCI 04-04" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00073"

Scenario Outline:#10 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Duke Cancer Institute 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00281" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:145:in `And It shall return the response which should include nci id "NCI-2009-00281"'
features/strap_api/bug_fix_tracker_149.feature:140:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "1232" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00281"

Scenario Outline:#10 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Duke Cancer Institute 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00338" 0s

And the local center trial ID: "ACNS0334" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00338" 0s + Show Error 

expected: "ACNS0334"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:146:in `And the local center trial ID: "ACNS0334" is correct for the cancer center: "Duke Cancer Institute" for the trial NCI ID: "NCI-2009-00338"'
features/strap_api/bug_fix_tracker_149.feature:141:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#10 CTRPSTRAP-149 Verifying new local_center_trial_id matches for ECOG-ACRIN Cancer Research Group 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 1s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2016-00326" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:158:in `And It shall return the response which should include nci id "NCI-2016-00326"'
features/strap_api/bug_fix_tracker_149.feature:154:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "EA8143" is correct for the cancer center: "ECOG-ACRIN Cancer Research Group" for the trial NCI ID: "NCI-2016-00326"

Scenario Outline:#10 CTRPSTRAP-149 Verifying new local_center_trial_id matches for ECOG-ACRIN Cancer Research Group 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2016-00366" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:159:in `And It shall return the response which should include nci id "NCI-2016-00366"'
features/strap_api/bug_fix_tracker_149.feature:154:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "CTSP-NLST" is correct for the cancer center: "ECOG-ACRIN Cancer Research Group" for the trial NCI ID: "NCI-2016-00366"

Scenario Outline:#10 CTRPSTRAP-149 Verifying new local_center_trial_id matches for ECOG-ACRIN Cancer Research Group 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2016-00385" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:160:in `And It shall return the response which should include nci id "NCI-2016-00385"'
features/strap_api/bug_fix_tracker_149.feature:154:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "CTSP-E5103" is correct for the cancer center: "ECOG-ACRIN Cancer Research Group" for the trial NCI ID: "NCI-2016-00385"

Scenario Outline:#11 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Fox Chase Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00158" 0s

And the local center trial ID: "EA8143" is correct for the cancer center: "Fox Chase Cancer Center" for the trial NCI ID: "NCI-2009-00158" 0s + Show Error 

expected: "EA8143"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:172:in `And the local center trial ID: "EA8143" is correct for the cancer center: "Fox Chase Cancer Center" for the trial NCI ID: "NCI-2009-00158"'
features/strap_api/bug_fix_tracker_149.feature:169:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#11 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Fox Chase Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00176" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:173:in `And It shall return the response which should include nci id "NCI-2009-00176"'
features/strap_api/bug_fix_tracker_149.feature:168:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "CTSP-NLST" is correct for the cancer center: "Fox Chase Cancer Center" for the trial NCI ID: "NCI-2009-00176"

Scenario Outline:#11 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Fox Chase Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01060" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:174:in `And It shall return the response which should include nci id "NCI-2009-01060"'
features/strap_api/bug_fix_tracker_149.feature:168:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "ACRIN 6678" is correct for the cancer center: "Fox Chase Cancer Center" for the trial NCI ID: "NCI-2009-01060"

Scenario Outline:#12 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Georgetown Lombardi Comprehensive Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01112" 0s

And the local center trial ID: "MC083I" is correct for the cancer center: "Georgetown Lombardi Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-01112" 0s + Show Error 

expected: "MC083I"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:186:in `And the local center trial ID: "MC083I" is correct for the cancer center: "Georgetown Lombardi Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-01112"'
features/strap_api/bug_fix_tracker_149.feature:183:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#12 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Georgetown Lombardi Comprehensive Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01126" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:187:in `And It shall return the response which should include nci id "NCI-2009-01126"'
features/strap_api/bug_fix_tracker_149.feature:182:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "08-378" is correct for the cancer center: "Georgetown Lombardi Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-01126"

Scenario Outline:#12 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Georgetown Lombardi Comprehensive Cancer Center 3 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-01454" 0s

And the local center trial ID: "2008-380" is correct for the cancer center: "Georgetown Lombardi Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-01454" 0s + Show Error 

expected: "2008-380"
     got: ""

(compared using ==)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_dt4_issues.rb:164:in `/^the local center trial ID: "([^"]*)" is correct for the cancer center: "([^"]*)" for the trial NCI ID: "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:188:in `And the local center trial ID: "2008-380" is correct for the cancer center: "Georgetown Lombardi Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-01454"'
features/strap_api/bug_fix_tracker_149.feature:183:in `And the local center trial ID: "(local_center_trial_id_val)" is correct for the cancer center: "(cancer_center_val)" for the trial NCI ID: "(nci_id_val)"'

Scenario Outline:#13 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Harold C. Simmons Comprehensive Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 2s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00363" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:200:in `And It shall return the response which should include nci id "NCI-2009-00363"'
features/strap_api/bug_fix_tracker_149.feature:196:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "ADVL0712" is correct for the cancer center: "Harold C. Simmons Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-00363"

Scenario Outline:#13 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Harold C. Simmons Comprehensive Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00369" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:201:in `And It shall return the response which should include nci id "NCI-2009-00369"'
features/strap_api/bug_fix_tracker_149.feature:196:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "AEWS0521" is correct for the cancer center: "Harold C. Simmons Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-00369"

Scenario Outline:#13 CTRPSTRAP-149 Verifying new local_center_trial_id matches for Harold C. Simmons Comprehensive Cancer Center 2 1 1

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 0s

Then service call status code returned "200" 0s

And It shall return the response which should include nci id "NCI-2009-00407" 0s + Show Error 

expected: true
     got: false

(compared using eql?)
 (RSpec::Expectations::ExpectationNotMetError)
./features/step_definitions/report_data_table_4.rb:57:in `/^It shall return the response which should include nci id "([^"]*)"$/'
features/strap_api/bug_fix_tracker_149.feature:202:in `And It shall return the response which should include nci id "NCI-2009-00407"'
features/strap_api/bug_fix_tracker_149.feature:196:in `And It shall return the response which should include nci id "(nci_id_val)"'

And the local center trial ID: "AEWS0521" is correct for the cancer center: "Harold C. Simmons Comprehensive Cancer Center" for the trial NCI ID: "NCI-2009-00407"

Scenario Outline:#1 Verify processing status "Submission Terminated" trials are not included in the DT4 report for City of Hope National Medical Center 5

Given "DT4" service is called by providing following CANCER CENTER name with the reporting preiod start date and end date 3s

And service call status code returned "200" 0s

And the trial: "NCI-2010-01976" lead org org family is: "City of Hope National Medical Center" 0s

And the trial: "NCI-2010-01976" processing status should be "Rejected" and "Submission Terminated" 0s

Then DT4 report SHOULD NOT contains following trials: "NCI-2010-01976" in the response 0s

Feature:A set of API tests to get report of CTRP Daily Override Flag 15

Scenario:#1 valid CTRP_DAILY_OVERRIDE GET endpoint response code should return 200 with parameters 2

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

Then service status code should return "200" 0s

Scenario:#2 GET endpoint response code should return 200 for CTRP_DAILY_OVERRIDE service endpoint without any params 2

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

Then service status code should return "200" 0s

Scenario:#3 malformed CTRP_DAILY_OVERRIDE trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#4 valid CTRP_DAILY_OVERRIDE GET endpoint response code should return 200 status code and contains correct data in response 3

Given the "CTRP_DAILY_OVERRIDE" report endpoint is called called with "" parameters 1s

Then the service status code should return "200" 0s

And the response for 'CTRP_DAILY_OVERRIDE' contains the correct data for "endpoint_no_params" parameters 0s

Scenario Outline:#5 valid CTRP_DAILY_OVERRIDE GET endpoint response code should return 200 status code and returns pdf document 4

Given the "CTRP_DAILY_OVERRIDE" report endpoint is called called with "csv" parameter 1s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Scenario Outline:#5 valid CTRP_DAILY_OVERRIDE GET endpoint response code should return 200 status code and returns pdf document 4

Given the "CTRP_DAILY_OVERRIDE" report endpoint is called called with "pdf" parameter 11s

Then the service status code should return "200" 0s

And check Content-Type header is "application/pdf" 0s

And check Content-Length header is greater than zero 0s

Scenario:#6 CTRP_DAILY_OVERRIDE report should be sort by "nci_id" as ascending order by default 3

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

Then service status code should return "200" 0s

And I want to verify CTRP_DAILY_OVERRIDE response sorted by: "nci_id" as "ASC" 0s

Scenario:#7 CTRP_DAILY_OVERRIDE report should be sort by "nci_id" as ASC 3

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

Then service status code should return "200" 0s

And I want to verify CTRP_DAILY_OVERRIDE response sorted by: "nci_id" as "ASC" 0s

Scenario:#8 CTRP_DAILY_OVERRIDE report should be sort by "nci_id" as DESC 3

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

Then service status code should return "200" 0s

And I want to verify CTRP_DAILY_OVERRIDE response sorted by: "nci_id" as "DESC" 0s

Scenario:#9 mime type "CSV" GET endpoint response code should return 200 2

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

Then service status code should return "200" 0s

Scenario:#10 verify exported CSV content type is "text/CSV" 3

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 1s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#11 mime type "PDF" GET endpoint response code should return 200 2

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 11s

Then service status code should return "200" 0s

Scenario:#12 verify exported PDF content type is "application/pdf" 3

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 11s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#13 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "CTRP_DAILY_OVERRIDE" service endpoint 6

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 2s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#14 verify exported PDF content type is "application/pdf" and PDF file download is successful "CTRP_DAILY_OVERRIDE" service endpoint 6

Given the "CTRP_DAILY_OVERRIDE" service endpoint is called by providing following parameters 12s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 12s

Then verify PDF file downloaded successfully 0s

Feature:A set of API tests to get report of ctrp trials counts 1 3

Scenario:#1 valid prs verification GET endpoint response code should return 200 status code and contains correct items with valid keys 3 1

Given the "CTRP_TRIALS_COUNT" endpoint is called 31s + Show Error 

765: unexpected token at '(html)
(head)(title)502 Bad Gateway(/title)(/head)
(body bgcolor="white")
(center)(h1)502 Bad Gateway(/h1)(/center)
(/body)
(/html)
' (JSON::ParserError)
./features/step_definitions/report_trial_verification.rb:12:in `/^the "([^"]*)" endpoint is called$/'
features/strap_api/report_ctrp_trials_counts.feature:6:in `Given the "CTRP_TRIALS_COUNT" endpoint is called'

Then the service status code should return "200"

And the response for ctrp-trials-counts is not null

And the response from ctrp-trials-counts contains correct data

Scenario:#5 malformed CTRP_TRIALS_COUNT trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "CTRP_TRIALS_COUNT" service GET endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#13 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "CTRP_TRIALS_COUNT" service endpoint 1 4 1

Given the "CTRP_TRIALS_COUNT" service GET endpoint is called by providing following parameters 32s

And service should return response with headers 0s + Show Error 

undefined method `split' for nil:NilClass (NoMethodError)
./features/step_definitions/report_data_table_4.rb:303:in `/^service should return response with headers$/'
features/strap_api/report_ctrp_trials_counts.feature:166:in `And service should return response with headers'

Then the exported file content type is "text/csv"

Then the exported file content length is grater than zero

And download CSV file

Then verify CSV file downloaded successfully

Scenario:#14 verify exported PDF content type is "application/pdf" and PDF file download is successful "CTRP_TRIALS_COUNT" service endpoint 1 4 1

Given the "CTRP_TRIALS_COUNT" service GET endpoint is called by providing following parameters 31s

And service should return response with headers 0s + Show Error 

undefined method `split' for nil:NilClass (NoMethodError)
./features/step_definitions/report_data_table_4.rb:303:in `/^service should return response with headers$/'
features/strap_api/report_ctrp_trials_counts.feature:183:in `And service should return response with headers'

Then the exported file content type is "application/pdf"

Then the exported file content length is grater than zero

And download PDF file

Then verify PDF file downloaded successfully

Feature:A set of API tests to get report of ctrp-users 20

Scenario:#1 valid ctrp-users GET endpoint response code should return 200 status code and contains valid data 4

Given the "CTRP_USERS" endpoint is called 0s

Then the service status code should return "200" 0s

And the response for ctrp-users is not null 0s

And the matching ctrp-users response data field contains correct structure and data 0s

Scenario Outline:#2 valid ctrp-users GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "CTRP_USERS" report endpoint is called called with "csv" parameter 0s

Then the service status code should return "200" 0s

And check Content-Type header is "text/csv" 0s

And check Content-Length header is greater than zero 0s

Scenario Outline:#2 valid ctrp-users GET endpoint response code should return 200 status code for pdf and csv params 4

Given the "CTRP_USERS" report endpoint is called called with "pdf" parameter 7s

Then the service status code should return "200" 0s

And check Content-Type header is "application/pdf" 0s

And check Content-Length header is greater than zero 0s

Scenario:#3 valid CTRP_USERS GET endpoint response code should return 200 with parameters 2

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#4 GET endpoint response code should return 200 for CTRP_USERS service endpoint with Start Date and End Date parameters 2

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#5 malformed CTRP_USERS trial type GET endpoint response code should return 404 NOT FOUND 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "404" 0s

And service should return message: "msg_not_found" due to missing parameter 0s

Scenario:#7 CTRP_USERS report should be sort by "first_name" as ASC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "first_name" as "ASC" 0s

Scenario:#8 CTRP_USERS report should be sort by "first_name" as DESC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "first_name" as "DESC" 0s

Scenario:#9 CTRP_USERS report should be sort by "last_name" as ASC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "last_name" as "ASC" 0s

Scenario:#10 CTRP_USERS report should be sort by "last_name" as DESC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "last_name" as "DESC" 0s

Scenario:#11 CTRP_USERS report should be sort by "affiliated_organization" as ASC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "affiliated_organization" as "ASC" 0s

Scenario:#12 CTRP_USERS report should be sort by "affiliated_organization" as DESC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "affiliated_organization" as "DESC" 0s

Scenario:#13 CTRP_USERS report should be sort by "family_name" as ASC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "family_name" as "ASC" 0s

Scenario:#14 CTRP_USERS report should be sort by "family_name" as DESC 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

And I want to verify CTRP_USERS response sorted by: "family_name" as "DESC" 0s

Scenario:#15 mime type "CSV" GET endpoint response code should return 200 2

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

Then service status code should return "200" 0s

Scenario:#16 verify exported CSV content type is "text/CSV" 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Scenario:#17 mime type "PDF" GET endpoint response code should return 200 2

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 7s

Then service status code should return "200" 0s

Scenario:#18 verify exported PDF content type is "application/pdf" 3

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 6s

And service should return response with headers 0s

Then the exported file content type is "application/pdf" 0s

Scenario:#19 verify exported CSV content type is "text/CSV" and content length is greater than "ZERO" and CSV file download is successfully for "CTRP_USERS" service endpoint 6

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 0s

And service should return response with headers 0s

Then the exported file content type is "text/csv" 0s

Then the exported file content length is grater than zero 0s

And download CSV file 0s

Then verify CSV file downloaded successfully 0s

Scenario:#20 verify exported PDF content type is "application/pdf" and PDF file download is successful "CTRP_USERS" service endpoint 6

Given the "CTRP_USERS" service GET endpoint is called by providing following parameters 6s

And service should return response with headers for the CTRP Users endpoint 0s

Then the exported file content type is "application/pdf" 0s

Then the exported file content length is grater than zero 0s

And download PDF file 7s

Then verify PDF file downloaded successfully 0s

Feature:Verifying reporting date range 3

Changing reporting date range should not return less data.

Scenario:#1 Default ONE MONTH reporting period date range to TWO MONTH date range should not return less data 6

Given the "DT4" service is called by providing following criteria: 2s

And service status code should return "200" 0s

Then I want to verify items_per_page: "ad_nci_id" and response contain "142" records 0s

And the "DT4" service is called by providing following criteria: 2s

And service status code should return "200" 0s

Then I want to verify items_per_page: "ad_nci_id" and response contain "144" records 0s

Scenario:#2 Default ONE MONTH reporting period date range to ONE YEAR date range should not return less data 6

Given the "DT4" service is called by providing following criteria: 2s

And service status code should return "200" 0s

Then I want to verify items_per_page: "ad_nci_id" and response contain "142" records 0s

And the "DT4" service is called by providing following criteria: 3s

And service status code should return "200" 0s

Then I want to verify items_per_page: "ad_nci_id" and response contain "211" records 0s

Scenario:#3 Default ONE MONTH reporting period date range to TEN YEAR date range should not return less data 6

Given the "DT4" service is called by providing following criteria: 2s

And service status code should return "200" 0s

Then I want to verify items_per_page: "ad_nci_id" and response contain "142" records 0s

And the "DT4" service is called by providing following criteria: 3s

And service status code should return "200" 0s

Then I want to verify items_per_page: "ad_nci_id" and response contain "559" records 0s

Feature:A set of API tests to get report of trial processing activity 1 1

Scenario:valid TRIAL_PROCESSING_ACTIVITY GET endpoint response code should return 400 status code and contains correct data in response 3

Given the "TRIAL_PROCESSING_ACTIVITY" report endpoint is called called with "" parameters 0s

Then the service status code should return "400" 0s

And the response for 'TRIAL_PROCESSING_ACTIVITY' contains the correct data for "endpoint_no_params" parameters 0s

Scenario:valid TRIAL_PROCESSING_ACTIVITY GET endpoint response code should return 200 status code and contains correct data in response 2 1

Given the "TRIAL_PROCESSING_ACTIVITY" report endpoint is called called with "?start_date=2016-01-01&end_date=2016-02-01" parameters 32s + Show Error 

765: unexpected token at '(html)
(head)(title)502 Bad Gateway(/title)(/head)
(body bgcolor="white")
(center)(h1)502 Bad Gateway(/h1)(/center)
(/body)
(/html)
' (JSON::ParserError)
./features/step_definitions/report_monthly_milestone.rb:13:in `/^the "([^"]*)" report endpoint is called called with "([^"]*)" parameters$/'
features/strap_api/report_trial_processing_activity.feature:12:in `Given the "TRIAL_PROCESSING_ACTIVITY" report endpoint is called called with "?start_date=2016-01-01&end_date=2016-02-01" parameters'

Then the service status code should return "200"

And the response for 'TRIAL_PROCESSING_ACTIVITY' contains the correct data for "endpoint_1_month" parameters

Feature:A set of APIs tests to verify nci-strap-api search family endpoints 34

Scenario:Get list of families name by query FAMILIES endpoint 2

Given "FAMILIES" endpoint is called 0s

Then the families name returned 0s

Scenario:Get families name using GET to nci-strap service query by FAMILIES and family_name attributes cannot be null 3

Given "FAMILIES" endpoint is called 0s

Then the list of families name returned 0s

And "family_name" attributes cannot be null 0s

Scenario:Get family names using GET to nci-strap service query by FAMILIES and verify RESPONSE SCHEMA 3

Given "FAMILIES" endpoint is called 0s

Then the nci-strap service returned json with family names 0s

And verify FAMILIES query response with the schema "schema_families" 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Abramson Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Cancer Therapy & Research Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Dana-Farber/Harvard Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Fox Chase Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Comprehensive Cancer Center - James Cancer Hospital & Solove Research Institute" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Harold C. Simmons Comprehensive Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Indiana University Melvin and Bren Simon Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Jonsson Comprehensive Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Mayo Clinic Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Masonic Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "NCI Center for Cancer Research (CCR)" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "OHSU Knight Cancer Institute" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Purdue University Center for Cancer Research" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Robert H. Lurie Comprehensive Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Salk Institute Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "The Barbara Ann Karmanos Cancer Institute" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "UAB Comprehensive Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Vanderbilt-Ingram Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Wake Forest Comprehensive Cancer Center" is one from the list in the json 0s

Scenario Outline:Get all families 3

Given "FAMILIES" endpoint is called 0s

Then the FAMILIES query returned a valid json 0s

Then the family name: "Yale Cancer Center" is one from the list in the json 0s

Scenario:Attempt get using invalid FAMILIES endpoint 5

Given I have a valid host service endpoint 0s

But the GET "FAMILIES" endpoint is invalid 0s

When GET invalid FAMILIES endpoint is called 0s

Then service status code should return "404" 0s

And service should return not found message 0s

Scenario:Attempt get using valid FAMILIES endpoint 5

Given I have a valid host service endpoint 0s

And the GET "FAMILIES" endpoint is valid 0s

When GET valid FAMILIES endpoint is called 0s

Then the response code should returned "200" 0s

And the response body should not be null 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Jonsson Comprehensive Cancer Center" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Jonsson Comprehensive Cancer Center" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Mayo Clinic Cancer Center" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Mayo Clinic Cancer Center" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Masonic Cancer Center" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Masonic Cancer Center" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "NCI Center for Cancer Research (CCR)" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "NCI Center for Cancer Research (CCR)" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Wake Forest Comprehensive Cancer Center" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Wake Forest Comprehensive Cancer Center" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Yale Cancer Center" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Yale Cancer Center" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "OHSU Knight Cancer Institute" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "OHSU Knight Cancer Institute" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Purdue University Center for Cancer Research" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Purdue University Center for Cancer Research" is returned 0s

Scenario Outline:Get a family name using filter parameters family_name 3

Given "FAMILY_NAME" service is called by providing family name: "Robert H. Lurie Comprehensive Cancer Center" 0s

Then the FAMILY_NAME query returned a valid json 0s

And only one matching family name: "Robert H. Lurie Comprehensive Cancer Center" is returned 0s

generated by @cucumber-html-reporter